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Abstract
Objectives Treatment with exclusive enteral nutrition (EEN) is an effective ther-
apy, successfully helping children with Crohn’s disease achieve remission without the
need for corticosteroids. The use of maintenance enteral nutrition (MEN) following
induction of remission using EEN, is thought to help maintain clinical remission.
Although the efficacy of EEN is well established, the mechanism remains unknown.
There is now strong evidence to support an aetiopathogenesis in Crohn’s disease
which implicates an interaction between environmental factors and the indigenous
gut microbiota in genetically susceptible individuals.
The aim of this prospective observational study was to test the hypothesis that clinical
response to EEN and reduction of colonic inflammatory markers are associated with a
characteristic bacterial taxonomy (composition) and short/medium chain fatty acids
(C2-C8) (functionality); and that maintenance of these profiles with MEN, while
returning to habitual diet, reduces the risk of relapse. The idea that gut bacteria can
be altered using diet, is an important area of research in paediatric Crohn’s disease,
hence this study also aimed to link the gut microbiota with dietary intake.
Methods Thirty-four children with Crohn’s disease; 10 with ulcerative colitis (UC);
11 patients without inflammatory bowel disease (non-IBD); and 25 healthy controls
were asked to provide faecal samples. Children with Crohn’s disease also provided
samples at 4-weeks, and 8-weeks of treatment with EEN; and then at 2-weeks and
8-weeks of MEN. Dietary intake was estimated using a food frequency questionnaire
(FFQ), at week-0 and at 2-weeks and 8-weeks post-EEN. Post-EEN, children were
treated with either 20% MEN, an immunosuppressant, or both. Bacterial DNA was
extracted using the chaotropic method followed by amplification of the 16s rRNA
gene (V4) for Illumina MiSeq sequencing. SCFA extraction was carried out with
diethyl ether followed by gas chromatography.
Results Baseline: Children with Crohn’s disease had retarded growth and weight
gain compared with healthy children (p<0.01). BMI z-scores correlated with inflam-
matory markers: albumin (rho=0.611; p<0.001), CRP (rho=-0.536; p<0.001) and
ESR (rho=-0.407; p<0.03), showing disease severity led to an increased risk of poor
growth outcomes. Faecal calprotectin was higher in children with Crohn’s disease
and UC than non-IBD patients and healthy children (p<0.001). Multi-dimensional
scaling using euclidean distance of white blood cell counts; ALT/AST; CRP; ESR and
albumin, shows children with Crohn’s disease have a blood marker profile which has
20% variance from children with UC and non-IBD conditions (R2=0.197; p<0.001).
Patients with Crohn’s disease and UC had reduced microbiota diversity compared
with healthy children (p<0.001). Many gram-positive commensal bacteria, includ-
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ing butyrate producing species of Firmicutes (particularly Clostridiales) were de-
creased; while gram-negative potential pathobionts including Gamma-proteobacteria;
Fusobacterium and Veillonella increased in children with Crohn’s disease compared
with healthy children. Akkermansia, a genus associated with healthy gut mucosa,
was also reduced in Crohn’s disease patients (mean log2 difference p<0.05).
The faecal short chain fatty acid valerate (p=0.02) and medium chain fatty acids,
hexanoate and octanoate (p<0.001), were reduced in children with Crohn’s disease
compared with healthy children. The profile of short/medium chain fatty acids in
children with Crohn’s disease differed from healthy children (p=0.01). Reduced hex-
anoate was associated with reductions in a number of Firmicutes in children with
Crohn’s disease (p<0.05). Estimated dietary intake suggested children with Crohn’s
disease also had reduced fibre intake, particularly fruit, along with reduced intake of
vitamins (A, E, B7 and C) (p<0.05).
EEN: Of 32 children who took EEN, 23 (72%) went into remission (wPCDAI <12.5).
Nine (28%) failed to respond and went on to corticosteroids. No differences were seen
for baseline faecal calprotectin or blood markers, between children who responded to
EEN and those who failed EEN. In children who responded to 8-weeks of EEN cal-
protectin, ESR and CRP were reduced (p<0.001, p=0.002 and p=0.02 respectively);
mirrored by an increase in albumin (p<0.001). Blood inflammatory marker profiles
after treatment with EEN were similar to non-IBD controls (R2=0.225; p<0.001).
Although 25 bacterial species discriminated responders from non-responders at base-
line, there was no pattern of taxonomic relatedness between these. Successful treat-
ment with EEN changed the microbiota community structure further from that of
healthy children (R2=0.070; p<0.001). During EEN gram-negative bacteria including
Pasteurellaceae, Bacteroidales S24-7, Fusobacteriaceae and Veillonellaceae (Negativi-
cutes) were reduced, while increases mostly came from gram-positive Clostridiales
(p<0.05). During EEN short/medium chain fatty acid profiles moved towards that
of healthy children (R2=108; p=0.002), while the concentration of short/medium
chain fatty acids decreased, particularly butyrate (p=0.001). Neither energy intake
nor composition of diet at baseline predicted response to EEN.
MEN: Of the 23 children who responded to EEN, 17 (74%) were treated with MEN
post-EEN. Although children responding to treatment had age appropriate growth
during EEN (p=0.056), growth velocity was not maintained once children went back
onto normal diet (p=0.96). No differences in growth were seen between types of
maintenance therapy. The use of MEN was not associated with an increase in length
of remission, however the number of children in the non-MEN group was too small
(n=6) to reject the null hypothesis.
Faecal calprotectin returned to near pre-treatment levels, having a significant increase
after only 8-weeks post-EEN (p=0.004), showing MEN failed to maintain the reduc-
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tion of inflammation achieved during EEN. Bacterial changes during EEN, were also
not maintained post-EEN. Patients using MEN, had increases in gram-negative bac-
teria (Veillonellaceae, Enterobacteriaceae, Bacteroidaceae, Prevotellaceae and Verru-
comicrobiaceae). Within 2-weeks post-EEN, short chain fatty acids including bu-
tyrate returned towards pre-treatment levels (p<0.001). The use of MEN did not
appear to prevent the ratio of short/medium chain fatty acids returning to pre-
treatment levels. One year after the start of treatment with EEN, only 8/23 (35%)
original respondents had maintained remission.
Conclusions Reduced fibre intake in children with Crohn’s disease appears to lead
to reduced diversity of Firmicutes, particularly Clostridiales. This reduction in
commensal bacteria opens a niche for gram-negative bacteria like the Enterobac-
teriaceae. These changes could lead to decreased short/medium chain fatty acids,
valerate, hexanoate and octanoate, which provide antimicrobial protection against
gram-negative bacteria; again opening a niche for Enterobacteriaceae and other gram-
negative pathobionts. Decreased intake of fibre may trigger some bacteria to switch
from fermenting fibre to feeding on mucin glycans, consequently damaging the pro-
tective layer of the gut mucosa. It is thus possible that low fibre intake, under certain
conditions, drives increased gut inflammation. Malabsorption, of vitamins A, C, D
and E, which have immunoregulatory roles, could further exacerbate inflammation.
As faecal calprotectin levels rise this limits bacterial access to zinc, manganese and
iron, thus further depleting Clostridiales and increasing dysbiosis. Therefore a chronic
escalation of calprotectin, could contribute in part to increased inflammation.
This study does not support the hypothesis that 20% MEN can extend remission
times in children with Crohn’s disease. The fact that 74% of children went onto MEN
post-EEN, but only 35% remained in disease remission after 1-year, suggests that
either MEN is dose dependent or that exclusion of the normal diet leads to reduced
inflammation. Altering normal diet in order to induce and maintain remission in
children with Crohn’s disease is an attractive option, for both patients and treatment
centres. Further studies are needed to explore whether increased fibre or vitamin
intake can protect against inflammation and relapse in Crohn’s disease. Studies also
need to examine the role calprotectin plays in modifying the gut microbiota.
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1 Introduction
The purpose of this introductory chapter is to provide a framework for the original
research presented in following chapters. Included are practical background descrip-
tions of the topics being researched. Detailed descriptions of selected methods can
be found in chapter 2 and the references cited herein, or in appendices where appro-
priate. The means by which the material presented in chapters 3-7 are interlinked
is discussed in chapter 8, and how these relate to our ability to address and answer
questions about the role the gut microbiota, bacterial metabolites and diet might
play in terms of risk and disease activity in inflammatory bowel disease (IBD) and
specifically Crohn’s disease.
As in all animals the human gut is home to millions of symbiotic micro-organisms
including bacteria, called the microbiota. The genomic information of all the micro-
biota that live in a particular organ or tissue such as the gut is collectively known
as the microbiome. The gut microbiota are not silent, they interact and communi-
cate with each other and the host to provide crucial and beneficial functions for the
human host, including stimulating immune development, digestion of food, provision
of essential vitamins and nutrients as well as protection against infectious agents like
pathogenic bacteria and viruses.
However, the homoeostasis of this mutualistic symbiosis between the microbiota and
its human host can become out of balance, potentially leading to disease. This ‘dys-
biosis’ is associated with a number of inflammatory diseases including IBD. There
are many factors that are potential modulators of the microbiota including our own
genome, diet, medication, environmental exposure to pathogens and other bacteria,
hence research into the microbiome is complex. To understand it, we must explore
interactions between diet, the microbiome and other functional systems in the body.
By understanding the relationship between the microbiota as a whole and how mi-
crobial changes impact on the health of the host, it might become possible to create
new personalised and targeted strategies to treat conditions like IBD.
1.1 Overview of inflammatory bowel disease
IBD is an inflammatory condition affecting the human gut and refers to two related
but distinct conditions, ulcerative colitis (UC), and Crohn’s disease (Fig. 1.1). The
key differences are firstly the location of inflammation and secondly the extent of the
inflammation. UC is restricted to the colon while Crohn’s disease can affect any part
of the digestive system from the mouth to the anus. In UC the inflammation only
affects the inner lining of the gut (mucosa) while in Crohn’s disease the inflammation
can extend through the entire thickness of the intestinal wall to the outer most wall
of the digestive tract. These differences lead to different outcomes and treatments. A
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Figure 1.1: Differences between Crohn’s disease and UC
small number of children with chronic inflammatory colitis cannot be classified into
either of the two sub-types of IBD after endoscopic and histological assessment and
are characterised as IBD unspecified (IBD-U).2
The major symptoms of UC and Crohn’s disease overlap (Table 1.1). These include
abdominal pain, changes in bowel habits, with additional symptoms such as weight
loss, decreased appetite, fever and fatigue. Symptoms can vary a great deal between
people and over periods of time, with patients having times when symptoms are
severe (flare-ups) and times with few or no symptoms (remission). Inflammation can
also affect the eyes (uvitis), skin, liver and joints.3 Both UC and Crohn’s disease can
also lead to growth delay in children. IBD is more commonly diagnosed in young
people aged 15-25 and there is an increased risk of IBD in those who have a family
member with the condition. The disease tends to be more severe in children with
IBD but there is no notable difference in the distribution of disease types between
children and adults.4 Defining the exact epidemiology of IBD can be challenging due
to the insidious nature of the condition, often marked by delays in disease diagnosis
as well as occasional incorrect diagnosis of patients with early stage disease. The
small number of children presenting with IBD can also hinder the speed at which the
correct diagnosis is reached.
1.2 Crohn’s disease
Crohn’s disease is a clinical classification of IBD, often presenting in childhood. It is
a chronic condition which relapses and remits throughout the patient’s life, having a
substantial impact on the child and their families quality of life, as well as a significant
cost to NHS resources.5
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Table 1.1: Typical symptoms in children with IBD
Diarrhoea, with or without blood and mucus
Severe cramping abdominal pain, often before passing a stool
Weight loss due to loss of appetite and malabsorption
Delayed growth and development
Tiredness and fatigue
Anaemia, due to poor dietary intake and blood loss
Mouth ulcers
Potential complications, especially in Crohn’s disease:
- strictures (scarring of tissue create narrowing of bowel)
- fistulas (channel connecting internal organs or to epidermis)
Because of variability in the severity and location of Crohn’s disease, as well as its
transmural nature, patients can have a wide range of presentations. In addition
to diarrhoea, children usually present with abdominal pain, particularly before a
bowel movement; and around 40% of patients can show a range of extra-intestinal
manifestations affecting the function of a wide range of body systems.6 Systemic
symptoms including fatigue, anorexia, and weight loss can also be present in more
severe cases. Although less common, children with Crohn’s disease may initially
present with stricturing or perforating complications.7 Around 10% of children have
perianal disease,8 possibly a distinct phenotype of Crohn’s disease linked with a
susceptibility locus on chromosome 5.9 A delay in puberty often complicates the
clinical course of young people with IBD, particularly in those with Crohn’s disease
and more often in boys.10 A 1994 study of children with Crohn’s disease showed
that in 73% (n=11) of girls menarche occurred 2-years later than girls with UC and
healthy girls (NS).11 Another study of fifty-five children with IBD found a mean delay
of puberty of 0.70 years (SD 1.14), while a more robust US study found that in 104
children with Crohn’s disease puberty was delayed by 1.5-years (p<0.01) compared
with 233 healthy children.12
Timely diagnosis in children is very important, since missing school due to symptoms
like pain, diarrhoea and fatigue as well as possible isolation from peers, exacerbated
by a prolonged diagnostic work-up, can have a long-term psychosocial and physical
impact on children.13
1.3 Classification of disease location and phenotypes of Crohn’s disease
Crohn’s disease is typically characterised by inflammation of the gastrointestinal tract
which is non-continuous unlike inflammation in UC which is continuous and restricted
to the colon and rectum. Treatment strategies for paediatric Crohn’s disease are de-
pendent on disease location and disease extent, however there is discordance between
endoscopic (macroscopic) and histological (microscopic) disease extent, which can
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make classification of disease location challenging, and inaccurate in terms of re-
search where microscopic evaluation might be unavailable.14 In order to properly
identify disease location it is normally recommended that the whole gastrointestinal
tract is examined by upper endoscopy, ileocolonoscopy, and ileal imaging.15 A num-
ber of studies, have suggested that disease location can be an indicator of treatment
outcomes in Crohn’s disease.
Disease classification as well as being a tool for clinical practice, also has a role to
play in research. In IBD research studies an increasing number of bio-banks are
being created to allow the sharing of molecular data linked with phenotypic clini-
cal data. Therefore high quality disease classification systems will become an im-
portant feature of clinical data used in multi-centre prospective research studies.
Previous classification methods such as the “Rome classification”16 used disease lo-
cation (stomach/duodenum, jejunum, ileum, colon, rectum, anal-perianal); disease
behaviour (primarily inflammatory, primarily fistulising, primarily fibrostenotic) as
well as extent of disease (localised, diffuse) and surgical history (primary, recurrent).
This method could theoretically result in as many as 756-subgroups of Crohn’s dis-
ease. It had also been shown that for some aspects of the classification, particularly
disease location and behaviour, there was inter-observer bias creating the potential
for non-comparable results between patients and over-time.17 Mucosal healing based
on histology is often referred to as the ‘true’ measure of disease remission, where
earlier clinical classification systems were based exclusively on endoscopic and radi-
ological disease extent. In 2000, the Vienna classification (Table 1.2) was created
to try and simplify the classification of the clinical phenotypes of Crohn’s disease.18
Following on from this in 2003 a group of investigators sought to resolve some of the
issues around creating a Crohn’s disease sub-classification that took into account the
clinical, molecular, and serological markers of IBD. The results were presented at the
Montreal World Congress of Gastroenterology in 2005 where they tried to address
issues that affect both the needs of clinicians and the needs of scientific researchers in
the field.1 In 2011 Levine et al.19 devised the Paris classification, containing further
sub-categories based on histology which also took into account growth abnormalities
in children. However, the small number of patients with Crohn’s disease limit the use
of the Paris disease classification sub-sets for research, as it can reduce the power of
data sets in small scale studies such as the current study.
Isolated upper disease Using upper gastrointestinal endoscopy in paediatric pa-
tients as well as the growing use of magnetic resonance imaging enterography and
computed tomography enterography have increased awareness of how common upper
disease is among children with Crohn’s disease. Upper involvement has been reported
as anywhere between 30%-80% in children and adults.20
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Table 1.2: Vienna, Montreal and Paris classification for Crohn’s disease
Vienna Montreal Paris
Age at diagnosis A1 <40 yrs A1 <17 yrs A1a: 0–<10 yrs
A1b: 10–<17 yrs
A2 >40 yrs A2 17-40 yrs A2 17-40 yrs
A3 >40 yrs A3 >40 yrs
Location L1 ileal L1 terminal ileal  limited
caecal disease
L1 terminal ileal  limited
caecal disease
L2 colonic L2 colonic L2 colonic
L3 ileocolonic L3 ileocolonic L3 ileocolonic
L4 upper L4 isolated upper disease* L4a upper disease proximal to
ligament of Treitz*
L4b upper disease proximal to
ligament of Treitz and proxi-
mal to distal 1/3 ileum*
Behaviour B1 non-stricturing,
non-penetrating
B1 non-stricturing, non-
penetrating
B1 non-stricturing, non-
penetrating
B2 stricturing B2 stricturing B2 stricturing
B3 penetrating B3 penetrating B3 penetrating
B2B3 both penetrating and
stricturing disease, either at
same or different times
p perianal disease modi-
fier!
p perianal disease modifier!
Growth n/a n/a G0 no growth delay
G1 growth delay
*In the Montreal and Paris classification L4 and L4a/L4b can coexist with L1-L3.
† is added to B1-B3 when concomitant perianal disease is present. Taken from
Satsangi et al. 20061 and Levine et al. 2011.19
The L4 category of the Montreal classification does not distinguish between ileal dis-
ease, and oesophageal or gastric involvement. A large 2011 study concluded that
patients with jejunal disease were at significantly greater risk of stricturing disease
and surgeries than either oesophageal, gastric, duodenal or ileal (without proximal)
disease, thus they suggested this category be further split in the new Paris classifica-
tion (Table 1.2). The study also found that adult patients with upper (L4) disease
were less likely to have concurrent colonic (L2) disease (12% vs. 21%; p<0.001).21
Very few patients have isolated upper (L4) disease without concurrent ileal/colonic
disease (L1-L3) making it difficult to include this group of patients in studies.
Ileal, ileocolonic and colonic disease The terminal ileum, ileocaecal valve, and
caecum are the most common sites involved at disease presentation. Disease location
is restricted to the ileum (ileal) in approximately 40%-50% of patients, while 30%-
40% involve both the ileum and colon (ileocolonic). The remaining cases are isolated
to the colon (colonic).2 The age of disease onset has been recorded as a factor in
disease location, with very early age onset usually being isolated colitis, while ileal
disease is found more often in children who are diagnosed after age nine.22;23
A retrospective study which evaluated pathology of Crohn’s patients that underwent
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surgery for either stricturing or fistulas, found no specific pathology differentiated
patients with stricturing from fistulising disease. However, in terms of histology they
did find that ileocolonic (L3) localisation was significantly more common in non-
perineal fistulising disease than in patients with strictures.24 Another 2016 study
recorded from 120 adults patients found that Crohn’s disease evolved, progressing to
more aggressive stricturing and penetrating phenotypes over a 5-year period. Inter-
estingly disease location remained relatively stable over time, with 93% of patients
showing no change in disease location. The study reported that ileal involvement,
stricturing, presence of fistulas and perineal lesions were predictive of surgery and
immunosuppressant or immunomodulatory treatment.25 With respect to treatment
with exclusive enteral nutrition (EEN), a meta-analysis of ten trials was unable to link
disease location and phenotype with efficacy of treatment, or time to relapse,26 de-
spite limited evidence suggesting that patients with ileal involvement respond better
to EEN.27;28
Extra-intestinal features Extra-intestinal features in Crohn’s disease can include
the eyes, mouth, skin, joints, liver, bile ducts and anus. Oral lesions, anal fissures,
abscesses, ulceration around stomas and anal skin tags being common features of
Crohn’s disease.29 In a 2015 European inception cohort, patients with Crohn’s disease
were found to be twice as likely as patients with UC to experience extra-intestinal
symptoms.30
Orofacial granulomatosis (OFG) is seen as swelling of the tissues around the mouth
due to granulomatous inflammation.31 It is often referred to as cheilitis (inflammation
of the lip). The swelling can cause midline fissuring of the lip called median cheilitis or
produce sores in the corners of the mouth called angular cheilitis. OFG is associated
with Crohn’s disease sometimes preceding gastrointestinal symptoms by a number of
years;32 however OFG might also be the only obvious symptom of underlying Crohn’s
disease. OFG can also be associated with oral ulcers, gingival inflammation and
cobblestone appearance of the buccal mucosa, the histological features of which are
indistinguishable from Crohn’s disease and systemic sarcoidosis.33 In 2007 Freysdottir
et al.34 showed in oral biopsies from ten patients with OFG that the Th1 immune
response resembled that seen in gut biopsies from patients with Crohn’s disease. Thus
there is no clear way to determine when OFG is a stand-alone condition and when it
is an oral manifestation of Crohn’s disease.
Studies of perforating perianal disease report an incidence of around 8-15% in children
with a diagnosis of Crohn’s disease.4 Perianal disease can also be a strong predictor
of developing a more complicated pathology in Crohn’s disease and in children can
be debilitating, either preceding or following intestinal inflammation.35 Perianal ab-
normalities can include lesions on perianal skin or the anal canal, as well as abscesses
and fistulas. This perianal component of Crohn’s disease can be asymptomatic in
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some children but for others it can be a serious source of disability and distress.36;37
Paediatric Crohn’s disease The extent of disease in adult Crohn’s tends to remain
more stable, unlike that found among children, where a significant and rapid change
in both disease location and behaviour was recorded over time in a large cohort of 276
Scottish paediatric patients.38 The same study found that disease location was more
dynamic in childhood disease onset, such that within 2-years of diagnosis, disease
progressed to involve additional sites in 39% of patients that did not have maximal
ileocolonic (L3) and upper (L4) involvement. It was also noted that disease behaviour
decreased in non-stricturing, non-penetrating disease (B1) from 91% to 83% by the
second year and 76% by the fourth year after diagnosis. Another study involving
404 children with childhood-onset Crohn’s disease found that complicated disease
behaviour (stricturing B2, and penetrating B3) doubled during a 7-year follow-up
from 29% at diagnosis to 59% plateauing after ∼9-years.39
1.4 Understanding chronic inflammation in Crohn’s disease
It is hypothesised that IBD occurs in genetically susceptible people after exposure to
unknown environmental factors which leads to aberrant immune responses. Although
a number of environmental factors have been suggested, the causal roles of these
potential disease triggers have yet to be determined.40 A number of tissue defects
have been described in both Crohn’s disease and UC, including gut tight junction
barrier function, defective trans-epithelial cell transport, extracellular matrix barrier
proteins, and Paneth cell antibacterial peptides.41 Also the polarisation of T-cells to
a Th1 cytokine profile has been a recognised feature of Crohn’s disease. More recent
studies also point to a role for Th17 cells, hence taken together, both Th1 and Th17
cells are important mediators of inflammation in Crohn’s disease.42
It has also been suggested that neutrophil dysfunction could be playing a role in
altered innate immunity in the early stage of Crohn’s disease development.43 There
are known genetic disorders with neutrophil function deficiency which give rise to
clinical symptoms and pathology that is indistinguishable from Crohn’s disease.44 The
exact mechanisms underlying disease pathogenesis are yet to be elucidated, however
the current hypothesis for the aetiology of Crohn’s disease suggests a T-cell driven
inappropriate mucosal immune response in the gut, leading to an overproduction
of inflammatory cytokines, most likely against endogenous bacteria.45 Unlike acute
inflammation, chronic inflammation continues for long periods (months or years),
leading to tissue damage and long term associated disease.46 Until recently, chronic
and acute inflammation were thought to be separate processes activated by different
mediators and outcomes, but it is now accepted that the processes are interlinked in
such a way that defects in the processes that drive acute inflammation play a role
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in chronic inflammation,47 with tissue damage being the net result of the activated
inflammatory process. Standard therapy for Crohn’s disease is therefore directed
towards suppression of this inappropriate immune response.
1.5 Growth failure in children with Crohn’s disease
Malnutrition is common in children with IBD, particularly in active Crohn’s disease
where weight loss at diagnosis is noted in up to 90% of cases,48;49 but there are
no standards or screening tools to specifically identify malnutrition in IBD. In 2016
Jansen et al.50 proposed a new screening tool which uses BMI, weight loss over 3-
months and plasma CRP levels to approximate a malnutrition score specifically for
IBD. The tool is limited in that BMI can be a poor predictor of malnutrition and
growth over the short term.50
As a result of weight loss and malnutrition, children with IBD, especially those with
Crohn’s disease, tend to present with lower BMI and lower body weight when com-
pared to the national reference range of healthy children.51;52 It is not always easy
to identify the cause of growth failure in individual children due to factors including:
reduced food and nutrient intake; malabsorption due to inflammation; and possibly
treatment with corticosteroids.48
More recent data suggests the risk of IBD patients being underweight is decreasing,
with some studies showing a large number of patients being overweight at diagno-
sis which is most likely linked with increases in obesity in the general population.
Although there is limited evidence showing the prevalence of obesity among newly
diagnosed patients with IBD, a number of paediatric and adult studies suggest that
the current number of overweight (BMI 25.0-29.9kg/m2) and obese (BMI 30.0kg/m2
or more) IBD patients matches that of the general population (∼20%-30%). One
US study found that in a population of 1598 children with IBD, around one in five
children with Crohn’s disease and one in three with UC were overweight or obese.53
A similar US adult study in 2015 found the rate of obesity to be 30.3% in Crohn’s
disease and 35.2% in UC patients.54 Another study of 489 Scottish IBD adults from
Tayside found that 18% were obese in comparison to ∼ 23% for the total Scottish
population. Another 38% were over-weight which was equivalent to the general Scot-
tish population. Overall, obesity was found to be more prevalent in Crohn’s disease
than in UC patients (p=0.05).55
A retrospective study in Philadelphia (1997-2002) looking at 126 patients with Crohn’s
disease found that 32.4% were overweight or obese at diagnosis. They also found that
time to first surgery for patients with a BMI of under 18.5kg/m2 was considerably
longer than patients with a BMI of 25kg/m2 or higher (p=0.04).
56 Although two of
these US studies found that an increase in BMI was associated with an increased need
for surgery, the other studies found that obesity in IBD (using BMI) was associated
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with a less severe disease course.56
A large Canadian time-trend analysis of body weight and disease activity between
1991-2008; including forty randomised controlled trials involving a total of 10,282
patients with Crohn’s disease, saw a significant increase in weight (r=0.36; 95% CI)
and BMI (r=0.14; 95% CI) as well as a significant increase in clinical disease activity
(r=0.109; 95% CI) and disease duration (r=0.063; 95% CI) in Crohn’s patients over
the time period.57 It is therefore possible that there is a link between adiposity and
inflammation in Crohn’s disease which needs to be studied further.
1.6 Risk factors for Crohn’s disease
The aetiology of Crohn’s disease is complex, with the most widely acknowledged hy-
pothesis being that Crohn’s disease is a dysregulation of the normal immune response
in genetically susceptible individuals, where the onset of disease is triggered by one or
more environmental factors that lead to gut inflammation and abnormal gut immune
responses to the gut microbiota.
Genetics The link with genetic risk factors is supported by ethnic and racial varia-
tion in the prevalence of IBD, with the highest rates being found among Caucasians,
particularly Ashkenazi Jews who have a two to ninefold greater prevalence of IBD.58
However, there is a trend towards growing prevalence in populations previous thought
not to be at risk, thus the balance between genetic risk and environmental fac-
tors are complex. The idea that IBD has a heritable component is well established
through family studies which show that 5-30% of these patients, particularly those
with Crohn’s disease, report a family member with IBD.58 A 2003 study suggested
IBD patients who have a family history of IBD are at risk of developing disease at
a younger age.59 They reported that in a group of eighty-two children with Crohn’s
disease, 42% of those under 11-years of age had a positive family history of IBD, sig-
nificantly greater than older children (19%). However this type of split age analysis
can be scientifically biased and misleading.
The genetic component of IBD risk is supported by the higher concordance rate found
among monozygotic twins, that is not seen in same sex dizygotic twins; as well as the
increased incidence among first degree relatives of those affected.60 It is likely that
some genetic variants affect the host relationship with the gut microbiota via immune
expression, which put some individuals at higher risk of developing IBD. As well as
understanding risk factors genetic studies are beginning to highlight the importance
of host–microbe interactions in the pathogenesis of IBD (see section 1.9.3).
Genome-wide association studies (GWAS) created a framework for new insights into
the aetiology of Crohn’s disease. Identification of 163 IBD loci with 30 being Crohn’s
specific, is more than any other complex disease.61 The strongest links are with genes
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involved with intracellular killing of bacteria and innate immunity (CARD15/NOD2,
IRGM, IL23R, LRRK2, and ATG16L1) as well as adaptive immune responses (IL-23 and
Th17).62 Current GWAS are based on samples from North America and Europe,
hence wider studies including non-Caucasian populations are needed to properly un-
derstand how these genes might put individuals at risk of IBD. Although there is
good evidence that NOD2, autophagy, and Th17 immune responses have strong links
in Crohn’s disease pathogenesis, susceptible loci only contribute around 14% of total
disease variance.61
North-south divide There is a higher incidence of both Crohn’s disease and UC
reported in northern latitudes, compared to southern latitudes in the northern hemi-
sphere.63;40;64 There is growing evidence that a relationship exists between IBD and
a north-south gradient in a number of countries, while some studies have shown a
relationship between latitude and incidence of Crohn’s disease linked with low ex-
posure to sunlight and vitamin D insufficiency.65;66 Higher dietary vitamin D levels
among fish eating coastal populations might explain why not all studies observe a
higher incidence of IBD at higher latitudes (Prof C. Edwards pers. comm.).
A 2010 clinical trial67 found that supplementing vitamin D (1,200IU) to the normal
diet of adults with Crohn’s disease resulted in the mean serum 25OHD going from
69nmol/L to 96nmol/L after 3-months (p<0.001) and a reduction in relapse rate
at 12-months (13% v 29%, p=0.06); although it should be noted, the group which
received the vitamin supplement had greater azathioprine use than the control group.
Nutrition Diet is known to have a role in the expression of IBD, however most
studies are retrospective case-controlled, meaning dietary habits are either asked to
be recalled from a time before the onset of the disease, or as the current diet, which
may not represent normal habitual diet prior to developing symptoms. In 2011 Hou
et al. carried out a systematic review, concluding that not only were total fats,
polyunsaturated fatty acids (PUFAs), omega-6 fatty acids, and meat associated with
an increased risk of IBD but that higher fibre and fruit intake reduced the risk of
Crohn’s disease.68
Gut microbiota The importance of the microbiota in the pathogenesis of Crohn’s
disease has been demonstrated since diverting the faecal stream results in healing
and prevention of Crohn’s disease relapse in humans and animal colitis models.69
Identifying a ‘high risk’ microbiota profile in IBD and Crohn’s disease has therefore
become a priority. A reduction in bacterial species abundance and diversity within
the commensal gut microbiota community of patients with IBD have become key
features however a link with causality has yet to be shown (Section: 1.9).70;71;72
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Antibiotics Lewis et al. 2015 using a multi-variable model which included use
of antibiotics within the last 6-months found that antibiotic use was independently
associated with dysbiosis in IBD.73 They also reported that genera associated with
Crohn’s disease in the absence of antibiotic use were different from those associated
with antibiotic use. This evidence was based on creating two bacterial composition
clusters of Crohn’s patients which may have introduced some bias into results.
1.7 Epidemiology of Crohn’s disease
The incidence of Crohn’s disease is increasing worldwide with prevalence being par-
ticularly high in the northern countries of Europe and America. A Canadian study
recorded the incidence rate of paediatric IBD rising from 9.5 per 100,000/yr in 1994
to 11.4 per 100,000/yr in 2005; including an incidence in Crohn’s disease of 6.2-7.0
per 100,000/yr.74 Crohn’s disease had previously been classed as a western disease
because it was more common in industrialised nations, due to low prevalence rates
in places such as South America, Eastern Europe and Asia.75;76 However, recently
it has become clear that Crohn’s disease is an emerging disease in countries with
previously low rates, such as Japan where the adult prevalence rate rose to 21.2 per
100,000 by 2005.77 The speed at which incidence is increasing in areas where Crohn’s
disease was previously absent suggests that environment, including diet, is pivotal in
triggering disease.76 It is possible that the introduction of a more westernised diet
in these countries is playing a role in the elevation of patient numbers. This is sup-
ported by the fact that there is an increase in occurrence of IBD among families when
they emigrate from a country where incidence is low to one where incidence is high,
highlighting the importance of identifying environmental triggers.76
Some limitations in describing the worldwide epidemiology of Crohn’s disease are
that increases in IBD have not been described in a uniform way, with many countries
lacking accurate estimates of incidence and prevalence particularly for paediatric IBD.
There is also a particular lack of data about rates of paediatric IBD from developing
countries in Asia, Africa, and South America,78 hence most of the data regarding
epidemiology is taken from European and North American cohorts. Additionally
most reports do not include the category of IBD-U thus the overall incidence of IBD
is higher than that inferred from available data.79 In Europe the highest incidence
and prevalence rates have been found in Scandinavian countries80 and the UK, with
the highest in Scotland.81 Scotland has one of the highest IBD rates in the world.
Since the mid-1990s the incidence of IBD in Scottish children has increased by 76%
including a 66% rise in Crohn’s disease (Table 1.3). There has also been a marked
increase over the past 10-years in the incidence of children with Crohn’s disease in
Ireland.82 These increases in the Scottish paediatric IBD population, which have
lead to an overall IBD incidence rate of 7.82/100,000/yr (derived from the 2003-2008
figures) may have continued to rise towards levels of incidence described in Canada
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(2005)74 and Scandinavia (2005-2007),83 which have reported rates of 11.4/100,000/yr
and 10.6/100,000/yr, respectively.
Table 1.3: Paediatric IBD incidence in Scotland per 100,000/yr
Year 1990-1995 2003-2008
(n=260) (n=436) difference sig. at
IBD 4.45 7.82 p<0.0001
Crohn’s 2.86 4.75 p<0.0001
UC 1.59 2.06 p=0.023
Taken from Henderson et al. 201084
Age of disease onset IBD is now being diagnosed at a younger age in Scotland,
particularly Crohn’s disease where the age at diagnosis has fallen from 13.2 in the
early 1990s to 12.1 years by 2008.84 Around a quarter of patients with Crohn’s disease
are diagnosed before the age of twenty, often presenting with severe nutritional defi-
ciencies.85 About 85% of these children present with weight loss, with up to 15–40%
of them failing to reach their growth potential.86;87 This risk of malnourishment can
impair growth and affect pubertal development,3 therefore nutritional therapy is an
integral part in the management of children with Crohn’s disease. The onset of IBD
in childhood tends to be characterised by a more extensive disease location as well
as more aggressive and severe disease condition than found in adult onset IBD.88;89
Overall the impact on the health of children with Crohn’s disease can be more serious,
leading to children requiring increased NHS resources.
Gender differences In Asian studies a male predominance has been recorded in
both, paediatric and adult populations.90;91;92;93 For European and North-American
studies the female/male ratio has varied from an even distribution to as much as
2.5:1.94 Many cultures have particular gender roles, potentially resulting in different
exposure to environmental risk factors, which could in part account for geographical
differences in IBD gender ratios.
Henderson et al. 201184 reported that among Scottish children with IBD that more
boys were affected than girls especially for Crohn’s disease. The adjusted male/female
ratio for the 2003-2008 figures was 1.29, rising from 1.07 in 1990-1995; and mainly due
to an increase in male/female incidence ratio in children with Crohn’s disease (1.22
to 1.38). It will be important for future studies in Scotland to look at the reasons
behind gender differences in Crohn’s disease which could be down to difference in
exposure to environmental risk factors; dietary choices; or hormonal differences. The
possibility that girls, especially in their teen years, are less willing to come forward
with bowel problems, to discuss diarrhoea and other gastrointestinal symptoms with
parents and clinicians, leading to a possible gender bias in mild cases, or greater time
to diagnosis in more severe cases, needs to be considered. It has also been noted in
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some clinical gender studies, that general practitioners can be more prone to interpret
male symptoms as physiological, while attributing a more psychological element to
the symptoms of female patients, which affects referral and diagnosis.95 Increased
side-effects from bowel preparation have been recorded in female IBD patients96;96
which could in turn affect the completeness and accuracy of an endoscopic result.
Another study has recorded a lower rate of follow-up colonoscopies in female IBD
patients.97 Hence there are a number of potential biases which could account for
gender ratio differences. However this type of bias could also be due to genuine
biological gender differences in the severity of symptoms, which need to be identified
by future research.
1.8 Current treatment strategies for paediatric Crohn’s disease
Crohn’s disease is currently incurable and thus therapeutic approaches aimed at
achieving clinical remission of the condition only provide short term relief from symp-
toms.98 The management of Crohn’s disease firstly involves inducing remission and
is then followed by medical treatment to maintain remission.99 The use of corticos-
teroids to induce remission in patients with active Crohn’s disease is effective.100
However the side effects over the long-term, particularly in children, make their use
less than ideal and they are ineffective at inducing mucosal healing. The side effect
of weight gain and acne as well as poor bone health and development can also be
a significant problem for adolescents with Crohn’s disease being treated with corti-
costeroids.101 Choice of treatment is not only determined by whether a child with
IBD has UC or Crohn’s disease but also the location, severity and extent of disease.
Due to the large range of disease phenotypes treatment is tailored according to the
individual needs of each child.
1.8.1 Medications used to treat Crohn’s disease
A recent NHS review in England has estimated that to treat adult IBD costs around
 720 million per year,102 with approximately 1/4 of costs taken up by medications
used to treat IBD.103 Medications used to treat Crohn’s disease and IBD are aimed
at inducing and maintaining disease remission through modification of immunomod-
ulatory processes (Table 1.4).104
Although the 2014 second European consensus on prevention, diagnosis and man-
agement of infections in IBD, concluded that IBD patients should not be routinely
considered to have altered immunocompetence per se, there are a number of im-
munomodulators used in the treatment of IBD which are associated with increased
risk of infections.105 These include corticosteroids, thiopurines, methotrexate, cal-
cineurin inhibitors, anti-TNF agents and other biologics. Unfortunately there is no
sound biological means to measure immunosuppression in IBD patients.
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Table 1.4: Medication used to treat children with Crohn’s disease in the UK.
Type Drug name Role Action
Antibiotics Metronidazole
Ciprofloxacin
induction of remission
(esp. perianal disease)
reduction of gut bacteria
Corticosteroids Prednisolone
Hydrocortisone
induction of remission down-regulation of pro-inflammatory
cytokines; interference of NFκB
inflammatory signalling
Immuno-
suppressant
Azathioprine
6-Mercaptopurine
maintain remission immune suppression and cytotoxicity;
induce T cell apoptosis
Biologics Infliximab induction of remission antibody against TNFα
Observational studies like the current one cannot control for the confounding effect
that medications might have on the composition and functional behaviour of the gut
microbiota, hence it is important to examine the potential impact drugs might have
on results. A 2007 study reported from mucosal biopsies that the suppressed mi-
gration of leukocytes in UC patients treated with azathioprine was associated with a
28-fold higher concentration of mucosal bacteria when compared with patients treated
with 5-ASA, and 1000-fold when compared with healthy controls.106 Therefore it is
important to know when measuring bacteria that changes are due to dietary treat-
ment like maintenance enteral nutrition (MEN) rather than the immunosuppressant
Azathioprine, which many children take along with MEN therapy.
Antibiotics Although medical therapy has targeted suppression of the immune sys-
tem, antibiotics are frequently used as an ancillary treatment in Crohn’s disease.107
There is conflicting evidence regarding the efficacy antibiotics to help induce remis-
sion on Crohn’s disease. A 2011 review paper concluded that in active Crohn’s disease
using data from ten RCTs involving 1,160 patients, that treatment with antibiotics
was superior to placebo (RR=0.85; 95% CI=0.73–0.99, p=0.03);107 however interpre-
tation is challenging due to the diversity of antibiotics used. It is unclear whether
antibiotics work due to reduction of a single species, or via changes to overall bacte-
rial composition.108 It is possible, gut bacteria are not driving IBD, but rather cause
secondary infection due to underlying inflammation, exacerbating disease activity.109
Immunosuppressants Immunosuppressants on their own cannot induce remission
and are therefore used to help maintain remission in IBD patients. As such azathio-
prine or 6-mercaptopurine are the primary treatment for maintenance of remission of
moderate to severe Crohn’s disease.
Biologics Tumour necrosis factor-α (TNF-α) inhibitors are biological agents intro-
duced in the 1990s for the treatment of IBD. It is recommended for treatment of
children aged 6–17 with severe active disease who have not responded to immunosup-
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pressants, corticosteroids and nutritional therapy.110 The introduction of anti-TNF
therapy has improved the quality of life as well as reducing time in hospital and
surgery for Crohn’s disease patients.111 The most common TNF-α antagonist used
for Crohn’s disease is infliximab. Although it is effective in lowering inflammation,
treatment-induced immunosuppression is suspected to increase infection risk.112
Corticosteroids Corticosteroids were first used to treat IBD in the 1950s with the
successful use of cortisone acetate in patients with UC.113 Since this time corticos-
teroids have become the cornerstone in treating IBD patients with moderate to se-
vere active inflammation.114 Despite the widespread use of corticosteroids, studies
concerning optimal therapeutic strategies have mostly been done in adults with IBD,
with as many as 80-90% of adults treated with corticosteroids reporting at least one
adverse event during their therapy.115 Although corticosteroids are clinically effica-
cious and induce remission, their use in children can have unwanted side effects such
as weight gain, growth impairment, increased acne as well as low mood,116 thus chil-
dren with IBD can be more sensitive to the side effects of corticosteroids than adults,
particularly with respect to impaired growth.117
A number of studies have shown that systemic use of corticosteroids work via a
number of routes including: inhibiting epithelial cell gene expression of cytokines
(IL-1β, IL-6, & TNF-α), growth factor and receptors (GM-CSF & TGF-β), as well
as various inflammatory chemokines of the CXC and CC families.118 They can also
reduce diarrhoea by increasing sodium and water absorption.119
1.8.2 Treatment with exclusive enteral nutrition (EEN)
As a chronic inflammatory condition of the gut, Crohn’s disease causes severe nutri-
tional complications. The use of exclusive enteral nutrition (EEN) to treat the dietary
and growth needs of children with Crohn’s disease led to EEN becoming an effective
therapy which could successfully help children achieve disease remission without the
need for corticosteroids.120
EEN is a liquid nutrition diet which exclusively replaces the child’s normal diet.121
Being a liquid preparation with no fibre, it is easily digested in the small intestine.
Once the individual calorific requirement for a child about to start EEN has been
calculated, the formula is normally introduced slowly over 2-4 days and continued
for around 6-12 weeks.122 Normal food is then reintroduced, although some centres
slowly reintroduce specific types of food first.122
Only one study has attempted to answer the question as to whether it is necessary
to have full exclusion of the normal diet in order to achieve remission in paediatric
Crohn’s disease, and they found that EEN increased the remission rate 3-fold when
compared to the energy requirement being met from 50% enteral nutrition and 50%
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normal diet.123 However paediatric centres often permit a variety of additional foods
in addition to EEN,124 including sugarless chewing gum,121 clear soup or carbonated
beverages such as lemonade. More than 40% of studies allow tea and coffee, and
almost half allow the introduction of additional sugar in the form of hard boiled
sweets.124 Further studies are needed to explore the efficacy of these additional food
items, before being added to EEN protocols.
It would be unethical not to treat patients with active disease, hence no placebo con-
trolled trial has ever been carried out to test the efficacy of EEN in IBD. The efficacy
of EEN to induce remission in active Crohn’s disease has therefore been measured
against medications, in particular corticosteroids.110 EEN has been shown to induce
remission in 80-85% of children with active Crohn’s disease,120 with recent guidelines
advising the use of EEN as the first line induction treatment for children with in-
flammatory luminal disease.125 A 2008 Cochrane review looked at the effectiveness of
EEN as primary therapy to induce remission in children with Crohn’s disease from
1966-2006.26 From the fifteen studies included they concluded corticosteroid therapy
was more effective than EEN for inducing remission of active Crohn’s disease, but
that EEN had the added benefit of mucosal healing. Many of these studies were of
low quality, and the two highest quality studies in this review had opposing find-
ings, with one in favour of steroid therapy126 and the other EEN;127 although neither
study reached statistical difference. However, recent reviews have shown EEN is just
as effective as corticosteroids in inducing remission (OR=1.26 [95% CI 0.77, 2.05]) in
children with Crohn’s disease; and mucosal healing was significantly higher in chil-
dren receiving EEN compared to corticosteroids (OR=4.5 [95% CI 1.64, 12.32]).128
Enough studies showing EEN to be a beneficial primary treatment for active Crohn’s
disease triggered the European Crohn’s and Colitis Organization (ECCO) in 2014
to revise their consensus guidelines and recommend EEN as the first line therapy to
induce remission in children with luminal Crohn’s disease (Table 1.5).98;125
There are factors which could influence the efficacy of EEN, including variation in
type and severity of Crohn’s disease, the way disease activity and remission is defined;
composition of EEN; duration of EEN, as well as the timing of clinical assessments.125
In some studies, length of treatment is effectively too short to properly evaluate
efficacy of EEN against corticosteroids. For example Tjellstrom et al. 2012 concluded
that children with active perianal Crohn’s disease, saw no improvement in clinical
status, or inflammatory parameters after treatment with EEN.129
There are trade-offs to using EEN as a therapy to induce remission over corticosteroids
including: palatability; distress caused by use of nasogastric tubes; and stress or
isolation from the social aspects of normal family/school meal times.110 These issues
are important considerations since the 2012 NICE guidelines110 reported that all
studies included in the Cochrane review26 of EEN are of low to very low quality.
Hence it might be premature to assume EEN is always the better option.
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Table 1.5: Studies since 2012 on exclusive enteral nutrition (EEN) showing remission rates, length of
treatment and type of feed.
Study
No. of
children
Type Feed Duration Remission
rate
Notes
Connors et
al. 2017130
111 Retrospective unknown 6-16
weeks
86.6% Remission with EEN was as-
sociated with reduced risk of
CS treatment over 2-years
Luo et al.
2015131
28 Retrospective Not given 8 weeks 90% Longer time to relapse in
those treated EEN vs CS
(significant)
Lee et al.
2015132
90 Prospective
cohort
Not given 8 weeks 88% Partial enteral nutrition in-
duced remission in 64% of
children
Levine et al.
2014133
201 Prospective
cohort
unknown 6-8 weeks 79% No difference seen between
EEN and CS
Hojsak et
al. 2014134
74 Retrospective Polymeric 6-8 weeks 84.2% Longer time to relapse in
those treated EEN vs CS
(significant)
Soo et al.
2013135
105 Retrospective 33 polymeric;
3 elemental
6 weeks 88.9% No difference seen between
EEN and CS
Lambert et
al. 2012136
57 Retrospective Polymeric 4-8 weeks 84% compared with corticos-
teroids
Saadah et
al. 2012137
50 Retrospective Polymeric 6 weeks 32% No comparison with corti-
costeroids
CS -corticosteroid therapy; EEN -exclusive enteral nutrition. Studies prior to 2012 are given in the ‘2012 NICE
guidelines’.110 Similar results have not been reproduced in adult studies, with EEN resulting in lower response rates
than using steroids (perhaps due to lack of compliance in adults).138
Effect on inflammation and mucosal healing Although the effect of EEN on mu-
cosal inflammation is not fully understood, it has been shown that clinical response to
treatment with EEN is associated with mucosal healing and down-regulation of mu-
cosal pro-inflammatory cytokine mRNA in the terminal ileum and colon.139 A 2005
study in patients with adult Crohn’s disease observed that EEN reduced mucosal
cytokine production, correcting an imbalance between pro- and anti-inflammatory
cytokines.140 Two 2006 paediatric studies also showed that EEN is more effective
than corticosteroids at healing inflammatory associated lesions in the gut.100;141 This
beneficial effect of enteral nutrition on mucosal healing has been shown to a lesser
degree during maintenance therapy for quiescent Crohn’s disease.45
Potential mechanisms How EEN works to induce remission is unclear. There are
a number of theories including removal of dietary antigens and reduction of microbial
antigens. In 2004, Bannerjee et al.142 conducted a study on twelve children with
active Crohn’s disease treated with EEN for 6-weeks. They saw changes in ESR
and IL-6 within 3-days; and in disease activity scores, CRP, and insulin-like growth
factor-1 within 7-days. They did not see nutritional improvements until 14-21 days;
hence suggest an early anti-inflammatory effect rather than nutritional improvement
is driving remission in Crohn’s patients. Recent studies have provided insight into
possible mechanisms linking changes in the gut microbiota and bacterial metabolites
with gut inflammation.143 These show EEN causes a reduction in bacterial diversity,
leading to changes in bacterial metabolites and functionality.144;145 However causality
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has yet to be established.
1.8.3 Treatment with maintenance enteral nutrition (MEN)
Following the success of EEN, studies have gone on to supplement the normal diet
with enteral nutrition (MEN), to try and maintain disease remission (Table 1.6), thus
reducing the need for corticosteroid therapy.101 Several approaches have been tested,
including overnight nasogastric feeds combined with normal eating during the day;
short periods of nasogastric feeds several times a year; and a daily supplement drink
used alongside normal eating. In one study overnight nasogastric feeding significantly
reduced relapse to 43% at 12-months compared with 79% for children who chose not
to take MEN.146 Another study using nasogastric enteral nutrition for one out of
every four months over a year, also saw a significant increase in remission rates.147 A
study on adults with Crohn’s disease saw an interim remission rate using MEN, which
was double that of the non-MEN treatment group, and hence felt it was inappropriate
to continue the study as they decided the benefit had been clearly demonstrated;148
a similar success rate to a paediatric study which reported 66% of Crohn’s disease
children in remission after 12-months on MEN.149 MEN has also been shown to reduce
relapse after surgery in Crohn’s disease adults, particularly in those with penetrating
disease and non-active lesions.150 A later Japanese study also found MEN reduced
recurrence rates after bowel resection.45
In a recent review, although ten studies found remission rates were significantly higher
in Crohn’s disease patients who received MEN compared with patients who did not,
only one of these was a randomised controlled trial.151 It could be argued that al-
though the sample size in these studies was small (∼20 MEN patients), combined they
represent a reasonable sample population. Eight studies took place in Japan, thus
these results may not translate to Western populations. Also, the studies as a whole
found that the ability of enteral nutrition to induce remission was dose-dependent
with higher doses resulting in higher remission rates.
A recent adult study compared MEN with the use of the immunosuppressive drug
6-mercaptopurine (6-MP) and non-treatment controls,152 reported a remission rate
of 46.9% for MEN which was comparable with 60% remission in the 6-MP group;
remission in controls were 27.2%. Two patients in the 6-MP group developed liver
injury and one alopecia, thus highlighting the need to develop safer forms of long
term treatment such a nutritional therapy. If MEN is an effective treatment for the
maintenance of remission in Crohn’s disease, as some studies suggest, more work
needs to be done to understand the mechanisms behind why EEN and MEN work,
so that treatment to induce and maintain remission can be optimised for Crohn’s
disease patients.
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1.9 Role of the gut microbiota and microbiome in Crohn’s disease
Involvement of the gut microbiota in Crohn’s disease pathogenesis was first shown
in studies where faecal stream diversion prevented recurrence of ileal disease159 and
that subsequent post-operative exposure to the gut microbiota resulted in relapse.69
Treatment with antibiotics is also associated with clinical improvement in IBD pa-
tients.160;161 Accumulating evidence now suggests, that IBD is linked to an inappro-
priate inflammatory response to the intestinal microbiota in genetically susceptible
hosts.162 If children with Crohn’s disease have a gut microbiota profile, both distinct
from healthy children and other inflammatory diseases including UC, it could have
potential as a clinical marker for Crohn’s disease. Understanding why the gut micro-
biota is altered in these children could also lead to improving treatment strategies.
The term microbiome refers to  the collective genome of the human indigenous mi-
crobes (microflora or microbiota), the idea being that a comprehensive genetic view
of Homo sapiens as a lifeform should include the genes from our microbiome!.163
The term microbiota refers to the actual microbes, but in the literature is often
interchangeable with the term microbiome.164 The human gut contains a surpris-
ingly complex ecosystem with an abundance of over a thousand different bacteria
and other micro-organisms. This structural composition in most people include the
dominant bacterial phyla, Bacteroidetes and Firmicutes, as well as the less abundant
Proteobacteria and Actinobacteria.
As well as their role in digestion and absorption, epithelial cells that line the luminal
surface of the gut form a physiochemical barrier to bacteria. In healthy individuals
intestinal goblet cells produce mucus which contain antimicrobial peptides all of which
keep the majority of bacteria to the more fluid outer layer of the mucus and the lumen
of the gut, keeping bacteria away from the surface of epithelial cells. However the
depth of the mucus layer varies significantly along the length of the gut. In the
colon where bacterial load is greater, goblet cells are very dense where they secrete
an additional sterile layer of mucus which acts as a barrier at the cell surface. It
has been shown in mice that lack the MUC2 gene that the mucus layer is unable to
prevent bacteria coming into contact with epithelial cells which can in turn result in
inflammation.165;166
Pattern recognition receptors (PRRs) towards bacteria have been shown to control
the production of microbicidal peptides produced by enterocytes and Paneth cells in
the gut.167 PRRs produced by epithelial cells include membrane associated toll like
receptors (TLR) and intracellular nucleotide binding oligomerisation domain con-
taining protein (NOD) like receptors (NLR) as well as retinoic acid inducible gene
related receptors (RIG) which are able to recognise microbial molecular patterns.
TLR1-5 and TLR9 can recognise bacterial motifs as can a number of intracellular
PRRs (NOD1/CARD4 NOD2/CARD15). The NOD2 gene encodes for a protein which
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is mostly expressed in peripheral blood leukocytes, recognising bacterial molecules
that contain a muramyl dipeptide moiety as well as activating NF-κB.168 Mutations
in this and other genes have been associated with Crohn’s disease,169 suggesting that
the way epithelial PRRs interact with commensal bacteria underpin host protection
against both resident and pathogenic bacteria.167
From altering gut composition as a treatment via probiotics; dietary changes or
faecal transplant, to searching for causative agents or risk factors amongst disease
groups like IBD, IBS and arthritis, crosstalk between bacteria and host cells, as well
as modulation of the immune system, are all important areas of current research.
Bacteria also produce bacteriocins, which play a role in competitive dynamics between
strains of bacteria, possibly helping to maintain microbial homoeostasis.170
Culture based plating was the primary method of investigating the gut microbiota
for many years, and was subsequently replaced by conventional DNA analysis using
either sequencing or fluorescent detection. These focused approaches did not account
for the vast array of bacteria that interact to make up the gut microbiota, resulting
in an incomplete picture.171 In the last decade culture independent detection meth-
ods have now progressed to include 16S rRNA sequencing and high throughput DNA
sequencing172 as well as third generation sequencing analysis.173 This has allowed
highly detailed bacterial classification as well as information about the functional
genes that make up the gut microbiome.174;175 These methods now allow us to char-
acterise phylogenetic disease-associated gut microbiota changes and highlight changes
in individual microbial species, as well as telling us something about the functional
capability of the gut bacterial community. As ‘omics’ technologies and analysis have
become more widely available and affordable, this has resulted in the exploration of
global gut microbial taxonomy and function, allowing a more comprehensive investi-
gation of the complex relationships between the gut microbiota and host tissues.
While a number of bacterial species have been linked with Crohn’s disease, such as
species from Mycobacterium, Campylobacter, Escherichia and Helicobacter, present
evidence does not support the idea that Crohn’s disease is caused by a single species or
strain of bacteria.176 Evidence from both stool and mucosal biopsy samples, suggests
that Crohn’s disease is associated with significant differences in gut microbiota at a
community-level often referred to as dysbiosis.176
1.9.1 Types of dysbiosis associated with Crohn’s disease
Loss of beneficial commensal bacteria In infancy, development of the core com-
mensal microbiota is vital for the maturation and development of the normal intesti-
nal immune response.177;178;179 The mucus layer is composed of mucin glycoproteins
which are secreted into the lumen by epithelial goblet cells. It consists of two layers:
an inner layer of stratified mucus which is adherent to gut epithelial cells (∼50µm
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thick); and a thicker outer non-attached layer which is home to the commensal flora.
Recent research into the identification and development of commensal bacteria are
beginning to shed light on some of the mechanisms responsible for driving the mat-
uration of host immunity in the gut. In order to establish homoeostasis the immune
response needs to prevent undesirable immune response towards self and beneficial
commensal bacteria while at the same time be primed to deal with potentially harm-
ful pathogens. Establishing this level of homoeostasis initially involves production of
mucus and antimicrobial peptides which create this protective, but dynamic barrier,
between the host gut wall and the commensal bacteria. Vaishnava et al. 2011 showed
in a mouse model that a secreted antibacterial lectin (Reg3γ), was necessary for main-
taining a 50µm layer that acts as a physical barrier to the luminal microbiota.180 Loss
of this barrier in Reg3γ-/- mice resulted in bacterial colonisation of the gut epithelial
surface along with increased adaptive immune responses to bacteria. These findings
suggest that antimicrobial peptides play a crucial role in maintaining host-bacteria
mutualism by regulating the spatial relationships between bacteria and the host. It
has also been shown that members of the commensal gut microbiota can inhabit the
intestinal mucus without activating the host inflammatory response.166 Hence the
mucus layer is not a simple physical barrier but is a dynamic layer that controls the
interaction between nutrients, antigens, commensal bacteria and the immune system.
Immunotolerance to self tissue and beneficial commensals is controlled in large part
by a subset of T-lymphocytes known as Treg.
181 Studies in germ-free mice have shown
that Treg function is compromised but can be restored by introducing the human com-
mensal bacterium, Bacteroides fragilis or with a combination of Clostridium strains
IV and XIVa.182;183 Although mouse models do not fully represent the human gut, it
is likely the molecular basis of the evolution of commensal tolerance is similar across
all mammals. There are other human strains of Bacteroides which have also been
shown to modulate the amount of colonic Treg in mouse models including B. caccae,
B. thetaiotaomicron, and B. vulgaris ;184;182 as well as a number of Clostridia spp.
isolated from humans;185;183 and a number of Lactobacillus strains as well as some
strains of Bifidobacterium in a cell culture model, suggesting the modulation of Treg
is a common mechanism to induce tolerance in the gut. However these experiments
do not test a comprehensive selection of bacteria therefore cannot represent the over-
all make-up or complexity of the developing human microbiota which modulate Treg
and other immune responses in the gut.
Reduced diversity Members of the gut microbiota have various functions that con-
tribute to host well-being, such as being involved in anti-inflammatory pathways or
the induction of inflammatory responses. Some members of the microbiota promote
the growth of anti-inflammatory networks within the host, as well as protective in-
flammatory responses. In a germ-free mouse model it has been shown that some
25
bacterial/host interactions such as changes in metabolite concentrations or accumu-
lation of gut Treg cells, are initiated only when a number of bacterial species are
present.184 This demonstrates a role for bacterial diversity in altering host immuno-
logical phenotype,184 and the loss of total microbial diversity is an important aspect
of dysbiosis in Crohn’s disease.
Treg function has also been shown to be compromised in germ-free mice, however
when human faecal sample enriched for chloroform-resistant bacteria (selecting for
thirty strains Clostridiales) were used to recolonise mice, it induced a 3-fold expan-
sion of Treg compared with controls.
186;183 If only one strain of Clostridia was used,
Treg induction was diminished.
186;183 This demonstrates that increased diversity, even
within the same family, maximises cellular development in the host gut. It is possible
that early exposure to a diverse microbiota is crucial to the development of healthy
host/microbial interactions.178 For example, a study looking at microbial diversity in
newborn babies at 1-week and 1-month has shown children who developed asthma at
7-years of age had lower microbial diversity in early infancy, but not at 12-months,
compared with healthy children in the study (p<0.05).187
Although studies of patients with IBD, regardless of disease activity, show they have
a marked loss of symbiont bacteria within the gut, specifically Clostridium groups
XIVa and IV,188;189 it is not yet clear whether lack of beneficial bacteria play a role in
driving inflammation, or conversely, inflammatory processes play a role in reducing
commensals.
Expansion of pathobionts The gut microbiota also contains bacteria that have
potential to cause harm. The term pathobiont was coined to describe members of the
‘normal’ commensal community that can, under certain circumstances, cause damage
to the host.190 The most commonly recorded incidence of pathobiont expansion is
that of the phylum of gram-negative bacteria, Proteobacteria, and particular the
family Enterobacteriaceae, including Escherichia coli, Shigella and Klebsiella.191 This
increase in Enterobacteriaceae has also been recorded in mouse models of colitis,192
especially those with the TLR5 mutation.193 It is not likely that pathobiont expansion
on its own could cause IBD, since recent years of study have failed to identify a single
organism specific to IBD patients.
Although three distinct forms of dysbiosis are described here, it is likely that gut
microbial dysbiosis, in any one individual, will include a mixture of all three types.
1.9.2 Evidence for microbial difference in Crohn’s disease
The idea of gut bacteria being altered as a collective, as opposed to a single species
or strain resulting in IBD is a crucial step forward in IBD research. The development
of ‘omics’ technologies,172 now permit analysis of microbiota in a way which allows
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researchers to see global changes in the gut which are being linked with the function-
ality of the microbiome, and its impact on the host. Both human and animal studies
are starting to provide clues as to how the microbiome could be altering mucosal im-
mune function, potentially leading to chronic inflammation. It is therefore vital that
research, not only aims to identify which groups of bacteria are changing in the gut,
but also tries to determine what impact these changes have on gut immunoregulation.
In 2014 Gevers et al.194 carried out a large study on 425 ileal and 300 rectal tis-
sue biopsies, and 199 faecal samples collected from children with Crohn’s disease
prior to treatment. They recorded an increased abundance in families Enterobacte-
riaceae, Pasteurellacaea, Veillonellaceae, and Fusobacteriaceae, as well as decreased
abundance of Bifidobacteriaceae, Erysipelotrichales, Clostridiales and Bacteroidales
compared to a control group of non-IBD children, which correlated well with dis-
ease status. The differences were less pronounced in faecal samples than was seen
in both ileal and rectal biopsies, but did include an increase in Streptococcus and a
loss in a taxa belonging to the order of Clostridiales, including Dorea, Blautia, and
Ruminococcus. They also found that antibiotic use amplified bacterial dysbiosis in
Crohn’s disease. Previous studies had mostly included patients with ongoing disease
and were small in scale hence lacked statistical power, and thus could not easily take
into account confounding factors such as medication use.195 It should also be noted
that although this study did a comparison with faecal samples only 12% (n=26) of
non-IBD controls gave a stool sample.
The study by Quince et al. 2015144 also highlighted that differences in gut bacteria
between children with Crohn’s disease are not uniform across genera with species
like Ruminococcus obeum being lower in children with Crohn’s while R. gnavus was
higher. It is therefore important to see the whole picture to understand how patterns
of gut microbiota might play a role in aetiology or patient symptoms.
Metagenomic studies have suggested Crohn’s disease can be identified from distinctive
microbiota compositions compared to healthy controls,196 supported by Davenport et
al. 2014197 who used 16S ribosomal sequencing of mucosal biopsies from twenty-one
Crohn’s disease patients and twenty-four healthy controls, to show an overall alter-
ation in the ratio between Firmicutes and Bacteroidetes, with a relative abundance
being significantly greater than healthy controls (p=0.05). The controls were not
age-matched (20-year mean difference) and it is therefore not just possible, but quite
probable that at least some of the observed difference, especially in Bacteroidetes,
are attributable to age related changes.198 Other meta-analysis studies have also
identified a dysbiosis characterised by a reduction in Firmicutes and an increase in
Proteobacteria.195 A study looking at the metagenomic profile of monozygotic twin
pairs discordant and concordant for Crohn’s disease also found that the faecal mi-
crobiota profile was more similar between healthy twins, than between twins with
Crohn’s disease, particularly if they were discordant for the disease.199
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A 2010 study using metagenomic sequencing has shown that not only did twenty-five
patients with IBD have lower bacterial diversity than ninety-nine non-IBD individu-
als, but also an average of 25% fewer genes.200 A loss in microbial functional genes
in IBD patients could affect crosstalk between host cells and the mucosal bacteria.
An IBD study looking at monozygotic twins went on to show bacterial abundance at
the genus level, when linked with transcriptomic profiles, demonstrates a loss of host
bacterial interaction in patients with UC.201 A linked study looking at six monozy-
gotic twins and their mothers, showed community level metabolic network changes
in the microbiome of Crohn’s disease patients, mostly at the periphery of these net-
works, highlighting the importance of the host/microbiome interface in the aetiology
of Crohn’s disease.202 Demonstrating links between the bacterial taxa, environmental
factors, and a host genome is complicated by the various disease states in Crohn’s
disease, as well as the large intra-and inter patient variability in microbial diversity.
A study has reported that mucosal biopsy samples in Crohn’s disease patients show
little difference in gut bacterial composition between inflamed and neighbouring non-
inflamed tissue, whereas those taken from UC patients appear to demonstrate clear
bacterial clustering between inflamed and non-inflamed tissue,197 suggesting that
any dysfunctional aspect of the mucosal bacteria in Crohn’s patients could be more
systemic than that of UC. However differences could be present, especially among
species of low abundance, which were not detected using these methods.
1.9.3 Interaction between host genome and the gut microbiota
It is an over simplification to suggest that a specific bacteria or group of bacteria cause
Crohn’s disease and hence these studies looking at changes in the gut microbiota need
to be interpreted in the context of the host genome as well as other environmental
factors.
Although studies have shown that some bacterial species such asAkkermansia muciniphila
(human) and Enterorhabdus mucosicola (mouse) have the ability to damage the in-
testinal mucosa,203 alterations in host genes such as the gel forming mucin MUC19
might make patients more susceptible to this type of microbial interaction allow-
ing some bacterial species that degrade mucus to thrive in the mucus layer.204 The
mucosal barrier which protects the lamina propria from bacteria in the lumen, has
been shown to be reduced in IBD patients.205 It has been suggested that inherited
mutations (NOD2 and IL23R) affecting mucosal composition in turn alter the com-
position of gut bacteria in contact with the mucosa. This in turn impairs the ability
of the mucosa to protect the gut, allowing opportunistic bacteria to colonise the mu-
cosa leading to a further increase in the immune response and chronic inflammation.
Defects in the genes SLC22A5A, GPR35 or GPR65 which are involved in sensing bac-
terial metabolites could also be responsible for triggering an inappropriate immune
28
response. Genetic susceptibility to bacterial dysbiosis has been demonstrated in col-
itis mouse models deficient in the NOD like receptor and pyrin domain 6 (NLRP6)
genes.61 However, to put the role of genetic variants into context, Jostins et al.
2012 have identified 163 susceptibility loci for IBD,61 which have been calculated
to contribute to only 33% of genetic susceptibility in Crohn’s disease and 16% in
UC.206 Although there is good evidence that NOD2, autophagy, and Th17 immune
responses have strong links to Crohn’s disease pathogenesis, it is important to note
that these susceptible loci only contribute around 14% of total disease variance.61
However, much of this genetic evidence still points towards a key role between the
host immune response and the gut microbiota.
Genetic variants do not explain why some people within a family develop IBD while
others do not. When exploring the aetiology of Crohn’s disease it is essential to
consider the context of a complex microbial milieu, rather than individual species, and
how changes in the environment might drive changes which activate an inflammatory
state. Bacteria associated with compromised gut mucosal barriers often consist of
mixed communities,207 and future research studies need to try and build study designs
and models of analysis which take these multiple factors into account.
1.9.4 The microbiome and innate immunity
The gut microbiome is a hub of signalling connecting input from the diet, with ge-
netically controlled immune signals to control metabolic processes, as well as innate
immune regulation of pathogens. Both haematopoietic and non-haematopoietic in-
nate immune cells are located at the host/microbiome interface, where they can sense
micro-organisms and metabolites, which can in turn be translated into an appropri-
ate host physiological response to regulate the microbial milieu. Dysfunction in this
communication network between the innate immune system and the gut microbiota
might play a role in the aetiology of a number of complex diseases including Crohn’s
disease.
1.9.5 The role of diet in shaping the gut microbiota
One of the most important factors which impact the human gut microbiota compo-
sition are dietary choices, a factor which has been shown to drive the evolution of
microbiome composition in mammals.208 Colonisation of the gut microbiota is estab-
lished very quickly in the newborn gut, reaching adult concentrations within only a
few days. Subsequent microbiota development is then usually characterised by an
increase in bacterial diversity until around three years of age.209 The process from
colonisation to a stable microbiota in homoeostasis is not well understood; however
it appears control mechanisms, particularly related to innate immunity, control the
establishment of the normal commensal microbiota which in turn acts to preclude
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further colonisation by exogenous bacteria. This might suggest that the primary in-
oculum after birth and initial microbial exposure are very important to development
of a healthy gut.
For the first six months of life, human milk is regarded as the optimal diet for in-
fant health, growth, and development, however for a number of reasons around 80%
of babies have been either fed fully or partially with formula milk.210 A study has
shown that the microbiota of six breastfed babies was predominately made up from
Bifidobacterium, while six babies fed formula milk generally had a more diverse mi-
crobiota with lower abundance of Bifidobacterium and higher levels of bacteria such
as Escherichia coli, Clostridium difficile, Bacteroides and Lactobacillus that have the
potential to act as pathogens.210 Another study looking at the gut bacteria of 3-month
old babies found higher levels of Clostridium cluster XVIII, Lachnospiracea incertae
sedis, Streptococcus, Enterococcus, and Veillonella in the formula fed group.211
A number of studies have also shown how changing the diet of healthy people can
alter the gut microbiota. In a controlled feeding study of ten adults, microbiota com-
position changed within 24-hours of taking a high-fat/low-fibre or low-fat/high-fibre
diet, affecting ratios of Bacteroides, Prevotella, and Firmicutes. Interestingly the
enterotype remained stable for the 10-days of dietary intervention, suggesting that
enterotypes are more stable in the longer-term, and that short-term changes may
have less impact.212 A strict vegan or vegetarian diet has been shown to have signif-
icantly lower counts of Bacteroides spp. (p=0.001), Bifidobacterium spp.(p=0.002),
Escherichia coli (p=0.006) and Enterobacteriaceae spp.(p=0.008) compared with an
omnivorous diet.213 Although the relationship between diet and the gut microbiota
is complex it has become a key target for therapeutic intervention in IBD.
In the last 20-years, interest in using nutritional therapy to induce remission of active
Crohn’s disease has increased.214 Recent studies investigating the suggested mecha-
nisms of action of enteral nutrition in Crohn’s disease, have highlighted the impor-
tance of interactions between nutritional therapy and the host gut microbiota.
1.9.6 Changes in gut bacteria during exclusive enteral nutrition
The idea that gut bacteria could be altered using diet, is a particularly important
area of research in paediatric Crohn’s disease. Treatment with corticosteroids can
reduce the speed of growth in children, making dietary alternatives attractive as a
strategy to induce disease remission, while also achieving optimum growth.
Although no specific diet has yet been identified which could directly induce, prevent,
or cure IBD, it is becoming more evident that the interaction between nutrition, nutri-
ents, and the gut microbiota have a role to play in disease aetiology. The therapeutic
effect of EEN in treating Crohn’s disease suggests that diet plays a crucial role in this
disease. However, to set up large scale dietary studies in humans is very challenging
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and hence the amount of data linking diet with IBD is limited. Most gut microbiota
studies into the effects of EEN have been carried out on children and usually with
small sample sizes. Comparing these studies is also difficult due to variation in meth-
ods such as type of formula; inclusion of non-EEN foods; percentage of EEN used and
method of delivery (oral/NGT). Also variation in sample type (stool/mucosal); gut
site of sample collection; inter-patient variation; geographical and genetic variation;
as well as differences in how samples were handled and processed for analysis, all
contribute to making comparison and interpretation of data challenging.
However as the role of gut bacteria in IBD has become more established, some inter-
esting patterns have emerged from gut microbiota studies looking into the effect of
EEN. In the past decade a number of studies, both human and animal, have looked
at changes in the gut microbiota before, during and after EEN (p197, Table 5.10).
In 2005, Lionetti et al.215 was the first to report on the modulating effect EEN had on
the gut bacteria of children with Crohn’s disease. They used temperature gradient gel
electrophoresis (TGGE) to visualise 16S rRNA bands from faecal samples taken from
nine children with active Crohn’s disease undergoing treatment with 8-weeks EEN
and five healthy controls. They reported that EEN could be characterised by changes
in banding patterns in all patients whereas healthy children were stable over time;
although they only show evidence for four of their patients and one healthy child.
They also failed to provide any data or formal analysis of bands and hence their results
were somewhat subjective. In a similar study, Leach et al. 2008216 using 16s rRNA
and denaturing gradient gel electrophoresis (DGGE) on stool samples taken from six
children with Crohn’s disease, showed that the percentage similarity was significantly
lower (p<0.05) before and after 8-weeks of EEN, than an 8-week duration in healthy
children for Eubacteria; Bifidobacteria; Bacteroides and two Clostridium species.
The study did find a strong positive correlation (r2=0.738, p=0.028) between the
percentage of Bacteroides/Prevotella group during EEN with a change in paediatric
Crohn’s disease activity index (∆PCDAI). They also recorded a correlation between
faecal calprotectin levels and PCDAI (R=0.529, p=0.002), but the strength of the
correlation might suggest the (PCDAI) scores were not entirely representative of gut
inflammation. It was also interesting to note that healthy children had only between
59% to 84% similarity in these bacteria groups, suggesting the gut microbiota of
healthy children is variable over time. However, as DGGE bands can only give an
estimate of diversity, some of this variance might be due to the method used.
Research had begun to identify differences in specific groups of bacteria in children
with Crohn’s disease, thus studies started to ask questions about whether specific
bacteria changed during an elemental diet of EEN (028 Extra), and if these changes
could be linked with disease remission after EEN. Particular emphasis was given
to the Firmicutes phylum, especially Faecalibacterium prausnitzii which had been
shown to be reduced in active Crohn’s disease.217 Interestingly, one study showed
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that in twenty adults with Crohn’s disease levels of one strain of F. prausnitzii A2-
165, decreased significantly after treatment on 2-weeks of EEN compared to baseline,
while levels of another strain F. prausnitzii M21/2 decreased without significance
(p=0.61).218 Their analysis showed the levels of both F. prausnitzii strains in Crohn’s
patients were significantly lower than those in other patients groups both before and
after successful treatment with 2-weeks EEN; hence EEN did not increase levels of
F. prausnitzii towards that seen in healthy controls.
Using terminal restriction fragment length polymorphism (T-RFLP) analysis of bac-
terial 16s rRNA, Shiga et al. 2012 went on to show a reduction of bacterial diversity
in the gut of eight adult patients treated with an elemental formula (Elental ),219
however results were not statistically significant. They also treated nine patients with
total parental nutrition (TPN), a method of feeding fluids into a vein thus bypassing
the gut. In these patients there was a significant reduction in bacterial diversity after
8-weeks treatment. Although when applied to complex microbial communities such
as the gut microbiota, T-RFLP compresses the output data to around only 20-50
peaks creating both a bias and oversimplification of actual bacterial diversity; the
group carried out further qPCR analysis which showed a reduction in Bacteroides
fragilis after treatment with EEN. It should be noted the reduction in Bacteroides
after EEN was matched by a non-significant reduction of Bacteroides in healthy con-
trols. This was inconsistent with the difference over time seen in other bacterial
groups, hence this result could be an experimental anomaly due to storage condi-
tions, or Bacteroides numbers could be more variable in the gut of healthy people
than other bacteria groups measured.
In 2014, Gerasimidis et al.145 using TTGE and qPCR went on to show that the
global bacterial diversity and abundance in fifteen children with Crohn’s disease de-
creased (p<0.05) after treatment with EEN. This was accompanied by a reduction
in the stability of bacterial composition in the gut in comparison to healthy children
(p<0.01). F. prausnitzii spp. was shown to decrease after 30-days on treatment with
EEN (p<0.05), a finding supported by an earlier adult study into EEN,218 and might
counter the previously held assumption that F. prausnitzii plays a protective anti-
inflammatory role in the gut.217 This paradoxical decrease in F. prausnitzii is not yet
understood, and a recent mucosal biopsy study on thirty-seven children with Crohn’s
disease has reported that F. prausnitzii is significantly more abundant in the gut
mucosa of Crohn’s patients than controls (p=0.02).220 The same study also reported
a non-significant trend for decreasing concentrations of Bifidobacteria after 4-weeks
(p=0.108) and 8-weeks (p=0.120) on EEN which went back to pre-treatment levels
once children went back to their normal habitual diet. Gerasimidis et al.145 also found
that in children with Crohn’s disease who went into remission after treatment with
EEN, the bacterial changes were greater and the amount of Bacteroides/Prevotella
was significantly reduced (p<0.05). All these recorded changes along with bacterial
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diversity, returned to pre-treatment levels once children returned to their normal ha-
bitual diet. In 2015 this group went on to carry out next generation sequencing of
these samples.144 During EEN, bacterial diversity in children with Crohn’s disease
decreased and the community profile moved further away form healthy children than
at baseline. They calculated that for every 10-days on EEN, there was a loss of 0.6
genus diversity equivalents. They also recorded that thirty-four genera had decreased
including F. prausnitzii while Lactococcus increased during EEN.
Lewis et al. 2015 evaluated changes in gut microbiota from faecal samples taken at
1-week, 4-weeks and 8-weeks EEN in a Canadian cohort of children with Crohn’s
disease. The treatment regime was approximately 90% EEN (formula not given)
hence some foods were consumed during the diet. They also included a group of
twelve children taking partial EEN, around 50% (PEN). Rather than using a dis-
ease activity index they chose to use a cut-off in faecal calprotectin below 250mg/g
which is less subjective to gauge levels of inflammation. They found that the gut
bacteria profile in children treated with EEN changed significantly within 1-week of
treatment, moving further away from gut microbiota profile of healthy children (rel-
ative to baseline p=0.005). The abundance of six out of forty genera were nominally
different but this did not reach significance. A similar pattern was not seen among
the PEN patients (p=0.83) or anti-TNF patients (p=0.02). Interestingly they found
that children treated with anti-TNF moved closer to healthy gut microbiota profile
within 1-week, the opposite of those on EEN.
Although only a single case study, D’argenio et al. 2013221 is the only study to
have looked at the mucosal microbiota (ileal) rather than faecal samples. Consistent
with faecal studies, when compared to a single control, dysbiosis was characterised
by reduced diversity, less Bacteroidetes and increased Proteobacteria. After treat-
ment with EEN the diversity and relative abundance of Bacteroidetes increased and
Proteobacteria decreased in-line with control sample levels. In a small study of only
four children with active Crohn’s taking EEN, Guinet-Charpentier et al. 2016222,
reported an increase in abundance of Alistipes along with a decrease in the genera
Escherichia-Shigella (p<0.01) and Sutterella (p<0.05) of the phylum Proteobacteria.
In another small study of five children with Crohn’s disease and five controls, Kaak-
oush et al. 2015,223 also recorded decreased microbial diversity, and that dysbiosis
was highly variable in Crohn’s disease. In-line with previous studies, after treatment
with EEN a further decrease in the number of OTUs and bacterial diversity was seen.
They also recorded a correlation between relative abundance of six Firmicutes fami-
lies (Erysipelotrichaceae, Ruminococcaceae, Lachnospiraceae, Streptococcaceae, Veil-
lonellaceae and Peptostreptococcaceae) with clinical improvements. However there
was a lot of variation in changes across these families between children.
Schwerd et al. in a small study of eight Crohn’s disease patients reported the mi-
crobiota was characterised by a reduction in Firmicutes complexity at baseline, but
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contrary to other studies, treatment with EEN increased their relative abundance,
particularly in the Christensenellaceae.224 They did however find that EEN decreased
the relative abundance of gram negative Bacteroidetes. The number of species (Shan-
non effective diversity) ranged between 8-50 per faecal sample and did not change
significantly during EEN. This conflicts with Kaakoush et al.223 who reported that
EEN induced remission was linked with reduced numbers of OTUs. Although Schw-
erd claimed to have used a more robust method for filtering OTUs, the small sample
size of these studies makes variability a serious problem. This study also saw no
significant difference in relative abundance of any single species (OTU) associated
with treatment on EEN.224
It has been suggested from previous studies that the microbiota profile pre-EEN
could identify which children will, or will not, respond to treatment with EEN. In
2016 Dunn et al. took faecal samples from ten children with Crohn’s disease un-
dergoing EEN and five healthy controls. They investigated this idea by comparing
gut microbiota profiles between those children who maintained remission for at least
6-months after EEN, and those who either failed EEN, or failed to sustain remission.
Interestingly in those who maintained remission after EEN, the pre-EEN relative
abundance of Verrucomicrobia, Firmicutes and Bacteroidetes were similar to healthy
controls. However those that failed EEN, or failed to stay in remission for 6-months,
had higher abundance of Proteobacteria, a commonly reported aspect of dysbiosis
in Crohn’s disease.225;221;226 This study also reported that in patients who failed to
respond after treatment with EEN, Proteobacteria saw a further increase. However,
studies which look at non-responders to EEN, need to keep in mind that failure to
adhere to dietary treatment could influence results. Dunn et al. also found that
during treatment bacterial diversity decreased in responders while increasing in non-
responders. This group went on to use a new Bayesian analytical framework to deal
with inter-individual variation, to show that the most common OTUs associated
with sustained remission were Akkermansia muciniphila, Bacteroides (B. fragilis &
B. ovatus), Lachnospiraceae and Ruminococceae. The OTUs associated with non-
response to EEN were from Bacteroides (including B. plebeius), Enterobacteriaceae
(Klebsiella), and Prevotella.227
A study using Denaturing Gradient Gel Electrophoresis (DGGE) examined mucosal
biopsies before treatment with EEN in six patients with Crohn’s disease and again
at post-treatment (8-weeks).228 16S rRNA was used to generate cluster diagrams of
similarity of the bacterial community, which showed not only was the mucosal bacteria
different between healthy individuals, but also that in these individuals there was
variation at different sections of the gut including between the ileum and colon. In
patients with active Crohn’s disease a similar pattern of variation was seen between
individuals, but without the same normal variation along the length of the colon found
in healthy individuals. What was interesting in the six Crohn’s disease children was,
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after treatment with EEN, this loss of variation across different sites in the gut,
returned back to normal colonic variability.228
Given that some of these studies record a swing in ratio from Firmicutes towards
Bacteroides, it will be interesting to see if future studies which look at changes in
gut bacteria during EEN, identify a reversal of this ratio associated with induction
of remission in Crohn’s disease patients; although the reduction in bacteria such as
F. prausnitzii seen in the Gerasimidis et al. 2014 study145 suggests that this is not
the case. Overall these studies show that EEN induces a rapid and complex change
in the gut microbiota profile which can be linked with reduction in clinical markers
of inflammation and clinical remission in children with Crohn’s disease.
Once remission has been induced using EEN, enteral nutrition given as a supplement
to normal diet has been trailed with the aim of keeping children in remission and
preventing disease relapse (p23, Table 1.6). However, the role of maintenance enteral
nutrition (MEN) has not been well studied in children with Crohn’s disease. If
induction of remission is driven by gut bacterial changes due to EEN, then the key
question would be, can these microbial changes be maintained using MEN to sustain
remission?
1.9.7 Changes in gut bacteria during maintenance enteral nutrition
Few studies have gone on to look at the gut microbiota composition in patients with
Crohn’s disease, who after treatment with EEN, have taken a course of maintenance
enteral nutrition (MEN) to try and maintain disease remission. The current study
aim is to fill major gaps in our understanding about how diet, and specifically MEN,
might alter microbial composition in children with Crohn’s disease.
In 2005 Lionetti et al.215 collected faecal samples from nine children with active
Crohn’s disease who were undergoing EEN using a polymeric formula (Modulen); and
five healthy children. After 8-weeks of EEN, children with Crohn’s disease returned
to their normal habitual diet but continued to supplement 40% of their daily energy
intake with the Modulen. The faecal bacteria were analysed by 16S-rRNA PCR
and temperature gradient gel electrophoresis (TGGE) with direct visual comparison
of band profiles of PCR products. Changes in bacterial composition were seen in
the gut of all nine children with Crohn’s disease after treatment on EEN, and these
changes continued once the child went back onto normal diet, but did stabilise after
several months. In healthy children the TGGE results showed a stable bacterial
profile over 3-months. A major drawback was that this study did not include a non-
MEN control group, making it impossible to tell if MEN had an effect which would
also been seen in children returning to normal diet without MEN supplementation.
The change in composition is consistent however, with that recorded in an earlier
study using TGGE which showed a similar difference in gut bacterial composition in
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eight adult Crohn’s disease patients with active disease, compared to eight patients
in remission.229
In 2008 Leach et al.216 carried out a small study to look at faecal samples from six
children with Crohn’s disease collected at diagnosis, during treatment with EEN and
then on MEN for 4-months after treatment; and compared these with seven healthy
children, where samples were collected 8-weeks apart. Although using 16S-rRNA
DGGE, they showed a significant change in the gut bacteria on EEN, the study was
completely underpowered to draw any conclusions about the use of MEN, with a
maximum of three children being followed up at 26-weeks for each bacterial group. It
was also interesting that in the five children who continued on MEN, although there
was a partial return to the bacterial profile found at the start of treatment (40%
similarity), the gut bacteria composition was still to some degree altered at 4-months
post treatment with EEN. For example a negative correlation between changes in the
C. leptum group and both changes in PCDAI and faecal calprotectin, suggested that
C. leptum stability after treatment with EEN, was associated with a reduction in
gut inflammation and disease activity.216 It is worth noting that although five of the
children went onto MEN, two of the six began medication on aminosalicylates while
two started azathioprine, hence we cannot be sure whether medication contributed
to these results.
MEN, if shown to be effective, is an appealing option for maintenance of remission
in children with Crohn’s disease, since it avoids the negative events associated with
drugs such as immunosuppressants and biologics. It is therefore vital to gain an
understanding of gut bacterial changes during MEN, in order to show whether MEN
is linked with an anti-inflammatory gut composition, and hence had real clinical
benefit in reducing inflammation in children with Crohn’s disease.
Partial enteral nutrition Although Lewis et al. 2015 evaluated changes in gut
microbiota from faecal samples taken at 1-week, 4-weeks and 8-weeks EEN they also
gave a group of children partial enteral nutrition which made up 53% of the child’s
daily intake. When they compared the gut bacteria profile in children treated with
EEN with those children treated with partial enteral nutrition the same pattern of
change was not seen (p=0.83) hence they concluded that either changes to bacterial
profile seen during EEN are dose dependant, or that only total removal of normal
diet is influencing the microbiota composition during this week of treatment.
1.10 Bacterial fermentation in the gut
As discussed in the previous section, the type of bacteria which ferment fibre have
been reported to be reduced in the gut mucosa and faeces of IBD patients. Therefore
the products of colonic fermentation in relation to their impact on immunoregulation
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in the gut, is a key area of interest, particularly because these metabolites could open
a potential new source of therapy for patients.
The key function of bacteria that reside in the colon is fermentation of food that has
escaped digestion or absorption in the upper gut. It is a complex process which in-
volves a large number of metabolic processes, products of which can be used by host
tissues and cells.230 The end products of colonic carbohydrate fermentation include or-
ganic acids, lactate and short chain fatty acids (SCFA), along with hydrogen, carbon
dioxide and methane. The branched-chain fatty acids, iso-butyrate and iso-valerate
as well as ammonia, amines and phenols are all products of protein fermentation.230
The main fatty acids associated with colonic fermentation are given in Table 1.7.
Fermentation activity varies throughout the large intestine, with highest production
of SCFA and reduced luminal pH in the caecum and ascending colon.230;231 As the
amount of available substrate diminishes in the distal colon, this is where protein fer-
mentation tends to occur, leading to increased branched-chain fatty acids, ammonia
and phenols. Here the pH increases towards neutral.
Table 1.7: Short and medium chain fatty acids produced and utilised by gut bacteria
Carbon chain length Common name Systematic name Ester/Salt
Short chain
C2 Acetic acid Ethanoic acid Acetate
C3 Propionic acid Propionic acid Propionate
C4 Butyric acid Butanoic acid Butyrate
C5 Valeric acid Pentanoic acid Valerate
Branched chain
i-C4 Iso-butyric acid Iso-butanoic acid Iso-butyrate
i-C5 Iso-valeric acid Iso-pentanoic acid Iso-valerate
Medium chain
C6 Caproic acid Hexanoic acid Hexanoate
C7 Enanthic acid Heptanoic acid Heptanoate
C8 Caprylic acid Octanoic acid Octanoate
1.10.1 Introduction to short chain fatty acids (SCFA)
Figure 1.2: Short chain fatty acids (SCFA) are carboxylic acids with aliphatic tails of between 1-6
carbons, with acetate (C2), propionate (C3), and butyrate (C4) being the most abundant in the gut
where they are an important source of fuel for colonocytes.
SCFA (Fig. 1.2) are produced via anaerobic fermentation of dietary fibres in the
gut,232 with dietary fibre being defined as ‘carbohydrate polymers with three or more
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monomeric units, which are neither digested nor absorbed in the small intestine of
humans’.233 A recent metabolic reconstruction, based on data from the Human Mi-
crobiome Consortium show that, although there is a great deal of variation in gut
microbiota profiles between individuals, the metabolic profile which includes SCFA is
more constant.234 This is because many biochemical pathways are consistent across
species and groups of bacteria. For gut bacteria, SCFA are a necessary waste product
which are needed to balance reduction-oxidation reactions in the anaerobic environ-
ment of the gut lumen.235 However, the absorption of SCFA as a product of bacterial
metabolism provides an additional source of energy to host cells from dietary fibre
which the host is unable to digest directly in the small intestine. Around 90% of
SCFA which are produced from the digestion of foods, are absorbed in colon, while
the remaining are excreted in faeces.236
The main products, acetate, propionate and butyrate, are usually found in an ap-
proximate ratio of 60:20:20, in the colon and stool of healthy individuals.230 The
production of SCFA depends on abundance and species of gut bacteria present, as
well as nutritional availability in the gut for fermentation.237 Also, depending on di-
etary composition, the total concentration of SCFA reduce from 70-140mM in the
proximal colon to 20-70mM in the distal colon.238 SCFA are mostly absorbed in the
caecum and colon hence only small amounts can be detected in the faeces.239 Once
absorbed into the body via the gut, SCFA are metabolised in tissues; the colonocytes
use butyrate as well as some propionate and acetate for energy production and cell
maintenance; in the liver hepatocytes metabolise propionate (gluconeogenesis) and
acetate (lipogenesis); while muscle cells can oxidise energy from residual acetate.239
The metabolic effects of SCFA appear to be tissue specific, and their role at particular
sites requires further research in humans. SCFA also have a role to play in controlling
tight junction proteins, which control permeability of the gut epithelial barrier, thus
regulating molecular transport across the gut lumen and hepatic portal.240
Acetate (C2) Acetate is the most abundant SCFA found in the gut, being produced
by a large range of gut bacteria, mostly from the phylum Firmicutes.241 The citric
acid cycle uses acetate in the form of acetyl co-enzyme A, along with water to reduce
NAD+ to NADH in cells. This energy is then utilised in the process of glycolysis to
generate pyruvate (Fig. 1.3). According to stable isotope studies acetate contributes
around 6-8% of energy expenditure.242 Acetate is consumed by butyrate and propi-
onate producing bacteria including Faecalibacterium prausnitzii, Roseburia spp., and
Eubacterium spp.243;244 Anaerostipes caccae has also been shown to utilise acetate to
produce butyrate in conjunction with the class of bacteria, Clostridia.245 The ratio of
acetate in faeces is therefore dependant on the ratio of butyrate producing bacteria
and fibre availability in the gut.246
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Figure 1.3: Most SCFA are produced via more than one pathway. The pathways represented are
the major routes of production. Adapted from Louis et al. 2014247
Propionate (C3) In non-ruminants, including humans, propionate arises from the
β-oxidation of odd chain and branched chain fatty acids. In humans it is relatively
minor substrate for gluconeogenesis in the liver compared with ruminants where
propionate is the principle gluconeogenic substrate.248 Propionate can be used in the
human gut as a source of energy by colonocytes, but is less efficient than butyrate.
Commensal gut bacteria which produce propionate are less diverse than butyrate
producers, with their distribution being dominated by only a few genera. Three
pathways (Fig. 1.3) have been described for the production of propionate.249 The
succinate pathway is the main route for hexose conversion to propionate by gram-
negative Bacteroides as well the class of bacteria Negativicutes (Firmicutes). The
acrylate pathway is restricted to members of the Lachnospiraceae family including
Coprococcus catus and Negativicutes, where lactate is converted to propionate. How-
ever, butyrate is the main source of lactate utilisation among gut bacteria.250 In the
propanediol pathway, propionealdehyde dehydrogenase has been shown to convert
deoxysugars such as fucose and rhamnose in members of the Lachnospiraceae family
including Ruminococcus obeum and Roseburia inulinivorans.249
Butyrate (C4) Butyrate in particular has been identified as being important for
maintaining the colonic epithelium, and being the preferred fuel utilised by colono-
cytes, it is the primary site of butyrate sequestration in the body.251;252 In 2012 Wang
et al. carried out a study using a cellular model of the colon, to show that butyrate
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was an important regulator of tight junction assembly proteins, increasing intestinal
barrier function via increased production of claudin-1, while inducing tight junction
proteins, ZO-1 and occludin, redistribution in the cell membrane.240
These SCFA, not only provide a source of energy for the host, but also have anti-
inflammatory and anti-apoptotic effects that could potentially protect the gut against
colitis.253;254;255;256 A recent 2014 study showed that butyrate could reverse the aber-
rant expression of ZO-1 as well as decreasing lipopolysaccharide translocation which
lead to inhibition of macrophage activation, pro-inflammatory cytokine production
and neutrophil infiltration in the liver of rats.257 Increasing permeability is also linked
with translocation of pathogens and antigens potentially triggering the inflammatory
cascade. More recently studies have shown that SCFA have a role to play in reg-
ulating human immune responses and inflammation. It has been known for some
time that butyrate is involved in regulation of the immune system via inhibition of
NF-κB activation in macrophages in the lamina propria of patients with UC.258 In
2010 Manco et al.259 showed that an increase in bacterial lipopolysaccharide triggers
a TLR4 mediated pro-inflammatory cascade in monocytes and macrophages. This in
turn activates downstream pathways including NF-κB and mitogen-activated protein
kinase, leading to cytokine (TNF-α and IL-6) driven inflammation.
The main butyrate producing bacteria in the gut belong to the Firmicutes phylum,
with species from the families Ruminococcaceae and Lachnospiraceae being the most
abundant.244;260 The lactate utilizing bacteria such as Eubacterium and Anaerostipes
species also contribute to butyrate production.244 The Ruminococcaceae species F.
prausnitzii is reduced in IBD patients, especially those with Crohn’s disease, which
accompanied by the evidence that F. prausnitzii has anti-inflammatory properties
has made it of particular research interest. Recently a 15kDa anti-inflammatory
protein (MAM) produced by F. prausnitzii has been shown to inhibit the NF-κB
pathway in intestinal epithelial cells lines, leading to the possible development of new
anti-inflammatory drugs for IBD in future.261
A few studies have suggested that administration of SCFA could have a positive
impact on the treatment of UC262;263;264;265 and Crohn’s disease patients with mild to
moderate ileocolonic disease.266 In 2013, two studies went on to show that butyrate,
in a dose dependant manner, promotes regulatory T-cell (Treg) generation through
inhibition of histone deacetylase.267;268 These studies also found that de novo Treg
cell generation in the periphery, was enhanced by propionate via histone deacetylase
inhibition. However acetate lacked this inhibitory functionality.
An in vitro study has shown that when T-cells are given butyrate under Treg inducing
conditions, acetylation of the Foxp3 promoter region increases along with enhancer
elements thus allowing Foxp3 to be expressed. A number of host receptors includ-
ing G-protein coupled receptors GPCR43 and GPCR109a can sense SCFA.269;270
GPCR43 expression is specifically increased on Treg within the gut epithelium,
269
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hence loss of GPCR43 or similar receptors could lead to host susceptibility to colonic
inflammation. This highlights a possible route for gut bacteria via bacterial metabo-
lites to alter the status of host immunity, theoretically affecting the balance between
pro-inflammatory and anti-inflammatory mechanisms.
Valerate (C5) A recent paper looking at the gut bacteria as potent class I his-
tone deacetylase inhibitor, which is primarily involved in cell survival, proliferation
and differentiation, suggest that valerate (C5) plays a role in its expression.271 After
screening seventy-nine diverse commensal bacteria for their histone deacetylase in-
hibitory properties, the three most potent strains were evaluated for specific class I
and class II histone deacetylase inhibition. All three were butyrate producing strains,
but one also produced substantial levels of valerate (C5) and hexanoic acid (C6).
This study identified valerate as a potential contributor to the histone deacetylase
inhibitory effect. This Megasphaera bacterial strain, was then assessed in a mixed
community where it was shown to increase the capacity of the community to produce
butyrate and valerate, showing that bacteria via SCFA production have the ability
to affect gene expression.271 The structure of valerate is similar to the inhibitory
neurotransmitter gamma-aminobutyric acid (GABA), and a recent study has shown
that plant extracted valerate could act as a GABA-agonist in rats.272
SCFA in the form mono-valerin and tri-valerin which are esters of valerate, when
given as feed additives to chickens have been shown to reduce the colonisation of
Salmonella enteritidis,273 as well as reducing the incidence of necrotic enteritis caused
by Clostridium perfringens.274
Branched-chain fatty acids (iC5 and iC4) The branched chain fatty acids, iso-
butyrate (iC4) and iso-valerate (iC5), are products of protein fermentation, specifi-
cally from the amino acids valine and leucine respectively.275 Ammonia, amino acids,
phenolic compounds, and branched chain fatty acid concentrations are higher in the
distal colon where substrate sources are more limited and conditions including in-
creased pH, allow protein fermentation to take place.230;231 The production of iso-
butyrate (iC4) and iso-valerate (iC5) are correlated, even under changes in diet, a
feature that has been replicated across animal models as well as humans.275 Although
products of protein fermentation such as ammonia, have been suggested as possible
causes of inflammation in IBD,276 studies measuring SCFA have not reported an in-
crease in iso-butyrate and iso-valerate (Chapter 6, Table 6.1) suggesting that protein
fermentation is not increased in IBD.
Medium chain fatty acids Hexanoate (C6) and Octanoate (C8) The medium
chain fatty acid (MCFA) octanoate (caprylic acid) is commercially used as an antimi-
crobial agent on surfaces in food handling businesses and drinks processing plants,
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as well as a disinfectant in health care facilities and schools. A 2010 study using
a rabbit model, showed a supplement of octanoate reduced the number of coliform
bacteria isolated from the stomach and caecum of rabbits, as well as a reduction in
the number of anaerobes isolated from the caecum.277
Animal husbandry studies have shown that sub-minimal inhibitory concentrations of
the fatty acids propionate (C3), butyrate (C4), octanoate (C8) and hexanoate (C6),
significantly alter the invasive capability of Salmonella typhimurium in piglets.278
This suggests that SCFA/MCFA, in optimum concentrations, have a role to play
in maintaining bacterial homoeostasis in the gut. Animal husbandry studies have
also shown that the MCFA hexanoate and octanoate affect the composition of the
intestinal microbiota as well as having inhibitory effects on bacterial concentrations
(Salmonella and coliform bacteria) in the digestive tract of weaned piglets.279 Inter-
estingly the inhibitory concentration of MCFA has been shown to be much lower
than SCFA such as propionate (C3) and butyrate (C4).279 It is therefore possi-
ble that within the gut microbiota, individual bacteria secrete particular profiles
of SCFA/MCFA which work to inhibit the growth of competing species.
In summary SCFA/MCFA have the potential to alter gut barrier integrity, by regu-
lating tight junctions;240 alter cytokine expression;280 promote Treg generation;
267;268;
and directly inhibit the growth of potential pathogenic species.278;279 These properties
of fatty acids suggest they might play a key role in driving or maintaining inflam-
mation in patients with IBD. Understanding the ways in which colonic fatty acid
profiles differ between patients with IBD and Crohn’s disease is therefore a vital area
of research.
1.10.2 SCFA levels in IBD and Crohn’s disease
The type of bacterial species which ferment dietary fibre to produce SCFA, are typ-
ically found to be reduced in the mucosa and faeces of patients with IBD when
compared to healthy individuals. Studies have indeed gone on to show that faecal
SCFA levels are reduced in patients with active IBD (Chapter 6, Table 6.1).
However, interpreting SCFA from samples has some limitations as the concentrations
found in faeces are also affected by a number of confounding factors within the colon;
including gut motility; transit time; SCFA absorption and host metabolism. Thus
using SCFA as an indicator of bacterial activity in the colon where the majority
are quickly absorbed or metabolised in the gut, means faecal levels cannot give an
accurate picture of fermentation processes in the proximal colon;281 such that two
individuals with the same level of butyrate in faeces may have different bacterial
fermentation and butyrate absorption capacities. Given this limitation, the potential
functional differences between IBD patients and healthy individuals make the study
of bacterial metabolites, an essential part of future research.
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Decreasing levels of butyrate have been linked with lower levels of microbiota diversity
in both UC and Crohn’s patients.195 Of SCFA producing bacteria, Phascolarctobac-
terium (Ruminococcaceae) and Roseburia have been shown to be reduced in Crohn’s
disease.195 Given that Ruminococcaceae metabolise hydrogen to produce acetate,
which can in turn be converted by Roseburia to butyrate, it makes sense that these
interdependent bacterial groups might decrease together in Crohn’s disease.195
If patients with IBD have impaired SCFA production, this would not only result
in reduced energy to colonocytes but also a loss of normal immunoregulation. Un-
derstanding the role of SCFA in Crohn’s disease could help us to understand why
bacterial dysbiosis drives inflammation in these patients, and how modulation of the
diet can alter SCFA levels in the gut, creating a pro-inflammatory state. The mech-
anisms of how SCFA, especially butyrate, regulate inflammation in IBD is still not
understood. Hence it is important to try and link SCFA production, the microbiota
and diet with inflammatory markers in individual patients in order to understand
how these factors affect each other.
1.11 Key concepts of this thesis
It has already been shown that dysbiosis in Crohn’s disease includes an increase in
the numbers of bacteria with reduced bacterial diversity, a decrease in abundance of
Firmicutes and an increase in Proteobacteria and Bacteroidetes. Although it is not
the main aim, the current study will test this assumption against healthy children,
but also a group of children with non-IBD conditions as well as children with UC.
In addition to exploring these differences in the gut microbiota between healthy indi-
viduals and those with Crohn’s disease, microbial studies looking at the use of EEN
as a treatment for children with Crohn’s disease, have given an interesting insight
into bacterial changes involved in remission and flare up in Crohn’s disease. As well
as being underpowered, these earlier studies were limited to using older technologies
which limit the number of bacterial groups/species that could be included. The cur-
rent study aims to fill this gap by using 16s rRNA and Illumina technology to build
a wider picture of which bacterial groups, down to species level, are changing during
treatment with EEN. This level of detail could give insight into why 1:5 children fail
to respond to EEN. It will also provide a better picture of whether EEN works by al-
tering the levels of specific pathogens or rather modifies the global balance of bacteria
in the gut. Understanding changes in the gut microbiota composition and bacterial
metabolic activity during the use of EEN, will help to increase our understanding of
the mechanisms that control inflammation in Crohn’s disease.
No previous studies had looked at gut bacterial or metabolite changes in children with
Crohn’s disease post-EEN who were being treated with MEN. The current study de-
sign was set up to explore whether MEN could maintain gut bacterial and metabolite
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changes achieved during EEN. This work is of particular importance since MEN is
currently being used as a treatment strategy, given as a supplement in addition to
normal diet (usually 20% of EAR), with little understanding of how it might work.
Although previous studies have looked at dietary intake in children with Crohn’s
disease, no study has tried to link diet with the microbiota in the same patients.
Thus the aim of the current study is to collect dietary data from children pre- and
post-EEN to see if dietary composition can be linked with bacterial and metabolite
composition.
Understanding what drives inflammation in Crohn’s disease will not only improve
delivery of treatment, but allow clinicians to predict which patients are most likely
to benefit from enteral nutrition in the form of EEN and MEN, increasing its success
rate. Although the successful use of EEN has been well demonstrated it is not used
universally across the globe, hence understanding the mechanisms that lead to these
distinct changes in gut microbiota composition which improve barrier function, could
help to widen its use, as well as develop consistent protocols across centres.
1.11.1 Hypotheses summary
 Children with Crohn’s disease have a gut microbiota and bacterial metabolite
profile, which is distinct from that of children with UC, non-IBD conditions and
healthy children.
 Gut microbiota profiles at baseline can predict which children with Crohn’s
disease will respond to treatment with EEN.
 Treatment with EEN is associated with changes in gut microbiota and metabo-
lite composition, which is linked with changes in inflammatory status.
 For children in disease remission post-EEN, supplementing return to normal
diet with (20%) maintenance enteral nutrition (MEN) can increase remission
times; and that MEN helps to maintain gut microbiota and metabolite profiles
associated with remission achieved during EEN.
 The profile of dietary intake at baseline for children with Crohn’s disease is
distinct from children with UC, non-IBD conditions and healthy children. Also
that dietary intake in children with Crohn’s disease post-EEN is associated with
time to disease relapse.
To test these hypotheses, bacteria and metabolites in the form of short/medium chain
fatty acids will be extracted from stool samples. Faecal markers of inflammation
(calprotectin) and blood markers of inflammation (CRP, ESR, albumin, FBC, LFT)
will also be collected. Dietary intake from food frequency questionnaires along with
patient characteristics (disease activity, disease location, height, weight, BMI) will
also be used (Chapter 2).
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2 Recruitment, Sample collection and methods
2.1 Study design
This chapter will describe the method of child recruitment as well as ethical con-
siderations and ethics approval including participant eligibility. It will also set forth
how samples were collected; detailed lab methods and the statistical design used to
answer the questions proposed in the hypotheses.
This prospective observational study was carried out in collaboration between Uni-
versity of Glasgow and the West of Scotland Paediatric Gastroenterology, Hepatology
and Nutrition (WoSPGHaN) network, with a core subspecialty service and endoscopy
at Royal Hospital for Children, Glasgow and outreach services with named paediatri-
cians at Forth Valley Royal Hospital, Wishaw General Hospital, University Hospital
Crosshouse and the Royal Alexandra Hospital allowing some children to be seen
within their own local centre. Within the University of Glasgow the study com-
bined expertise from the Department of Human Nutrition and Glasgow Polyomics
Facility, University of Glasgow. The study was approved by the West of Scotland
Research Ethics committee and the NHS Greater Glasgow & Clyde Research and
Development department to run from 24/6/14 for 4-years (study reference number
14/WS/1004) under the title, Gut Microbial Taxonomy and Metabolism in Paediatric
Crohn’s Disease during Exclusive and Supplementary Enteral Nutrition using OMICS
Technologies (appendix 1). This study is publicly registered with ClinicalTrials.gov
under the reference NCT02341248.
Observation, replication, and prediction are fundamental to all sciences. One of
the key qualities of a scientist is to be a good observer, recording and reporting
observations in a sufficient amount of detail to allow other scientists to replicate
the study. Over recent years there has developed a pressure in publication to create
shorter articles. It is true that papers can be reduced in size without any fundamental
loss of meaning, however this can be more problematic when describing detailed
methodology. Sadly, it has become often impossible to replicate studies because of
insufficient detail in methods, and contacting authors to request these details can be
difficult, particularly where the author is no longer working in academia or has died.
Methodologic issues section of journals have to some extent helped to overcome this
problem, as well as encouraging discussion around methodologies and facilitating
the practice of experimental replication. As such this chapter will aim to provide
sufficient detail and discussion around methods used, which should allow replication.
Another problem with biomedical research is that due to improvements in technol-
ogy; company updates; or current understanding of processes, methodologies are
constantly being updated or superseded by newer methods. Thus researchers need to
keep themselves up to date with current improvements and make decisions based on
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cost and the degree of improvement, about whether the questions they are trying to
answer would be better served by moving to newer methods. Although using newer
methods can make it difficult to compare across similar studies that have used differ-
ent methods, hence decisions are sometimes made to use an older method if linking
in with other studies is of key importance. Also within existing methodologies it is
important that the researcher undertaking lab work understands, and designs exper-
iments that account for the role that experimental variables play in producing data
that help to power studies and answer research questions. In this chapter I will try
to discuss where possible some of the issues around experiment variables and identify
where improvements could be made.
This study is a prospective observational study and as such there is no placebo and
no correction for any type of treatment bias. Observational studies lack the aspect of
randomised allocation of a treatment as it would be unethical to withhold treatment
that is known to be effective. Hence the current study is limited to discussing any
bias which is observed and trying to understand results in light of these limitations.
2.2 Subjects
2.2.1 Identification and recruitment of participants
Patients were identified from the West of Scotland Paediatric Gastroenterology, Hep-
atology and Nutrition (WoSPGHaN) network which covers a wide range of areas in
the west of Scotland. Children from distant rural or island communities however were
not recruited on to the study, as it was impracticable to collect a series of six stool
samples over these distances. Three groups of children aged between 3 and 18-years
were included in the study (Fig. 2.1).
Figure 2.1: Groups of children recruited on to the study.
The first group invited to join the study were children undergoing endoscopic in-
vestigation (colonoscopy) to rule out colonic inflammation, including both ulcerative
colitis (UC) and Crohn’s disease. Only children who received a diagnosis of Crohn’s
disease then went on to participate in the follow up aspect of this study i.e. those
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undergoing treatment with exclusive enteral nutrition (EEN). The second group in-
vited to join the study were children with a previous diagnosis of Crohn’s disease
who were about to start on an 8-week standard course of treatment with EEN due
to disease flare up. The final group invited to join the study were a cohort of age
and sex matched healthy children, unrelated to Crohn’s disease patients, who were
recruited as a control group.
Group A. Children undergoing endoscopic investigation for IBD
Prior to diagnosis This study group were recruited from all children age three
to eighteen years old, booked in to have a colonoscopy to investigate possible gut
inflammation by a paediatric gastroenterologists at the Royal Hospital for Children,
Glasgow. Eligible participants were identified through endoscopy appointment lists
with assistance from the paediatric gastroenterologists who were co-investigators of
this study. The clinician informed potential participants about the study during
their routine appointment and asked them if they would be happy to speak with
a researcher after their appointment. If the child and their parent/guardian were
agreeable, the researcher met with them after their appointment to explain the study
in full, and answer any questions they had. The family were given an information
pack which contained a leaflet for the parents and an age appropriate leaflet for
the child. If both parent/guardian and the child were willing to take part in the
study the researcher requested to collect urine, a faecal sample, bloods if these were
already being taken for clinical diagnostic reasons, and eight additional tissue biopsy
samples from the gut lining if the patient was having a colonoscopy. We also requested
permission to collect relevant medical information, such as information on medication
and disease status from their patient notes.
After obtaining informed consent, the parent/guardian and child were asked to com-
plete a food frequency questionnaire (FFQ). They were given a faecal and urine
sample kit along with detailed instructions (appendix 2.3) and requested, if possible,
to provide a faecal and urine sample prior to their colonoscopy. If unable to provide a
sample before colonoscopy, a sample was requested before they started any treatment.
After diagnosis Once children had given the first set of samples and undergone
their colonoscopy, only children who had a confirmed diagnosis of Crohn’s disease
continued on the study. The samples collected from children who were not diagnosed
with Crohn’s disease, were retained and used as patient control groups made up from
those who had UC; and a second non-IBD group who had a range of other conditions.
These two groups of children were not requested to give any further samples.
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Figure 2.2: The target time points and type of sample collected from children with Crohn’s disease
undergoing treatment with exclusive enteral nutrition (EEN).
Group B. Children with previous diagnosis of Crohn’s disease
Children with a previous diagnosis of Crohn’s disease about to start on an 8 week
course of treatment with EEN, were recruited from across the West of Scotland
Paediatric Gastroenterology, Hepatology and Nutrition (WoSPGHaN) network, in-
cluding centres at Glasgow, Wishaw, Larbert (Forth Valley) and Crosshouse (Ayr-
shire). Eligible participants were identified through hospital appointment lists with
the assistance of medical staff, including IBD nurses and dietitians. The process of
recruitment was as described for group A, except this group of children were not
asked to provide any mucosal biopsy samples, since they were not about to undergo
a colonoscopy.
Children from patient groups A and B, diagnosed with Crohn’s disease and under-
going 8-weeks of treatment with EEN, were asked to provide a total of six faecal
and urine samples: at baseline; 2-samples during treatment with EEN and 3-samples
post-EEN (Fig. 2.2). A sample of blood was requested during routine clinical blood
collection. A food frequency questionnaire (FFQ) was requested at baseline then at
three collection points post-EEN. An estimated 3-day food diary, to record detailed
dietary intake, was requested at 2-weeks and 8-weeks post-EEN (Fig. 2.2).
Once children in group A and B had completed their treatment with EEN some
children opted to take a maintenance form of enteral nutrition (MEN) along with
their normal habitual diet. However some chose not to continue with MEN, due to
the supplement becoming unpalatable during their exclusive diet or because they saw
no benefit from taking it, if they had failed to respond to EEN. Both children who
took MEN and those who did not, were retained on the study for the full 36-weeks.
Group C. Healthy children (control group) Healthy children unrelated to Crohn’s
disease patients, aged between 2 and 17-years were identified and invited to take
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part in the study via word of mouth or advertising through posters and leaflets.
Where possible, they were recruited from the same geographical areas as our patient
cohort. After introducing the study to children and their parent/guardian and giving
them age appropriate detailed information leaflets (appendix 2.2), healthy children
who consented were requested to give a single faecal and urine sample and complete
dietary questionnaires in the form of a 3-day food record and an FFQ.
2.2.2 Consent and ethical considerations
The recruitment strategy we chose followed the tried and tested procedure used for
children at Yorkhill in the ‘BISCUIT study’ (IRAS Ref:09/S0802/24). A clinician
informed potential participants about the study during their routine appointment and
ask them if they would be happy to speak with a researcher after their appointment.
If the child and their parent/guardian were agreeable, the researcher met with them
to explain the study in full and answer any questions they might have at this stage.
The parents/guardians were given a detailed information leaflet (appendix 2.1) which
was specific for each of the three groups: (A) children prior to diagnosis; (B) chil-
dren with Crohn’s disease; (C) healthy children. Children who were age seven or
under were provided with a pictorial form of the information leaflet to help them to
understand what the study involved and the researcher or parent/guardian read the
simplified age appropriate information leaflet to them (appendix 2.2). The language
used in each age appropriate information leaflet was carefully chosen, with the advice
of primary school teachers, to be easy to understand yet detailed enough so that
children were fully informed about the study. Participants willing to take part in the
study were invited to sign a consent form in duplicate: one for the participant and
one for the research site file. A third copy of the consent form was placed in the
hospital medical notes of all hospital patients who took part. Parents were asked to
sign an assent form to confirm they agreed with their child taking part. For children
of primary school age it was the parent who signed consent and the child an assent
form. If the child was unable to write their own name the parent completed a consent
form on their behalf. It was also made clear that they could withdraw from the study
at any time without giving a reason. In the interest of participant welfare, an external
contact name and phone number was provided to all participants, whom they could
contact if they had concerns or wished to raise a complaint.
To ensure the well being and safety of participants the researcher undertook NHS
Greater Glasgow & Clyde Good Clinical Practice training courses. Access to patient
medical records and storage of sensitive data by the researcher followed the rules
governed by the NHS Code of Practice (Scotland) Version 1.0 and current data pro-
tection laws.282 Only the researchers named in the study ethics had access to this
information.
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2.2.3 Inclusion and exclusion criteria
A health check questionnaire was used to screen patients. Patients were excluded
if they had treatment with antibiotics or surgery to remove part of the gut, in the
previous 6-weeks, since this would likely alter gut microbiota composition. Healthy
children were also excluded if the had any gastrointestinal symptoms in the last
6-weeks.
Medication A note of all medications taken in the last 6-weeks was recorded at
baseline as part of the health check questionnaire. Any additional medications as
well as those taken as part of standard treatment during the term of the study were
recorded from patient notes.
2.3 Treatment with exclusive and maintenance enteral nutrition
This was a prospective observational study and as such children with Crohn’s disease
who took part in the study underwent a standard course of treatment with EEN
to induce disease remission under the care of the West of Scotland Paediatric Gas-
troenterology, Hepatology and Nutrition team. Normal treatment requires them to
complete 8-weeks of exclusive feeding with the polymeric enteral nutritional formula
Modulen IBD (Nestle, Switzerland) or in children with cow’s milk protein intoler-
ance, Elemental O28 extra (SHS international, Liverpool, UK). The amount given
was calculated for each child to meet their estimated average requirement (EAR) for
age. This was usually increased by up to 10% for children who were underweight
at the time of starting treatment.283 As per normal treatment, at the end of the
8-weeks children either continued taking enteral nutrition (about 25% of EAR) as a
supplement to their normal diet (MEN) or stopped enteral nutrition altogether and
went back to their normal habitual diet. The study made no alteration or addition
to the child’s normal treatment for Crohn’s disease, and only collected samples and
monitored their progress under normal treatment conditions.
Children who were unable to tolerate EEN orally were given Modulen IBD via naso-
gastric intubation which involves the insertion of a plastic tube (NG tube) through
the nose and throat to reach down into the stomach. The duration from the start of
remission to subsequent disease relapse over the course of 28-weeks after treatment
was documented for each child with Crohn’s disease. Disease relapse was defined as
an increase in disease activity resulting in a repeat course of treatment with either
EEN or corticosteroids; or a step-up in medical treatment such as biologics or surgery.
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2.4 Measurements and samples collected from participants
2.4.1 Anthropometric measures
The height of children was measured using a Seca Leicester stadiometer (Seca 213,
Birmingham, United Kingdom) to the nearest centimetre by the researcher or by
nursing staff in clinics. Body weight and body composition were measured where
possible with a TANITA (TBF300, TANITA, Japan) body composition weighing
scales; however as this method was not used by nursing staff in clinics, only height,
weight and BMI was used to assess anthropometric measures in this study. All
children had their height and weight measured at baseline. For children with Crohn’s
disease measurements were taken at time points: 0-weeks (pre-treatment with EEN);
8-weeks EEN; then 2-weeks and 8-weeks post-EEN.
LMS (lambda, mu, sigma) method software, based on the UK 1990 reference growth
standards data, was used to calculate percentiles which were converted to standard
deviation scores (SDS), commonly referred to as z-scores.284 Theses growth standards
provide sex and age specific LMS parameters that allow the calculation of z-scores
that indicate how close each individual is to the population median. An example of
typical conversions for comparison is shown in Table 2.1.
Table 2.1: List of usually used percentile and SDS
z-score conversion values
percentile Z-scores (standard deviation scores)
0.2nd -3.00
2.3rd -2.00
2.5th -1.96
5th -1.64
15th -1.04
16th -1.00
50th (median) 0
84th +1.00
85th +1.04
95th +1.64
97.5th +1.96
97.7th +2.00
99.8th +3.00
In statistics the z-score or standard deviation score
(SDS) is the signed number of standard deviations
above the mean. See equation (1).
z-score or SDS =
observed value - median value of reference population
standard deviation value of reference population
(1)
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Interpreting the results for height and weight as z-scores has advantages. Firstly the
z-score scale is linear, and thus has a fixed height or weight difference for all children
of the same age in the population. In terms of analysis, z-scores make comparison
across different age groups possible. Secondly z-scores are produced independently
for girls and boys, which means children’s growth status reflects differences in both
sex and age.
The BMI z-score categories were used to work out whether children were under or
over weight as per the NHS National Obesity Observatory (NOO) guidelines:285 A
simple guide to classifying body mass index in children (Table 2.2).
Table 2.2: BMI z-score categories
Catergory BMI z-score Centiles
very underweight ≤ -2.67 BMI z-score (≤ 0.4th rounded centile)
low weight ≤ -2 BMI z-score (≤ 2nd rounded centile)
healthy weight > -2 to < 1.34 BMI z-score (> 2 to < 91st rounded centile)
overweight ≥ 1.34 BMI z-score (≥ 91st rounded centile)
obese ≥ 2 BMI z-score (≥ 98th rounded centile)
extremely obese ≥ 2.67 BMI z-score (≥ 99.6th rounded centile)
NHS NOO guidelines 2011: A simple guide to classifying body mass index in children
2.4.2 Socioeconomic status
The Scottish Index of Multiple Deprivation (SIMD) was used to estimate socioe-
conomic status.286 In all, seven indicator ‘domains’ are used: income, employment,
education, health, access to services, crime and housing. These seven domains are
then used to create a rank from 1 (most deprived) to 9,976 (least deprived). The
resulting 9,976 individual zones are divided into areas of equal population size.286
To visualise the data, the 6,976 SIMD data zones were subdivided into quintiles (5-
bands) using the SIMD rank scores. Each band contains 20% of the data zones, with
rank-1 containing the 20% most deprived and rank-5 containing the least deprived
zones in Scotland.
52
Figure 2.3: The Scottish Index of Multiple Deprivation 2016 by area distribution286
The SIMD scores need to be used with some caution. They are not always a clear
indicator of deprivation because the difference between two ranks could be very small
or quite large. The emphasis of different domains might also vary with some areas
having similar scores for different reasons hence making it difficult or inaccurate to
associate with health outcomes. Also not everyone who is deprived lives in a deprived
area and vice versa, hence in a small study like this one there is some limitation in
using the SIMD score to assume the socioeconomic status of any individual child in
the study. It is however useful to look at any potential differences between groups of
patients and outcomes, because it can help to target resources towards where they
are needed, where socioeconomic status plays a role in risk or treatment outcomes.
When the national 2016 SIMD figures are split into the different health boards, they
show that Greater Glasgow & Clyde followed by Ayrshire & Arran, then Lanarkshire,
have the highest income deprivation and health deprivation in Scotland as well as the
highest overall deprivation shown by SIMD scores286 (Fig. 2.3). As these are the
areas this study recruited from our cohort of patients may not be representative of
Scotland or the UK as a whole, in terms of socioeconomic status.
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2.4.3 Measurement of disease activity and location
Disease activity Although it is by no means a perfect tool, the Paediatric Crohn’s
Disease Activity Index (PCDAI) is the standard outcome measure in paediatric
Crohn’s disease research. The inclusion of blood results, a perianal examination,
and measuring height velocity can make constructing the PCDAI score difficult, par-
ticularly if doing this retrospectively from patient notes. In our study a new weighted
version (wPCDAI), now being used by clinicians in West of Scotland Paediatric Gas-
troenterology, Hepatology and Nutrition network, was used because it has been shown
to perform better than the previous PCDAI being more feasible to complete and eas-
ier to use in practice. In 2011 Turner et al. tested the wPCDAI against the PCDAI
for 437 children with Crohn’s disease, and concluded that the wPCDAI performed
better in construct validity and responsiveness, as well as discriminating better be-
tween disease activity categories (ROC: 0.97; 95% CI: 0.95–0.99);287 with a recent
2017 study confirming these findings.288 In the current study children with Crohn’s
disease were assessed for wPCDAI scores at baseline, after 8-weeks of EEN, and
8-weeks post-EEN on normal diet (wPCDAI shown in appendix 3).
Table 2.3: Montreal classification for Crohn’s disease (Satsangi et al. 2006).1
Montreal
Age at diagnosis A1 below 17 yrs
A2 between 17 and 40 yrs
A3 above 40 yrs
Location L1 ileal
L2 colonic
L3 ileocolonic
L4 isolated upper disease *
Behaviour B1 non-stricturing, non-penetrating
B2 stricturing
B3 penetrating
p perianal disease modifier †
* L4 is a modifier that can be added to L1-L3.
† is added to B1-B3 when concomitant perianal disease is present.
Disease location Crohn’s disease is typically characterised by non-continuous in-
flammation which can effect the entire gastrointestinal system. The Montreal clas-
sification1 was used to categorise disease location in children with Crohn’s disease.
Although not the most recent classification system, the small number of patients with
Crohn’s disease in our study limit the research use of the newer Paris disease classifi-
cation sub-sets,19 as these would reduce the power of our data sets. The problem with
using disease extent in the classification system is that due to the dynamic nature of
Crohn’s disease, there is instability of disease extent over time, and children were not
given a follow-up colonoscopy unless their condition deteriorated (Table 2.3).
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2.4.4 Sample collection and processing
Faecal and urine samples: After giving consent, each participant was given a
faecal/urine sample collection kit, which contained a pre-weighed stool collection
pot, a plastic bag which could be sealed with the pot inside, an anaerobic sachet
(Anaerocult A Merck KGaA 62471 Darmstadt, Germany) and a sterile universal
container for urine. The aim was to enclose the pot and limit expose to oxygen to
protect anaerobic bacteria. The pack also contained an ice-pack and instruction sheet
which included contact details. A potential sample collection day was agreed between
the family and the researcher; courtesy calls and reminders were made every few days
to provide support and answer any questions. As soon as the sample was ready, the
family would call or text the researcher for collection with the aim to collect and have
it in the lab within 4-hours. Samples where collected in person by the researcher form
a wide range of areas in the west of Scotland (Fig. 2.4).
Figure 2.4: Map shows the distribution of children recruited onto the study. Children with Crohn’s
disease (green); UC (yellow); Non-IBD (red); healthy (blue).
Mucosal tissue biopsies: In children who were due to have a colonoscopy for di-
agnostic purposes, and with the consent of participants and their parent/guardian,
an additional six mucosal pinch biopsy samples; two from the terminal ileum when
possible; two from the ascending colon and two from the descending colon were taken
by the gastroenterologist (14-16 are collected at normal colonoscopy for diagnostic
purposes). An additional two biopsy samples were also collected from the duodenum
during upper endoscopy. These samples were taken during routine biopsy sampling
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Figure 2.5: Two pinch biopsies were collected from sites highlighted with blue boxes, a) duodenum;
b) terminal ileum; c) ascending colon; d) descending colon.
carried out as part of disease diagnosis at the Royal Hospital for Children, Glasgow.
Biopsy samples were taken using standard endoscopic forceps by the gastroenterol-
ogist and transferred by the researcher from the forceps using a sterile blunt ended
needle to a 2mL screw top tube. These were kept on ice for between 1-3 hours before
being stored at -80 C. Biopsies were held in a biobank by the department of Human
Nutrition to be included in a another study.
Bloods: Bloods were only collected from patient groups (5-8ml) and were only taken
if the child was having routine bloods taken as part of their normal treatment. Hence
no additional needle insertion was required. If the child had any anxieties about
giving routine blood and the nurse felt the additional blood might add anxiety we
did not request bloods.
Baseline bloods were normally taken from patients along with diagnostic bloods while
the child was under general anaesthetic during their colonoscopy (week-0). The child
was fasted and had taken an age appropriate dose of Picolax (sodium picosulfate
combined with magnesium citrate) as a bowel emptying preparation for colonoscopy.
Subsequent blood samples were not fasted. A blood sample was collected around
8-weeks of EEN during the child’s end of treatment review; and after 8-weeks of
normal diet post-EEN (Fig. 2.2). Bloods were held in a biobank by the department
of Human Nutrition to be included in a another study.
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Sample processing
Figure 2.6: Immediately after collection faecal samples were homogenised and processed as shown,
before being stored for further analysis.
Faecal and urine samples: To minimise any possible changes in bacterial compo-
sition, the aim was to start processing faecal samples within 4-hours after collection.
This was not always possible due to travel distances and the collection of multiple
samples. The mean elapsed time between production (telephone call) and arrival of
sample for laboratory processing is shown in (Table 2.4).
Table 2.4: Time between stool sample production and lab processing
group
CD UC non-IBD HC
mean number of hours 05:31 03:09 03:28 02:39
standard deviation 02:15 02:13 03:24 01:16
<4-hours (%) 70% 83% 60% 78%
On arrival in the lab the sample was weighed and then homogenised using a sterile
blender in a class-2 laminar flow cabinet. A summary of sample processing is given
in Figure 2.6. 1.5g of homogenised faecal sample was weighed into a 5mL bijoux
in quadruplicate and immediately stored at -80 C. 1g of faecal sample was weighed
into 5mL bijoux containing five glass beads in quadruplicate. 1M NaOH (1:1 w/v)
was added to samples to stabilise volatile short chain fatty acids such as acetate and
stored at -80 C. These samples were then freeze dried within 4-weeks as described in
section 2.7.1.
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Bloods: After bloods were taken by the nurse they were decanted in two 4mL
blood tubes, one containing K2EDTA and one with lithium heparin. These were
stored in a cool bag on ice and immediately transferred to the lab, where they were
centrifuged at 3 000g for 15-minutes (4 C). The plasma from each tube was split into
three eppendorf tubes and the remaining red blood cells transferred into a another
eppendorf tube. These were stored at -80 C.
Data on clinical markers C-reactive protein (CRP); erythrocyte sedimentation rate
(ESR); serum albumin; as well as full blood count (FBC); liver function test (LFT)
and urea and electrolytes (U/Es) were obtained from routine clinical lab results.
Although blood, urine, and mucosal biopsies were collected, these were not used in the
current project. These will be analysed as part of an ongoing wider research extension
to this study by the department of Human Nutrition, University of Glasgow.
2.5 Collection of dietary information
This study is based on the relationship between the effect of diet in the form of enteral
nutrition (EEN and MEN) and the outcome it has on gut inflammation and whether
a positive outcome has a direct effect on changes in the gut bacteria profile. It was
therefore necessary to gather additional information about the child’s dietary intake
at different time points over the course of the study, both before and after treatment
with EEN to determine if differences in diet could be correlated with changes in the
gut microbiota and inflammatory status of children with Crohn’s Disease (Fig. 2.7).
An ideal record of food intake should measure the true intake during the period of
study to create a valid dietary record which is a comprehensive and precise record of
all food consumption on recorded days. Due to the complexity of human behaviour
this is actually quite difficult to achieve.
Figure 2.7: Dietary questionnaire time points. 24-hour recalls were replaced with 3-day food diaries.
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After reviewing a number of methods we decided to use the five-step multiple pass
24-hour dietary recall questionnaire to collect data on the actual diet at the time
faecal and urine samples were collected. A dietary recall is a retrospective method
of dietary assessment whereby an individual is interviewed about their food and
beverage consumption during a defined period of time, typically the previous day or
the preceding 24-hours. Recall of intake over a longer time period is problematic due
to the limitations of memory. Several national surveys use the 24-hour recall method
because of its high response rate and its ability to obtain detailed information. The
interview can be carried out in person, by telephone or increasingly via the Internet.
The Norwegian arm of the EPIC software study showed no significant differences in
dietary data between face to face (n=102) and telephone 24-hour recalls (n=103).289
We planned to take this record on three separate days over the period of one week
(two week days and one weekend day).
However after 2-weeks of starting to use this method it became apparent that the
burden on patients of completing this questionnaire was greater than had been an-
ticipated. Firstly many children had after school activities and it was difficult to
find 3-evenings they were free to complete it. Secondly, on testing this method on
adults, the questionnaire took between 15-25 minutes; however in practice telephone
interviews often did not work well because parents/guardians found it difficult to an-
swer questions unless their child was sitting with them, being unsure what children
had eaten at school or away from home. The children found it difficult to report
their own eating habits, because they often did not have the skills to describe food
or portion sizes without parental help. The discussion between parents and children
resulted in the average time to conduct the interview being 45-minutes, much longer
than anticipated. Also a number a parents had very young children at home making
demands on them and interviews were thus interrupted or ended before completion.
It was not possible to visit the homes of children three times per week to carry out
these interviews and after listening to feedback from patients, and a problem with
non-compliance, it was decided to switch to a 3-day food record (Appendix 7.1.1)
which could be filled out at the families convenience. Hence although we had chosen
the best scientific method, in the context of young children, busy adolescents and
parents coming to terms with chronic IBD, the time burden was too much for most
families.
2.5.1 Food frequency questionnaire (FFQ)
The FFQ is a constructed list of foods and drinks with a frequency response tick-box
section for participants to report how often each item was consumed over a specific
period of time. Participants were shown pictures of portion sizes and asked to count
larger portions as two incidences rather than one. Calculations for nutrient intake
were then estimated by the diet survey team at the University of Aberdeen. These
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calculations multiply the reported frequency of each food eaten by the amount of
nutrient in that serving of food.290
FFQs are good when measuring habitual intake which can be variable from day-to-
day and are relatively easy for participants to complete, as well as being low cost.
Craig et al. 2010 compared the child FFQ with a 4 day food diary in 150 children.
Children age 12-16 filled out their own questionnaire while parents completed it for
those age 3-11 years. The study found that Spearman rank correlation coefficients
were significant (p<0.05) for all nutrients, with the exception of energy, total fat
and vitamins C and E, in the FFQ for children aged 12-16. Although the ranking
agreement was best in the 3-11 age group, absolute intakes agreed best between the
two methods for children in the 12-16 age group. Therefore the FFQ is a useful tool
to look at generalised differences between groups.290
It does however have some drawbacks. It is a retrospective method that relies on the
participant having a reasonably good memory and it is not very sensitive to measures
of absolute intake for specific nutrients. Also the way foods are grouped might not
make sense for some participants or may not contain foods popular with families
originating from other countries or who choose to shop outside of mainstream UK
stores. These factors might lead to inaccurate data if not taken into account.290
Paper copies of the Scottish Collaborative Group validated FFQ (Appendix 7.1.2)
provided by the University of Aberdeen were used. These include around 150 commonly-
eaten types of UK food or drink which are grouped into 19 sections.291 Two versions
were used: the children’s FFQ which is designed for children aged 3-11 and is nor-
mally completed by the parent. The second version of the children’s FFQ used is
designed for children aged 12-17. It has additional foods such as coffee and alcoholic
drinks, and is completed by the young person themselves. An FFQ was given to
each participant both patients and healthy children at the start of the study. The
researcher explained the FFQ in detail paying particular attention to the portion
sizes shown on the front of the questionnaire (Appendix 7.1.2) and explaining how to
record this in the tick boxes. They were also prompted to think about hidden foods
in composite foods such as milk and sugar in tea; or butter in sandwiches. They were
asked to record the foods and drinks they had consumed in the previous 2-weeks. An
FFQ was also collected 2-weeks, 8-weeks and 28-weeks post-EEN (Fig. 2.7).
2.5.2 3-Day dietary records
It was decided in the current study to avoid using weighed food diaries, because
it is known that asking participants to weigh food can alter the behaviour of the
participant.292 Weighing food takes extra time thus, subconsciously or consciously,
participants may choose a meal that is easier to weigh to save time. There is also the
problem that asking participants to weigh food makes them consider food types and
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portion sizes that might be considered to be socially desirable.292 This can lead to
an inaccurate record of the actual ‘normal’ habitual diet. After researching different
methods the current study chose to use the 5-step multi-pass 24-recall which has been
shown to be an excellent method to help the participant recall all food consumed
by using prompts which remind the participant to recall drinks and snacks out-
with normal meal times, or forgotten items such as sugar added to hot drinks.293
Participants were asked if the researcher could call them on the telephone on two
typical weekdays and one weekend day to conduct the interview. For the first five
recruited patients three refused to give dietary information over the phone as they felt
it was either too inconvenient, or could not find time due to other activities. Another
had difficulty completing the interviews due to the needs of young children in the
home. The other interview went very well. Given the low level of participation in
3-day food records over the phone, and after listening to feedback from participants,
it was decided to change the method to a 3-day written diary, which had the effect
of increasing compliance, as participants could complete it at times more suitable to
their own individual needs. An introductory instruction sheet based on the 5-day
multi-pass interview was given to participants along with the dietary record, to try
and prompt participants to remember snacks (Appendix 7.1.1).
Three-day food records were requested from participants once they had completed
treatment with EEN and had returned to habitual diet for 2-weeks; then 8-weeks; and
at disease relapse or seven months after completing treatment with EEN, whichever
came first. Three day food records were not requested prior to the start of treat-
ment, firstly because patients were being asked to fast as part of their preparation
for colonoscopy, and secondly because a large number of patients started treatment
within a few days of recruitment and hence would not have sufficient time to record
three separate days before starting enteral nutrition either as the eight week course
of EEN treatment or as ‘tasters’in preparation for EEN.
Many people after filling out an FFQ failed to complete and return the 3-day food
record. Compliance was so poor it was decided not to include these in the study.
2.6 Detailed lab methods
2.6.1 Stool sample consistency as a measure of disease activity
Bristol Stool Chart The Bristol stool chart was used to record the consistency
of faecal samples before they were processed for analysis. It is a system of seven
categories often used by health professionals to classify the form of human faecal
samples. It was developed in 1997 at the University of Bristol294 as proxy measure
of colonic transit time. Although it has been shown that it has limited use in terms
of measuring transit time,295 it is a useful research tool to evaluate the effectiveness
of treatments used to reduce inflammation in the gut.296 Type 1 and 2 represent
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constipation while 3 and 4 are ideal stools which are easy to pass. 5 & 6 contain
excess liquid tending towards severe diarrhoea at type 7 (Fig. 2.8).
Figure 2.8: Bristol Stool Chart: Types 1 and 2 show constipation; 3 and 4 are ideal stools with 5,
6 and 7 tending towards diarrhoea.
2.6.2 Faecal calprotectin as a marker of disease activity
Faecal calprotectin was measured using the commercial ELISA kit CALP-0170 (CalproLabTM,
CALPRO, Lysaker, Norway) according to the manufacturer’s instructions.
Sample extraction: Previously homogenised frozen (-20 C) faecal samples where
thawed at room temperature and ∼100mg weighed into 15mL corning tubes using an
inoculation loop. The loop was left inside the tube as an agitator. The manufacturer’s
extract buffer was added (w/v 1:50) and the samples vortexed before being shaken
for 45-minutes on an orbital shaker (IKA VIBRAX VXR BASIC) at 1000rpm. Samples
were then centrifuged at 3,000g for 5-minutes at 4 C before 1.8mL of the supernatant
transferred to 2mL eppendorfs. These extracts were stored at -20 C until used.
ELISA: On the day of analysis, extracts were thawed at room temperature and
centrifuged at 3,000g for 5-minutes at 4 C. The extracts were then diluted 1:100
in the manufacturer’s dilution buffer, vortexed and then 100µL added to wells in
62
duplicate. A set of six standard dilutions (0, 7.8, 31.3, 62.5, 125, 500) along with a
high and low control sample were set up as per the manufacturer instructions and
also added to the plate along with a negative control. The plate was incubated on a
plate shaker (500rpm) in the dark for 45-minutes at room temperature then washed
five times with 300µL of manufacturer’s wash buffer. 100µL of manufacturer’s ALP
enzyme conjugate was then added to wells using a multi-channel pipette (reverse
pipetting) and again incubated on a plate shaker (500rpm) in the dark for 45-minutes
at room temperature. Solution was removed by inverting the plate, tapping dry and
then washed five times with 300µL of manufacturer’s wash buffer. Finally 100µL
of pNPP enzyme substrate solution was added to wells and incubated in the dark
for 30-minutes at room temperature before adding 100µL of 1M NaOH to stop the
reaction. The OD values at 405nm were then read on an ELISA reader (ThermoLab
Systems Multiskan Spectrum). The concentration of calprotectin in faecal samples
was calculated with reference to the standard curve (4-parameter logistic non-linear
regression model) and expressed as mg/kg of dry faecal material.
2.6.3 Faecal pH
Faecal pH was measured from a 1:3 w/v faecal slurry: 1g of homogenised faecal
sample was suspended in 3mL of distilled water with four glass beads. The slurry
was vortexed until completely dispersed. Measurement of pH was performed using
an auto-calibrated portable digital pH meter (Hanna HI98140, Portugal).
2.6.4 Faecal ammonia (NH3)
Faecal ammonia was measured from the 1:3 w/v faecal slurry used for measurement
of pH. This slurry was further diluted with water to 1:500. 10mL of slurry was then
passed through a 0.22µL filter (Millex GP, Millipore, USA cat. SLGP033RB) into
a glass vial. This was used to obtain a blank measurement on the ammonia analyser
(Hannah Electrical HI93715; Hannah manual.pdf) before adding 4-drops each of the
proprietary reagents (Hannah HI-93715-01: Nessler method). The vial was inverted
to mix reagents and the measure of ammonia (NH3) recorded as mg/L (ppm).
2.7 Measuring short chain fatty acids (SCFA)
2.7.1 Sample preparation and storage
Short chain fatty acids (SCFA) are the major end product of bacterial metabolism
in the colon, and are associated with nutritional benefit for colonocytes and the host
in general. Due to the importance of SCFA it was important to use an efficient,
economical, and sensitive method to measure the range of short and medium chain
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fatty acids in a large number of faecal samples. SCFA (C2-C8) and branched chain
fatty acids (BCFA) iso-butyrate, iso-valerate, and iso-hexanoate (Table 2.5) were
extracted and then measured using gas chromatography.297
Principle of extraction The pKa of acetic acid is 4.8 (other SCFA are similar)
which means at 4.8 the ratio of the acid or anion (salt) form is equal. In their natural
acidic form SCFA are volatile. However the base sodium hydroxide (NaOH) can
be added to faecal samples to lock SCFA in their ionic form (salt) to prevent loss
from the sample. To then unlock the SCFA the addition of a strong acid such as
orthophosphoric acid decreases the pH to less than 1; and at this pH more than 99%
of SCFA return to their acidic form. SCFA can then be extracted using the organic
solvent diethyl ether which forms two phases when mixed with faecal slurry. The
acidic form which is miscible in ether can then be extracted for analysis using Gas
chromatography. Although this method recovers close to 100% of SCFA an internal
standard (2-ethyl-butyrate) is added to faecal samples prior to extraction to account
for any possible loss.297
Stabilisation of SCFA for storage Approximately 1g of faecal sample was added
to a bijou tube containing 4 glass beads along with an equal volume of 1M NaOH
w/v. The tube was vortexed until the sample was fully homogenised. Samples were
then stored at -80 C until freeze dried and analysed.
Freeze drying faecal samples Faecal samples for short chain fatty acid analysis
were removed from -80 C and holes made in the lids of sample tubes using syringe
needles. The samples were returned to -80 C for one hour and then freeze dried
(Edwards apparatus Micro Modulyo, Thermo Scientific ) for 36-hours. Fresh lids
were placed on freeze dried samples after they had been homogenised with a sterile
wooden spatula. Sealed tubes were stored at room temperature with a silica gel
desiccant until further analysis.
Determination of water content Water content was determined by weighing sam-
ples before and after freeze drying. Once faecal sample dry weight was known, water
content was then expressed as percentage of water per mass of stool sample less the
weight of added NaOH.
SCFA extraction 100mg of freeze dried faecal sample was weighed out into 15mL
corning tubes (Corning , Mexico, USA). The sample was homoginised with 300!L
of distilled water by vortexing. 100!L of orthophosphoric acid and 100!L of 2-ethyl
butyric acid (as internal standard) was added to samples. 1.5mL di-ethyl ether was
added to the tube and vortexed on an orbital shaker (IKA Vibrax Orbital Shaker)
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at 1200rpm for one minute. The upper ether phase was removed to a separate 15mL
corning tube and the process repeated 3 times. The extracted supernatant was then
transferred to 1.5mL glass vials (Agilent technologies , USA, cat. 5181-3375) and
sealed with silicone rubber seal crimp tops to avoid evaporation(Fisher scientific ,
UK, cat. 11588150) in preparation for gas-chromatography.
SCFA standards Gas chromatograph does not give an equimolar response to sam-
ples being measured so an external standard to quantify the amount of SCFA in
samples was used. An external set of 11-standards (Table 2.5) was extracted with 6
dilutions (10, 25, 50,100, 200, and 300µL) using the same protocol as for the unknown
samples to obtain the retention times and draw quantification calibration curves. The
concentration of individual acids used to construct standard curves were previously
optimised by Laurentin and Edwards (2004).297
Table 2.5: Concentration of external standards used in SCFA extraction
no. of carbons acid name concentration (mmol/L)
2 Acetic acid 183.50
3 Propionic acid 134.52
4 Butyric acid 111.74
5 Valeric acid 89.92
6 Hexanoic acid 80.12
7 Heptanoic acid 68.53
8 Octanoic acid 57.59
4 Iso-butyric acid 104.22
5 Iso-valeric acid 85.51
6 Iso-hexanoic acid 52.41
Concentrations were based on those previously optimised by Laurentin & Edwards.297
2.7.2 Gas chromatography
A TRACE 2000 gas chromatograph (GC) (ThermoQuest Ltd, Manchester, UK) using
a flame ionisation detector (250 C) and a Zebron ZB-Wax capillary column (15m
x 0.53mm idx1µm film thickness), (Cat. 7EK-G007 Phenomenex, Cheshire, UK).
Nitrogen set at a flow rate of 1.89cc/min was used as the carrier gas. 1µL of sample
was auto injected at 230 C onto the column. The column temperature was held at
80 C for one minute ramping 15 C/min to a final oven temp of 210 C (Fig 2.9).
Samples were analysed on the GC using 32 bit Chrom-card (version 2.2 2003 Thermo-
Scientific , Milan Italy). Individual peaks were identified based on the retention
times calculated from the analysis of known external standards (Table 2.5). To
check the column prior to sample analysis 100% ether containing only the internal
standard (sample blank) was run and the chromatogram checked for any potential
contamination in the column or ether. The needle was washed with ether and absolute
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methanol between each sample.
Figure 2.9: In gas chromatography (GC) sample is injected in and vaporised (210 C under pressure);
it then flows through a column with a carrier gas (nitrogen). Via a mobile and static phase the
sample separates into components. The detector then generates peaks on a chromatogram to identify
and quantify SCFA.
Each sample was extracted in duplicate but as separate extractions and in reverse
order to the previous extraction to account for any evaporation over time of volatile
SCFA. If the variance between duplicates was low the mean between these was used.
Samples with high variance were re-extracted. A standard control sample was in-
cluded at the beginning and the end of the run to test repeatability of the extraction
over time. The 100µL dilution of external standard was run after every 12-samples
to test the coefficient of covariance. Measurement of SCFA concentration were based
on the area under the curve calculated from chromatogram peaks. The concentration
was expressed as µg/g of freeze dried faecal material. The area ratio for each indi-
vidual SCFA was calculated by taking the area under the curve (AUC) for individual
acid and dividing by the AUC for the internal standard.
Area Ratio =
AUC forsample SCFA
AUC Internal Std
The relative response factor accounts for difference in the area ratios between SCFA
in the external and internal standards.
Relative Response Factor =
Area Ratio of SCFAin100µL ExtStd
Conc. Each SCFA in sample/Conc. Int Std in sample
Finally the concentration of SCFA was calculated using the formula:
SCFA Conc. =
Area Ratio of Individual SCFA
Relative Response Factor
× Conc. of Internal Std
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2.7.3 Potential limitations of SCFA extraction
Although the extraction of SCFA using diethyl ether measures SCFA concentrations
with a good level of accuracy it does have some limitations. Some faecal samples
may hive a higher proportion of undigested food remnants. We removed any obvious
undigested food items like seeds and thoroughly homogenised the sample with a
blender. Diethyl ether is volatile and thus can facilitate the loss of SCFA such as
acetate during sample handling and analysis after they are extracted from the sample.
We checked and corrected for this by using an internal standard.
2.8 DNA extraction methods
The development of culture independent techniques has been followed by a need for
the methods used to determine the microbial composition to be robust. This begins
with obtaining good quality and yield of genomic bacterial DNA. Faecal samples
contain a mixture of undigested food, mucosa, dead cells, bile, enzymes, and other
substances, which can degrade bacterial DNA and inhibit PCR amplification. Thus
optimal DNA recovery should take these factors into account and choice of a good
DNA extraction method very important. There are a number of easy to use com-
mercial kits available which can be used specifically for extracting DNA from faecal
samples (Table 2.6) Although these kits are known to be efficient in extracting bacte-
rial DNA, a number of studies have recorded variation in the quantity and purity of
DNA between these kits,298 which could to some extent explain differences in relative
abundance between different studies.299 There is also controversy about whether the
temperature of storage and freezing has a significant300;301 or minor302;303 impact on
the population of gut bacteria recorded after sequencing. There is also evidence that
bacterial profiles change while in storage after as little as 2-months and can alter the
amount of specific groups of bacteria such as Bifidobacteria.304 This is a major issue
when comparing the findings of different studies, and may play a role in why studies
have contradictory findings.299
Table 2.6: Commonly used DNA extraction kits for stool samples
Kit Manufacturer
PowerSoil DNA Isolation kit MoBio Laboratories Inc. Carlsbad, USA
Qiagen DNeasy kit Qiagen, Hilden Germany
QIAamp DNA Stool Mini kit Qiagen, Valencia CA USA
ZR Faecal DNA MiniPrep Zymo Research Corp. Irvine USA
Faecal samples The chaotropic DNA extraction method305, combined with bead-
beating was chosen as it has a higher yield compared to commercial kits, and when
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tested against other methods is better at capturing sub-dominant groups of bacte-
ria.145 This method had already been used by previous researchers in the same lab145
allowing us to cross reference and potentially pool data. A number of components in
samples cause PCR inhibition including: heme; bilirubins; bile salts and complex car-
bohydrates. The chaotropic method uses guanidine thiocyanate in extraction process
to effectively remove these potential inhibitors. This method was chosen not only
due to extensive cleaning and purification steps but because it is good at maintaining
the gut microbiota composition because it keeps extracted DNA intact. Previous
work has also shown that this method gives the highest yield and good purity of ge-
nomic bacterial DNA (on spectrophotometry and agarose gel electrophoresis) when
compared to methods such as the QIAamp DNA Stool Mini Kit, and phenol chlo-
roform method.298 A summary of reagents used in bacterial DNA extraction along
with their concentrations and functions are given in Table 2.7.
Faecal samples were collected and homogenised as previously described. Approxi-
mately 200mg faecal sample was stored in 1.5mL screw cap tubes in quadruplicate
and immediately stored in -80 C. Before starting DNA extraction, each sample was
thawed at room temperature. To avoid variability of extraction between the samples
and to maintain efficiency of the researcher, DNA was extracted from a set of twelve
samples each time with all samples from the same patient included in the same run.
Each set of DNA extractions needed 2-days to complete.
To lyse cells and virus particles in the sample and to prevent activity of RNase
and DNase enzymes by denaturing them, 250!L of 4M Guanidine thiocyanate 0.1M
Tris-Cl (pH7.5) (Sigma Aldrich, UK) and 40!L of 10% N-Lauroylsarcosine (Sigma
Aldrich, UK) was added to each sample before being vortexed then centrifuged for
3-seconds at 15,000g. The sample was then incubated at room temperature for 10-
minutes. Anionic surfactant, N-Lauroylsarcosine (5%) and 500!L, already prepared
in 0.1M Phosphate buffer (pH8.0), was added to the sample. The sample was vortexed
and centrifuged for 3-seconds before being incubated for 1-hour at 70 C in a dry
bath (Dri-Block Teche, UK). The sample was vortexed at 20-minute intervals, then
centrifuged for 3-seconds before adding 750mg of sterile 0.1 mm zirconia glass beads
(Biospec Products. USA). Samples were vortexed before being placed on an MP
FastPrep -24 benchtop homogeniser for 2x30 seconds at 6m/s, resting between each
burst for 15-seconds to allow cells to cool down. Samples were then placed on ice for
5-minutes before homogenising again for 2x30 sec at 6m/s. The samples were cooled
on ice for 5-minutes and centrifuged for 3-seconds before adding 15mg of PVPP
powder (Sigma Aldrich Co) and vortexed upside down to mix the pellet. Samples
were then placed on a shaker for 5-minutes (1,000rpm) and centrifuged for 3-minutes
at 15,000g (4 C) before recovering the supernatant in sterile 2mL safe-lock tubes.
200mg of TENP buffer was used to wash the pellet by vortexing and then centrifuging
for 3-min at 15000g (4 C). The supernatant was recovered in the same tube. This was
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repeated 3 times. The supernatant was then centrifuged for 10-minutes at 15,000g
(4 C) before being split into two 2mL tubes. An equal volume of isopropanol (v:v)
was added to each sample to precipitate DNA and gently mixed by hand before being
incubated at room temperature for 10-minutes. Samples were then centrifuged for 5-
minutes at 15000g (4 C) and the supernatant discarded. Tubes containing the pellet
were inverted and tapped onto absorbent paper until dry and then left to air dry
in the hood for 30-minutes. 225µL of 0.1M phosphate buffer (pH 8) and 25µL 5M
potassium acetate were added to each sample and tubes placed on an orbital shaker
for 5-minutes to dissolve pellet. Samples were then stored overnight at 4 C.
The next day samples were shaken on an orbital shaker for 10-minutes before duplicate
samples were combined in to one 2mL tube. Samples were centrifuged for 30-minutes
at 15,000 g (4 C) and the supernatant recovered in a new 2mL tube. To remove
RNA 5µL of RNAase (RNAse ONE, M426A, Promega ) 10mg/mL was added to
each sample. Samples were vortexed, pulsed for 3-seconds to bring contents down,
before being incubated for 45-minutes on a shaking dry bath at 37 C. 25µL of 10%
SDS (Sigma Aldrich Co), along with 12.5µL of proteinase K 800units/mL (Sigma
Aldrich Co) were added to the sample to digest proteins which have the potential
to inhibit PCR reactions. The samples were vortexed and incubated at 45 C for 2-
hours on a shaking dry bath. Samples were then pulsed for 3-seconds before adding
54µL of 3M sodium acetate buffer (S2889, Sigma Aldrich ) and 1mL 100% ethanol
(-20 C) which was mixed by inverting. The sample was then kept at -20 C for 1-
hour. Samples were then placed on an orbital shaker for 10-minutes and centrifuged
for 10-minutes at 15,000g (4 C).
The supernatant was discarded and 240µL DNase/RNase free water added to the
pellet and vortexed to dissolve it. 560µL 100% ethanol (stored at -20 C) was added to
the pellet and transferred to an orbital shaker for 10-minutes at 1,000rpm. The sample
was centrifuged for 10-minutes at 15,000g (4 C) and the supernatant discarded; these
washing steps were repeated 3 times. The pellet was then tapped dry on lint-free
paper and air dried under a class-2 biological cabinet for 1-hour. Samples were re-
suspended in 300µL of TE buffer and after 10-minutes on an orbital shaker, aliquoted
to 0.2mL PCR-tubes and stored at -20 C for further analysis. Negative extraction
controls were performed using the same method protocols and then evaluated by gel
analysis after both PCR amplification and sequencing. The DNA was then measured
using Qubit dsDNA broad range assay reagents. See section 2.14.4.
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Table 2.7: Reagents used in chaotropic DNA extraction method
Reagent Conc. preparation Function
guanidine thio-
cyanate
4M 12.37g; ddH2O 13.5ml; Tris-
Cl 1M (pH7.5) 2.6ml
Lyse cells; denature RNase and
DNase
N-Lauroylsarcosine 5% 1g; Phosphate buffer 0.1M
(pH8) fill to 20ml
anionic detergent
N-Lauroylsarcosine 10% NLS 1.1g + 19ml ddH2O anionic detergent
phosphate buffer 0.1M Na2HPO4 1M with NaH2PO4
1M pH8
buffer
Tris-Cl pH7.5 and
pH8
1M Trizma base 12.11g; ddH2O
fill to 100ml
dispersion agent to clean DNA
Sodium Acetate 3M 2.461g; ddH2O fill to 10ml buffer (source of monovalent
cations)
Polyvinylpyrrolidone PVPP 15mg per sample dispersion agent; removes
polyphenol (can inhibit PCR)
TE buffer 10mM Tris-CL (pH8) add 1ml
TENP buffer 1M Tris-Cl (pH8) 1ml dispersion agent to clean DNA
0.5M 1mM EDTA (pH8) add 0.8ml
5M NaCl (pH8) add 0.4ml
ddH2O fill to 20ml
1% PVPP add 200mg
ethanol 70% precipitate DNA
isopropanol v/v precipitate DNA
potassium acetate 5M salt for isopropanol precipita-
tion of DNA
salt aids precipitation of DNA
in ethanol
RNAase 10mg/ml 1mM EDTA (pH8) add 0.8ml denatures RNA
Sodium Dodecyl
Sulphate (SDS)
10% SDS 10mg in 90ml ddH2O strong anionic detergent; dena-
ture proteins
Proteinase K 800units/ml 12.5µl per sample digests proteins
2.9 16S ribosomal RNA gene amplicons
Profiling the gut microbiota can be undertaken by analysing the prokaryotic 16S
ribosomal RNA gene (16S rRNA), which is approximately 1,500bp long. It contains
nine variable regions which are inter-spaced between highly conserved regions of DNA.
These variable regions can be used in phylogenetic classification down to genus or
species level allowing us to profile diverse microbial populations such as those found
in the gut microbiota. The choice of 16S rRNA region to sequence is a current area of
debate and is influenced by experimental objective; methods used and type of sample
being analysed. The current study used 16S rRNA primers covering the variable V4
region (Fig 2.10), which is the most commonly used in microbiota research. V4 not
only captures an optimum range of sequence variants, but also results can be reliably
compared with similar studies.306 Di-methyl sulfo-oxide (DMSO) was added to PCR
reactions to prevent non-specific primer binding.
A point of note is that the copy number of the 16S rRNA gene per individual species
or strain of bacterium is variable. Therefore a sequence of high frequency could ei-
ther represent, a high copy number per bacterium of lower abundance, or a low copy
number per bacterium of higher abundance. Therefore when we report relative abun-
dance of 16S rRNA genes this may not fully represent true community structure.307
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Although this has the potential to be a significant source of systematic bias in 16S
rRNA studies, and there are ways to estimate copy number and correct this bias, do-
ing so creates another potentially more serious bias, since different strains of bacteria
have known to have widely varying copy number per bacterial strain. Therefore the
correction for copy number was not used in this study as it would simply replace one
bias with another.
2.9.1 16S rRNA amplicon sequencing library preparation
To create the amplicon library for paired-end community sequencing on the Illumina
MiSeq platform, the V4 region of 16S rRNA was amplified using Golay fusion adaptors
with the barcode added to the reverse strand (806R), in combination with the forward
degenerate 515F primer (shown below).306
Using degenerate primers widens the scope of bacterial species represented by 16S am-
plicons giving a better representation of the gut bacterial profile.304 Around 10ng/µL
of template was added to each 25µL reaction. PCRs were run in triplicate along with
a non template control. PCR components were added as shown in Table 2.8. The
HiFi HotStart Kit (KAPABIOSYSTEMS , USA, KK2502) was used for PCR, and
DMSO (SIGMA-Aldrich D1970-5VL) added to improve reaction efficiency.
The reagents for four reactions were mixed in one tube, vortexed, and then 23µL
transferred to each of the remaining PCR tubes. 2µL of DNA template was added
to three of the PCR tubes the and same volume of water added to the non template
control. Ten samples were amplified in each run (i.e. 40 tubes). Samples from disease
and control groups were included in each set of ten to account for any environmental
variation. All PCR tubes were vortexed and spun down before being placed in the
thermal-cycler The samples were amplified as follows: 95 C for 5min; (98 C for 20sec;
60 C for 15sec; 72 C for 1min; for 25 cycles); 4 C ∞.
2.9.2 16S rRNA gel electrophoresis
2g agarose in 200mL 1X TAE buffer was melted in a microwave until clear. Once
cooled to 55 C 20µL SYBR safe DNA gel stain 10,000X in DMSO (Invitrogen ,
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Figure 2.10: Diagram showing the structure and regions of 16s rRNA
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Table 2.8: 16S rRNA PCR reagents
reagent volume per reaction
Nuclease Free water 13.76µL
KAPA HiFi Fidelity buffer (5x) 5.00µL
KAPA dNTP 10mM mix 0.75µL
KAPA HiFi hotstart polymerase 0.50µL
forward Primer (same for all samples) 0.87µL
Reverse Primer (different for each sample) 0.87µL
DMSO(Di-Methyl Sulfo-Oxide) 1.25µL
DNA template (5ng/µL) 2.00µL
Total volume 25.00µL
USA) was added (1µL/10mL). The 1% gel was cast and allowed to cool for 50-minutes
in the dark (covered by foil), before being transferred to the electrophoresis tank filled
with 1X TAE buffer.
One of the triplicate sample tubes was distributed between the other two sample
tubes, and 5µL blue/orange loading dye 6x (Promega Corporation, USA) was added.
The dye contains xylene cyanol, bromophenol blue, and orange G to help optimise gel
running time by tracking the smaller fragments. A 100bp DNA ladder was used to
quantify the base-pair size of DNA template. Three wells were loaded for each sample
(non-template control and replicate template). The gel was run for 60-minutes at 100
volts before being visualised under UV light using Gel Doc 2000 (Bio Rad). Each
sample resulted in two bands: proximal band containing the amplified sample and
a distal band containing residual primers, primer dimers, and any degraded DNA.
The non-template control shows only a distal band indicating that only the target
template was amplified. If smearing, indistinct bands, absent bands, or multiple
bands were seen, these were re-amplified (Fig. 2.11).
Figure 2.11: Electrophoresis gel showing amplified 16S rRNA bands done in duplicate with a negative
control between. The PCR was not always successful due to poor quality samples containing mucus
or blood.
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Extraction of bands using Zymo-Spin extraction kit Amplicon bands were viewed
under UV light (Fig. 2.11) and excised from the gel by cutting bands and placing in
2mL DNA low-bind eppendorf tubes. The Zymoclean Gel DNA recovery kit (ZYMO
Research cat. no. D4002) was used to recovery the target DNA. Gel fragments
were weighed and the correct amount of agarose dissolving buffer added to tubes
(3:1 w/v). The mixture was then incubated at 55!C for 10 mins in a shaking dry
bath (Thriller Peqlab) to dissolve the gel fragment. The melted agarose solution was
added to a Zymo-Spin Column in a collection tube and centrifuged at 10,000g for
1min. The flow-through was then discarded. 200µL of DNA wash buffer containing
ethanol was added to the column and centrifuged at 10,000g for 1min. This wash
step was repeated and the flow-through again discarded. 12µL of elution buffer was
added directly to the column and centrifuged at 10,000g for 1min to recover DNA,
which was then stored at -20!C.
Qubit fluorometric quantitation Unlike Nano-drop , Qubit is based on the de-
tection of target-specific fluorescence, making it more reliable than UV absorbance
for DNA quantification. Hence Qubit is a better tool for measuring double stranded
DNA concentration in preparation for running on the Illumina HiSeq platform. Qubit
has the additional advantage of having a range of high sensitivity reagents which mea-
sure very small amounts of DNA reliably and accurately.
The concentration of amplicons was measured using a working solution prepared by
adding 1µL dsDNA high sensitivity assay reagent with 199µL buffer (Life technolo-
gies, USA). Standards were used to calibrate the unit before 1µL of amplicon was
mixed with 199µL of the working solution in specialised 500µL PCR tubes supplied
with the kit. Any sample with a concentration of less than 2.5ng/µL was re-amplified
and extracted until this minimum concentration was reached.
2.9.3 Pooling the amplicons for running on MiSeq
The final DNA concentration of each sample was standardised to 5ng/µL. 3µL from
each sample was transferred to a single 0.5mL DNA low-bind eppendorf tube to
make an amplicon pool which was then stored at -20!C. DNA concentration of five
samples measured by Qubit, selected in random, showed a median concentration of
2.45ng/µL. From this 300µL pool, 100µL was aliquoted into another 0.5 ml DNA
lowbind tube and transported to the laboratory for sequencing, in dry ice.
2.9.4 16S rRNA sequencing on MiSeq Illumina
Defining microbial communities by sequencing 16S rRNA genes has grown dramati-
cally due to an increase in lower cost high-throughput instruments. Illumina MiSeq
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was chosen for these reasons, along with it’s higher accuracy rate.308 When com-
pared with 454-pyrosequencing, Illumina MiSeq has a lower error rate and is not as
prone to insertion/deletion errors in homopolymer stretches. The brightness of light
indicates the length of the homopolymer in 454-pyrosequencing hence distinguishing
the brightness of light in a sequence AAAAA and AAAAAA can cause errors.309
Sequencing of the V4 region of the 16S rRNA gene was performed on the MiSeq plat-
form (Illumina, Essex, UK) using our pooled 2x250bp paired-end reads. The TruSeq
LT assay was used on FASTQ only to generate FASTQ files.
2.10 Bioinformatics and statistical methods
2.10.1 Creation of 16S rRNA abundance tables
Operational Taxonomic Units (OTU) based approach: Sickle v1.200310 was used
to trim and filter Illumina paired-end reads using a sliding window approach. Reads
were trimmed when the average base quality fell below twenty. A 10bp length thresh-
old was set below which reads were discarded. BayesHammer 311 from SpadesV2.5.0
assembler was then used as a read error correction tool. Pandaseq V(2.4) was used to
assemble overlapping pair-end read while correcting mismatches and uncalled bases
using a minimum overlap of 50bp to assemble the reads. This workflow has been
shown to be effective with substitution errors being reduced in MiSeq datasets by
between 77% and 98% (mean 93.2%).312
To generate clusters in the form of OTUs the UPARSE (v7.0.1001) pipeline was
used (url:UPARSE.link) According to research analysis on mock communities carried
out by Edgar et al. 2013,313 UPARSE generates OTUs that are superior to other
frequently used methods, making these OTU sequences accurate predictions of actual
biological sequences to represent species.
Briefly reads were pooled together from different samples (barcodes used to track
sample origin). Reads were dereplicated and sorted by decreasing abundance while
discarding singletons. Reads were then clustered by 97% similarity, discarding those
shorter than 32bp. Although the cluster otu command had removed chimeric reads,
a few chimeras may remain, especially if parents are absent from reads or have
very low abundance. Hence, a reference-based chimera filter was used from the
‘gold database’ (ChimeraSlayer reference database in the Broad Microbiome Utili-
ties (url:ChimeraSlayer.link).The original sample barcode reads were then matched
with OTUs with 97% similarity and an OTU table generated containing a total of
1,205 unique sequences for all samples.
OTU free approach: As a comparison a more recent method, divisive amplicon de-
noising algorithm, (DADA2)314 was used to infer species from the sample sequences
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taken from our amplicon sequencing reads. These will be referred to in chapters as
single-nucleotide variants (SNVs). DADA2 is a reference free method which does
not create OTUs. Rather it infers sample sequences exactly, being able to resolve
differences of as little as one nucleotide and thus giving output data of a much higher
resolution. The method is built on a model of the errors in Illumina-sequenced
reads, and assigning an ’abundance p-value’ to unique sequences that have associated
abundance, as a ‘goodness of fit’ criteria to the Poisson density function. Starting
by placing all sequences in a single partition, the algorithm iterates by forming new
partitions (with their associated Poisson density function) whenever the criteria is not
met, and allowing unique sequences to join the partition most likely to have produced
them. When the algorithm has converged, all the partitions represent unique variants
the central most abundance sequence of each partition as representative sequence.
The DADA2 workflow (DADA2.link)http://benjjneb.github.io/dada2/tutorial.html
learns the error model from the data first, dereplicates the reads and then runs the
DADA2 algorithm separately on both forward and reverse reads. The SNVs are then
reduced by merging the overlapping reads from both forward and reverse reads. For
our data set this generated a SEQ table containing a total of 2,751 unique sequences
for samples, more than double that of the OTU table.
The accuracy of the DADA2 approach has been tested on two mock communi-
ties and was found to be closer to the expected number of strains than any other
methods.315 At genus level DADA2 was able to identify 25/26 expected taxonomies
(Bokulich mock community 1688), with the one missed taxonomy likely being absent
from the sequencing data and 18/18 in a second dataset (Bokulich mock community
1685). DADA2 also detected some unexpected genera, all of extremely low abun-
dance (<0.01%) likely to be correctly identified contaminants. DADA2’s F-score
at the genus level was 0.7659574, which was higher than any other methods tested
(0.39-0.54).315
The OTUs and SNVs used in the current study were taxonomically classified against a
custom database using the packageQiime ‘assign taxonomy.py’ script workflow.316 To
calculate the phylogenetic distances between sequences, multi-sequences were aligned
using multiple sequence alignment programMAFFT v7.04.317 FastTree v2.1.7318 was
then used to infer ‘approximately-maximum-likelihood’ phylogenetic trees from align-
ments of sequences. Finally ‘make otu table.py’ was used to combine the abundance
table with taxonomic information to create a Biological Observation Matrix (BIOM)
file for both OTU and SNVs.
2.10.2 Modelling limitations
Describing microbial communities using mathematical models, in which the bacterial
population are represented by global empirical functions does not fully describe the
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complex functional workings of the human gut microbiota. Sequencing technologies
now allow us to record the diversity of the gut microbiota in unprecedented detail.
These new data sets can represent a relatively unbiased compositional snapshot,
of not only the bacteria present, but also the genes and metabolites that might
give insight into the functional activities present in both diseased and healthy gut
environments. However, the challenge to translate this empirical data into testable
predictions which lead to meaningful research used to improve the quality of life for
patients, is challenging.319
Because of the way sequence variation differs in terms of defining bacterial species
the following issues need to be kept in mind. Firstly the exact same genome can
have difference in their sequences, due to multiple copies of the 16S target gene.
The DADA2 method can detect these. Secondly two different strains of the same
species might have the same sequence in the specific 16S region amplified. It is also
possible on some occasions that two different species might have the same sequence
in the region we amplified and no method can tell the difference between strains
when this is the case. Also two different strains from the same bacterial species can
have different sequences in the 16S region amplified and in this case DADA2 can
frequently tell these apart, even when they differ by only one nucleotide. However
these are usually classed under the same species by the taxonomic classification step.
2.10.3 Statistical methods and graphics
The statistical package R320 was used to carry out statistical analysis and functions.
The community ecology package vegan 321 and high-throughput microbiome handling
package phloseq 322 was used for alpha and beta diversity analyses. phloseq 322 was
used to calculate phylogenetic distances, including unweighted UniFrac and weighted
UniFrac distance. More traditional plotting methods such as linear and scatter plots
have been replaced by non-metric multidimensional scaling (NMDS) plots where large
data sets are compressed into a readily viewable format. This provides an overview
of data trends which would be impossible to obtain from data tables. NMDS plots
of OTUs and SNVs were generated using the following packages: phyloseq; vegan;
ggplot2; ape and phangorn. Phyloseq is used to organise, link, store, and analyse the
phylogenetic sequencing data.
(Vegan adonis) was used to carry out permutational multivariate analysis of vari-
ance using distance matrices (PERMANOVA) to calculate statistical significance.323
Adonis function fits linear models to distance matrices (Bray-Curtis, Unweighted
UniFrac, Weighted UniFrac) and uses a permutation test with pseudo-F ratios to
give sources of variation for metadata (it returns R2 values for a predictor, and if
significant, p<0.05, is the percentage variability in community structure contingent
upon the possible observable values of that predictor).
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Alpha diversity (within sample) Alpha diversity is the species richness, or number
of taxa, present within a single microbial environment or sample; i.e. how many
different bacterial species can be detected in a specific patient sample? This seems
like a simple question, however it is not always easy to define a bacterial species.
Therefore in microbiota analysis operational taxonomic units (OTUs) are often used,
where this proxy for ‘species’ is any bacteria with 97% genetic similarity.
Although an OTU count (richness) gives useful information about diversity it can
be misleading because it fails to capture information about species relatedness. For
example, sample A may contain three species from the same genus: sample B may
contain two species from the same genus and one from another genus; sample C may
contain bacteria from three different genera. A simple count would conclude that
sample A, B and C had a species count of three, suggesting these three groups were
equally diverse which is not really true. Hence using a phylogenetic tree and adding
up the branch lengths between different species (or OTUs) in a sample to give a
measure of phylogenetic diversity can be more useful. Using a phylogenetic approach
would show sample A had the least diversity and sample C had the greatest diversity.
Another drawback with species richness is that it does not take into account the ratio
of each species present in a given sample. A bacterial community which is dominated
by one or two species is considered less diverse than one where several different
species have a similar abundance. The Shannon diversity index324 can account for
both species richness and the evenness of bacterial species present, where species
evenness is a measure of the relative abundance of bacterial species.
H = −
S∑
i=1
pi ∗ ln pi
H= Shannon diversity index; S= the number of genera; pi= where pi is the fraction of total species comprised
by species i; [Richness=exp(H); giving estimated number of taxa observed in the rarefied samples]
Beta diversity (between samples) The term β-diversity was first introduced in a
1960 paper by Whittaker325 where he defined it as “the extent of change in commu-
nity composition, or degree of community differentiation, in relation to a complex-
gradient of environment, or a pattern of environments”.325 He proposed several ways
to quantify β-diversity. In its simplest form, β-diversity is defined as the ratio be-
tween regional and local diversities and as such for the gut microbiota, β-diversity
represents the diversity in microbial community between different groups.
Non-metric (ordinal) distance scaling (NMDS) was used to visualise cluster differ-
ences in microbiota data. Bray-Curtis dissimilarity was used to incorporate species
abundance counts.326 Bray-Curtis is used to quantify the compositional dissimilarity
between two different groups based on counts within each group. It is simple in that
78
unlike unifrac, it does not make assumptions about the genetic relationship between
bacteria.326 Samples were grouped around the mean ordination value using vegan or-
diellipse, with the ellipse showing the 95% CI for each grouping. Bacterial community
analysis including alpha and beta diversity analyses was done in R using Vegan.321
Phylogenetic distances were calculated using phyloseq.322 Pair-wise ANOVA was used
to calculate p-values.
Metric distance scaling (MDS) plots were used to analyse metadata such as short
chain fatty acids, using the capscale function. Data was normalised using auto-
scaling, before using vegdist ‘euclidean’ to calculate the distance between samples
and adonis function (PERMANOVA) to test for significance. The ordiplot function
(ordihull & ordispider) were used to visualise the data.327
Permutational Multivariate Analysis of Variance Using Distance Matrices To
calculate multivariate homogeneity of groups dispersions between multiple condi-
tions, Vegan betadisper function was used. Betadisper is a multivariate analogue of
Levene’s test328 for homogeneity of variances. Vegan adonis was used to carry out
permutational multivariate analysis of variance using dissimilarity matrices Bray-
Curtis. Adonis analyses and partitions sums of squares using semi-metric and metric
dissimilarity matrices of multivariate data sets and hence is directly analogous to the
multivariate analysis of variance (MANOVA). Although previously know as a ‘non-
parametric MANOVA’, McArdle and Anderson 2001 coined the term permutational
MANOVA (PERMANOVA).323;329 Because its inputs are linear predictors and it has
a response matrix of arbitrary number of columns ranging from two to millions it is
a robust choice over both parametric MANOVA and other ordination methods for
describing how variation is linked to different treatments or covariates.
Temporal and space–time analysis of community composition data Local con-
tribution to beta diversity (LCBD)330 was calculated by using the Hellinger trans-
formation to work out total sum of squares of species composition for all samples,
from which sample-wise local contributions to β-diversity could be shown as a pro-
portion of total beta diversity. These were plotted as bubbles under stacked bar
plots (TAXAplots) to represent marked differences in species composition. ANOVA
of LCBD values between different treatment groups was carried out to show signifi-
cance.
Estimation of microbiota fold change between groups using DESeq2 To test if
there was a significant difference in abundance between selected groups or conditions,
differential expression analysis DESeq2 was used in R. It is based on the ‘Negative
Binomial’ (Gamma-Poisson) distribution. This method enables a more quantitative
analysis which is focused on the strength rather than the presence of differential ex-
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pression.331 Results are expressed as the log2 fold change between patient/treatment
groups and controls. R script was adapted from Albertsen.332
sPLS-DA Discriminant Analysis Sparse Projection to Latent Structure- Discrimi-
nant Analysis (sPLS-DA) was used within R’s mixOmics package.333 This procedure
constructs artificial latent components of the predicted dataset (genera table de-
noted as X(N × P ) collated at genus level) and the response variable (denoted as Y
with categorical sample data) by factorising these matrices into scores and loading
vectors in a new space such that the covariance between the scores of these two ma-
tricescov (Xhah, Yhbh) in this space is maximized under two constraints: ‖ah‖2 = 1;
and ‖ah‖1 ≤ λ, where ah and bh are the corresponding loading vectors for X and
Y , and h represents the number of components (similar to PCA analysis). The first
constraint ensures the loading vector to have unit magnitude (requirement of the pro-
cedure) and the second constraint (also called l1 penalty) to ensure that in features
that do not vary between the categories, the corresponding loading vector coefficients
go to zero. This is achieved by using the sparsity control parameter λ in the above
equation, enforcing shrinkage of loading vector coefficients. The recommendations
in mixOmics package (http://www.mixomics.org), are to pre-filter 1% of the lowest
abundant genera and then perform Total Sum Scaling followed by Centralised Log
Ratio (TSS+CLR) normalisation, before applying splsda. To predict the number
of latent components (associated loading vectors) and the number of discriminants,
the perf.plsda and tune.splsda functions were used, respectively. The model was fine
tuned by using leave-one-out cross-validation, by splitting the data into training and
testing sets and then finding the classification error rates employing two metrics,
overall error rates and balanced error rates (BER), between the predicted latent vari-
ables with the centroid of the class labels using the centroid distance. BER accounts
for differences in number of samples between different categories.
The BVSTEP routine The BVSTEP routine, a method for linking multivariate
community structure to environmental variables,334 was used to search for the high-
est correlation, in a Mantel test, between dissimilarities of fixed and multivariate
datasets. The BVSTEP algorithm is part of the sinkr package version 0.6.335 It was
used to best correlate dissimilarities (Bray-Curtis distance) of samples using subsets
against dissimilarities of the samples given using all the genera. This analysis is
complementary to the sPLS-DA which was used to identify which genera are causing
major shifts in β-diversity but without considering their grouping (e.g. time points)
allowing the identification of the genera that change the most in the sample space.
Kendall rank correlation coefficient Kendall tau test is a non-parametric test
for statistical dependence based on the tau coefficient.336 This was used to examine
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correlations between gut microbiota and meta data in the form of a facet-grid using
ggplot2 in R. P-values were adjusted for multiple comparison using Benjamini &
Hochberg (1995).337
Kernel density estimation Kernel density estimation338 is a non-parametric method
used to estimate the probability density function of a random variable i.e. inferences
about a population are made, based on smoothing our finite data set.
The grouping of variables was created using pairwise Pearson correlation coefficients.
The threshold correlation value for this grouping was set between 0.99 and 0.60
depending on the number of features or variables in different data sets. Under the
chosen threshold for each data set, features were grouped into feature-sets. Then for
each feature-set a distance based kernel score test and a stratified kernel score test
were applied.338
A probabilistic PCA (ppca) was used which combines an expectation maximisation
(EM) method for PCA with a probabilistic model. The EM method is based on an
assumption that the latent variables as well as the noise have normal distribution.
By using ppca the function is defined such that the likelihood for data to be far from
the training set is lower, even when they are close to the principal subspace, allowing
improved estimation accuracy.
Pearson’s chi-squared test The Pearson’s chi-squared test (χ2) was used to assess
the likelihood that an observed difference between sets of categorical data were due
to chance. The Yates’ correction339 which is designed to prevent the overestimation
of statistical significance in small data set was not used at it has been shown that
the Yates formula has a tendency to over correct the P value, resulting in a type II
error. Sokal et al. suggest that the Yates’ correction can therefore be unhelpful where
sample sizes are smaller.340
Kruskal Wallis/Dunn’s test To look at differences between different groups of
patients the Kruskal Wallis test followed by the Dunn’s Test of multiple comparisons
using rank sums was used. The Dunn’s test341 reports results among multiple pairwise
comparisons after a Kruskal-Wallis test for stochastic dominance among groups.342
The null hypothesis for each pairwise comparison is that the probability of observing
a randomly selected value from the 1st group that is larger than a randomly selected
value from the 2nd group equals one half. The Dunn’s test can be understood as a
test for median difference.
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3 Participant characteristics
This chapter will provide more detailed information on the disease condition of chil-
dren, as well as participant demographics including: socioeconomic background, gen-
der and age. For children with Crohn’s disease the medications taken before, during
and after treatment with exclusive enteral nutrition (EEN) and maintenance enteral
nutrition (MEN), and the implications of these will be discussed. The chapter will go
on to describe details about disease activity and location of disease within the gut.
It will then go on to explore body composition data as an objective measure of how
well children were achieving growth targets, as well as assessing if children and study
groups as a whole were achieving optimal height and weight for their age. In this
section the question of whether EEN as a treatment for children with Crohn’s disease
has an impact on both short and long term growth outcomes will be studied; as well
as asking if low weight or BMI at the start of EEN predicts how successful EEN
is in inducing remission in children with Crohn’s disease. The study subgroups are
examined to judge whether they are a good representation of the Scottish population
of children as a whole and identify any bias or limitations, as well as exploring what
lessons could be learned from the recruitment process of this study which could ben-
efit the planning of similar studies in future. Finally any limitations in the data set
will be explored along with a discussion about the robustness of the data which will
be used to help answer questions about how diet, bacterial composition and microbial
metabolic status might play a role in disease activity in subsequent chapters.
3.1 Summary of hypotheses
 Children with IBD will have reduced height/weight/BMI at baseline compared
to those with non-IBD conditions and healthy controls.
 Increased disease activity in children with Crohn’s disease is associated with
poorer growth outcomes.
 BMI at baseline in children with Crohn’s disease can predict response to treat-
ment with exclusive enteral nutrition (EEN).
 Disease location in children with Crohn’s disease can predict response to treat-
ment with EEN.
 For children in disease remission post-EEN, supplementing return to normal
diet with (20%) maintenance enteral nutrition (MEN) will maintain the growth
velocity associated with growth outcomes achieved during EEN.
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Figure 3.1: Numbers and groups of children recruited onto the study
3.2 Research participants
Of 102 children invited to join the study ten declined to take part (Fig. 3.1). Twenty-
five, all of whom gave a stool sample, were a healthy cohort of children with no
gastrointestinal symptoms or family history of inflammatory bowel disease (IBD),
recruited from the West of Scotland general population. The remaining sixty-seven
were children referred to hospital because of suspected IBD. Of these sixty-seven
children twelve were unable to provide a baseline stool sample (ten dropped out of
the study). After diagnosis thirty-four children were found to have Crohn’s disease,
ten had ulcerative colitis (UC), two were classified as IBD undetermined (IBD-U) and
eleven had other conditions such as irritable bowel syndrome or colonic polyps which
were not related to IBD (non-IBD). This non-IBD group were included in the study as
a patient control group with the caveat that five of these had a family history of IBD
and hence it cannot be ruled out that some of these children could have subclinical
IBD. Of the thirty-four children recruited with Crohn’s disease two were subsequently
excluded from the study: one because they had additional treatment with antibiotics
during treatment with EEN which would affect the composition of gut bacteria and
the other because they stopped treatment with EEN via nasogastric tube after only
3-days, once the results of their colonoscopy showed very mild disease. Of the twenty-
three children who went into remission on EEN, seventeen (74%) children took MEN
once they returned to their normal diet, while only six (26%) children opted not to
take MEN (Fig. 3.2).
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Figure 3.2: Flow chart showing numbers of children on each dietary treatment. EEN- Exclusive
enteral nutrition; MEN- maintenance enteral nutrition
Sample collection Samples were collected over a period of 22-months (July 2014
to May 2016). Detailed methods and a summary of faecal, urine and stool sample
collection as well as any issues, are described in Methods, section 2.4.4. The number
of faecal samples collected for each group and time-point are shown in Table 3.1.
Table 3.1: Number of samples collected for each group
Group HC non-IBD UC Crohn’s disease time-points
︷ ︸︸ ︷
wk-0 wk-4 wk-8 wk-10 wk-16 wk36
faecal samples 25 11 10 34 24 21 21 23 13
FFQs 21 5 6 22 - - 12 9 7
HC- healthy controls; UC- ulcerative colitis
FFQ- food frequency questionnaire
3.3 Demographics
Patients who were successfully recruited on to the study all fell within the West
of Scotland Paediatric Gastroenterology, Hepatology and Nutrition (WoSPGHaN)
network which covers a wide range of areas in the West of Scotland (Methods, section
2.4.4; Fig. 2.4). The healthy control cohort were successfully recruited from the same
geographical areas as our patient cohort.
Socioeconomic characteristics The postcode of participants was used to gener-
ate Scottish Index of Multiple Deprivation (SIMD) scores. The 6 976 SIMD data
zones were subdivided into quintiles (5-ranks) with each rank containing 20% of total
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zones (Methods, section 2.4.2). Of the thirty-two children with Crohn’s disease who
provided samples around 18% came from each deprivation rank giving a very even
SIMD distribution, with the exception of Rank-2 containing 28% of children with
Crohn’s disease (Fig. 3.3). Although 4/10 children with UC (40%) came from the
most deprived group (Rank-1), four children with UC (40%) also came from the least
deprived areas (Ranks-4 & 5). The control group of eleven non-IBD patients came
from all socio-economic backgrounds with a slightly higher proportion (4, 36%) from
Rank-3. Of the twenty-five children who were recruited as healthy controls ten (40%)
came from the least deprived areas of Scotland (Rank-5) and only three (12%) came
from the most deprived areas (Rank-1).
Figure 3.3: Scottish Index of Multiple Deprivation (SIMD) data zones were divided into 5-bands
with each band containing 20% of total data zones. Rank-1 (pink) contains the 20% most deprived;
rank-5 (blue) contain the 20% least deprived zones in Scotland. The number of children in the 20%
band is shown on each band of the bar.
The difference between the median SIMD score for children with Crohn’s disease
(3454; IQR 3507) and healthy children (5034; IQR 2611) did not reach statistical
significance (p=0.12). The group of children with non-IBD conditions (3477; IQR
3308) also came from an even spread of deprivation and were just as likely to come
from the least or most deprived areas. The median SIMD score for children with UC
(2879; IQR 4404) was not substantially different from other groups (p>0.12).
Gender Of thirty-two children with Crohn’s disease nine were female (28%) and
twenty-three were male (72%). The gender difference for the twenty-five healthy
children was eleven female (44%) and fourteen male (56%). Of the nine children with
UC four were female (44%) and five were male (56%). The patient control group of
eleven children with non-IBD conditions also had a gender difference of two female
(18%) to nine males (82%).
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Age The median age for children with UC were, as a group, slightly older than chil-
dren with Crohn’s disease (p=0.24); Non-IBD (p=0.07) and healthy children (p=0.02)
(Fig. 3.4).
Figure 3.4: The age distribution of each group of children at the start of the study. Median age for
children with UC was higher than the three other groups. Difference significant for healthy children.
(Dunn’s test of multiple comparisons was used following a significant Kruskal-Wallis test).
3.4 Disease characteristics at baseline
3.4.1 Non-IBD participants
The group of children who were found not to have IBD (non-IBD), had a number of
different conditions including: no known medical condition; intestinal polyps; irritable
bowel syndrome (IBS) and gastritis (Table 3.2). The five children who were not
diagnosed with a medical condition all had a first or second degree relative with IBD.
Table 3.2: Diagnosis of patients with non-IBD conditions
diagnosis no. of children family history of IBD
no medical condition diagnosed 5 5
intestinal polyps 1 0
irritable bowel syndrome (IBS) 1 0
gastritis/enteritis 2 0
anal fissure 1 0
umbilical hernia 1 0
3.4.2 Disease location in Crohn’s disease patients
The Montreal classification was used to subdivide children with Crohn’s disease into
groups based on disease location (Methods, section 2.4.3). Of the thirty-two children
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with Crohn’s disease four (13%) had isolated ileal disease (L1); nine (28%) had colonic
disease (L2) and nineteen (59%) had both involvement of ileum and colon (L3) (Table
3.3). The overlapping relationship between disease locations in each patient is shown
in figure 3.5. Twenty-three (72%) children had upper involvement (L4): three (9%)
with orofacial granulomatosis (OFG); nineteen (59%) had gastric involvement and
eleven (34%) children had duodenal involvement. Additionally two (6%) children
with L3 had perianal disease.
Figure 3.5: Venn diagram showing number of children with ileal, colonic and isolated upper disease.
Overlap shows number of children who fall into two or all three disease location categories.
Table 3.3: Montreal classification of disease location of the
thirty-two children with Crohn’s disease.
classification of disease distribution n (%)
L1 terminal ileal +/- limited caecal disease 4 (13)
L2 colonic 9 (28)
L3 ileocolonic 19 (59)
L4* isolated upper disease* 23 (72)
*may coexist with L1, L2 and L3
3.5 Changes in disease activity during EEN
Disease activity was assessed by clinicians using the weighted paediatric Crohn’s
disease activity index (wPCDAI)(Methods, section 2.4.3).287 Scores were calculated
for each patient at pre-treatment (week-0); after treatment with EEN (week-8); and 8-
weeks normal diet (week-16) (Table 3.4). Disease remission was defined as a wPCDAI
score of <12.5. Mild disease between 12.5-40; moderate disease >40-57.5 and severe
disease as >57.5.287
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Table 3.4: Number of children with Crohn’s disease in each disease
activity category (wPCDAI) before and after treatment with EEN
Treatment Timepoint
week-0 week-8 week-16
baseline end of EEN normal diet
in remission 1 ( 3%) 23 (72%) 18 (56%)
mild disease 14 (44%) 9 (28%)* 12 (38%)
moderate disease 7 (22%) 0 ( 0%) 2 ( 6%)
severe disease 10 (31%) 0 ( 0%) 0 ( 0%)
* 6 of these children did not complete the full 8-weeks of EEN. wPCDAI
scores: remission <12.5; mild 12.5-40; moderate 40-57.5; severe >57.5
Of the thirty-two children diagnosed with Crohn’s disease at baseline, one was in dis-
ease remission (wPCDAI score 7.5); fourteen had mild disease; seven had moderate
disease and ten had severe disease. Although macroscopically the child in disease
remission had mild to moderate disease and histologically mild disease, their cal-
protectin (inflammatory marker) was high (>1800 mg/kg); hence this child chose to
undertake a course of EEN and was included in the study group.
After 8-weeks EEN, 72% of children were in disease remission (wPCDAI <12.5). The
remaining 28% had mild disease. Five of these children who failed EEN were in the
mild category at the start and end of treatment, however three had reduced their
wPCDAI score by the end of EEN. Two children who failed treatment with EEN
had stopped treatment after only 1-week. Another four of the children who did not
respond well to EEN stopped treatment early; two after 4-weeks and two after 6-
weeks. The remaining three children who failed EEN completed the full 8-weeks of
treatment before going onto corticosteroids. In total nine children failed to achieve
remission on EEN and went onto treatment with corticosteroids.
Of the seventeen children with Crohn’s disease who had either moderate or severe
disease at the start of treatment, all had reduced disease activity after the 8-weeks
of EEN. Of twenty-three children who responded well to treatment with EEN one
relapsed 6-weeks after returning to normal diet. Another child relapsed after 10-weeks
of normal diet. Two children relapsed within 16-weeks and another two children
within 24-weeks (∼6 months). Another two children relapsed within 36-weeks. At
the 36-week timepoint (28-weeks of normal diet), fifteen children were still in disease
remission. One year after the start of treatment with EEN, only eight of the original
twenty-three respondents were still in remission. The number of days to relapse for
each patient is shown in figure 3.6.
3.6 Medications taken by children
Of the thirty-two children diagnosed with Crohn’s disease twenty-three were medica-
tion free at the start of the study (Table 3.5). The child taking an immunosuppressant
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had a previous diagnosis of Crohn’s disease at the time of recruitment. Of the nine
children with UC, seven were medication free. For the group of eleven patients with
non-IBD conditions ten were medication free; the child using a bronchodilator had
asthma. Of the twenty-five healthy children all were medication free except two
children using paracetamol occasionally for headaches and a one child using a bron-
chodilator for asthma. Children with IBD, especially Crohn’s disease were more likely
to be taking some form of dietary supplement (Table 3.5).
Table 3.5: Numbers of children in each study group taking medication prior
to treatment
Crohn’s UC non-IBD healthy
medication n=32 n=9 n=11 n=25
prescribed medication
none 23 7 10 22
corticosteroids 0 0 0 0
immunosuppressant 1 0 0 0
antibiotic 0 0 0 0
biological 0 0 0 0
anti-acid (omeprazole/ranitidine) 2 0 0 0
laxative (movicol) 3 1 0 0
antispasmodic (buscopan) 2 0 0 0
anti-diarrhoeal (imodium) 1 0 0 0
pain killer (paracetamol) 3 1 0 2
bronchodilator 0 0 1 1
dietary supplement*
multivitamin 7 2 1 1
probiotic 4 1 3 0
iron 6 0 0 0
omega 3 2 1 0 0
vit C 1 0 0 0
*nutritional supplements are discussed in chapter on dietary intake
Prior to 8-weeks treatment with EEN no children with Crohn’s disease were taking
regular medications with the exception of two children: one who was taking a proton
pump inhibitor to control gastric acid (omeprazole); and another who was already
on immunosuppressants due to pre-existing diagnosis of Crohn’s disease (Table 3.6).
This child was included in the study as one of four children with existing Crohn’s
disease who were undertaking a second course of treatment with EEN.
Table 3.6: Types of medication given to Crohn’s disease patients
during treatment with EEN and MEN
week-0 week-8 week-16
number of children pre-treatment end of EEN normal diet
corticosteroids 0 5 7
immunosuppressant 1 15 22
antibiotic 0 1 0
biologic 0 0 1
omeprazole 1 7 6
no medication 30 10 4
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By the end of 8-weeks treatment with EEN: five children were on steroids; fifteen
were on an immunosuppressant; one was taking an antibiotic and seven were taking
omeprazole. Ten children at this point were still taking no medication. At week-16
(2-weeks post-EEN) seven children were on steroids; twenty-two were taking an im-
munosuppressant; one was taking the chimeric monoclonal antibody biologic, inflix-
imab, and six were taking omeprazole. Only four children were taking no medications
at week-16 (Table 3.6).
3.7 Treatment with maintenance enteral nutrition (MEN)
Figure 3.7: Number of days to disease relapse after end of EEN for children taking a) an immunosup-
pressant (IM); b) maintenance enteral nutrition (MEN) or an immunosuppressant plus maintenance
enteral nutrition (IM plus MEN). KW-test p=0.82
It was predicted using clinical data from the previous 2-years,283 that approximately
55% of children who had undergone a course of 8-weeks EEN would refuse MEN
as a course of treatment to maintain disease remission. However, out of twenty-
three children who went into remission on EEN only six (26%) children opted not to
take MEN (Table 3.7). Another issue was treatment with immunosuppressants: all
six children who declined MEN were on an immunosuppressant; whereas only 8/17
children taking MEN were on immunosuppressants. The number of days to disease
relapse for each treatment group is shown in figure 3.7. All children were given some
form of maintenance therapy post-EEN.
Table 3.7: Number of children with Crohn’s disease taking maintenance enteral
nutrition (MEN)
declined MEN taking MEN
n=6 n=17
immunosuppressants 6 8
(26%) (35%)
no immunosuppressant 0 9
(0%) (39%)
∗ All children on immunosuppressants were taking azathioprine, except for 4 chil-
dren taking mercaptopurine (2 on MEN and 2 not).
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3.8 Anthropometric characteristics and growth
Body composition data was collected from both patients and healthy children as an
objective measure of how well they were achieving growth targets, as well as assessing
if children and study groups, as a whole, were achieving optimal height and weight for
their age. To correct for age, the standard deviation scores (z-scores)284 for height,
weight and BMI are used to describe differences between groups. The actual height,
weight and BMI are also shown for reference but are not used for statistical analysis
since z-scores better represent whether a child is reaching expected growth targets
for their age (Methods section 2.4.1).
Table 3.8: Body composition in patient groups and healthy children (median; IQR)
Crohn’s UC non-IBD Healthy Kruskal-Wallis Test
Category n=32 n=9 n=11 n=23
Height (m) 1.47 1.58 1.48 1.50 -
(0.27) (0.21) (0.44) (0.35)
Weight (kg) 35.6 49.9 34.9 40.0 -
(18.6) (39.4) (23.0) (25.9)
BMI (kgm2) 16.0 18.8 17.9 18.8 -
(3.33) (12.15) (2.78) (4.73)
Height z-score -0.110** 0.061 -0.670** 0.763 p<0.001
(1.45) (2.20) (0.87) (1.50)
Weight z-score -0.429*** -0.385 -0.134 0.793 p<0.001
(1.89) (3.87) (1.94) (1.42)
BMI z-score -0.447* -0.557 -0.255 0.512 p=0.03
(2.31) (3.72) (2.40) (2.51)
Age 11.5 13.6* 11.3 11.0 p=0.03
(5.04) (1.67) (7.88) (5.67)
Data shows median and (IQR). Only SDS (z-scores) were tested for significance us-
ing Kruskal-Wallis, and multiple comparisons (Bonferroni). Difference from healthy
children significant at * p<0.05, ** p<0.01, *** p<0.001
3.8.1 Height and weight
The pre-treatment median height z-score of children with Crohn’s disease and non-
IBD patients was significantly lower than healthy children (p=0.009 & p=0.004 re-
spectively)(Table 3.8). Children with UC had a lower height z-score than healthy
children (not significant p=0.07). The median weight z-score of children with non-
IBD conditions (NS; p=0.34), UC (NS; p=0.25) and Crohn’s disease (p<0.001) was
less than healthy children. Children with UC had a much greater weight/height/BMI
z-score range compared with the other three groups (Table 3.8).
3.8.2 Body mass index (BMI)
The median BMI z-score was lower in all patient groups when compared to healthy
children; only reaching significance in children with Crohn’s disease (p=0.02) (Table
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Table 3.9: BMI SDS z-score categories in patients and healthy children
Crohn’s UC non-IBD healthy
Category n=32 n=9 n=11 n=23
clinically very underweight 4 1 0 0
clinically low weight 2 0 0 0
clinically healthy weight 26 5 6 16
clinically overweight 0 1 4 3
clinically obese 0 0 1 3
clinically extremely obese 0 2 0 1
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3.8). No child with Crohn’s disease fell into the overweight or obese category, and
six were underweight (≤–2 BMI z-score), four of which fell into the very underweight
category (≤–2.67 BMI z-score) (Table 3.9). For UC patients 3/9 (33%) were over-
weight (≥1.34 BMI z-score); with two of these children being extremely obese (≥2.67
BMI z-score). 1/9 children with UC had low weight, but this child fell under the
very underweight category with a (-5.85 BMI z-score). No non-IBD patients had low
weight, but five (45%) were clinically overweight, with one falling into the category
of obese. Anthropometric measures were available for twenty-three healthy children,
showing seven (30%) were overweight; with three falling into the obese category (≥2
BMI z-score) and one into the extremely obese category. No healthy children were un-
derweight. No differences were seen at baseline between boys and girls with Crohn’s
disease for height, weight or BMI z-scores (Fig. 3.8).
Figure 3.8: Gender differences in height, weight and BMI z-scores at baseline
In children with Crohn’s disease at baseline, there was no significant correlation
between BMI z-scores and either the wPCDAI or calprotectin as a marker of disease
activity (Fig. 3.9), however the disease markers albumin, CRP and ESR did correlate
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with BMI (Fig. 3.10) showing disease severity has the potential to lead to poorer
growth outcomes.
3.8.3 Change in body composition after treatment with EEN
To explore the effect of 8-weeks of treatment with EEN on growth outcomes in chil-
dren with Crohn’s disease, the change in height and weight between baseline and
the end of the 8-week treatment with EEN (0-8wks) was measured; then again after
8-weeks of normal habitual diet (8-16wks); and again after 28-weeks of normal ha-
bitual diet (16-36wks). The overall change in height and weight was also measured
(0-36wks). Children who failed to enter full remission on treatment with EEN and
went onto corticosteroids (non-responders) were compared with those children who
went into remission on EEN (responders) (Table 3.10; Fig 3.11).
Table 3.10: Change in body composition after 8-weeks treatment with EEN, then
8-weeks and 28-weeks of normal diet. Median (IQR).
week 0-8 week 8-16 week 16-36 week 0-36
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n=9 n=22 n=8 n=21 n=8 n=11 n=8 n=12
△ Height (cm) 0.45 1.24 0.20 0.88 1.86 1.15 2.93 3.22
(1.37) (1.73) (0.68) (1.01) (3.18) (1.47) (3.67) (1.51)
△ Weight (kg) 0.92 2.74 2.93 0.47 0.51 0.29 6.34 4.58
(4.85) (3.07) (6.70) (2.42) (4.38) (6.21) (9.49) (4.48)
△ BMI (kgm2) 0.13 0.95 1.17 -0.14 -0.31 -0.02 1.92 1.03
(1.89) (1.33) (2.37) (0.98) (2.22) (2.07) (3.30) (1.21)
△ Height z-score 0.03 0.06 -0.06 0.00 0.02 -0.12* -0.05 -0.04
(0.15) (0.17) (0.12) (0.16) (0.20) (0.15) (0.22) (0.21)
△ Weight z-score 0.02 0.41 0.32 -0.02* -0.13 -0.18 0.51 0.22
(0.81) (0.62) (0.68) (0.36) (0.93) (0.57) (1.02) (0.30)
△ BMI z-score 0.00 0.44 0.47 -0.08* -0.18 -0.09 0.61 0.40
(1.36) (0.94) (1.03) (0.51) (1.19) (0.90) (2.00) (0.68)
* Differences between responders and non-responder significant at p<0.01
At the end of 8-weeks treatment with EEN (0-8wks), children who did not respond to
EEN had the similar height gain as those who responded to treatment (p=0.77)(Fig.
3.11a). However responders to EEN had more weight and BMI gain than children
who failed EEN (p=0.056 & p=0.062 respectively)(Fig. 3.11d, 3.11g). Once back
onto normal diet for 8-weeks (8-16wks), responders to EEN had slightly more height
gain than those who failed EEN (p=0.074). Conversely for weight and resulting
BMI, non-responders had a larger weight and BMI increase after 8-weeks normal diet
(p=0.005 & p=0.002 respectively)(Fig. 3.11e, 3.11h).
In the following 20-weeks (16-36wks) children who had responded to EEN had a
median drop in growth rate in terms of height which was poorer than those who had
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p=0.162; rho=-0.253
(a)
p=0.181; rho=-0.247
(b)
Figure 3.9: Relationship between adiposity (BMI z-score) and disease activity given by (a) wPCDAI
and (b) faecal calprotectin as a marker of inflammation.
p=0.028; rho=-0.407
(a)
p<0.001; rho=0.611
(b)
p=0.001; rho=-0.536
(c)
Figure 3.10: Correlation between BMI z-score and disease markers (a) ESR, (b) albumin and (c)
CRP. All were significant
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EEN 0-8 wks
(a)
post-EEN 8-16 wks
(b)
post-EEN 16-36 wks
(c)
(d) (e) (f)
(g) (h) (i)
Figure 3.11: Change in body composition (z-scores) at (a)(d)(g) after treatment with EEN; (b)(e)(h)
8-16 weeks post EEN; and (c)(f)(i) 16-36 weeks post EEN for height, weight and BMI. Responder -
child who went into remission on EEN; Non-Responder - child who failed to respond to treatment
with EEN.
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Table 3.11: BMI of children with Crohn’s disease at baseline, after EEN and post-EEN
week 0 week 8 week 16 week 36
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very underweight 2 2 0 0 0 0 0 0
low weight 2 0 0 2 0 0 2 0
healthy weight 19 7 21 7 18 7 7 6
overweight 0 0 2 0 2 1 2 1
Total 23 9 23 9 20 8 11 7
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failed EEN (non-responders)(p=0.013)(Fig. 3.11c). Over this period there was no
difference in weight or corresponding BMI gain between the two groups of children
(p=0.96 & p=0.84 respectively)(Fig. 3.11f, 3.11i). Overall from pre-treatment to
36-weeks there was no difference in growth outcomes for height (p=0.62), weight
(p=0.44) & BMI (p=0.79) between responders and non-responders (Table 3.10).
3.8.4 Change in BMI categories after treatment with EEN
For children with Crohn’s disease who underwent the 8-weeks treatment with EEN,
among those who responded to treatment, none were underweight. However, two chil-
dren who failed to respond to EEN were in the low weight category; one of these had
been very underweight prior to treatment and had only managed to complete 5-weeks
of EEN; while the other had been at a healthy BMI pre-treatment but continued to
lose weight despite 8-weeks on EEN (Table 3.11). One of the two non-responders who
was very underweight at baseline only took EEN for 2-weeks before failing treatment
and going onto steroids. At the end of their 2-week course they had moved from
very underweight to low weight and it was only after 4-weeks on steroids, this child
moved to the healthy weight category. One child who was a healthy BMI at baseline
and failed treatment with EEN after only 4-weeks, went on to become overweight by
week-16 (8-weeks of normal diet) and remained overweight at 36-weeks.
Among the children with Crohn’s disease who responded to treatment with EEN two
moved from a healthy BMI at baseline, into the overweight category by the end of
EEN. One of these children went back to a healthy BMI once back onto normal diet,
however the other was still overweight at week-16 and week-36. Another two children
continued a consistent rise in BMI to become overweight, one after 8-weeks (week-16)
and the other after 28-weeks (week-36) of normal diet (Table 3.11).
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3.8.5 Effect of nasogastric feeding (NG-tube) on growth
To explore whether children who were given EEN via NG-tube had better growth
outcomes, changes in body composition z-scores, were compared between children
with Crohn’s disease taking EEN via NG-tube and those taking EEN orally. No
difference was observed for changes in height, weight or BMI z-scores (Fig. 3.12)
(a) (b) (c)
Figure 3.12: Change in body composition (z-scores) after 8-weeks treatment with EEN for children
who took EEN orally or via nasogastric tube (NGT) for (a) height, (b) weight and (c) BMI. No
difference between groups.
3.8.6 Gender differences in growth
To explore whether gender might play a role in response to treatment with EEN
we looked at gender differences in growth. There was no gender difference observed
between girls (n=9) and boys (n=23) for median height increase, before and after
treatment on EEN. Although the median weight gain after treatment with EEN for
girls (0.91kg; IQR 3.75) was less than boys (2.25kg; IQR 3.05), the difference was
not significant (p=0.154). The median BMI gain for girls (0.23kg/m2; IQR 1.78) was
less than boys (0.80kg/m2; IQR 1.49) but again the difference was not significant
(p=0.220). Although boys had higher median z-score increases in weight and BMI
after treatment on EEN, these were not significant (p=0.230) (Fig. 3.13).
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(a) (b) (c)
Figure 3.13: Change in body composition (z-scores) for girls (F) and boys (M) after 8-weeks treat-
ment with EEN for (a) height, (b) weight and (c) BMI. No difference between groups.
Baseline body composition as a predictor to growth outcomes on EEN To test
if height, weight or BMI at baseline, could predict growth outcomes after 8-weeks of
treatment with EEN, the baseline anthropometric measures of children with Crohn’s
disease were plotted against growth increase after treatment. No correlation was seen
between height z-scores of children with Crohn’s disease and gain in height during
EEN for both children who responded to treatment with EEN (responder)(p=0.060)
and those who failed treatment (non-responder)(p=0.321)(Fig. 3.14a).
There was however a strong negative correlation between weight z-score at baseline
and weight gain during EEN. This was more apparent in children who responded
to treatment (p<0.001) than in non-responders (p=0.029)(Fig. 3.14b). Children
who had the lowest weight z-score at baseline had the greatest weight gain during
EEN, and children who were less underweight pre-treatment had the least weight gain
during the 8-week treatment. The correlation with weight translated to BMI where
children with the lowest BMI had the greatest increase in BMI and those with higher
BMI had the least increase during treatment. The correlation for BMI was also more
apparent in children who responded to treatment (p<0.001) than non-responders
(p=0.013)(Fig. 3.14c).
3.8.7 Impact of maintenance enteral nutrition (MEN) on growth outcomes
To look at whether treatment with MEN post-EEN given with or without an im-
munosuppressant, could alter growth outcomes, the change in height, weight and
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(a) (b) (c)
Figure 3.14: Relationship (Pearson’s) between baseline anthropometric data (z-scores) and growth
during 8-weeks of EEN for a) height, (b) weight and (c) BMI, for children who failed to respond
(non-responder; n=9) and those who did respond (responder; n=23) to treatment with EEN. Shaded
area represents the 95% confidence interval.
BMI between week-8 and week-16 was measured. No difference in growth outcomes
was seen between treatment groups (Fig. 3.15). However a child in the MEN only
group with the largest decrease in z-score for height/weight/BMI was known to be
struggling with MEN, and may have failed to comply with the treatment. The sample
size was too low to reject the null hypothesis.
Figure 3.15: Change in height, weight and BMI (growth wk 8-16) in children who took both an im-
munosuppressant plus maintenance enteral nutrition (IM and MEN)(n=8); an immunosuppressant
only (IM only)(n=6); or maintenance enteral nutrition only (MEN only)(n=6). Sample size too low
for reliable statistical analysis.
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3.9 Predicting response to EEN
Socioeconomic status To explore any potential impact of socioeconomic depriva-
tion on the severity of disease the SIMD scores were plotted against markers of disease
activity. No correlation was found between disease activity and socioeconomic status
(Fig. 3.16).
(a) (b)
Figure 3.16: Disease activity and deprivation: scatter-plot showing there is no relationship between
SIMD rank and either (a) wPCDAI or (b) calprotectin as marker of inflammation for children with
Crohn’s disease at the time of recruitment.
To explore whether children with Crohn’s disease, who were from more socially de-
prived areas, were more likely to fail treatment with exclusive enteral nutrition (EEN),
the SIMD deprivation ranks were compared between children who responded to treat-
ment and those who failed treatment (Fig. 3.17). No difference was seen in median
SIMD scores between those who responded and went into remission on 8-weeks of
treatment with EEN and those who failed to respond.
Figure 3.17: Deprivation score (SIMD) of 23 children with Crohn’s disease who responded to treat-
ment with EEN (responder) compared with 9 children who failed treatment (non-responder). No
difference observed between groups (p=0.609).
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Gender In children with Crohn’s disease there was no difference in disease activity
between girls and boys, either in terms of the wPCDAI score or calprotectin (50;
IQR 31.2 and 37.5; IQR 40.0 respectively). Although girls in this study with Crohn’s
disease were more likely to fail treatment with EEN (5/4; 56%) compared with girls
who responded to treatment (4/19; 17%), the sample size was too low to determine
if girls were truly more likely to fail EEN. Of the five girls who failed treatment
with EEN: one had ileal disease; three had colonic disease and one had ileocolonic
disease. Although girls who undertook 8-weeks of treatment with EEN relapsed in a
fewer number of days than boys (median 99 days; IQR 265 and 236 days; IQR 277
respectively), this difference was not statistically significant (Fig. 3.18).
Figure 3.18: Days from start of EEN to disease relapse in boys and girls with Crohn’s disease; no
difference between groups (p=0.366). 6 boys and 1 girl still in remission at 1-year are not shown.
Age Children across all age groups were just as likely to fail to respond to treatment
with EEN. Thus age did not predict response to treatment with EEN (Table 3.13).
(a) (b)
Figure 3.19: (a) Age and (b) disease activity (wPCDAI) at baseline did not predict whether children
would respond to treatment with EEN. Responders were compared with non-responders.
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Disease activity To see if children with more severe disease activity at baseline were
less likely to respond to EEN, the median wPCDAI scores were compared between
responders (42.5; IQR ) and non-responders (52.5 IQR ) (Fig. 3.19b). No difference
was seen between groups.
Table 3.12: Disease location in children with Crohn’s disease who did
and did not attain disease remission after 8-weeks of exclusive enteral
nutrition (EEN)
total responder non-responder
Disease location (n=32) (n=23) (n=9)
L1 ileal 4 (13%) 3 (13%) 1 (11%)
L2 (isolated colonic) 9 (28%) 3 (13%) 6 (67%)
L3 (ileocolonic) 19 (59%) 17 (74%) 2 (22%)
L4 ⋆ upper GI involvement 23 (72%) 19 (83%) 4 (44%)
Ileal involvement *
ileal 20 3
non-ileal 3 6
⋆ Can co-occur with L1, L2 & L3. Sample sizes too low to test location
categories but when looking at * ileal/non-ileal involvement significant
difference were observed between responders and non-responders (χ2 with
Yates correction p=0.009).
Disease location To explore whether disease location could predict children’s re-
sponse to treatment with EEN, children were categorised into disease location groups
using the Montreal classification. Of the thirty-two children with Crohn’s disease
one child with ileal disease (L1) failed treatment with EEN, while six children with
colonic disease (L2) failed EEN. Only two children with ileocolonic disease (L3) failed
treatment (p=NS) (Table 3.12). A significant difference between response and non-
response to EEN was seen between ileal/non-ileal involvement suggesting that chil-
dren with ileal disease were more likely to response to EEN. Children with ileal
involvement also had a greater median number of days to disease relapse than those
with isolated colonic disease (Fig. 3.20).
Figure 3.20: Crohn’s disease location and days to relapse. L1 -ileal; L2 -isolated colonic; L3 -
ileocolonic (Dunn’s test of multiple comparisons following a significant Kruskal-Wallis test: p=0.01).
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Baseline body composition Baseline height, weight and BMI z-score in children
with Crohn’s disease who failed to respond to EEN was essentially no different from
the group of children who responded well to treatment. As such height, weight and
BMI z-scores at baseline, did not predict response to treatment (Table 3.13).
Table 3.13: Summary of baseline body composition in children with Crohn’s
disease who did and did not attain disease remission after 8-weeks of exclusive
enteral nutrition (EEN). Shown as median (IQR)
total responder non-responder p value
Characteristic (n=32) (n=23) (n=9) R vs non-R
height for age † -0.31 (1.06) -0.58 (1.03) 0.08 (1.29) p=0.102
weight for age † -0.60 (2.05) -0.43 (1.94) -1.07 (2.46) p=0.834
BMI for age † -0.36 (2.15) -0.24 (1.85) -1.04 (3.50) p=0.502
wPCDAI score 41.2 (31.9) 42.5 (35.0) 37.5 (37.5) p=0.414
age 11.6 (5.0) 11.6 (4.6) 14.2 (7.8) p=0.197
No difference seen between children who failed EEN (non-responders) and those
who went into remission (responders)(MWU test). † standard deviation z-scores.
3.10 Links between patient characteristics
Looking at the relationship between different patient characteristics can help to iden-
tify and understand potential limitations of the study data, helping to better inter-
pret results. To ensure the study included children from a representative range of
backgrounds the Scottish Index of Multiple Deprivation 2016 (SIMD) score of the
twenty-eight children with Crohn’s disease who were able to provide a baseline stool
sample was compared with the six children who were unable to provide a stool sample.
No difference in SIMD score was seen between the two groups (Fig. 3.21). Therefore
those children who were unable to provide a faecal sample came from an even spread
of socioeconomic groups.
Figure 3.21: The Scottish Index of Multiple Deprivation 2016 (SIMD) score of children with Crohn’s
disease who provided a baseline stool sample (sample) and those who were unable to provide a sample
(no sample).
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3.11 Discussion
3.11.1 Recruitment
Hurdles to recruitment and ethical considerations. Approximately one in ten
children, all of whom were patients, declined to take part in the study (Fig 3.1).
There are a number of reasons why children might decline to take part. Most children
were waiting for a diagnosis which is a stressful time and some families said they felt
taking part could place an extra unnecessary burden on their child. It was observed
that mothers per se, were more positive about the idea of taking part in research,
and seemed to view research as a potential benefit to the long-term well-being of
their child. When fathers were present at recruitment meetings they were, generally
speaking, more likely to dissuade their child from taking part in the research study.
Fathers more often expressed concerns, and often asked more questions about the
potential impact research might have, in the short term, on the health of their child.
It might be helpful for future studies to try and record any gender difference in
attitudes toward research so these differences, if any, could be addressed in the way
recruitment studies are explained to parents and guardians.
Another interesting observation was children themselves, often said that they were
happy to take part ‘especially if it helped another child’. It was surprising children
projected the potential benefits of future research on to ‘other children’ rather than
their own need. This may have been an artefact of the way we explained the study.
While explaining the study it was made clear that this research would not benefit
them directly so as not to mislead children into thinking the study could find a cure
for their condition. Thus children may have taken these comments at face value and
assumed there could be no benefit to themselves, even in the long-term.
As the study progressed it became apparent, taking part in research had a positive
psychological effect on a number of individual children and their families. As with
other documented studies,343 many parents and children who took part in this study
reported they derived comfort from knowing research into IBD was taking place, as
well as satisfaction from being directly involved in that process, even although they
derived no direct benefit from it.343 Therefore it would be an interesting add-on to
future IBD studies to measure any positive impact that knowledge about research
has on patient well-being and health.
There were a number of practical hurdles to recruitment. When planning the study,
effort was made to include a number of different centres where follow-up treatment
for children with Crohn’s disease took place. However, clinics in different locations
could overlap making it impossible for one person to carry out recruitment effectively.
A substantial part of recruitment time was spent travelling between clinics, hence it
would have been more cost-effective to try and include staff who were based on site to
help with recruitment at individual centres, or limit the number of centres involved.
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Table 3.14: Steps taken to optimise recruitment and suggestions for improvement
Strategy Techniques employed Suggestions for improvement
Preparation & Assess study feasibility at start Increase speed of ethical approval
planning Identify centres in surrounding hospitals Shared database of eligible patients
Establish links with clinical support staff
Engendering Research introduced by patient’s doctor Reduce time commitment required
patient support Advertise the study for healthy volunteers Better rewards for healthy children
Detailed participant information sheets
Discuss concerns with IBD-nurse
Contact for complaints or concerns
Use of text messaging for convenience
Collaboration Integrated clinical and academic team Improve links with outreach clinicians
with clinicians Research meetings providing updates Involve NHS staff in recruitment process
Another issue identified during recruitment was the duplication of patient research
questions and measures, which were already being done by clinical staff. The team
in one of the hospital centres came up with the solution of inviting the researcher
into the dietetic clinical appointment which saved the duplication of questions and
measurements. This reduced the burden on both parents and children, allowing them
to leave the hospital more quickly and missing less school/work time. Reducing the
time burden on patients would likely result in more patients completing studies.
Meeting recruitment targets From previous hospital records283 we estimated around
fifty to sixty children would come into the Royal Hospital for Children in Glasgow to
undergo colonoscopy over 12-months, and be newly diagnosed with Crohn’s disease.
Within the 18-month recruitment time frame of this study, we aimed to approach
around seventy-five treatment naive patients as well as about twenty children with
existing Crohn’s disease. With a recruitment success rate of 65% this would have
given a potential of sixty-two Crohn’s disease participants over 18-months. We pre-
dicted a study retention rate of 65% to give a final number of forty-two Crohn’s
disease patients. Our aim was to age and sex match these with a group of forty-two
healthy children as controls. We managed to approach seventy-six patients: 13%
declined to take part; 14% were unable to provide a baseline stool sample; 14% had
non-IBD conditions and 14% had either UC or IBD-U. This left thirty-four children
diagnosed with Crohn’s disease which at 55% was 10% less than the original target
of 65%. The retention rate was slightly better than the predicted 65%, with 71%
of children with Crohn’s disease completing the study. This left a final number of
twenty-four children with Crohn’s disease who completed the study (57% of original
target); and twenty-five healthy controls (60% of original target).
Recruiting the target number of research participants was extremely challenging for a
number of reasons. Firstly, we needed to ensure a strategy to identify all potentially
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eligible patients were invited to join the study. Coming into recruitment from a non-
clinical background with no prior NHS experience, it took time to establish links
with clinical teams and to gain training and understanding of how hospital systems
such as patient databases worked. Obtaining permissions to access hospital databases
also took time. During this period of establishing links with clinics, obtaining access
and learning how to work NHS databases, a number of potential participants were
missed. The study recruitment was also dependant on the involvement of clinical
staff who were involved in a number of other research studies. The result being, if
staff over several hospitals, including clinicians, nurses, dietitians were not constantly
reminded about our recruitment aims, identifying potential participants was missed.
This complex and time-consuming reminder system did not always work well due
to time constraints, hence future studies may find it more efficient and effective to
have the onus of identifying patients based within the NHS clinical setting. Despite
these challenges we recruited sixty-six patients and twenty-five healthy children due
to the clinicians in Paediatric Gastroenterology at the Royal Hospital for Children
in Glasgow having an active interest in research and inviting patients to meet with
the researcher. Extending the responsibility of recruitment for this study by having
an IBD nurse or dietitian actively involved in carrying out recruitment would also
have lessened the burden on patients and helped with patient retention; although it
would have a greater financial impact on running costs. Creating a shared research
database of potentially eligible patients is one way which the complex situation of
dealing with many different staff over a number of clinics could possibly be improved
(Table 3.14).344
Patient travel times can also be an issue with recruitment and participation. We
recruited a number of patients from outside the greater Glasgow area who attended
hospital in Glasgow. However for those with Crohn’s disease it was often problematic
to collect samples, as patients were not able to come into Glasgow to drop these
off, hence a huge amount of research time was spent driving around the west of
Scotland collecting samples. It would have been more cost effective and time efficient
to either only recruit children within the Glasgow area or to have employed someone
to collect samples. Using existing lab transport services could also have improved
sample collection by facilitating the collection of samples from local GP clinics which
might have been a convenient drop off point for many patients.
Retaining participants Over the course of the study participant retention was
improved by making telephone reminders to parents, and using text messages where
the parent chose this as an option, which all participants with Crohn’s disease did.
One advantage of using text messages as a reminder was, busy parents could call
back at a time that was convenient for them, rather than being disturbed by a phone
call while at work, while shopping, or preparing family meals. Text messages also
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contained useful information such as dates which were at hand, therefore parents
were less likely to forget when the next sample was due. The use of text messages
made it easier for patients to communicate with the researcher. They could easily ask
questions if their child had problems providing samples or inform us if the child was
too fatigued to provide a sample, thus allowing us to be more sensitive to individual
child needs. Good participant communication was key to the successful retention of
participants over the course of the study.
By keeping a detailed patient log (required by ethics), it was noted that children who
failed to provide stool samples and dropped out of the study, tended to be children
who gained the least enjoyment from taking part. As the study progressed it was
easier for researchers to identify any child who was not enjoying taking part and may
wish to drop out; allowing researchers to make leaving the study as easy as possible
for the family. Future studies may want to consider identifying why many children
gain pleasure, while some find it a burden to take part in research. This might help
to identify those likely to drop out at an earlier stage of the study, allowing us to
either help them leave the study before it becomes a burden, or to adapt the study
to better fit their needs.
3.11.2 Representative sampling
Recruitment is a challenging process and it is important to be aware of the limita-
tions of any recruitment bias. There are a number questions to address in terms of
understanding whether the children who were recruited onto the study were a fully
representative subset of the Scottish population of children with IBD and healthy
children. The focus of this study was to look at children with Crohn’s disease hence
our recruitment of healthy children was not random, but designed to match, as far
as possible, the age and gender with our study group.
Social deprivation By checking whether children from more deprived areas were
less likely to partake in the study, it was shown children who failed to provide sam-
ples, were just as likely to come from deprived areas, hence there was no bias in
socioeconomic status for samples collected (Fig. 3.17).
It can be very challenging to recruit healthy controls on studies for a number of rea-
sons. Firstly many volunteers come from personal friends, children of staff/students,
who work within the same environment where the study takes place. This can have
the effect of creating a bias towards a less deprived demographic. Based on a pre-
vious study,64 there was a ‘preconception’ that children with Crohn’s disease tended
to come from less deprived backgrounds, and hence this assumption influenced the
effort which was made to recruit healthy children from this demographic.64 To avoid
this bias, future studies should look at the SIMD scores during recruitment, and
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use the SIMD website interactive map,345 to identify areas for targeting recruitment
of healthy controls, in order to better match deprivation scores. This could have
avoided the slight difference we had between children with Crohn’s where 48% came
from more deprived areas (Rank 1 & 2) compared with only 20% of healthy controls
coming from these two more deprived ranks (Fig. 3.3). This difference could be par-
ticularly important in studies related to nutrition, since low income and differences
in access to education might affect dietary choices.
A control group should aim to match the study group not only for sex and age, but also
for other factors contributing to differences between the groups unrelated to disease,
such as differences in activity levels or diet. It is unlikely that the small difference in
deprivation scores in our study, between children with Crohn’s disease and our healthy
control group, will affect results. However, understanding how confounding factors
might affect the interpretation and conclusions drawn from data is very important.
It should be noted that deprivation scores are for areas, and not individuals, such
that any child who lives in an area of social deprivation, is not necessarily deprived
and vise versa; i.e. the six children with Crohn’s disease who resided in the most
deprived areas may have fairly affluent lifestyles.
The national 2016 SIMD ranks show different health boards have marked differences
in deprivation scores with Greater Glasgow & Clyde, Ayrshire & Arran and La-
narkshire, having the highest income deprivation and health deprivation in Scotland
(Methods Fig. 2.3).286 Hence the population of children we recruited from these ar-
eas may not fully represent the whole Scottish population in terms of deprivation. It
would be interesting for future studies to look at patient outcomes in health author-
ities across Scotland, to see if those under the strain of dealing with more deprived
populations, negatively impacts on patient outcomes for children with IBD. Fami-
lies with low socioeconomic status and restricted income, might have less access to
healthy food choices. If dietary choice is a risk factor for Crohn’s disease then we
might expect to see a higher prevalence at one end of the socioeconomic spectrum.
If dietary choice affects the likelihood of relapse we might also expect to see a dif-
ference in disease outcomes. However in this study no evidence was seen linking
socioeconomic status with risk of Crohn’s disease (Fig. 3.3).
Gender The ratio of girls to boys was 1:2.56 for Crohn’s disease, matched by 1:1.27
for healthy children. It was harder to recruit healthy boys, who appeared not to be
as motivated to take part by our offer of a  10 gift voucher. Increasing the value of
the gift may have attracted more healthy boys to volunteer, but for future studies
it would be worth looking at any gender differences which might act as a barrier to
volunteering, so these can be accounted for at the planning stage.
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Age Although we successfully managed to recruit a good match in terms of age
for children with Crohn’s disease, non-IBD patient controls and healthy controls, the
group of children with UC were slightly older than the other three groups (Fig. 3.4).
This needs to be kept in mind when interpreting any differences in variables such
as gut microbiota, metabolites or dietary intake which are examined in subsequent
chapters.
Body composition The study aimed to match at recruitment, the BMI of healthy
children with that of children with Crohn’s disease. However as the study progressed,
it became obvious this was unrealistic, given that children with Crohn’s have often lost
enough weight prior to diagnosis to be classified as underweight to very underweight.
The seven healthy children we recruited that were overweight, have the potential to
create a bias in our dataset when comparing data from gut metabolites or bacteria to
children with Crohn’s disease who were either normal weight or underweight; i.e. any
effects attributed to disease aetiology might in fact be due to differences in energy
intake or body fat mass, hence this needs to be considered when interpreting data in
subsequent chapters.
3.11.3 Patient Characteristics
Gender As reported in European and North American studies, the current study
also saw a higher number of boys than girls with Crohn’s disease in a ratio 1:2.5. To
date no studies have identified whether these gender differences are due to environ-
mental factors such as a gender difference in diet, or if genetic differences related to
gender, such as sex hormones, increase the risk of Crohn’s disease for boys.
Age In 2012 Henderson et al.84 compared 260 Scottish children with IBD from
1990-1995 with 436 children from 2003-2008 and found the age at diagnosis had fallen
from 12.7 to 11.9 years (p<0.01). This was driven by a decrease in age at diagnosis
of children with Crohn’s disease CD from 13.2 to 12.1-years (p<0.001). These mean
ages are in line with the current study of 12.2-years (n=43) for all children with
IBD and 11.8-years (n=34) for children diagnosed with Crohn’s disease. This is of
concern as earlier onset has more potential to impact on linear growth and pubertal
development in children.10;11
Body composition Although a measure of height and weight might seem relatively
straightforward, when measuring children over the short term who are undergoing
height growth in a non-linear manner with ‘growth spurts’ and the affect of puberty;
special consideration needs to be given as to whether height is a good tool to measure
whether a child is thriving, and nutritional goals set for the child are being met. This
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is not a problem when using height or BMI as a measure of growth over a longer time
period such as a year, but in this study measures taken at 4-week intervals using
height would produce misleading data. To illustrate this, if we take two children the
same age and height, and improve their nutrition, both might gain 1kg in weight over
four weeks. If one of these children did not gain in height while the other gained 1cm
in stature, the child who grew taller would have a lower BMI and our data might
mislead us into thinking the child who grew less in stature is thriving better in terms
of BMI than the child who is taller. If we use height as a measure of growth then the
reverse would be true. Therefore over the time period of this study weight increase
is considered a more accurate indicator of improved nutritional status in growing
children.
Also when measuring growth impairment in children, static height measurements
may be misleading as they are affected by genetic limitations (parental height) and
pubertal status. A child with Crohn’s disease might be normally short, or a tall child
might not have grown for several years but might still be of average stature for age
and gender.
The current study saw no difference in height/weight/BMI z-score between boys and
girls at baseline (Fig. 3.8) suggesting both genders were equally at risk of poor growth
prior to diagnosis. Failing to reach optimum height for age is of concern, especially in
girls, as delayed linear growth has been linked with around 2-year delay in pubertal
development.10;11 If the onset of puberty is significantly delayed beyond the age of
14-years, the final height of girls may be permanently compromised.10;11 Boys have
also been shown to have delayed pubertal growth but this did not appear to be linked
with linear growth.10 In Crohn’s disease impairment of linear growth can also precede
weight loss and thus be an early indicator of disease.
Body mass index (BMI) BMI is only an estimated measure of body fat, as it makes
a potentially inaccurate assumption about how much weight is body fat. Nonetheless
studies have shown BMI correlates well with other measures of body fat including
underwater weight and dual energy x-ray absorptiometry.346 Unlike other methods
BMI requires only measures of height and weight, making it a reliable, easy and
affordable way to record changes in body composition or differences between study
groups. Its universal acceptance as a method also has the advantage of allowing
researchers to compare historical data with current measures, as well as pool data
from different studies and regions across the world.
BMI has limitations, which should be kept in mind when interpreting or using BMI
data to reach conclusions from data sets. As well as not actually measuring fat, it
does not discern between muscle tissue, bone mass and adipose tissue, genetics and
muscle mass, all of which have the potential to alter the accuracy and reliability
of BMI as a measure of body fat.346 For example old people tend to have a larger
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proportion of body fat than young adults even although they have the same BMI.347
Female adults tend to have larger proportions of total body fat than men with the
same BMI,348 and people with an athletic physique such as rugby players, can have
a BMI which would suggest they are overweight due to having large muscle mass.349
There are additional issues when using BMI for children/adolescents. Factors affect-
ing variation in growth rate such as nutrition and genetics, as well as levels of sexual
maturity, alter the relationship between BMI and body fat in children.346 It has also
been shown the reliability of BMI as a measure of body fat varies with percentage
of body fat. In obese children with a BMI for age which is ≥ 95th percentile, BMI is
a reliable indicator for body fat. However in overweight children which have a BMI
for age between the 85th and 94th percentiles, an increase in BMI can be due to in-
creased fat-free mass rather than adipose tissue.346 In addition differences in BMI in
relatively lean children can be due to differences in the proportion of fat-free mass.346
Since a proportion of the children with IBD in this study are underweight, the results
of BMI measures when compared with healthy children should be interpreted with
caution.
As we might expect, children with Crohn’s disease in the current study had a sig-
nificantly lower height, weight and BMI score than healthy children (p<0.05). Only
one child with UC was underweight; five normal weight and the rest overweight,
while none of the children with Crohn’s disease were overweight. Identifying the
cause of growth failure in individual children is not straight forward, since a number
of factors can be involved such as reduction of food/nutrient intake, malabsorption
due to inflammation, as well as side effects of medications like steroids. Although
western studies particularly those in North America would suggest the risk of IBD
patients being underweight is decreasing, with some studies showing a large number
of patients being overweight at diagnosis, our study found 19% (6/32) of children
with Crohn’s disease were underweight compared with 11% (1/9) of our UC patients.
Given the time constraints of this study it was not possible to track the time taken
from first GP contact to diagnosis. It would however have been interesting to see
if the children who were most underweight had taken longer to be referred by their
GP. Future studies could easily monitor these time-scales to see if strategies can be
identified which would result in less children have clinically low weight prior to treat-
ment. The current study, in line with large North American studies,53 found that
more UC (3/9) than Crohn’s disease (0/32) patients were overweight, but numbers
were too small to establish significance. The height, weight and BMI of our healthy
cohort had z-scores above the norm with 7/23 children being overweight-obese. The
z-scores are based on 1990 norms hence it is unclear if our 2014-16 healthy cohort
are representative of overall national increases in child body composition. A large
Scottish study on adults with IBD reported 18% were obese in comparison to 23% for
the total Scottish population.55 Another 38% were over-weight which was equivalent
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to the general Scottish population.55 However, we need to be careful when comparing
adult studies with paediatric studies as Crohn’s disease tends to be more severe in
children, which could impact on the rate of weight loss prior to diagnosis.
In the current study it was interesting that for BMI at baseline in children with
Crohn’s disease, a significant correlation between BMI z-scores and serum disease
markers albumin, CRP and ESR were seen (Fig. 3.10). This highlights the impor-
tance of using body composition measures such as low BMI as an important early
warning sign of potential inflammation and IBD.
3.11.4 Disease Characteristics
In the patient control group diagnosed with non-IBD conditions, the five children
who had a first or second degree relative with IBD, none were diagnosed with a
gastrointestinal condition. Therefore care needs to be taken looking at results in
later chapters, to see if any of this group of five children overlap with our study
group who have IBD, suggesting that they might have subclinical IBD.
Disease location in children with Crohn’s disease Upper gastrointestinal involve-
ment (L4) in Crohn’s disease has been reported in previous studies as anywhere be-
tween 30%-80% in children and adult studies.20 72% of children in our study had
isolated upper disease showing just how important it is to understand upper involve-
ment. None of the patients included on the study had isolated upper disease without
concurrent ileal/colonic disease (L1-L3). Normally around 40%-50% of patients have
ileal disease (L1) however only 13% of our cohort had ileal disease and the numbers
of ileocolonic (L3) numbers at 59% were higher than previously reported figures of
around 30%-40%.20 The number of children with colonic disease (L2) was much closer
to previously reported figures at 28%.
Studies linking efficacy of EEN with disease location are limited,26 with some evidence
suggesting children with ileal involvement respond better to EEN.27 However this
Japanese study showing children with active Crohn’s disease fail to respond well
to EEN when ileal involvement was not present are not supported by an Italian
paediatric study127 or a later Japanese adult study.140
In 1990 Teahon et al.350 concluded from a large number of case studies that adult
Crohn’s patients with isolated ileal involvement were more likely to remain in remis-
sion after EEN for longer when compared with patients with colonic, or ileocolonic
disease. Gavin et al.153 found, after EEN induced remission children with colonic
disease tended to relapse earlier.
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3.11.5 Predicting response to EEN
Socioeconomic status and response to EEN The current study saw no correlation
between disease activity and socioeconomic status (Fig. 3.16). Children with Crohn’s
disease who were from socially deprived areas were as likely to fail treatment with
EEN as those from less deprived areas, as there was no difference in SIMD scores
between the children who responded well and went into remission on 8-weeks of EEN
and those who failed EEN (Fig. 3.17).
Gender and response to EEN Although the current study saw a gender difference
in response to treatment on EEN, 3/5 girls who failed EEN had colonic disease, which
did not seem to respond as well to treatment in both girls and boys. For those children
who went into remission on EEN, results show no gender differences in the number
of days to disease relapse once children were back onto their normal habitual diet.
Disease location and response to EEN As the sample size of the current study was
underpowered in terms of disease location, it was not possible to assess whether ileal,
colonic or ileocolonic (L1, L2, L3) disease played a role in how well children responded
to treatment with EEN. However figures are in line with other research studies which
show a significantly greater number of children with ileal involvement respond well to
treatment with EEN, when compared to children with isolated colonic disease (Table
3.12). Results from Kim et al. 2016351 found no difference in disease location between
children who were responders (n=58) and non-responders (n=8) to EEN. Although
the current study saw a higher number (67%) of children with isolated colonic disease
in the non-responder group, Kim et al. saw no children with isolated colonic disease
failing EEN. A meta-analysis of ten trials was unable to link disease location and
phenotype with efficacy of treatment, or time to relapse, despite studies suggesting
patients with ileal involvement respond better to EEN.26 Therefore further studies
are needed to clarify whether isolated colonic disease could be a separate subcategory
of IBD.
Age and response to EEN The current study explored the possibility that children
of a particular age group might be at greater risk of failing treatment with EEN,
perhaps due to younger children becoming distressed and not complying with the
diet; or teens finding the diet too difficult to maintain among their peer groups at
school. However since those who failed treatment on EEN ranged in age from 3-16
(median 14.2) it was concluded that no particular age group appeared to be more
at risk of failing treatment (Fig. 3.19a) A 2016 Irish study concluded that EEN was
less effective in patients aged under 10-years (p=0.04).352 However given the fairly
low number of children who went into remission (n=18), creating an artificial split
114
Table 3.15: Age-related response to treatment with EEN in children
with Crohn’s disease: showing potential error in age categorisation
Response to EEN
responder non-responder
Lafferty 2014 352 0 -<10 8 9
≥10 33 9 p=0.04
BIG study 0 -<10 6 3
≥10 16 6 NS
BIG study 0 -<12 15 4
≥12 8 5 NS
The current study (BIG) has been split into two different age bands,
to show how creating an artificial divide can bias results.
above and below the age of ten was not a robust way to analyse the risk of failing
treatment. If the current study analysed data using the same cut-off age similar ratios
are produced. However if we were to ask if there is a difference between primary and
secondary age children and thus choose a cut-off age of 12-years rather than 10-years,
the data would then suggest the converse is true, i.e. that children over the age of
12-year respond less well to treatment than younger children (Table 3.15). Hence
without a good reason for doing so and a clearly defined research question it is not
helpful or advisable to create age categories, but better to analyse as continuous
data.353
Body composition and response to EEN Knowing whether the baseline height,
weight or BMI z-score in children who failed treatment with EEN was different from
those who responded was important, since any differences at baseline could introduce
a bias, potentially leading us to identify differences between the response groups
in research variables which were due to differences in nutritional status at baseline.
However height, weight and BMI z-scores at baseline did not predict the response to
treatment (Table 3.13).
3.11.6 Effect of 8-weeks treatment with EEN
Weight gain after EEN It is worth considering how using EEN as a treatment
option to achieve disease remission in children with Crohn’s disease might impact
on growth targets for children who fail to respond to treatment with EEN. Of the
9/32 children with Crohn’s disease who failed to respond to EEN, only 56% gained
weight compared with 95% of responders. Although it might be assumed children
who failed EEN put on less weight due to being on EEN for less weeks, this was not
the case (Fig. 3.22). It appears that among non-responders, children who managed
to stay on EEN for 6 to 8-weeks did not gain any benefit in terms of weight gain
compared to those who stopped EEN early. This was explained when looking at
the effect of baseline weight (pre-EEN) on weight gain (post-EEN). There was clear
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relationship for both responders and non-responders whereby children which were
most underweight at baseline put on the most weight over the 8-weeks regardless of
how long they were on EEN (Fig. 3.23), (Spearman’s rank p<0.001 Rho -0.664).
Figure 3.22: Relationship between number of weeks on EEN and weight gain in children with Crohn’s
disease who failed to respond to EEN (non-responders). The 2 children with most weight gain had
very low BMI at baseline (z-score -3.53 and -4.32).
Figure 3.23: Relationship between baseline weight z-score and change in weight z-score after EEN
in responders and non-responders. For combined groups Spearman’s rank p<0.001 Rho -0.664.
This has important implications for studies such as Gavin et al. 2017,153 where they
report a significant gain in BMI among those who took MEN (p=0.004). In the Gavin
study, the children who took MEN were those who had a significantly lower BMI at
baseline (p=0.004) than those who took normal diet alone; and looking at the strong
correlation between baseline weight and weight gain in the current study, it could be
argued that baseline BMI is more likely giving rise to this increase than MEN. Gavin
et al. saw no difference in BMI between children taking EEN and steroid therapy
over a 12-month period.153
In the current study children who failed EEN, were not more underweight at baseline
than children who responded well to EEN; thus weight gain does not give any clues as
to whether children who failed EEN might have had compliance issues. When asked
at their clinic appointment, all children reported they had fully complied with taking
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EEN. It is difficult to know with certainty whether children who fail to respond to
EEN as a treatment, fail to adhere fully to the treatment regime. It is possible loss
of weight or failure to gain weight was due to malabsorption where EEN had not
succeed in reducing disease activity and inflammation in those who failed treatment.
Although the nutritional benefits of EEN as reported in other studies,283;49;153 led
to weight gain (p=0.056) and increased BMI z-scores (p=0.062), inline with these
studies, the current study did not see a corresponding increase in height z-scores
(p=0.77).283;49;153 The time frame of 8-weeks is however not long enough to reliably
measure changes in height (section 3.11.3). It is believed that corticosteroid therapy is
responsible for the negative impact on growth, however some studies have suggested,
age at diagnosis, disease activity and possibly disease location in Crohn’s disease,
may have a larger impact on linear growth than steroid use.354
For children who fail EEN, it is important that future studies look at the effect
of combining EEN with corticosteroids to establish if these children have the same
opportunity to obtain target growth outcomes as well as achieve disease remission.
3.11.7 Effect of treatment with MEN
Since the current study was an observational study, we could not influence the num-
bers of children choosing to take maintenance enteral nutrition (MEN) post-EEN.
It was predicted from previous years at the Royal Hospital for Children that ap-
proximately 55% of children would refuse MEN as a course of treatment to maintain
disease remission. However only 6/23 (26%) of children who went into remission on
EEN opted not to take MEN (Fig. 3.6), one then going onto MEN around 17-weeks
post-EEN. Another problem was, although all children who opted not to take MEN
were on an immunosuppressant, only 8/17 children taking MEN were taking an im-
munosuppressant, creating a third subgroup. Children taking an immunosuppressant
as well as MEN creates a confounding factor, as it could have an effect on the gut
microbiota profile and metabolites, making understanding differences between these
three groups more challenging.
It is unclear why more children chose to take MEN than in previous years. It is
possible that in explaining the study to parents/guardians and children with Crohn’s
disease, made them more aware of the possible benefits of MEN as a therapy. It is
also conceivable that in discussions with clinical staff, IBD-nurses and dietitians we
influenced the likelihood they would recommend MEN as maintenance treatment. A
combination of both of these may have influenced the choices participants made when
offered MEN.
Although no difference was seen in number of days to relapse between children with
Crohn’s disease who took MEN, an immunosuppressant or both together (p=0.82),
the sample sizes were too low to detect any differences which have been reported in
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other studies (Chapter 1, Table 1.6). It is possible that children who are more likely
to relapse are more likely to be given more aggressive therapy by clinical staff. In
fact, in the current study children with higher disease activity (wPCDAI scores) at
baseline were more likely to be given MEN plus an immunosuppressant post-EEN
(p=0.01)(Fig. 3.24), therefore the treatment groups have a bias in terms of disease
activity, making it impossible to determine if treatment has an effect on days to re-
lapse since those who have more severe disease might relapse sooner. No correlation
was seen between disease activity at baseline (wPCDAI score) and days to relapse
(Spearman’s rank, p=0.480; rho=-0.155); thus having more severe disease at base-
line did not affect how quickly children relapsed. Although baseline disease activity
affected treatment, baseline height/weight/BMI z-scores did not affect whether chil-
dren took MEN, an immunosuppressant or both together (p=0.73, p=0.77, p=0.56
respectively).
Figure 3.24: Effect of baseline disease activity (wPCDAI score) on treatment with maintenance
therapy for children taking a) immunosuppressant (IM); b) maintenance enteral nutrition (MEN)
or c) immunosuppressant plus maintenance enteral nutrition (IM plus MEN). IM plus MEN was
significantly higher than IM (p=0.01) and MEN (p=0.03). Dunn’s test of multiple comparisons was
used following a significant Kruskal-Wallis test.
It was important to look at whether treatment with MEN (with or without an im-
munosuppressant), could affect growth outcomes. There was no overall difference
seen between treatment groups (Fig. 3.15). However the child who had the largest
drop in z-score for height, weight and BMI over the 8-weeks of MEN was recorded to
be struggling with MEN, and may not have complied with the treatment. Although
removing this child from the analysis may have given a more accurate assessment of
the effect of MEN on growth outcomes, the remaining sample size of five children was
too low to be meaningful. It is possible in terms of weight change, that children who
took MEN were better able to maintain and gain weight; however as we do not have
a non-treatment control group it is also possible that taking an immunosuppressant
negatively affects the child’s ability to gain weight. A larger sample size is required
to enable reliable statistical analysis.
MEN is an attractive therapy option, because evidence to date suggests when com-
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pared with normal habitual diet, MEN may be effective in maintaining remission
in children with Crohn’s disease (Chapter 1, 1.8.3; Table 1.6). It could also be as
effective as some medication with one study suggesting MEN can delay the need
for corticosteroid therapy101 as well as improving the child’s growth and nutritional
status. A problem with interpreting MEN studies is different doses and feeding ap-
proaches have been used, such as overnight nasogastric feeds combined with normal
eating during the day; short periods of nasogastric feeds several times a year; and a
daily supplement drink used alongside normal eating with variable success rates.151
Since the 2007 Cochran systematic review,355 suggesting MEN could be effective at
extending remission post-EEN, studies have been few, usually with small sample sizes
which lack statistical power, making it difficult to draw conclusions.356 While larger
studies are still needed, and given that MEN could be dose dependant,148 studies
using murine models could shed some light on whether lower doses of around 25%
MEN are likely to be ineffective.
Medications It is important to consider the medications children take at the start
of and during treatment with EEN since these have the potential to influence the gut
microbiota profile and metabolites. 23/32 (72%) of children diagnosed with Crohn’s
disease were medication free at baseline, giving a good study size free of medication
as a confounding factor. 7/9 children with UC (77%) and 10/11 (91%) non-IBD
children were also medication free (Table 3.5), meaning the study control groups also
had a low chance of being affected by any influence of medication.
Treat to Target Although it is evident that inducing and maintaining clinical re-
mission of symptoms for patients with Crohn’s disease are the main therapeutic goals,
they may not be enough to prevent longer term damage to the gut. As such corticos-
teroids have been the cornerstone treatment and provide effective control of symptoms
in the shorter term; however they fail to prevent the long-term progression of dis-
ease.357 Therefore biochemical markers are becoming a much more important aspect
of monitoring disease progression and gut inflammation. More consistent monitoring
of inflammatory markers such as calprotectin in children with Crohn’s disease could
in future be linked with therapeutic doses of MEN to better control the likelihood of
relapse.
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3.11.8 Summary of key findings
 Children with Crohn’s disease had significantly lower height/weight/BMI z-scores than healthy
children at baseline.
 In children with Crohn’s disease, markers albumin, CRP and ESR, correlated with BMI z-
scores, suggesting increased disease severity results in poorer growth outcomes.
 72% of children with Crohn’s disease attained remission after 8-weeks EEN; and all children
with moderate to severe disease at baseline had reduced disease activity.
 Of children diagnosed with Crohn’s disease, 72% had upper involvement; with 59% having
gastric disease.
 Children with Crohn’s disease who were underweight pre-EEN put on more weight during
EEN than those who were normal weight at baseline.
 No differences in BMI or growth were seen between responders and non-responders to EEN,
either at baseline or at 28-weeks post-EEN.
 1-year after the start of treatment with EEN, only eight of the original twenty-three respon-
dents (35%) were still in disease remission.
 Children with ileal disease were more likely to respond to EEN (NS).
New findings from this study:
 Although children with Crohn’s disease had age appropriate growth during EEN, growth
velocity was not maintained once children went back onto normal diet.
 No differences in growth were seen between the three types of maintenance therapy (MEN,
MEN+IM, IM).
Future research goals:
 Growth can be used as an outcome to measure the effectiveness of paediatric Crohn’s disease
therapies, however studies to date have focused on short-term growth. There is an urgent
need to study not only clinical outcomes, but also the long-term growth outcomes of treatment
with EEN and MEN.
 Patients with non-IBD conditions should not be used as healthy controls. The current study
shows that these children, when recruited from gastroenterology clinics, have conditions which
should exclude them as controls. Nearly half of the non-IBD controls were given no diagnosis,
and all of these children had a family history of IBD; hence it is possible some could have
subclinical IBD.
 The reality in clinics is therapy for children with Crohn’s disease involves multiple strategies,
which often take place simultaneously making it impossible to ascertain if changes or out-
comes are due to a single therapy or a combination approach; and appropriate controls are
unavailable. Animal studies which trial single and combined therapies with controlled diets,
using well designed controls, would give more robust results which could then form the basis
of more informed human trials.
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4 Markers of inflammation in Crohn’s disease
4.1 Introduction
Chronic and persistent disease activity in IBD is linked with poor prognosis and
hence monitoring inflammatory markers in these patients would allow the potential
suppression of sub-clinical inflammation as a method of treatment.358 Disease markers
are also a priority, because not only is monitoring disease activity by endoscopy
invasive for the patient, particularly for children who have to undergo a general
anaesthetic, but it is also expensive and diverts valuable resources which might better
benefit IBD patients if these were redirected to long term treatment and care.
Crohn’s disease has historically been managed in a step-wise manner with evaluation
of disease activity and treatment mostly based on active symptoms. Failing to keep
patients in remission worsens the long-term outcomes of patients with Crohn’s disease
and places them at risk of bowel damage.359 Identifying and using specific disease
markers for Crohn’s disease to regularly monitor disease activity would allow the
identification of sub-clinical disease. This concept called ‘treat to target’ has been
beneficial in other autoimmune conditions such as rheumatoid arthritis.360
In the current study where treatments and outcomes are assessed, it is important to
have reliable markers of inflammation, which are independent of any potential bias.
4.1.1 Stool characteristics and markers of inflammation
Faecal calprotectin Henderson et al.361 have shown that faecal calprotectin can act
as a better marker of colonic inflammation than other commonly used blood markers
such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), platelet
count, haemoglobin, total white cell count, and albumin in children with IBD. Faecal
calprotectin is a measure of the amount of the protein calprotectin present in the
stool of patients. An increase in calprotectin, is an indicator of neutrophil migration
into the intestinal mucosa, which occurs during the type of gut inflammation caused
by IBD. Testing for calprotectin could reduce the need for repeated and invasive
colonoscopy.362
Human calprotectin is a 24kDa dimer of the calcium binding proteins S100A8 and
S100A9.363 It can chelate iron,364 manganese and zinc,365 and this ability to sequester
essential metals gives calprotectin its antimicrobial properties.363 Calprotectin, makes
up around 60% of protein content in the cytosol of neutrophils; it is resistant to
enzymatic degradation, and can be easily measured from stool samples using an
ELISA.366
There are a number of diseases that cause an increased excretion of faecal calprotectin
including IBD, coeliac disease, infectious colitis, necrotising enterocolitis, intestinal
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cystic fibrosis and colorectal cancer.367 However, faecal calprotectin is now frequently
used as indicator for active disease in IBD.367 Measurement of faecal calprotectin has
been shown to be strongly correlated with 111-indium-labelled leukocytes which are
considered the gold standard measurement of intestinal inflammation.366 However,
the European Crohn’s and Colitis Organisation (ECCO) suggest that faecal calpro-
tectin only be used as a secondary outcome measure in Crohn’s disease due to high
variability in results, which leads to low levels of precision and unclear cut-off levels
for assessing disease activity.125
By measuring faecal calprotectin as a marker of colonic inflammation in the current
study, and confirming it correlates with measures of clinical disease remission (wPC-
DAI), changes in this continuous data set could be used to help answer the current
study hypotheses. Stool markers such as calprotectin have emerged as a new diag-
nostic tool to detect intestinal inflammation. However, stooling frequency and the
Bristol stool chart score (Methods, Fig. 2.8), an indicator of water content, also have
the potential to act as low cost approximate indicators of gut inflammation in IBD.
4.1.2 Blood markers
C-Reactive protein (CRP) CRP is a pentameric protein present in blood plasma.
It is synthesised in the liver and increases in response to macrophage and T-cell IL-6
production.368 A normal concentration of CRP in the blood serum of healthy humans
lies between 5-10mg/L and tends to increase with age. CRP is involved in a number
of functions linked with host defence, including its ability to recognise both pathogens
and damaged host cells. As such the level of CRP in plasma increases during acute
phase response to tissue injury, infection, and other inflammatory stimuli and is
therefore routinely used as a marker of inflammation in IBD.358 It is however less
sensitive than faecal calprotectin as a marker of inflammation.369
Erythrocyte sedimentation rate (ESR) ESR is the rate that red blood cells sedi-
ment in one hour and is used as a non-specific measure of inflammation. Inflammatory
processes result in a high level of fibrinogen in the blood which causes red blood cells
to clump into stacks called ‘rouleaux’. Due to increased density these settle more
quickly. However in patients with Crohn’s disease, ESR can be within normal lim-
its while CRP is elevated, and CRP tends to return to normal faster than ESR in
response to treatment.370
Human serum albumin Serum albumin is the most abundant protein found in
human blood plasma, making up around half of all serum protein. It is produced in
the liver and transports compounds such as hormones, fatty acids, as well as buffering
pH and maintaining the colloid osmotic pressure of blood vessels. Serum albumin is a
122
negative acute-phase protein which is down regulated in inflammatory conditions. As
such it can be used as a non-specific marker of disease activity in IBD.370 Both ESR
and albumin are criteria used in the weighted Paediatric Crohn’s Disease Activity
Index (wPCDAI) (Appendix 3).
Full blood count Results from a full blood count can show inflammation from the
white blood cell count and anaemia can be detected via red blood cell results.370
Liver function test This test helps to monitor if the liver is functioning properly,
and is important in relation to the side effects of some medications used to treat
IBD. Methotrexate and Infliximab have been reported to cause liver damage in IBD
patients.371;372 However the prevalence of altered liver function test results in IBD
patients has been difficult to establish because various studies have used different
methods to collect data, as well as different diagnostic and patient selection crite-
ria.373;374;375 Issues with liver (hepatobiliary) function can be due to inflammation in
patients with IBD but the causal relationship between abnormal liver function test
results and IBD is unclear.376;377 Although Mercaptopurine and Azathioprine induced
hepatotoxicity is not common in the adult IBD population, it has been reported in
10-15% of paediatric patients,378 hence liver function monitoring is important for
children taking these drugs as maintenance therapy.
Urea and electrolytes (U/Es) Urea and electrolytes (U/Es) are routinely measured
from bloods taken from paediatric IBD patients. Measuring an electrolyte panel
including sodium, potassium, chloride, bicarbonate as well as urea and paediatric
creatinine (estimates glomerular filtration rate by age and gender),379 can be used
to check for dehydration; the side effects of medication, and toxic megacolon (a rare
complication of Crohn’s disease).380
4.1.3 wPCDAI as an indicator of disease activity in Crohn’s disease
Although not a perfect tool, the weighted Paediatric Crohn’s Disease Activity In-
dex (wPCDAI) is a standard outcome measure in paediatric Crohn’s disease research
(Methods, section 2.4.3), and is currently used by clinicians in West of Scotland Pae-
diatric Gastroenterology, Hepatology and Nutrition network to assess disease activity.
The wPCDAI form is shown in appendix 3 and includes raised ESR and albumin as
part of the scoring index.
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4.1.4 Missing observations
One of the limitations of a study looking into inflammatory markers over time is that
it can be challenging to obtain bloods close to the study time-points for a number of
reasons. This was an observational study and as such we were dependent on children
having bloods taken as part of their routine monitoring. On occasions children failed
to turn up to clinic or were on holiday and bloods were not taken until a following
appointment, which did not then coincide with the study time-points. Sometimes
bloods were taken at the planned time but the clinical lab tests were unable to yield
a viable result from the sample, and the test was then not repeated within the time-
point of interest. This had the effect of creating gaps in the dataset which reduces
the power of our ability to look at changes over time.
4.1.5 Hypotheses summary
 Children with Crohn’s disease have an inflammatory marker profile which is
distinct from that of children with UC, non-IBD conditions and healthy children.
 Inflammatory marker profiles at baseline can predict which children with Crohn’s
disease will respond to treatment with exclusive enteral nutrition (EEN).
 For children in disease remission post-EEN, supplementing return to normal
diet with (20%) maintenance enteral nutrition (MEN) will maintain reduced
levels of inflammatory markers associated with remission achieved during EEN.
4.2 Methods
Faecal samples were collected and processed as described in Methods, section 2.4.4.
Bristol stool chart scores and stooling frequency were recorded on sample collection
(Methods 2.6.1). Faecal water content was calculated by weighing samples before and
after freeze-drying (Methods 2.7.1). Faecal calprotectin was measured using the com-
mercial ELISA kit CALP-0170 (CalproLabTM CALPRO, Lysaker, Norway) according
to the manufacturer’s instructions (Methods 2.6.2).
Data on clinical markers CRP; ESR; serum albumin; as well as full blood count
(FBC); liver function test and U/Es were obtained from routine clinical lab results.
To explore the relationship between different inflammatory markers the differential
expression analysis of the blood data was used. A challenge in research datasets based
on biological sampling is that of missing values, which restrict our ability to carry out
this type of analysis accurately. Hence a kernel-based method (KMDA) was used to
account for missing values.338 Kernel density estimation is a non-parametric method
used to estimate the probability density function of a random variable (Methods
2.10.3). Correlation coefficients were used to group variables into feature sets, thus
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allowing us to see the relationship between those variables for each experimental
patient group.
Disease activity was also assessed using the weighted paediatric Crohn’s disease activ-
ity index (wPCDAI)(Methods 2.4.3).287 Disease remission was defined as a wPCDAI
score of <12.5. Mild disease between 12.5-40; moderate disease >40-57.5 and severe
disease as >57.5.287
4.3 Results
4.3.1 Markers of inflammation at baseline
Collecting markers of inflammation at baseline helps to build a picture of patient
characteristics prior to treatment with EEN and MEN, as well as disease severity.
Markers provide a useful comparison to compare not only against other inflammatory
conditions, but also as a measure of the success of treatment over time.
Calprotectin The pre-treatment median calprotectin concentration for children with
Crohn’s disease was not different from children with UC. Children with Crohn’s dis-
ease and UC had significantly higher faecal calprotectin levels than healthy children
(p<0.0001) and patients with non-IBD conditions (p<0.01) (Table 4.1; Fig. 4.1a).
Bristol stool chart scores and stool water content Baseline median Bristol stool
chart scores for children with Crohn’s disease were not different from children with
UC. Children with both Crohn’s disease and UC had significantly higher median Bris-
tol stool chart scores than both healthy children and those with non-IBD conditions
(Table 4.1; Fig. 4.1b).
Table 4.1: Faecal inflammatory markers between patient groups (median; IQR)
Group
Crohn’s UC non-IBD Healthy K-W Test
Calprotectin (mg/kg) **††1337 (690) **† 1533 (809) 53 (184) 18 (31) p<0.001
(n=32) (n=9) (n=11) (n=20)
Water content (%) **†† 83.5 (11.0) *† 87.0 (11.0) 70.0 (11.0) 72.0 (9.0) p<0.001
(n=32) (n=7) (n=11) (n=19)
Bristol stool chart **†† 6.0 (2.0) *† 7.0 (3.5) 2.0 (3.0) 3.0 (1.5) p<0.001
(n=32) (n=9) (n=11) (n=25)
Daily stooling frequency ** 3.0 (2.0) ** 6.0 (7.0) * 3.0 (1.5) 1.0 (1.0) p<0.001
(n=27) (n=7) (n=6) (n=19)
Kruskal-Wallis test with Bonferroni correction for multiple testing. Difference from healthy children was
significant at * p<0.01, ** p<0.001. Difference from non-IBD patients is significant at † p<0.01, †† p<0.001.
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(a) (b)
Figure 4.1: Difference in inflammatory markers (a) calprotectin and (b) Bristol stool chart scores
between children with Crohn’s disease, UC, non-IBD conditions and healthy children. KW test:
children with IBD were significantly different from both the non-IBD control group and healthy
children (p<0.01).
The percentage of water content of stool samples (Fig. 4.2) shows that the Bristol
Stool chart scoring is a good a marker of stool sample water content in patient
groups. However for healthy children who had much lower stool chart scores there
was no correlation between these lower scores and stool water content.
Figure 4.2: The relationship (Pearson correlation) between Bristol Stool chart scores (BSC) and %
of water in faecal samples in patients with (a) Crohn’s disease (s=0.788; p<0.001); (b) UC (s=0.897;
p=0.006); (c) non-IBD (s=0.877; p<0.001) and (d) healthy children (s=-0.199; NS). Shaded area
represents the 95% confidence interval.
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Table 4.2: Blood markers measured at baseline, median (IQR)
Crohn’s UC non-IBD reference range
Test (n=30) (n=9) (n=11)
CRP 6.0 (20.0) 3.0 (3.5) 3.0 (2.2) 0-10 mg/L
ESR 21.0 (26.2) 20.0 (15.5) 5.0 (3.0) 1-9 mm/hr
Full blood count
white blood count (WBC) 9.20 (4.08) 9.70 (3.85) 6.40 (3.40) 4.5-13.5  109L
red cell count (RCC) !**4.86 (0.63) 4.21 (1.24) 4.68 (0.63) 4.0-5.10  1012L
haemoglobin 112.0 (27.5) 108.0 (38.0) 127.0 (19.0) 115-155 g/L
haematocrit 0.36 (0.06) 0.33 (0.12) 0.36 (0.09) 0.350-0.450 L/L
MCV 76.7 (13.8) 79.9 (3.4) 82.3 (9.2) 77.0-85.0 fL
MCH *24.6 (6.2) 26.6 (1.4) 27.4 (3.4) 25.0-33.0 pg
platelet count **425.0 (218.5) 384.0 (130.5) 301.0 (125.0) 150-400  109L
neutrophils *5.4 (3.3) *5.5 (2.9) 3.4 (1.6) 1.5-8.5  109L
lymphocytes ⋄ !2.0 (0.9) 2.9 (0.8) 2.1 (1.8) 1.5-6.8  109L
monocytes *0.80 (0.65) *1.00 (0.75) 0.60 (0.30) 0.2-1.0  109L
eosinophils 0.30 (0.55) 0.50 (0.55) 0.30 (0.20) 0.1-1.0  109L
Liver function test
total bilirubin 6.0 (3.5) 5.0 (1.0) 7.0 (9.8) <20 "mol/L
alanine transaminase (ALT) 11.0 (7.0) 16.0 (27.5) 13.5 (5.5) 10-45 U/L
aspartate transaminase (AST) *!19.0 (10.5) 24.0 (32.0) 27.0 (16.2) 15-45 U/L
alkaline phosphatase 144.0 (116.5) 208.0 (134.0) 221.5 (64.0) 60-425 U/L
albumin **32.0 (11.5) 35.0 (7.5) 40.0 (5.2) 35-50 g/L
Urea and Electrolytes
sodium 138.0 (2.0) 137.0 (2.5) 137.5 (2.5) 133-146 mmol/L
potassium 4.0 (0.3) 4.0 (0.4) 4.2 (0.6) 3.5-5.0 mmol/L
chloride ⋄ !104.5 (2.2) 106.0 (2.0) 104.5 (5.5) 95-108 mmol/L
bicarbonate 24.0 (4.5) 22.0 (4.5) 21.5 (3.8) 19-28 mmol/L
urea 3.1 (0.8) 3.1 (1.7) 3.9 (1.2) 2.5-6.5 mmol/L
paediatric creatine 46.5 (12.5) 48.0 (19.0) 41.0 (31.2) 20-50 "mol/L
serum ferritin θ !25.5 (27.0) 14.0 (16.0) 26.5 (51.3) 7-140 ng/mL
1 Kruskal-Wallis test with Bonferroni correction for multiple comparisons. Difference from non-IBD patients
significant at * p<0.05 ** p<0.01, *** p<0.001. Difference from UC patients significant at  p<0.01,   p<0.001.
θ n= 18,7,11 respectively. ⋄ Significance is likely a type 1 error.
Stooling frequency Although children with UC had the highest median number
of stools per day, they also had the most variation in number of stools per day
(Table 4.1). Healthy children were stooling significantly less than all three patient
groups: Crohn’s disease; UC and non-IBD patients (p<0.0001, p<0.0001 and p<0.001
respectively). There was no correlation between daily stooling frequency and either
faecal water content or the Bristol stool chart scores for any group of children.
Blood markers To explore differences in inflammatory marker profiles between pa-
tient groups, standard clinical lab results for C-Reactive protein (CRP); erythrocyte
sedimentation rate (ESR); full blood count (FBC); liver function test (LFT) and
urea/electrolyte test (U/Es) were obtained from patient records (Table 4.2). Blood
test results were not available for the cohort of healthy children who took part in this
study.
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Although median CRP was higher in children with Crohn’s disease compared to
children with UC and non-IBD patients, this did not reach significance. With the
exception of one non-IBD patient with gastritis, children with non-IBD conditions
and UC did not have raised CRP. However 11/30 (37%) of children with Crohn’s
disease had elevated CRP (>10mg/l).
ESR was higher in both Crohn’s disease and UC compared with non-IBD controls
but the difference did not reach significance, due to high levels of variability in IBD
patients. Only one non-IBD patient with gastritis had raised ESR, compared with
68% Crohn’s and 75% UC patients with elevated ESR (>10mm/hr).
Full blood count (FBC) The red blood cell count was significantly lower in chil-
dren with UC than those with Crohn’s disease (p=0.007) and children with non-IBD
conditions (p=0.009). Although median haemoglobin and the ratio of the volume
of red blood cells to the total volume of blood (haematocrit) were reduced in UC
this was not significant. For children with Crohn’s disease their median corpuscular
haemoglobin (MCH) was lower than non-IBD children (p=0.02) and children with
UC (NS)(Table 4.2). White blood cell count was higher in both IBD groups but did
not reach significance. The number of neutrophils and monocytes was higher in both
children with UC and Crohn’s disease (p≤0.05), compared with non-IBD controls.
Although numbers of lymphocytes in children with Crohn’s disease are higher than
non-IBD controls (NS) and those with UC (p=0.03), this is likely a type 1 error as
the non-IBD control group have a range that encompasses both IBD groups (Table
4.2). Platelet count was higher in children with Crohn’s disease (p=0.009) and UC
(NS) compared to non-IBD controls (Table 4.2).
Liver function test (LFT) Median aminotransferases (ALT & AST) and alkaline
phosphatase were lower in children with IBD (Table 4.2), but only reached significance
for AST in children with Crohn’s disease. Albumin was reduced in IBD compared
with non-IBD controls but only reached significance for Crohn’s disease (p=0.003).
17/30 (57%) children with Crohn’s disease; 3/9 (33%) UC and 2/10 (20%) with non-
IBD conditions (one with gastritis; one with intestinal polyps) had albumin levels
lower than the reference range (<35g/L).
Urea and Electrolytes (U/Es) Although children with Crohn’s disease had a me-
dian chloride level that was significantly higher than children with UC, this is likely a
Type 1 error ‘false positive’ as the chloride range in children with non-IBD conditions
encompassed both IBD groups. No difference from the non-IBD control group was
seen between groups for the other measures in the U/E test (Table 4.2).
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Serum ferritin as a measure of iron storage Children with UC had significantly
lower median ferritin levels than children with Crohn’s disease (p<0.01). This dif-
ference did not reach significance in children with non-IBD conditions because the
range of ferritin levels (IQR) was too high (Table 4.1).
4.3.2 A Kernel approach for differential expression analysis of blood data
Pearson correlation coefficient with a threshold of 0.70 followed by KMDA, showed
children with Crohn’s disease compared to non-IBD controls, had a higher WBC
grouped with an increase in neutrophils (p<0.001). ESR and CRP in Crohn’s dis-
ease also had a correlated increase (p<0.001); alkaline phosphatase and albumin were
independently lower in children Crohn’s disease when compared to non-IBD controls
(p<0.001 & p=0.01 respectively) (Fig. 4.4b). When children with UC were compared
to non-IBD controls increased WBC correlated not only with neutrophils and mono-
cytes but also with increased platelet count and ESR (p<0.05). In children with UC,
a decrease in RCC was correlated with haemoglobin and haemacrit, as well as al-
bumin (p<0.05). Children with UC also had significantly more eosinophils (p<0.05)
and less serum ferritin (p<0.05) than non-IBD control patients. Serum ferritin, which
was lower in UC (p=0.003) was the only marker to be significantly different between
Crohn’s disease and UC.
The overall blood profile differences between patient groups are shown in figure 4.3.
Although 95% confidence intervals for groups overlap, children with Crohn’s disease
have profiles which are further from the non-IBD control group than children with
UC.
Figure 4.3: Difference in blood result profiles between children with Crohn’s disease, UC and non-
IBD conditions shown by metric multi-dimensional scaling (MDS) spider plot. PERMANOVA:
R2=0.197; p=0.0001 (vegan; euclidean). MDS polygon plot shown in appendix 4.
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Figure 4.4: Kernel based differential analysis (KMDA) on blood markers at baseline for (a) children
with Crohn’s vs those with UC, (b) children with Crohn’s vs those with non-IBD conditions and
(c) children with UC vs those with non-IBD conditions. Correlation coefficients were used to group
variables into feature sets, allowing visualisation of the relationship between those variables for each
patient group.
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4.3.3 Changes in markers of inflammation during EEN
After treatment with EEN, inflammatory markers faecal calprotectin, ESR and CRP
were significantly reduced in children with Crohn’s disease, along with a significant
increase in albumin (Table 4.3). Changes in inflammatory markers were accompanied
by an overall reduction in disease activity scores (wPCDAI) (Fig. 4.5).
Figure 4.5: Weighted paediatric Crohn’s disease activity index (wPCDAI) pre-EEN, after 8-weeks
treatment with EEN and 8-weeks post-EEN. Samples are paired across all three time-points (n=18)
Children responding to EEN had a significant reduction in faecal calprotectin, which
was not seen in non-responders (Fig. 4.6). Two non-responders had reduced cal-
protectin after 4-weeks EEN: one of which increased CRP from 1 to 13mg/L during
EEN; while the other had very high levels of calprotectin at baseline which only re-
duced slightly after treatment, and went onto corticosteroids post-EEN (Fig. 4.6a).
In the response group one child had no change in calprotectin levels during EEN,
however their CRP fell from 45 to 3mg/L, ESR fell from 73 to 39mm/hr and albumin
increased from 21 to 38g/L; hence their wPCDAI score fell to zero (Fig. 4.6b).
Table 4.3: Changes in key inflammatory markers in children with
Crohn’s disease at baseline and after 8-weeks EEN.
Baseline EEN Wilcoxon
number Week-0 week-8 p value
Calprotectin mg/kg n=16 1518 (517) 672 (826) p<0.001
ESR mm/hr n=17 17 (24) 5 (10) p=0.002
CRP mg/L n=13 5 (20) 3 (3) p=0.023
albumin g/L n=17 31 (12) 41 (6) p<0.001
Median (IQR) Differences were analysed with Wilcoxon matched-pairs
signed rank test.
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(a) (b)
Figure 4.6: Changes in calprotectin during EEN in (a) responders and (b) non-responders to EEN.
Wilcoxon paired test. Time-points were (wk-00) baseline and (wk-04) after 4-weeks treatment with
EEN.
The Bristol stool chart (Methods Fig. 2.8) was used to measure faecal consistency
(Fig. 4.7b) during EEN. The median Bristol stool chart score after 8-weeks EEN
showed a reduction in water content (4.5; IQR 4) from baseline (6; IQR 2). Once
back onto normal diet for 8-weeks, stool consistency remained similar (4; IQR 4).
The daily stool frequency of children with Crohn’s disease reduced after treatment
with EEN (Fig. 4.7d): from a median of 3 stools per day (IQR 2.0) at pre-treatment
to 1 per day (IQR 0.5) after 8-weeks EEN. Once children were back onto normal diet
for 8-weeks there was a slight increase to 1.5 stools per day (IQR 1.0). Daily stooling
frequency is one of the indicator questions in the wPCDAI score, and a reduction in
water content and stooling frequency was maintained post-EEN (Fig. 4.7).
Blood profiles Clinical blood markers were used to generate a multi-dimensional
scaling profile, which in children with Crohn’s disease moved towards non-IBD con-
trols after EEN (Fig. 4.8). A kernel based differential analysis between blood markers
at baseline and after 8-weeks EEN show changes in CRP and ESR are correlated.
Changes in markers from the U/E test including ALT/AST are also correlated in a
separate subset (Fig. 4.9)
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(a) (b)
(c) (d)
Figure 4.7: Changes in disease activity pre-EEN and post-EEN were measured using a number
of indicators: (a) calprotectin; (b) the Bristol stool chart; (c) faecal water content and (d) daily
stooling frequency. Time-points were (wk-00) baseline; (wk-04) after 4-weeks treatment with EEN;
(wk-08) after 8-weeks treatment with EEN; (wk-10) after 2-weeks and (wk-16) after 8-weeks of
normal habitual diet.
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Figure 4.8: Changes in blood result profiles between baseline (week 00) and after 8-week treatment
with EEN (week 08) in children with Crohn’s disease; shown by metric multi-dimensional scal-
ing (MDS) spider plot. PERMANOVA: R2=0.225; p=0.0001; Children with non-IBD conditions
(black) are shown for reference. MDS polygon plot shown in appendix 4
Figure 4.9: Kernel based differential analysis (KMDA) on blood markers in children with Crohn’s at
baseline (week 00) and after 8-weeks treatment with EEN (week 08). Correlation coefficients were
used to group variables into feature sets, allowing visualisation of the relationship between those
variables for each patient group.
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4.3.4 Predicting response to EEN
The median baseline levels of calprotectin as a marker of inflammation were slightly
higher in children who failed to respond to treatment with EEN but the difference
was small and did not reach significance (Table 4.4). No significant difference was
seen for ESR, CRP or albumin between responders and non-responders to EEN. ESR
and albumin are included in the disease activity score index (wPCDAI) which also
saw no difference between responders and non-responders (Table 4.4).
Table 4.4: Predicting response to EEN: Difference in key inflam-
matory markers at baseline between children who responded to
EEN and those who failed EEN.
responder non-responder MWU
n=22 n=8 p value
Calprotectin mg/kg 1328 (639) 1566 (547) p=0.298
ESR mm/hr 21.5 (24) 18 (24) p=0.430
CRP mg/L 6.5 (19.8) 3 (12) p=0.395
albumin g/L 31 (11.5) 36 (8.2) p=0.259
wPCDAI score 42.5 (35.0) 37.5 (37.5) p=0.414
Median (IQR). No significant difference between responders and
non-responders (MWU-test).
4.3.5 Changes in markers of inflammation during MEN
For children who went into remission on EEN, calprotectin significantly increased
after only 8-weeks of normal diet post-EEN. ESR and CRP also increased but failed
to reach significance for ESR. The median disease activity index score (wPCDAI)
had also increased inline with these inflammatory markers after 8-weeks of normal
diet, but failed to reach statistical significance (Table 4.5; Fig. 4.7).
Table 4.5: Inflammatory markers in children who responded to EEN; at the
end of EEN and after 8-weeks normal diet (post-EEN).
end of 8-wks end of 8-wks Wilcoxon
n value on EEN normal diet p value
Calprotectin mg/kg n=14 485 (847) 1140 (638) p=0.004
ESR mm/hr n=12 5.5 (4.8) 8 (25.8) p=0.057
CRP mg/L n=10 3.0 (2.2) 4.5 (5.0) p=0.050
albumin g/L n=12 40 (5.5) 39 (7.2) p=0.157
wPCDAI score n=14 0 (9.4) 6.2 (19.4) p=0.066
Median (IQR). Wilcoxon signed rank test with continuity correction.
After children had reached remission on EEN, children chose to either take 20%
maintenance enteral nutrition (MEN) or none (non-MEN). The median level of cal-
protectin was no different between those who took MEN and the non-MEN group
after 2-weeks (study wk-10) and 8-weeks (study wk-16) of normal diet (Fig. 4.10).
The number of children in the non-MEN group was too low to test significance.
135
Figure 4.10: Faecal calprotectin as a marker of inflammation during maintenance therapy. Patients
were given either 20% maintenance enteral nutrition (MEN) or none (non-MEN). Sample sizes were
too low to determine significance
A key factor omitted from most studies on MEN, is that children often take an
immunosuppressant (IM) such as azathioprine, as well as MEN as part of maintenance
therapy post-EEN. When children were split into groups which factored in both MEN
and IM use, it appears possible that children with lower calprotectin at the end of
EEN are less likely to be given an IM as part of maintenance therapy (Fig. 4.11).
Figure 4.11: Faecal calprotectin as a marker of inflammation during maintenance therapy. Sample
sizes were too low to determine significance
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4.4 Discussion
The results of the current study from baseline samples show that faecal calprotectin
is significantly higher in children with IBD than in healthy children. Daily stooling
frequency, faecal water content and Bristol stool chart scores were also significantly
increased in children with IBD. These faecal characteristics were not different between
children with Crohn’s disease and UC. Although not significant, clinical blood marker
profiles in children with Crohn’s disease were shown to have potential differences from
both UC and non-IBD patients.
After 8-weeks of EEN, calprotectin, ESR and CRP were significantly reduced mir-
rored by a significant increase in albumin. Daily stooling frequency, faecal water
content and Bristol stool chart scores were also decreased. Clinical blood profiles af-
ter 8-weeks of EEN became similar to that of non-IBD controls. No differences were
seen for either baseline faecal or blood markers, between children who responded to
treatment with EEN or those who failed EEN.
The current study showed how quickly faecal calprotectin returned to near pre-
treatment levels, with calprotectin having a significant increase after only 8-weeks
return to normal diet. MEN appeared to have no effect in maintaining reduced faecal
calprotectin levels post-EEN.
Markers for disease activity are important in IBD, both for diagnostic and differential
diagnostic reasons. They can help to assess disease activity as well as the risk of com-
plications, or predicting time to relapse. They are particularly useful for measuring
the effects of therapies, however the choice of marker may influence which patients
are classed as responders to a particular treatment. This is a big problem where
more than one disease marker is widely used, or a new disease marker is not used
universally in all centres.125
4.4.1 Indicators of disease activity in children with Crohn’s disease
Calprotectin While CRP may be useful in some patients, it has limited specificity
compared to faecal calprotectin which correlates much better with active disease.
Faecal calprotectin is one of the most reliable, non-invasive diagnostic tools used
in the management of Crohn’s disease in both adults and children.381 A study by
Schoefer et al.369 showed that when evaluated against the Simple Endoscopic Score
for Crohn’s disease (SES-CD), calprotectin correlates better with disease activity
than CRP, blood leukocytes and the Crohn’s disease activity index. The current
study was not able to collect SES-CD score data as these were not routinely available
from patient notes. Schoefer et al. also found that calprotectin was the only marker
to discriminate between inactive, mild, moderate and active disease in patients with
Crohn’s disease. Hence, although not specific to IBD, faecal calprotectin is now
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regularly used as indicator for active disease in both Crohn’s disease and UC.367 In
this context it is used as a alternative marker of neutrophil influx into the gut lumen
and as such is a good non-invasive test for IBD.382;383 The current study showed
that clinical scores of disease activity (wPCDAI) correlated with faecal calprotectin
although the relationship was weak (R2=0.156, p=0.03).
In 2015 Degraeuwe et al.384 carried out a meta study on the faecal calprotectin lev-
els in children with IBD, which included nine individual studies and a total of 853
patients. They established for this data set that faecal calprotectin, as a marker for
diagnosing IBD, had a high sensitivity of 0.97 (95% [CI] 0.92-0.99) and a specificity of
0.70 ([CI] 0.59-0.79). A previous meta-analysis362 which included both children and
adults with IBD, concluded that faecal calprotectin was a useful screening tool for
identifying which patients to bring forward for endoscopic evaluation. This is partic-
ularly important for children where it helps to reduce unnecessary risk from a general
anaesthetic required for paediatric colonoscopy, as well as the risk from perforation,
bleeding or infection, which although very low are still present.385 The meta-analysis
went on to use individual participant data to create an algorithm showing the prob-
ability of having IBD was dependant on faecal calprotectin levels relative to the age
of the child.362
A draw back with meta-analysis of calprotectin levels is that different studies have
used different threshold cut off values.386 The variation in thresholds varies between
centres, as well as changes over time, have affected the numerical thresholds which
defines a faecal calprotectin test result as positive or negative387. In the current
study, calprotectin values are used as continuous data, since using cut-off values for
the purpose of assessing inflammation in research, could result in flawed assumptions.
Clinical use of faecal calprotectin for the management of inflammatory bowel disease,
as a marker of intestinal inflammation is increasing. A study by El-Matary et al.
2017 looked at the impact of faecal calprotectin measurements on the decision mak-
ing process and the clinical care of children with IBD. They found that when high
calprotectin levels were taken into account, it resulted in treatment escalation and
clinical improvement for the majority of children.388
The competition between the host and gut bacteria for transition metal ions is an im-
portant consideration in IBD, with calprotectin being the only known manganese se-
questering defence protein in mammals.363 Understanding the way calprotectin mod-
ulates bioavailability of metal ions, and the impact on bacterial growth using in vitro
models, are key areas for future research in IBD. Metal ion requirements vary between
different gut bacteria hence it is important to understand the impact that high levels
of calprotectin might have in driving microbiota compositional changes in the gut.363
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Stooling frequency The current study saw no link between stooling frequency and
the water content of stool samples. It is possible that some children with IBD,
particularly younger children, are under-reporting stooling frequency. Some older
children communicated at recruitment, that they had altered dietary habits by eating
less to reduce stooling frequency during school hours. Stooling frequency is one of the
questions used in the disease activity index for both Crohn’s disease and UC, however
it may not be a good measure of disease activity if children are under reporting or
fasting to deliberately alter stooling frequency.
Bristol stool chart The current study shows that the Bristol stool chart corresponds
well with disease activity. Therefore future studies could investigate whether teaching
children with Crohn’s disease to use the stool chart, to help them communicate
stooling habits with clinical staff, might alert children to potential relapse sooner and
allow them earlier access to treatment.
Disease activity index (wPCDAI) A problem with clinical scoring indexes is that
some patient questions can be subjective. Particularly where younger children have
to describe severity of pain, well-being or stooling frequency. Also clinical staff might
report a reduction in pain, not because the pain is less, but because the child reports
their pain is no longer interfering with their ability to take part in normal activi-
ties. Hence the score can vary to a small extent depending on clinician and patient
interpretation of questions.287 To check for inter-observer variability in the current
study questions 1 and 2 of the wPCDAI, which cover pain and general well being
(appendix 3), were reviewed via patient and research notes to check for consistency
of interpretation across all clinical staff. wPCDAI questions which relate to blood
tests (ESR and albumin), or weight loss, perirectal disease and extra-intestinal mani-
festation were straight forward,287 and hence scoring was consistent between patients
and over time.
4.4.2 Blood markers
Exploring which disease markers correlate with mucosal healing was not within the
scope of the current study and has been covered in other studies. The aim was to see
if blood markers, which are carried out as part of normal clinical routine, could be
used as an inexpensive way to assess disease activity or differentiate disease location
in children with Crohn’s disease.
Kernel based approach ESR is used as a non-specific measure of inflammation,
however it can remain within normal limits even although CRP is elevated.389 Al-
though our data did not see a significant difference in ESR due to low sample size
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when a standard Kruskal-Wallis test was used, the Kernel approach which took into
account missing data, did show that when compared with non-IBD controls that ESR
was significantly higher in children with Crohn’s disease (Fig. 4.4b) and was associ-
ated with a rise in CRP, showing the kernel method to be a more powerful tool (Fig.
4.4). ESR was also significantly increased in children with UC when compared with
non-IBD controls and was linked with increased white blood cell count (neutrophils
& monocytes) and increased platelet count (Fig. 4.4c).
The kernel based approach allows the rejection of more hypotheses at the same level
of statistical confidence, potentially providing better insights into the aetiology of dis-
ease. Zhan et al.338 developed the KMDA kernel method for use with metabolomics
data. Here we have translated its use to look at the relationship between differ-
ent blood markers, while at the same time accounting for missing data values to
strengthen the power of the dataset. It may appear that using an algorithm to fill in
blank data with ‘smoothed’ data could lead to errors based on what are essentially,
assumptions. However the error created by missing data is a serious problem, since
studies are forced to exclude participants who might only have a single result missing,
which in itself creates potential bias or lack of statistical power. The ability of this
method to shift the unit of analysis from individual blood markers, to groupings of
markers, is a very attractive feature of this kernel-based methodology, since it helps
us to think about the biological relationship between these markers. In comparison to
the traditional differential analysis where each marker is analysed individually using
Kruskal-Wallis followed by a Bonferroni correction for multiple testing to generate a
p-value for each blood marker, the kernel approach is less limiting.
Zhan et al.338 tested this method against four other tests and found performance of
the Kernel method with a false discovery rate of 0.05 was better other tests including
Wilcoxen and 2-sample t-test. In the current study a threshold correlation value of
0.70 was used on blood markers, whereas the metabolite study used 0.95. At 0.95
threshold value the current study had 13-feature sets but no grouping of markers,
hence at this cut-off no potential relationships between markers could be seen. The
current study tested correlation thresholds from 0.60 to 0.99 and chose 0.70 since it
provided four groupings which might give some clues towards relationships between
markers without creating errors due to very weak correlations. Ideally this method
would work better with a larger data set, where the threshold could be set nearer to
an ideal of 0.95; however it was a useful tool despite of the limited size of our data
set.
4.4.3 Inflammatory markers during EEN
In the current study the most marked changes seen during EEN were those of reduced
faecal calprotectin, followed by blood markers ESR and CRP. This was also mirrored
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by an increase in albumin. What was particularly interesting was that blood marker
profiles using differential analysis in children with Crohn’s disease look similar to
patient controls after 8-weeks treatment with EEN.
The effect which EEN has on faecal calprotectin levels in children with Crohn’s disease
has been shown in a number of studies. One study showed that in fifteen children with
Crohn’s disease, faecal calprotectin decreased only in children who achieved clinical
remission.390 Another study looked at whether the difference of faecal calprotectin
levels between baseline and 2-weeks of treatment on EEN could predict the clinical
response in thirty-eight children with newly diagnosed Crohn’s disease. However they
found that difference in calprotectin at 2-weeks could not predict the clinical response
at 6-weeks (p=0.18). Although they found that the difference could predict failure
to respond p=0.006 with a sensitivity 58% and specificity 92% for cut-off of faecal
calprotectin increase by 486µg/g, the accuracy was too low to be used as a predictor
of which patients should stop EEN early and switch to steroid therapy.391 A review
by Day et al. also showed an improvement in ESR, CRP and albumin after 8-weeks
on EEN in those who achieved remission.392 Two studies have shown improvements
in blood markers ESR and CRP in as little as one week.142;141
The current study saw no significant differences for either faecal or blood markers
at baseline, between children who responded and those who failed to respond to
treatment on EEN. Another study has also shown that changes in calprotectin levels
during EEN did not predict length of remission post-EEN.393
4.4.4 Maintenance enteral nutrition (MEN) post-EEN
For children who went into remission on EEN in the current study showed inflamma-
tory markers returning to pre-treatment levels after only 2-weeks of return to normal
diet. An increase in disease activity (wPCDAI) was also seen after 8-weeks of normal
diet, but did not reach significance. After children had reached remission on EEN,
children who chose to take 20% MEN showed no difference in calprotectin levels from
children in the non-MEN group, although numbers were too low to determine sig-
nificance. The evidence to support the benefits of MEN is inconsistent (Table 1.6),
with the largest of these studies in agreement with the current study, that there is no
difference in relapse rates between MEN and non-MEN patients.153 Treatment with
MEN and days to relapse in the current study, is shown in Chapter 3, figure 3.7.
A key factor which is omitted from studies on MEN, is that children often take an
immunosuppressant (IM) such as azathioprine, as well as MEN as part of maintenance
therapy post-EEN. When children were split into groups which factored in both MEN
and IM use, it appears possible that children with lower calprotectin at the end of
EEN are less likely to be given an IM as part of maintenance therapy (Fig. 4.11).
This is of paramount importance because it suggests that maintenance treatment is
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Figure 4.12: Kaplan-Meir survival analysis showing days to disease relapse in children who went into
remission after treatment with EEN. Patients were given either 20% maintenance enteral nutrition
(MEN)(n=7) an immunosuppressant (AZA)(n=4) or both (MEN+AZA)(n=6). Sample sizes were
too low to determine significance
dependent on disease activity post-EEN, thus children on an IM should be put into a
separate group of MEN or non-MEN so that treatment with IM is factored into the
analysis. Low numbers of participants on maintenance therapy studies make this an
unattractive option because it reduces the power of the studies. In the current study
no difference in days to relapse (survival rates) were seen between the three groups
(Fig. 4.12).
4.4.5 Summary
The current study was unable to reject the null hypothesis that children with Crohn’s
disease have an inflammatory marker profile which is distinct from that of children
with UC, non-IBD conditions and healthy children. Although faecal markers includ-
ing calprotectin were not different between children with Crohn’s and UC, clinical
blood marker profiles using differential analysis suggest that it might be possible to
develop a test based on multiple markers that could then be tested in larger popula-
tions for sensitivity and specificity.
Inflammatory marker profiles at baseline could not predict which children with Crohn’s
disease responded to treatment with EEN, hence this hypothesis was rejected. For
children in disease remission post-EEN, supplementing return to normal diet with
(20%) maintenance enteral nutrition (MEN) did not maintain reduced levels of in-
flammatory markers associated with remission achieved during EEN; hence this hy-
pothesis was also rejected.
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4.4.6 Summary of key findings
 Blood inflammatory markers and faecal calprotectin are increased in IBD pa-
tients compared with controls.
 Baseline faecal and blood inflammatory markers, did not predict response to
EEN.
 EEN is a successful treatment for Crohn’s disease induction as shown by reduced
disease activity (wPCDAI) and faecal calprotectin.
New findings from this study:
 Differential analysis may be able to use normal clinical blood markers, a cost
effective method, to identify Crohn’s disease from UC.
 Differential analysis show that clinical blood marker profiles in children with
Crohn’s disease look similar to patient controls after treatment with EEN.
 A kernel-based approach offers a robust new method to look a blood markers
in children with IBD.
 Faecal calprotectin returns to pre-treatment levels more rapidly than previously
recognised once children return to normal diet; and that MEN has no effect in
maintaining the anti-inflammatory effect of treatment with EEN.
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5 The role of gut microbiota in inducing and maintaining
remission in children with Crohn’s disease
5.1 Introduction
Evidence suggests that IBD is linked to an inappropriate inflammatory response to
the gut microbiota in genetically susceptible hosts.162 Although some bacteria have
been linked with Crohn’s disease, such as species of Mycobacterium, Campylobac-
ter, Escherichia and Helicobacter, current evidence does not support the idea that
Crohn’s disease is caused by a single species or strain of bacteria.176 Evidence from
faecal and mucosal biopsy samples suggests that Crohn’s disease is associated with
significant differences in gut microbiota at a community-level. Hence understand-
ing these differences along with changes in gut bacterial profiles are crucial to our
understanding of Crohn’s disease and IBD.
Studies which have gone on to examine the use of exclusive enteral nutrition (EEN) as
a treatment for children with Crohn’s disease, have highlighted bacterial changes in-
volved in remission and flare up in Crohn’s disease. Since studies were underpowered
and used technologies which limited bacterial groups/species that could be included,
the current study aims to fill this gap using 16S rRNA with Illumina technology to
build a wider picture of which bacterial groups, down to species level, are changing
during treatment with EEN. This will provide a clearer picture of whether EEN works
by reducing pathogens or rather modifies the global balance of bacteria in the gut.
No previous studies had examined gut microbiota changes in children with Crohn’s
disease post-EEN, treated with maintenance enteral nutrition (MEN) with the aim
of preventing disease relapse. The current study design is set up to explore whether
MEN could maintain gut bacterial changes achieved during EEN. This is of particular
interest since MEN is currently being used as a treatment strategy, given as a supple-
ment in addition to normal diet (usually ∼20% of EAR), with limited understanding
of any mechanisms. Understanding differences in the gut microbiota composition at
baseline and changes during treatment with EEN and MEN, could help to increase
our understanding of the mechanisms that control inflammation in Crohn’s disease.
Microbial dysbiosis Dysbiosis refers to any change in the composition of the com-
mensal gut bacterial community relative to the community structure found in healthy
people.394 Our current understanding of what constitutes a healthy gut microbiota
composition comes from studies such as a north American study of 129 male and 113
female healthy adults, carried out as part of the Human Microbiome Project.394 Their
study shows that patterns within samples (α-diversity) differ notably from differences
between samples (β-diversity) from the same habitat (oral, gut, skin, vaginal) among
individuals. The consortium also found that with-in individual variation over time,
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was consistently lower than between-individual variation for both bacterial compo-
sition and metabolic functionality; showing an individual’s microbial composition to
be relatively stable over time.394
The human gut microbiota is dominated by five bacterial phyla: Bacteroidetes, Fir-
micutes, Actinobacteria, Proteobacteria and Verrucomicrobia. In individuals consid-
ered to be healthy, over 90% of species come from the Firmicutes and Bacteroidetes
phyla.176 In 2017 a study looking at 1252 healthy control subjects taken from a
cross-study meta-analysis of 3048 public metagenomic datasets (four different stud-
ies), showed that the key genera that correlated with the healthy state of control
subjects were Barnesiella, Ruminococcaceae UCG-005, Alistipes, Christensenellaceae
R-7 group as well as a member of Lachnospiraceae family genera.395 However, these
results need to be treated with caution as they combined both biopsy samples and
stool samples; included both Illumina and 454-sequencing methods; and each of the
four included studies used a different set of 16S rRNA primers. This led to some
conflicting results between these studies used to make up the meta-analysis.395 In the
last decade studies have recorded significant changes in bacterial community struc-
ture in patients not only with IBD, but also other conditions such as diabetes,396
asthma,187 allergies and autistic spectrum disorders.397 This evidence suggests that
either changes in bacterial composition, or development of the microbiota during
childhood, is a risk factor in a number of diseases, including Crohn’s disease. It
has been shown that loss in diversity of symbiotic groups such as Bifidobacterium
and Clostridia species, along with increases in Bacteroidetes and Enterobacteriaceae
species associated with inflammation, are key features of Crohn’s disease. Under-
standing these changes is complex because a number of factors can contribute to
changes in gut bacterial composition including host genetics, dietary choices, infec-
tions and medications such as antibiotics.162 Not only has research identified dysbiosis
in Crohn’s disease but it has linked dysbiosis with disease progression.200 Three cate-
gories of dysbiosis have been described:398 a loss of indigenous beneficial microbiota;
overgrowth of less dominant indigenous pathobionts or colonisation by new bacterial
pathogens; and loss of overall microbiota diversity, all of which can occur at the same
time (Chapter 1, section 1.9.1).
The following chapter will examine differences in gut microbiota community struc-
ture seen in the current study, between children with Crohn’s disease, UC, non-IBD
conditions and healthy children. It will also identify any changes in the gut micro-
biota in children with Crohn’s disease undergoing treatment with EEN; and examine
if these changes are maintained once children go back onto normal diet, with or
without maintenance enteral nutrition (MEN). It is hypothesised that each of these
condition states is associated with specific changes in the gut microbiota and that
these changes are associated with disease relapse in children with Crohn’s disease.
145
5.1.1 Hypotheses summary
 Children with Crohn’s disease have a gut microbiota which is distinct from UC,
non-IBD conditions and healthy children. In addition the microbiota profile in
children with Crohn’s disease is distinct depending on disease location.
 Treatment with EEN is associated with distinct changes in gut microbiota com-
position; which can be linked with changes in inflammatory status.
 Gut microbiota profiles at baseline can predict which children with Crohn’s
disease will respond to treatment with exclusive enteral nutrition (EEN).
 For children in disease remission post-EEN, supplementing return to normal
diet with (20%) maintenance enteral nutrition (MEN) will maintain the gut
microbiota profile associated with remission achieved during EEN.
Figure 5.1: In children with Crohn’s disease, faecal samples were collected at baseline; 4-weeks
treatment with EEN; end of EEN (8-weeks); then after 2-weeks and 8-weeks of normal habitual diet
plus maintenance therapy with either MEN, an immunosuppressant or both combined.
5.2 Methods
A detailed description of participants and methods used are given in Methods section
2.2.1. Briefly, children with Crohn’s disease (n=34), children with UC (n=9) and a
control group of children with non-IBD conditions (n=11) were recruited from the
Gastroenterology clinic at the Royal Hospital for Sick Children Glasgow. An age and
sex matched group of healthy children (n=25) were recruited from the community. A
faecal sample was collected from each participant at baseline, and for children with
Crohn’s disease at five time-points (Fig. 5.1). DNA extracted from stool samples was
sequenced (Illumina MiSeq platform) from the 16S rRNA gene (Fig. 5.2) as described
in Methods section 2.8 and 2.9.
Local contribution to beta diversity (LCBD)330 was used to work out the total sum
of squares of species composition for all samples, from which sample-wise local contri-
butions to β-diversity could be shown as a proportion of total β-diversity (Methods
section 2.10.3). An aid to understanding the classification of bacteria which are most
associated with IBD is given in Appendix 5.
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Figure 5.2: Summary of methods used to process faecal samples for 16s rRNA analysis. 16s rRNA
sequences were then used to determine bacterial groups from the resulting sequence variants. Full
details in Methods section 2.8 and 2.9.
5.3 Results
5.3.1 Microbiota differences between patient groups at baseline
To investigate differences in gut microbiota community structure between children
with Crohn’s disease and those with UC, non-IBD conditions and healthy children,
faecal bacterial profiles determined from 16S rRNA, were compared between groups.
Richness (α-diversity) The number of species (richness) measured as operational
taxonomic units (OTUs) and the Shannon index, a measure of richness and evenness
were compared between groups (Methods section 2.10.3). Both richness and Shannon
index, using OTUs to define species, showed that children with IBD (Crohn’s disease
and UC) had lower faecal bacterial diversity than healthy children (p<0.001). Chil-
dren with non-IBD conditions also had less bacterial diversity than healthy controls
(p<0.05) (Fig. 5.3a).
For comparison, divisive amplicon de-noising algorithm (DADA2), a reference free
method to infer species from single-nucleotide variants (SNVs) rather than OTUs,
was used to examine species level diversity (Methods section 2.10.1). It has previously
been shown, using mock communities that it is more accurate than other methods315
(Methods section 2.10.1). This method confirmed, from bacterial richness and Shan-
non index, that children with Crohn’s disease and UC had significantly less species
level diversity than healthy children (p<0.001) and that children with non-IBD con-
ditions also had less species level diversity than healthy controls (p<0.05) (Fig. 5.3b).
Since using DADA2 single nucleotide variants is a better method than using OTUs,315
all subsequent analyses were done using DADA2 single nucleotide variants (SNVs) as
a measure of bacterial species level taxonomy.
Abundance (β-diversity) Bacterial abundance (β-diversity) was used to look at
difference in bacterial community structure between groups. Non-metric distance
scaling (NMDS) (Methods section 2.10.3) showed a significant difference in species
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level community structure between healthy children and both children with Crohn’s
disease and UC (Fig. 5.4a); which was still significant at phylum level (Fig. 5.4b).
Children with Crohn’s disease tended to have a greater degree of dysbiosis, clustering
further away from healthy children than children with UC (Fig. 5.4a). Children with
non-IBD conditions had a wide range of bacteria profiles that overlapped the other
groups (Fig. 5.4c), showing that some children in the non-IBD group also have a
dysbiotic community structure while others cluster closer to healthy children.
In the current study local contribution to beta diversity (LCBD) shows that β-
diversity of individual healthy children as a proportion of total β-diversity had greater
similarity to one another (between samples) than children with Crohn’s disease and
UC (p=<0.001 and p=<0.01 respectively) (Fig. 5.5). Thus healthy children appear
to have microbiota community profiles which are less prone to high levels of LCBD
than children with IBD, where higher levels represent outliers which sit well outside
the community structure mean.
Taxon differences in microbiota community structure
The current study data set generated a total of 2,751 unique bacterial sequences
representing species (SNVs), and 161 of these SNVs (5.8%) discriminated Crohn’s
children from healthy children (Table 5.1). This shows more bacteria at species level
were down-regulated in all three patient groups than were increased, and that chil-
dren with non-IBD conditions also had a degree of bacterial difference from healthy
children, with significant decreases in seventy-one SNVs (species level taxa). Thirty-
six SNVs were significantly increased and eighteen decreased in children with Crohn’s
disease when compared with UC (2.0%). Details of which species (SNVs) were up or
down regulated are provided in appendix 5.3.
Table 5.1: The number SNVs as a proxy for species, which were significantly different
(detected from log2 mean abundance) between patient groups
number of SNVs (species) % of
increased decreased total SNVs
Distinct from Healthy
Crohn’s vs healthy 39 122 (5.8%)
UC vs healthy 17 110 (4.6%)
Non-IBD vs healthy 8 71 (2.9%)
Distinct from Crohn’s
Crohn’s vs UC 36 18 (2.0%)
Total number of SNVs was 2,751. Differences in species level abundance was significant at
p<0.001 (PERMANOVA). A full list of species level taxa (SNVs) are given in appendix 5.3.
Stacked bar plots were used to visualise phylum (Fig. 5.6); family (Appendix 5.1) and
genus (Fig. 5.7) level community structure in individual children from each group.
The phylum level bar plot (Fig. 5.6) shows that children with Crohn’s disease and
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species level
R2=0.074; p<0.001
(a)
phylum level
R2=0.069; p=0.046
(b)
phylum level
PERMANOVA Groups:
R2=0.081; p=0.068
(c)
Figure 5.4: Difference in bacterial community structure between patient groups and healthy children
shown by NMDS plot in: (a) children with Crohn’s and UC at species level (SNVs) (b) and the
same at phylum level; showing that differences are still present at higher taxonomic levels. Figure
(c) shows that some children with non-IBD conditions overlap with healthy controls while others
have a similar profile to children with IBD. Ellipse shows 95% CI.
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Figure 5.5: Local contribution to β-diversity (LCBD) showing how individuals across groups vary
from the β-diversity group mean; in children with Crohn’s disease; UC; non-IBD conditions and
healthy children; showing that children with IBD have a community structure which has much
greater variation from the mean than seen in healthy children. Significance calculated using
ANOVA; Bray-Curtis.
UC have higher relative abundance of the gram-negative phyla Bacteroidetes, Pro-
teobacteria and Fusobacteria, as well as lower relative abundance of Actinobacteria
and Verrucomicrobia which include Bifidobacterium and Akkermansia respectively.
The taxa plot at genus level clearly shows the large degree of inter-patient varia-
tion in children with IBD, as quantified by LCBD bubble size on the base on each
bar. To test for a significant difference in log2 fold change from mean abundance
between groups, differential expression analysis was used based on the negative bi-
nomial distribution. Results are expressed as the log2 fold change (Methods section
2.10.3) between patients and healthy controls. The mean abundance of Bacillales
Family XI, Fusobacteriaceae and the Proteobacteria families Enterobacteriaceae and
Pasteurellaceae, were all increased in both UC and Crohn’s compared with healthy
children. Neisseriaceae were significantly increased in Crohn’s disease but not in UC
and the family Carnobacteriaceae, were increased in UC but not in Crohn’s disease
when compared with healthy children (p<0.001). The Carnobacteriaceae were also
significantly increased in children with UC when compared with those with Crohn’s
disease. Fusobacteriaceae were further increased in Crohn’s disease compared with
UC.
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The following were reduced compared with healthy children in both Crohn’s disease
and UC: Methanobacteriaceae; Defluviitaleaceae; Clostridiales vadin BB60 group;
Verrucomicrobiaceae and Rhodospirillaceae. Christensenellaceae and Peptococcaceae
were also significantly reduced in Crohn’s disease, but not in UC. The family Bac-
teroidales S24-7 group, were reduced in UC but not in Crohn’s disease when compared
with healthy children (p<0.001). No families were significantly increased and only
two families were decreased (Bacteroidales S24-7 group and Rhodospirillaceae) in
children with non-IBD conditions when compared with healthy children (p<0.001).
In order to show the relatedness of taxa, the phyla, class, order, family, and genera of
bacteria which were significantly decreased/increased in abundance in children with
Crohn’s disease compared with healthy children are shown in a phylogenetic tree (Fig.
5.8); (species level taxa (SNVs) are shown in appendix 5.3). It is noteworthy that
the phylogenetic trees formed by health associated and Crohn’s disease associated
bacteria are separate, with the gram-negative Proteobacteria and Fusobacteria along
with genera from the class Negativicutes increased, while most bacteria that are
reduced in children with Crohn’s come from the phyla Actinobacteria and Firmicutes.
Figure 5.7 shows that children with Crohn’s disease have higher relative abundance
of Veillonella (Negativicutes), a genus which is not prevalent in any of the healthy
children.
The bacterial community structure in children with Crohn’s disease at baseline was
also defined by a significant decrease in abundance of the phylum Euryarchaeota (Ar-
chaea), including the family Methanobacteriaceae; reduced Tenericutes consisting of
the order Mollicutes RF9; and Verrucomicrobia made up from the family Verru-
comicrobiaceae. A number of Firmicutes families from the order Clostridiales were
also decreased in children with Crohn’s disease, including Clostridiales vadinBB60,
Christensenellaceae, Peptococcaceae and Defluviitaleaceae. The family Rhodospir-
illaceae from the Proteobacteria phylum were also significantly reduced in children
with Crohn’s disease (p<0.001)(Fig. 5.8).
To visualise differences in bacterial community structure between groups, a heatmap
of discriminant genera (Fig. 5.9) was created based on sparse projection to latent
structure discriminant analysis (Methods section 2.10.3). From faecal samples taken
at baseline, clear blocks of differences in bacterial abundance were seen, with healthy
children mostly clustering together; a group of children with UC and Crohn’s clus-
tering; and a third cluster containing only children with Crohn’s disease. Healthy
children had higher abundance (red) of commensals such as Ruminococcus and Lach-
nospiraceae which were reduced (blue) in children with IBD. The opposite was true of
gram-negative bacteria such as Bacteroides, Prevotella, Haemophilus, Enterobacter,
Cronobacter, Citrobacter and Fusobacterium, where levels were clearly increased in
many IBD patients, especially children with Crohn’s disease.
152
F
ig
u
re
5
.6
:
C
om
m
u
n
it
y
st
ru
ct
u
re
at
P
h
y
lu
m
le
v
el
,
in
ch
il
d
re
n
w
it
h
C
ro
h
n
’s
d
is
ea
se
,
U
C
,
n
on
-I
B
D
an
d
h
ea
lt
h
y
ch
il
d
re
n
.
B
u
b
b
le
si
ze
in
cr
ea
se
at
b
as
e
of
b
ar
p
lo
t
sh
ow
lo
ca
l
co
n
tr
ib
u
ti
on
to
β
-d
iv
er
si
ty
(L
C
B
D
).
It
ca
n
b
e
se
en
th
at
ov
er
al
l
ch
il
d
re
n
w
it
h
C
ro
h
n
’s
d
is
ea
se
h
av
e
in
cr
ea
se
d
P
ro
te
ob
ac
te
ri
a
B
ac
te
ro
id
et
es
an
d
F
u
so
b
ac
te
ri
a
as
w
el
l
as
re
d
u
ce
d
F
ir
m
ic
u
te
s,
A
ct
in
ob
a
ct
er
ia
an
d
V
er
ru
co
m
ic
ro
b
ia
co
m
p
ar
ed
w
it
h
h
ea
lt
h
y
ch
il
d
re
n
p
<
0.
00
1.
N
on
-I
B
D
p
at
ie
n
t
S
04
6
h
ad
ga
st
ro
en
te
ri
ti
s
h
en
ce
th
e
h
ig
h
le
ve
l
of
P
ro
te
ob
ac
te
ri
a
(E
sc
h
e
ri
c
h
ia
-S
h
ig
e
ll
a
).
F
am
il
y
le
v
el
ta
x
a
is
sh
ow
n
in
A
p
p
en
d
ix
5.
1
153
F
ig
u
re
5
.7
:
C
om
m
u
n
it
y
st
ru
ct
u
re
at
ge
n
u
s
le
ve
l,
in
ch
il
d
re
n
w
it
h
C
ro
h
n
’s
d
is
ea
se
,
U
C
,
n
on
-I
B
D
an
d
h
ea
lt
h
y
ch
il
d
re
n
.
T
w
en
ty
-o
n
e
m
os
t
ab
u
n
d
an
t
ge
n
er
a
ar
e
sh
ow
n
.
B
u
b
b
le
si
ze
in
cr
ea
se
at
b
as
e
of
b
ar
p
lo
t
sh
ow
lo
ca
l
co
n
tr
ib
u
ti
on
to
β
-d
iv
er
si
ty
(L
C
B
D
).
N
on
-I
B
D
p
at
ie
n
t
S
04
6
h
ad
ga
st
ro
en
te
ri
ti
s
sh
ow
n
b
y
th
e
ve
ry
h
ig
h
ab
u
n
d
an
ce
of
E
sc
h
e
ri
c
h
ia
-S
h
ig
e
ll
a
.
154
F
ig
u
re
5
.8
:
P
h
y
lo
ge
n
et
ic
tr
ee
sh
ow
in
g
d
iff
er
en
ce
s
in
m
ea
n
lo
g
2
b
ac
te
ri
al
ab
u
n
d
an
ce
b
et
w
ee
n
ch
il
d
re
n
w
it
h
C
ro
h
n
’s
d
is
ea
se
an
d
h
ea
lt
h
y
ch
il
d
re
n
at
b
as
el
in
e.
S
ig
n
ifi
ca
n
t
ta
x
a
w
h
ic
h
w
er
e
d
ec
re
as
ed
in
C
ro
h
n
’s
d
is
ea
se
ar
e
sh
ow
n
in
b
lu
e
an
d
in
cr
ea
se
d
ta
x
a
in
re
d
.
N
ot
e
th
at
th
e
p
h
y
lo
ge
n
et
ic
tr
ee
s
fo
rm
ed
b
y
h
ea
lt
h
as
so
ci
at
ed
an
d
d
is
ea
se
as
so
ci
at
ed
b
ac
te
ri
a
ar
e
se
p
a
ra
te
d
,
su
gg
es
ti
n
g
th
e
ev
ol
u
ti
on
ar
y
h
is
to
ry
an
d
ge
n
et
ic
tr
ai
ts
of
th
es
e
gr
ou
p
s
of
b
ac
te
ri
a
ar
e
fa
ir
ly
d
is
ti
n
ct
in
te
rm
s
o
f
gu
t
h
ea
lt
h
.
155
Figure 5.9: Heatmap showing discriminant genera, in children with Crohn’s disease, UC and healthy
children. Rows and columns are ordered using hierarchical clustering (average linkage) to identify
blocks of interest. Heatmap depicts TSS+CLR (total sum scaling + centered log ratio) normalised
abundances: high abundance (red); low abundance (blue). Blocks of interest show that children
with IBD have lower gram-positive commensals such as Ruminococcus spp. and higher levels of
gram-negative species such as Fusobacterium and Enterobacter spp. as well as Negativicutes like
Veillonella. 156
5.3.2 Crohn’s disease location and microbiota composition
The Montreal classification was used to subdivide children with Crohn’s disease into
groups based on disease location (Methods section 2.4.3). These groups were then
used to look for differences in gut bacteria community structure across these location
groupings. No difference was seen in community structure between disease locations:
L1 ileal +/- limited caecal disease (n=4); L2 isolated colonic (n=9); or L3 ileocolonic
(n=16) (Fig. 5.10). Sub-set analysis (BVSTEP routine), a method for linking mul-
tivariate microbiota community structure to environmental variables. This method
works by imploding the microbiota abundance table to those essential features that
explain β-diversity, highlighting which bacterial genera are the main source of varia-
tion between all the samples. A number of genera subsets were found to explain 0.95
variability in microbiota structure for disease location but these were not significant
(Table 5.2).
Table 5.2: Subset analysis showing which genera explain the percentage variability in microbiota
community structure for disease location in children with Crohn’s disease
Subset Subset of most abundant genera
correlation with full
abundance table
PERMANOVA
subsets
S1 Veillonella + Haemophilus + Subdoligranulum +
Bifidobacterium + Faecalibacterium + Prevotella
7 + Prevotella 9 + Blautia + Bacteroides
0.95 R2=0.106
p=0.115 (NS)
S2 Veillonella + Haemophilus + Bifidobacterium +
Faecalibacterium + Prevotella 7 + Prevotella 9 +
Blautia + Bacteroides
0.95 R2=0.106
p=0.131 (NS)
S3 Veillonella + Haemophilus + Bifidobacterium +
Faecalibacterium + Prevotella 9 + Blautia +
Bacteroides
0.94 R2=0.111
p=0.105 (NS)
Subsets were generated using the BVSTEP (see detailed Methods section 2.10.3). PERMANOVA of
subsets were performed against disease location: L1(ileal); L2(colonic); L3(ileocolonic) in patients,
with R2 explaining the percentage variability in microbiota structure between groupings.
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(a) (b) (c)
(d)
Figure 5.10: sPLS-DA Discriminant Analysis showing how disease location affects microbiota
community structure in children with Crohn’s disease. The algorithm is a 2-step process where
two components are found reducing the classification error rates (using max.dist) in the algorithm,
with (a) showing the ordination of samples using all the species (SNVs) in the first two components
(PLS-DA) with ellipses representing 95% confidence interval and percentage variations explained by
these components in axes labels. In step two, (b) the number of discriminating species (SNVs) were
found for each component, highlighted as diamonds. In (c) the ordination used the discriminants
from all two components (sPLS-DA). (d) is a heatmap of discriminant species inferred from SNVs,
with rows and columns ordered using hierarchical clustering (average linkage) to show patterns
of interest. Heatmap depicts TSS+CLR normalised abundances: high abundance (red) and low
abundance (blue).
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5.3.3 Microbiota changes in children with Crohn’s disease during EEN
The largest gut microbiota paediatric IBD study, did not follow children over time,194
therefore this current longitudinal study, chose to look at changes in gut microbiota
diversity, and changes in specific bacterial groups associated with Crohn’s disease
at baseline, by following children during treatment with exclusive enteral nutrition
(EEN). The microbial composition was compared, from faecal samples taken at base-
line, with those taken after 4-weeks and 8-weeks treatment with EEN (Table 5.3).
Table 5.3: Number of faecal samples available at each time-point during EEN
Time-point
Res
pon
ded
to E
EN
Fail
ed E
EN
week-0 (Pre-treatment baseline 20 8
week-4 (4 weeks treatment on EEN) 15 6
week-8 (8 weeks treatment on EEN) 15 4
13 children able to provide a faecal sample at all 3 time-points, 4 of these failed EEN.
Richness (α-diversity) During EEN there was no change in median number of
species inferred from SNVs (richness); however the median Shannon diversity index
(evenness) reduced in children with Crohn’s disease after 4-weeks and at 8-weeks
EEN but this was not statistically significant (Fig. 5.11). Although there was no
significant difference in α-diversity after 4-weeks EEN, in children who responded to
treatment with EEN and those who failed to respond, it should be noted that most
individual children either saw an increase or decrease in numbers of species (SNVs):
with 8/13 responders and 2/6 non-responders having an increase in the number of
species (richness) during EEN (χ2=0.43; p=0.52). Although there was no change in
species richness during EEN for children who responded to EEN, children who failed
treatment had a non-significant median decrease in species richness (Fig. 5.12).
Figure 5.11: Species (SNVs) level α-diversity shown by richness and Shannon index in children with
Crohn’s disease during treatment with exclusive enteral nutrition (EEN), who provided samples
at all three time-points (n=13). Species diversity is shown at baseline (week-0); 4 weeks on EEN
(week-4); and 8 weeks on EEN (week-8). Significance tested at p<0.05 ANOVA.
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Figure 5.12: Species (SNVs) level α-diversity shown by richness and Shannon index in children with
Crohn’s disease during treatment with exclusive enteral nutrition (EEN). Paired samples shown for
baseline (wk-0) and 4-weeks on EEN (wk-4); for responders (R) and non-responders (NR) to EEN.
Difference in diversity between 0-4wks were not significant (ANOVA).
Abundance (β-diversity) Changes in bacterial community structure (β-diversity)
was explored using PERMANOVA (Methods 2.10.3; Fig. 5.13a). There was a sig-
nificant shift in community structure between baseline and 4-weeks of EEN with a
further, less distinct, shift at 8-weeks of EEN (R2=0.099; p=0.001). When children
with Crohn’s disease were split into those who responded to treatment on EEN and
those who failed to respond, there was a significant difference in gut bacteria diversity
during EEN for responders, but not for non-responders (Fig. 5.13).
Table 5.4: Number of species inferred from SNVs which significantly changed in
abundance after 4-weeks of EEN
number of species inferred from SNVs %
increased decreased of total bacteria
After 4wks EEN
Responders 102 47 (5.4%)
Non-Responders 126 41 (6.1%)
Total number of SNVs was 2,751. Differences in species level taxa were significant at
p<0.01. (Differential expression analysis DESeq2)(χ2=1.58; p=0.21).
Taxon differences The mean abundance in gut microbiota at species level (SNVs)
changed after 4-weeks EEN, in both those who responded to EEN and those who
failed EEN. There was no difference in the number of bacterial species (SNVs) which
increased/decreased between children who responded to or failed treatment with EEN
(Table 5.4; Fig. 5.14).
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Treated with EEN
PERMANOVA Groups: R2=0.099; p<0.001***
(a)
Responded to EEN
R2=0.070; p<0.001***
(b)
Non-responders
R2=0.112 ; p=0.56 (NS)
(c)
Figure 5.13: NMDS plot showing changes in bacterial community structure in (a) children with
Crohn’s disease at baseline (week-0); after treatment with EEN (week-4) and (week-8), when com-
pared with healthy children; Changes from baseline (wk0), and 4-weeks EEN (wk4) and 8-weeks
EEN (wk8) are shown in children with Crohn’s who (b) responded (R) to treatment and (c) those
who were non-responders (NR). Plots show SNVs (species) level taxa. Ellipse shows 95% CI.
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Responded to EEN
(a)
Failed EEN
(b)
Figure 5.14: SNVs (proxy for species) that are log2 fold different from mean abundance between
baseline and 4-weeks of EEN in (a) children with Crohn’s who responded (R) to treatment with
EEN and (b) those who were non-responders (NR). Dots shown in black are species (SNVs) similar
in abundance between baseline and 4-weeks EEN. Dots shown in red are species (SNVs) significantly
increased or decreased in each patient group during EEN where p<0.001. (Differential expression
analysis DESeq2).
The small number of species which decrease in abundance is surprising, as we might
expect a liquid feed with no fibre, mostly absorbed in the small intestine, would result
in a large reduction in the abundance of many species and with fewer increases in
abundance. However decreases in the number of species (α-diversity) appear to be
accompanied by increased abundance (β-diversity) in many bacterial species (SNVs)
during EEN.
In-terms of over all changes in abundance at family level during EEN (Fig. 5.15)
there was a decrease mainly in gram-negative bacteria. Veillonellaceae which belongs
to the subclass Negativicutes was also decreased during EEN with this group of
Firmicutes having a cell wall similar to gram-negative bacteria. Although two families
of gram-negative bacteria were also increased during EEN, the Enterobacteriaceae
and Verrucomicrobiaceae (Akkermansia) these were of low abundance. All other
bacteria with increased abundance were from the phylum Firmicutes, along with a
small increase in Corynebacteriaceae from the phylum Actinobacteria.
Discrimination analysis show that 4-weeks treatment with EEN shifts the microbiota
community towards a structure, distinct form both children with Crohn’s at baseline
and healthy children (Fig. 5.16). This illustrates that EEN did not restore the
microbiota towards a state similar to healthy children, but further from it.
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Figure 5.15: The log2 fold difference in family level abundance for children with Crohn’s disease
after 4-weeks EEN. Only families significant to p<0.001 are shown.
Figure 5.16: Heatmap of discriminant species inferred from SNVs, in children with Crohn’s disease
at baseline, then after 4-weeks treatment with EEN, and healthy children for comparison. Rows
and columns are ordered using hierarchical clustering (average linkage) to identify blocks of interest.
Heatmap depicts TSS+CLR normalised abundances: high abundance (red); low abundance (blue).
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5.3.4 Changes in individual children during EEN
To explore individual changes in gut bacterial community structure during EEN
two children who failed EEN (non-responders) and four children who respond to
treatment with EEN (responders) are shown in figure 5.17 as typical examples of gut
microbiota changes. Changes in microbiota community structure at genus level are
shown at baseline; 4-weeks EEN; 8-weeks EEN and 2-weeks normal diet.
Patient
Figure 5.17: Changes in microbiota community structure (relative abundance) for genus level at (A)
baseline; (B) 4-weeks EEN; (C) 8-weeks EEN and (D) 2-weeks normal diet: in two children with
Crohn’s disease who failed to respond to EEN (NR) and four children who respond to treatment
with EEN (R). Patient R036 relapsed ∼6-weeks post-EEN.
In participant NR005, a child who completed 8-weeks of EEN but failed to respond
and subsequently went onto corticosteroids, the gut microbiota at baseline (S005A)
was dominated by the abundance of Prevotella 7 which was reduced after 4-weeks
of EEN (S005B). This was accompanied by an increase in abundance in a number of
genera including Alstipes and Rumminoccaceae UGG002. The gut microbiota com-
munity structure at 8-weeks EEN (S005C) was similar to 2-weeks post-EEN (S005D)
which is likely because this child was back onto normal diet for 2-days before man-
aging to provide the end of EEN stool sample. In non-responder NR009 who also
completed 8-weeks on EEN, the abundance of Akkermansia, which was not detected
at baseline, dominated the gut microbiota composition during EEN, but was not
detected at 2-weeks post EEN (009D). Escherichia-Shigella which had not been de-
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tected at baseline or during EEN, was present in abundance once this child stopped
EEN and started corticosteroid therapy (S009D).
In participant R015, a child who responded to EEN, there was an increase in rela-
tive abundance of the butyrate producer Lachnoclostridium during EEN, which was
reduced once this child went back onto normal diet (S015D). This child also had
increased abundance of the butyrate producer Blautia during EEN which was sus-
tained when they back onto normal diet (S015D). In participant R018, an other child
who responded to EEN, the Firmicutes Eubacterium hallii was increased during EEN
as well the abundance of another butyrate producer Lachnoclostridium. E. hallii is
important to intestinal metabolic balance because of its ability to utilise glucose,
acetate and lactate to form butyrate and hydrogen.399
Responder R016 had increased abundance of Escherichia-Shigella during EEN which
was still present once they had gone back onto their normal diet for 2 weeks (S016D).
They also had increases in Actinobacteria Bifidobacterium and Varibaculum, which
were not sustained once the child had returned to their normal diet. Bifidobacterium
uses a unique fructose-6-phosphate phosphoketolase pathway to ferment oligosac-
charides. In this child, Bacteroides was the dominant genus at baseline, however
abundance was greatly reduced after 4-weeks of EEN and was not present at 8-weeks
EEN. Bacteroides was absent from all following samples collected from this child:
2-weeks; 8-weeks; and 28-weeks post-EEN, suggesting that treatment with EEN may
have eradicated what is considered a dominant commensal in healthy individuals.
Responder R036 also had increased Lachnoclostridium during EEN but this was not
sustained once this child went back onto their normal diet (S036D). Patient R036
had a high abundance of the Proteobacteria Haemophilus at baseline and although
this was not detected during EEN it was detected at 2-weeks post EEN and had in-
creased in abundance further by 8-weeks post EEN. The Proteobacteria Cronobacter
was absent at baseline but was present during EEN with further increase by 2-weeks
post-EEN (S036D). By 6-week post-EEN this child had relapsed and was on corti-
costeroids. The faecal sample given at 8-weeks post-EEN showed that Escherichia-
Shigella had replaced Cronobacter as the most abundant genera.
Since children who responded saw increases in Proteobacteria during and after EEN
while at the same time going into disease remission, it seems unlikely that these
strains of Proteobacteria are directly linked with inflammation. It is possible however
that less prevalent strains which were not detected could be decreasing during EEN.
Looking at the abundance of the most common genera (Fig. 5.17) do not show any
obvious differences in bacterial changes during EEN between responders and non-
responders.
Given that all children went on to an identical diet during EEN it is surprising that
there is such a wide variety in the way bacteria from the same genera respond to the
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diet in different individuals. The results from this current study would suggest that
the complexity of which bacteria species are present at baseline and/or host genetics,
appear to play a larger role in the gut bacteria community structure than diet across
different individuals over time.
5.3.5 Predicting Response to EEN
There was no significant difference between responders and non-responders in terms
of either richness or Shannon diversity at baseline, hence microbiota diversity did not
predict response to EEN (Fig. 5.12).
The genera at baseline which were higher in abundance in responders compared with
non-responders, did not appear to show any pattern in terms of Phyla or Family
which could explain differences in response to EEN (Table 5.5).
sPLS-DA discriminant analysis (Fig. 5.18) show that twenty-five species (SNVs)
could be used to discriminate between responders and non-responders to EEN (or-
dination ellipses). Children with Crohn’s disease that responded to EEN cluster to-
gether, where as non-responders although distinct from responders, are also distinct
from one another (heatmap fig. 5.18d).
Species richness and response to EEN sPLS-DA discriminant analysis (Fig. 5.19)
was carried out between those children who had increased number of species inferred
by SNVs during EEN and those children who decreased in number of species (SNVs)
to see if these children had differences in microbiota structure at baseline. The
ordination ellipses did not over lap suggesting that these two groups of children have
distinct differences in microbiota community structure at baseline (Fig. 5.19c). The
heatmap (Fig. 5.19d) of discriminating bacterial species level taxa (SNVs) shows
that with exception of one participant (S036) these two groups of children show some
patterns of differences at baseline which might determine the impact the EEN has
on the gut microbiota during EEN. Two children who failed EEN (S045,S048) were
among the group that increased species richness during EEN and four children who
failed EEN (S002,S005,S009,S029) where in the group who decreased species richness
during EEN. The sample size was not large enough to test whether a decline in
species richness during EEN was more likely to result in children failing to respond
to treatment.
In summary those children who responded to EEN had a more distinct shift in micro-
biota community structure during EEN and children who failed to respond may have
increased in abundance in more species during EEN. Although twenty-five species
could distinguish responders from non-responders there was no obvious pattern in
term of the phylogeny of these species (Fig. 5.18).
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(a) (b) (c)
(d)
Figure 5.18: sPLS-DA Discriminant Analysis showing the difference in microbiota community
structure at baseline, between children with Crohn’s disease who either responded to or failed
treatment with EEN. The algorithm is a 2-step process where two components are found reducing
the classification error rates (using max.dist) in the algorithm, with (a) showing the ordination of
samples using all the SNVs (species) in the first two components (PLS-DA) with ellipses representing
95% confidence interval and percentage variations explained by these components in axes labels.
In step two, (b) the number of discriminating SNVs (species) were found for each component,
highlighted as diamonds. In (c) the ordination used the discriminants from all two components
(sPLS-DA). (d) is a heatmap of discriminant SNVs (species), with rows and columns ordered using
hierarchical clustering (average linkage) to show patterns of interest. Heatmap depicts TSS+CLR
normalised abundances: high abundance (red) and low abundance (blue).
Table 5.5: Genera which were more abundant at baseline in children who responded
to or failed treatment (non-responders) with EEN
log2 fold p-value up-regulated
Genus base mean change adj in
Anaerococcus 5.79 -2.92 2.98E-03 Non-responders
Cronobacter 5.03 -2.91 3.95E-03 Non-responders
Peptostreptococcus 65.60 -3.94 3.95E-03 Non-responders
Actinobacillus 9.72 3.47 9.34E-03 Responders
Aggregatibacter 6.85 3.15 2.86E-02 Responders
Akkermansia 66.00 5.38 4.77E-04 Responders
Fusobacterium 54.72 3.27 2.86E-02 Responders
Phascolarctobacterium 137.18 6.40 3.46E-05 Responders
Prevotella 9 1291.23 7.65 2.84E-06 Responders
Ruminococcaceae UCG-004 9.95 2.80 2.86E-02 Responders
Ruminococcaceae UCG-014 8.98 3.35 1.93E-02 Responders
Differential expression analysis DESeq2.
(a) (b) (c)
(d)
Figure 5.19: sPLS-DA Discriminant Analysis showing the difference in microbiota community
structure at baseline between children with Crohn’s disease who increased species richness or de-
creased in species richness on EEN. The algorithm is a 2-step process where two components are
found reducing the classification error rates (using max.dist) in the algorithm, with (a) showing
the ordination of samples using all the species (SNVs) in the first two components (PLS-DA) with
ellipses representing 95% confidence interval and percentage variations explained by these compo-
nents in axes labels. In step two, (b) the number of discriminating species (SNVs) were found for
each component, highlighted as diamonds. In (c) the ordination used the discriminants from all two
components (sPLS-DA). (d) is a heatmap of discriminant species (SNVs), with rows and columns
ordered using hierarchical clustering (average linkage) to show patterns of interest. Heatmap depicts
TSS+CLR normalised abundances: high abundance (red) and low abundance (blue).
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5.3.6 Microbiota changes in children with Crohn’s disease during MEN
Once children with Crohn’s disease had completed 8-weeks of EEN, nine children
had failed to respond, and twenty-three children had gone into disease remission
and were subsequently placed on maintenance therapy to help maintain remission.
Maintenance therapy was either given as maintenance enteral nutrition (MEN); an
immunosuppressant plus MEN; or as an immunosuppressant (IM) only. Faecal sam-
ples available for analysis in each group are shown in Table 5.6.
Table 5.6: Number of faecal samples available for analysis at each time-
point during maintenance therapy
Study time-point
ME
N o
nly
ME
N p
lus
IM
IM
onl
y
week-8 (end of treatment with EEN 5 5 4
Back on to normal diet
week-10 (2 weeks maintenance therapy) 4 6 4
week-16 (8 weeks maintenance therapy) 6 7 4
IM-immunosuppressant; MEN- maintenance enteral nutrition. All chil-
dren went onto some type of maintenance therapy (i.e. there was no
non-treatment control group).
It is important to note that children who had higher levels of inflammation after
8-weeks of treatment on EEN, as indicated by calprotectin levels, were more likely
to be given an immunosuppressant drug as part of maintenance therapy (Fig. 5.20).
Therefore any differences in gut microbiota between treatment groups at study week-
8, week-10 and week-16 could be linked to differences in disease severity, rather than
differences due to maintenance therapy.
Figure 5.20: Calprotectin prior to maintenance therapy (study week-08) in children with Crohn’s
disease. Difference seen between groups was not significant p=0.1 (Kruskal-Wallis). IM - immuno-
suppressant; MEN - maintenance enteral nutrition.
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Richness (α-diversity) Although there was a slight increase in the median number
of species (SNVs)(richness) and species evenness (Shannon index) after 2-weeks on
normal diet (study week-10) and 8-weeks normal diet (week-16) this was not sig-
nificant in any of the three maintenance treatment groups (Fig. 5.21). When all
treatment groups were combined, no difference in species level richness or Shannon
entropy was seen as children returned back on to normal diet at week-10 and week-16.
Figure 5.21: Gut bacteria α-diversity shown by richness (no. of SNVs/species) and Shannon index
(evenness), in children with Crohn’s disease at end of EEN (wk-08); then 2-weeks (wk-10); and
8-weeks (wk-16) of normal diet plus maintenance therapy. Children were treated with an immuno-
suppressant (IM) only (n=4); IM plus maintenance enteral nutrition (MEN) (n=6 at wk-10; n=7
at wk-16); or MEN only (n=4 at 10-wks; n=6 at 16-wks). No significant difference seen between
time-points (ANOVA).
Abundance (β-diversity) Although difference in microbiota community structure
was not significant (Fig. 5.22), there is a clear move in all maintenance treatment
groups showing that once back onto normal diet, at week-10 and week-16, the gut
bacteria community structure starts to move towards a structure associated with
healthy children. This is most evident when all maintenance groups were combined
(R2=0.055, p=0.112; Fig. 5.22d). Access to a non-treatment control group was
unfortunately not possible, since all children who chose not to take MEN were given
an immunosuppressant drug; therefore no child on the study returned to normal
habitual diet without some form of maintenance therapy.
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MEN
(R2=0.125; p=0.713)
(a)
MEN plus IM
(R2=0.096; p=0.831)
(b)
IM
(R2=0.169; p=0.606)
(c)
All groups
(R2=0.048; p=0.019)
(d)
Figure 5.22: NMDS showing change in microbiota community structure in children with Crohn’s dis-
ease during maintenance therapy, who were treated with (a) maintenance enteral nutrition (MEN);
(b) MEN plus an immunosuppressant (IM); or (c) IM only. (d) shows all children on maintenance
therapy combined. Healthy controls (HC) are shown for comparison but were not included in test
for significance. Samples were taken at end of EEN (Week-08); then 2-weeks (Week-10) and 8-weeks
(Week-16) after return to normal diet. Change in community structure over time on normal diet
was not significant for any treatment group (PERMANOVA). Ellipse shows 95% CI.
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(a) (b) (c)
(d)
Figure 5.23: sPLS-DA Discriminant Analysis showing the change in microbiota community
structure at species level taxa (SNVs) between the end of EEN (week-8) in children with Crohn’s
disease and then once they go onto normal diet plus maintenance therapy (week-16). The algorithm
is a 2-step process where two components are found reducing the classification error rates (using
centroid.dist) in the algorithm, with (a) showing the ordination of samples using all the species
(SNVs) in the first two components (PLS-DA) with ellipses representing 95% confidence interval
and percentage variations explained by these components in axes labels. In step two, (b) the number
of discriminating species (SNVs) were found for each component, highlighted as diamonds. In (c)
the ordination used the discriminants from all two components (sPLS-DA). (d) is a heatmap of
discriminant species (SNVs), with rows and columns ordered using hierarchical clustering (average
linkage) to show patterns of interest. Heatmap depicts TSS+CLR normalised abundances: high
abundance (red) and low abundance (blue).
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Table 5.7: Number of species level taxa (SNVs) which changed in abundance between the end of EEN
(study week-8) and 2-weeks/8-weeks of maintenance therapy (study week-10/week-16)
MEN MEN + IM IM
number of SNVs number of SNVs number of SNVs
increased decreased increased decreased increased decreased
normal diet plus
2-wks maintenance therapy 49 (1.8%) 37 (1.3%) 68 (2.5%) 45 (1.6%) 50 (1.8%) 53 (1.9%)
8-wks maintenance therapy 70 (2.5%) 73 (2.6%) 45 (1.6%) 70 (2.5%) 50 (1.8%) 79 (2.9%)
Total number of SNVs (proxy for species) was 2,751. Differences shown by log2 fold change in species were sig-
nificant at p<0.01. (Differential expression analysis based on negative binomial -DESeq2) (χ2=0.43; p=0.52).
MEN -maintenance enteral nutrition; IM- immunosuppressant
,
The number of SNVs (a proxy for species) which significantly increased in abundance
after 2-weeks and 8-weeks normal diet varied between maintenance treatment groups
as well as over time (Table 5.7). However all three treatment groups showed a very
similar pattern of decreased abundance resulting in between 2.5% (70) and 2.9% (79)
of total bacterial species variants (SNVs) having reduced abundance after 8-weeks
of normal diet (study week-16) (Table 5.7). Therefore once back onto normal diet,
although there was no reduction in the number of bacterial species (α-diversity), there
was a significant reduction in the abundance (β-diversity) of many bacterial species
(SNVs) in children on all forms of maintenance therapy. This change in abundance
is visualised as a heatmap for species level (SNVs) in figure 5.23d and for genus level
in figure 5.24.
Using differential expression analysis to look at changes after 8-weeks of normal ha-
bitual diet plus maintenance therapy (study week-16), no significant log2 fold change
in relative abundance of bacteria was seen at family level taxa. However a number of
Proteobacteria genera were significantly (p<0.01) decreased in abundance in the MEN
only treatment group including Citrobacter, Cronobacter Enterobacter and Pantoea
after 8-weeks of normal diet (Fig. 5.25a). The MEN plus immunosuppressant (IM)
group also had decreased Proteobacteria including Citrobacter, Cronobacter, Campy-
lobacter and Sutterella (Fig. 5.25b). The IM-only group also had reduced Citrobacter,
Cronobacter, Enterobacter, and Eikenella (Fig. 5.25c). Not all children saw a reduc-
tion in Enterobacteriaceae once they returned to normal diet. Patient S036, a child
who took MEN plus IM, had high abundance of Enterobacteriaceae (Cronobacter) at
then end of EEN (study week-8), which increased in abundance at 2-weeks normal
diet (week-10); which was then replaced by a high abundance of Escherichia-Shigella
at 8-weeks normal diet (week-16). This child had relapsed by 8-weeks normal diet
(week-16) and gone onto corticosteroids (Fig. 5.26). Another participant (S012) who
took MEN plus IM had a large increase in Escherichia-Shigella after 2-weeks normal
diet but this had reduced in abundance by 8-weeks normal diet. Participant S016,
a child on IM only, had a high abundance of Escherichia-Shigella at end of EEN
(study week-8), however abundance reduced once the child returned to normal diet
174
(Fig. 5.26). These patients show that having high abundance of Proteobacteria at the
end of EEN does not seem to determine whether this group of bacteria will increase
or decrease once children return to normal diet.
Discriminant analysis (sPLS-DA) at species level (SNVs)(Fig. 5.23) show that most
species variants which discriminate between the end of EEN and a return to normal
diet were from the order Clostridiales. This was characterised by are a drop in the
abundance of five Ruminococcaceae species variants (SEQ 92, 69, 413, 341, 472) and
an increase in eight Lachnospiraceae species variants (SEQ 112, 18, 189, 128, 32, 98,
52, 78) once back onto normal diet for 8-weeks (study week-16). The Bacteroidetes
species Alistipes (SEQ 312, 47) and Parabacteroides (SEQ 76) were also reduced along
with the Proteobacteria Cronobacter and Parasutterella (SEQ 54, 724) on normal diet
(Fig. 5.23d).
Subset analysis of the microbiota data from children on maintenance therapy (Table
5.8) shows which bacterial genera are the main source of variation from all samples
between the end of EEN (study week-8) and return to normal diet (week-16). These
included the Actinobacteria, Bifidobacterium and Collinsella; the Bacteroidetes Bac-
teroides, Alistipes, Prevotella 7 and Prevotella 9 ; the Firmicutes, Ruminococcaceae
UCG-002, Faecalibacterium, Lachnoclostridium and Blautia; Proteobacteria, Escherichia-
Shigella as well as the Verrucomicrobia Akkermansia (Table 5.8).
Table 5.8: Subset analysis showing which genera explain the percentage variability in microbiota
community structure between end of EEN (week-8) and normal diet (week-16)
Subset Subset of most abundant genera
correlation with full
abundance table
PERMANOVA
subsets
S1 Unknowns + Alistipes + Ruminococcaceae UCG-
002 + Escherichia-Shigella + Collinsella + Akker-
mansia + Bifidobacterium + Faecalibacterium +
Lachnoclostridium + Prevotella 7 + Prevotella 9
+ Blautia + Bacteroides
0.95 R2=0.083
p=0.006 **
S2 Unknowns + Ruminococcaceae UCG-002 +
Escherichia-Shigella + Collinsella + Akkermansia
+ Bifidobacterium + Faecalibacterium + Lachno-
clostridium + Prevotella 7 + Prevotella 9 + Blau-
tia + Bacteroides
0.95 R2=0.083
p=0.004 **
S3 Unknowns + Ruminococcaceae UCG-002 +
Escherichia-Shigella + Akkermansia + Bifidobac-
terium + Faecalibacterium + Lachnoclostridium
+ Prevotella 7 + Prevotella 9 + Blautia + Bac-
teroides
0.94 R2=0.087
p=0.003 **
S4 Unknowns + Ruminococcaceae UCG-002 +
Escherichia-Shigella + Akkermansia + Bifidobac-
terium + Faecalibacterium + Lachnoclostridium
+ Prevotella 9 + Blautia + Bacteroides
0.94 R2=0.090
p=0.009 **
Subsets were generated using the BVSTEP routine in R. PERMANOVA of subsets were performed
against children on EEN and the same children 8-weeks post EEN (normal diet) with R2 explaining
the percentage variability in microbiota structure between groupings. Where the SNVs had no genera
assignment, they were binned together in the category ‘Unknowns’.
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(a)
(b)
(c)
Figure 5.25: The log2 fold change in genera abundance for children with Crohn’s disease after 8-
weeks maintenance therapy on (a) MEN only n=5; (b) MEN plus and immunosuppressant (IM)
n=6 and (c) an immunosuppressant (IM) only n=4. Bacterial genera shown were all significant to
p<0.001.
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5.4 Discussion
5.4.1 Summary of results
The results of the current study from baseline samples highlight some key features of
interest when comparing children with Crohn’s disease with healthy children. Chil-
dren with both Crohn’s and UC have a significant reduction in bacterial diversity
(Fig. 5.3). The results looking at β-diversity between children with Crohn’s disease
and healthy children show that differences in community structure are not limited
to species but are also significantly different at phylum level (Fig. 5.4). Phyla level
changes are indicative of more widespread change across the gut microbiota com-
munity. Local contribution to β-diversity also highlighted a key feature of Crohn’s
disease, that dysbiosis as well as being distinct from healthy children, also has the
feature of being distinct from other children with Crohn’s disease; such that inter-
patient variability is very high among Crohn’s patients (Fig. 5.5). Results also
suggest children with UC have less extreme dysbiosis than those with Crohn’s dis-
ease (Fig. 5.5). Taxa differences in children with Crohn’s disease showed a distinct
community structure which is characterised by reduced healthy commensals, partic-
ularly gram-positive Clostridia from the Firmicutes phylum. This was accompanied
by an increase in gram-negative bacteria including Fusobacteria, Enterobacteriaceae
and the Negativicutes (Fig. 5.8).
It was not possible to reliably address questions about differences in gut microbiota
profiles by Crohn’s disease location, since dividing the study group up resulted in low
sample numbers, particularly for isolated ileal disease which is less common. However
the discrimination analysis (Fig 5.10) hints that ileal disease might have a community
structure with features which are different from children with colonic involvement,
warranting further research with larger samples sizes.
Results from the current study suggest it is not possible to predict response to EEN
from baseline microbiota profiles; and although twenty-five species (SNVs) were dis-
tinct between responders and non-responders, no obvious pattern in species type
could be identified. Results went on to show that successful treatment with EEN
changes the microbiota community structure, but rather than correcting baseline
dysbiosis, EEN pushed the gut bacteria profile further away from that of healthy
children (Fig 5.12). However no difference was seen in species richness, except for a
non-significant decrease in children who failed to respond to EEN. (Fig 5.13). More in-
terestingly all the family groups which were reduced during EEN were gram-negative
bacteria including Pasteurellaceae, Bacteroidales S24-7, Fusobacteriaceae; or Veil-
lonellaceae (Negativicutes). Increases in abundance mainly came from gram-positive
Clostridiales families and Corynebacteriaceae (Actinobacteria).
Gut bacterial changes which occurred during EEN, were not maintained once chil-
dren went back onto normal habitual diet, even when children were given a dietary
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supplement of enteral nutrition (MEN) to try and maintain remission. In individual
patents using MEN, increases in gram-negative bacterial families such as Veillonel-
laceae, Enterobacteriaceae Bacteroidaceae, Prevotellaceae and Verrucomicrobiaceae
could be seen increasing on normal diet (Fig 5.26).
5.4.2 Results in the context of wider evidence
As increasing evidence in the aetiology of IBD points towards a link between en-
vironmental factors and the gut microbiota in genetically susceptible individuals, a
great deal of recent effort has gone into investigating the composition and function
of the gut microbiota. Although reduced bacterial diversity is a key feature of IBD,
it is still unclear if this microbial dysbiosis is a symptom of an inappropriate immune
response, or is actively driving inflammation in the gut.
Although some studies have suggested specific bacterial species such as Mycobac-
terium; Campylobacter; Escherichia and Helicobacter cause Crohn’s disease, evidence
does not support this theory.176 Comprehensive studies using both faecal and mucosal
biopsy samples, suggests that Crohn’s disease is associated with significant differences
in gut microbiota at a wider community level. The current study in line with previ-
ous studies (Table 5.9) saw decreased abundance of Clostridia and Bifidobacterium
species; along with increased Proteobacteria, in Crohn’s disease patients. This was
accompanied by a non-significant increase in Bacteroides also reported by Andoh
et al.400 and Kaakoush et al.223 who saw a significant increase in Bacteroidetes, in
children with Crohn’s disease. However, an equal number of studies have reported
a decrease in Bacteroidales. Enough studies have also reported no change in Bac-
teroidetes (Table 5.9), to suggest that either, there are changes in both directions
among genera within Bacteroidetes which is picked up as natural variation between
studies; or that possible variation in storage times and freezing of faecal samples, prior
to DNA extraction, known to alter the detection rate of Bacteroidetes genera, may
make it difficult to detect true differences in some studies300 (Methods section 2.8).
Therefore a loss in gut bacterial diversity of symbiotic groups of gram-positive bac-
teria, particularly the Clostridia and Bifidobacteriaceae; along with increases in the
gram-negative bacteria Bacteroidetes and Enterobacteria are key features of Crohn’s
disease (Table 5.9).
In 2014 the Crohn’s and Colitis Foundation of America ran a prospective study (RISK
study), which reported on 447 treatment na¨ıve children with Crohn’s disease and
221 non-IBD controls from twenty-eight different sites in USA and Canada between
2008-2012, which has lead to further analyses of this cohort by Gevers et al.;194
Wang et al.401 and Haberman et al.402 (Table 5.9). An interesting aspect to the
Haberman study was that they compared the mucosal microbiota between Crohn’s
disease children with and without ileal inflammation, and found that the identified
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pattern of Crohn’s disease dysbiosis, was no different between the two groups; and
thus independent of inflammation. They suggest therefore, that bacterial dysbiosis
precedes inflammation and is not caused by inflammation.402
5.4.3 Reduced diversity in Crohn’s disease at diagnosis
Ecology research has shown that complex multi-species communities are by their na-
ture, vulnerable to destabilisation.403 The human gut microbiota manages to main-
tain a stable state in healthy individuals175 despite high levels of species diversity,404
however it is clear from this current study and other studies that children with IBD
have lower than normal species diversity, which in itself could leave the microbiota
community more vulnerable to destabilisation.175 Low bacterial diversity has also
been identified in a number of other conditions including IBS,405 arthritis218 and
obesity,406;407 and although Crohn’s disease and IBD have reduced bacterial diversity
at baseline in this (p<0.001) and other studies, it should be noted that the non-IBD
group in the current study also had reduced diversity when compared to healthy
children (p=0.042). Therefore clearly defining the specific pattern of diversity, will
become important in distinguishing Crohn’s disease and IBD from other conditions,
before microbiota profiles can be used as a markers of disease.
5.4.4 Significance of taxa which are reduced in Crohn’s disease
Some of the taxa which have low abundance in children with Crohn’s disease com-
pared with healthy children, are known to provide positive metabolic functions in the
gut. Bacteria in the order Clostridiales, such as Roseburia, Blautia, and Faecalibac-
terium prausnitzii are important butyrate producers, providing essential energy for
epithelial cells in the gut.243 Many of the predominant healthy commensal bacteria
also produce antimicrobial activity which can help to maintain the overall homoeosta-
sis of the many species of bacteria in the gut, preventing the overgrowth of potential
pathogens and increasing overall diversity. Future research may go on to reveal, if
probiotic treatment or improved diet could increase clostridial diversity in children
with Crohn’s disease, replacing this loss in metabolic function with the aim of reduc-
ing inflammation. However, if loss of diversity is a product of an inflammatory state,
a probiotic or pro-clostridial diet would have little or no effect on patient outcomes.
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Actinobacteria (Bifidobacteriaceae) A number of studies have recorded reduced
abundance of the family Bifidobacteriaceae,410;402;194 in Crohn’s disease patients while
others have reported a decrease at genus level (Bifidobacterium).144;413 The current
study saw a significant decrease in Bifidobacterium at species level. Frank et al.412
reported an increase at phylum level (Actinobacteria), but this has been the only
study to report an increase. Their methods were different from other studies, in that
they used tissue samples taken from resected surgery; patients were not treatment
na¨ıve; and they used MegaBACE 1000 rather than Illumina to sequence their samples.
Bifidobacterium gut colonisation involves vertical transmission from mother to child,
with recent studies showing that specific Bifidobacterium strains are shared between
mother and child.415 It is known that strains of Bifidobacterium, via production
of acetate, can prevent the colonisation of pathogenic E. coli by inhibiting Shiga
toxin,416 hence reduced levels of Bifidobacterium may open a niche for some genera
of Enterobacteriaceae such as Escherichia-Shigella to increase in number. Results
from mouse models have suggested that exo-polysaccharides produced by a strain of
B. longum induced IL-10 secretion in macrophages as well as lower levels of TNF-
α secretion.417 An earlier study has also suggested that exo-polysaccharides from a
B. adolescentis strain can increase cell division activity in murine splenocytes and
Peyer’s patch cells.418 Therefore Bifidobacterium species play a range of different roles
in immunomodulation potentially affecting inflammatory processes in IBD.
Bacteroidetes Although Bacteroidetes have been reported to be increased in three
studies looking at Crohn’s disease, these studies tended to have small sample sizes,
and used older technologies such as 454 sequencing or T-RFLP.223;400;413 The larger
better quality paediatric USA studies which use Illumina sequencing,194;412 report a
decrease in the Bacteroidales. Bacteroidetes have also been reported to be decreased
in Chinese adults with Crohn’s disease (NS), with the same study finding that the
relative abundance of Bacteroidetes showed a negative correlation with Crohn’s dis-
ease activity index scores.408;409 Although the increase in Bacteroidetes in the current
study was not significant perhaps due to sample size it is clear that our findings agree
with the larger studies which suggest a reduction in Bacteroides species.
Bacteroides fragilis, a prominent gut commensal, has been shown to protect against
intestinal inflammation.419 Round et al. showed that monocolonisation of a germ-
free mouse model with B. fragilis increases the suppressive ability of Treg to induce
anti-inflammatory cytokine production from Foxp3+ T-cells in the gut. B. fragilis
expresses polysaccharide-A, which aids the conversion of CD4+ T-cells into Foxp3+
Treg cells that produce IL-10 during commensal colonisation. Polysaccharide-A also
produces functional Foxp3+ Treg cells during gut inflammation, and toll-like receptor
2 signalling is required for both Treg induction and IL-10 expression. Their study
showed that Polysaccharide-A produced by B. fragilis was not only able to prevent,
184
but also cure experimental colitis in mice,182 which suggests that B. fragilis and
other related bacteria could have a potentially vital role in regulating inflammation
in humans.
Mouse models suggest that low Bacteroides abundance is both a risk factor and
a potential driver of Crohn’s disease.420 One study has shown that reconstitution
of germ-free mice with a diverse microbiota which did not contain the phyla Bac-
teroidetes failed to restore full immunity, suggesting that some Bacteroidetes species
could have the ability to modulate pro- and anti-inflammatory responses in the gut.420
Thus, uncovering the immunological role of individual Bacteroides species, could be
an important avenue of research in understanding inflammation in Crohn’s disease.
Firmicutes; Clostridiales Studies have shown that in children with Crohn’s dis-
ease the relative abundance of genera within the class Clostridia: including Roseburia;
Faecalibacterium; members of the family Lachnospiraceae and Ruminococcaceae are
decreased in abundance223;195;401 (Table 5.9). The current study saw significantly re-
duced abundance in six genera of Ruminococcaceae and five genera of Lachnospiracae
as well as Eubacterium. The Christensenellaceae were also significantly reduced in
children with Crohn’s disease (Fig. 5.8).
A recent study has gone on to show that Treg cell-inducing strains of Clostridia
species, can be used to attenuate disease in mouse models of colitis and allergic
diarrhoea.183 This suggests that the loss of Clostridia species, a key feature of Crohn’s
disease in this and other studies, could be a factor in maintaining inflammation. It
is therefore possible that the future clinical use of isolated strains might provide a
tailored way to reduce inflammation in patients with IBD.
Verrucomicrobia In the current study there was a significant decreased abundance
in the family Verrucomicrobiaceae made up from the genus Akkermansia, in children
with Crohn’s disease, a finding also seen by Haberman et al.402 and Lewis et al.73
Akkermansia muciniphila is a gram-negative bacterium able to use mucin as a sole
source of carbon and nitrogen, a specialisation which allows it to colonise the gut
mucosa, making it a key player at the interface between the gut lumen and epithelial
cells.421 Although isolated fairly recently, it has been of significant interest to mi-
crobiota research due to reduced levels being observed in patients with IBD422 and
obesity, as well as gut Akkermansia abundance been shown to be dramatically re-
duced in a number of knock-out or diet-induced mouse models that develop obesity,
including mice fed a high fat diet.423;424;425 Researchers restored normal levels of A.
muciniphila by feeding the same mice live A. muciniphila along with a prebiotic diet.
In comparison to controls, mice lost weight, had reduced insulin resistance and inter-
estingly a thicker layer of intestinal mucus, which suggests A. muciniphila may play
an important role in maintaining the mammalian gut mucosal layer which protects
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the gut epithelium from damage and potential pathogens. This could have clinical
importance as it suggests that a probiotic containing A. muciniphila may have the
potential to promote mucosal healing in patients with IBD.
5.4.5 Significance of taxa which are increased in Crohn’s disease
As seen in the current study the majority of taxa that are increased in Crohn’s
disease come from the class γ-proteobacteria, many being known as opportunistic
pathogens.226 Studies have also recorded, as seen in this current study, increases in
Fusobacteriaceae from the phylum Fusobacteria, and a number of Firmicutes families
mainly from the class Negativicutes and Bacilli (Table 5.9).
Firmicutes Although as a phylum Firmicutes are decreased in Crohn’s disease,
some families within the Firmicutes are often reported to increase, particularly the
Veillonellaceae (Negativicutes).194;402 Veillonellaceae although belonging to the gram-
positive Firmicutes phylum, have a peculiar cell wall with a lipopolysaccharide outer
membrane which stains gram-negative,426 which may have been laterally acquired
from Proteobacteria.427 The 2017 study by Mancabelli395 which combined data sets
from three previous studies also recorded a higher relative abundance in Veillonella
(p<0.001). Although the current study did not see a significant overall increase in
Veillonellaceae, two children with Crohn’s disease did have much higher levels of
Veillonellaceae than any healthy children on the study (Appendix 5.1, S012A and
S049A).
Other Firmicutes families and orders including Family XI/Gemellaceae (class:Bacilli);194;402
Lactobacillales; Staphylococcaceae (class: Bacilli)401;144 and Enterococcaceae (class:
Bacilli)401;73 have also been reported to increase in Crohn’s disease (Table 5.9). The
current study also saw a significant increase in the abundance of Gemellaceae, which
although a normal part of the mucous membranes of the oral cavity and upper gut
in healthy humans, they have the ability to become opportunistic pathogens in non-
healing wounds.428 Hence these increases in Gemellaceae and Veillonellaceae may be
opportunistic, filling a niche left by decreasing numbers of other Firmicutes. These
families have been overlooked in terms of immunological research and future research
should investigate whether these bacteria have the potential to increase inflammation
in the gut.
Proteobacteria In 2016 Wang et al.401 using data from the ‘RISK’ study, log10
transformed bacteria abundance and found a number of Proteobacteria families were
increased in children with Crohn’s disease, which had not been detected by the orig-
inal ‘RISK’ study by Gevers et al.194 Both of these studies, in line with the current
study, recorded a significant increase in Neisseriaceae in children with Crohn’s disease
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when compared with healthy children. The genus Neisseria is best known for the
human pathogens, N. meningitidis and N. gonorrhoeae. However this genus is an
abundant part of the normal commensal oropharyngeal microbiota as well as being
successful at finding niches over a number of body sites including the gut. Although
commensal Neisseria species are less virulent than N. meningitidis and N. gonor-
rhoeae they have been shown to be opportunistic pathogens in humans.429 Hence the
family Pasteurellaceae, particularly Haemophilus, which are significantly increased in
the gut microbiota of children with Crohn’s disease in four previous studies, as well
as the current study,410;402;72;401 should be examined further as potential drivers of
inflammation in Crohn’s disease.
Given that patients with Crohn’s disease and UC have an inappropriate response
to altered gut microbiota, leading to a protracted immune response and chronic
inflammation, it is not surprising that opportunistic species of Proteobacteria are
able to thrive in this environment. Strains of the family Enterobacteriaceae have
been shown to do well in the presence of inflammation, out-competing the healthy
microbiota in a colitis mouse model.430 A 2004 study of Crohn’s disease patients
found from ileal tissue, that adherent invasive E. coli (AIEC) strains were present
in 36.4% ileal mucosa and 22.2% of healthy control mucosa (p=0.034). However in
colonic mucosa, AIEC strains were only found in 3.7% of Crohn’s disease patients; 0%
of UC patients, and 1.9% of control patients, therefore suggesting that AIEC strains
are associated with the ileal mucosa of Crohn’s disease patients.431 Proteobacteria
such as E. coli are incapable of digesting complex polysaccharides, and since beyond
the ileocaecal valve most unabsorbed carbohydrates are complex polysaccharides,
this could explain why Proteobacteria are more often associated with ileal Crohn’s
disease. The question that remains to be answered, is whether these E. coli, either as
individual species/strains or as part of symbiotic relationships with other bacteria,
are part of the aetiology of Crohn’s disease or simply opportunistic pathogens that
thrive in inflammatory conditions in the gut. The finding of this current study that
Enterobacteriaceae, Neisseriaceae and Pasteurellaceae were increased in children with
Crohn’s disease, is in line with the findings of other studies including the ‘RISK’
study72 (Table 5.9).
Fusobacteria As seen in other paediatric studies194;410 (Table 5.9), the current study
saw a higher abundance of Fusobacteria in children with Crohn’s disease compared
with healthy children. Interestingly although Fusobacterium is a known butyrate pro-
ducer, when its butyrate production pathway composition was compared with com-
mensal Firmicutes such as Roseburia, Lachnospiracea species and Faecalibacterium,
it has been shown that glutarate and lysine pathways were utilised by Fusobacteria
rather than the the pyruvate pathway used by commensal Firmicutes associated with
a healthy gut. The loss of the pyruvate pathway for butyrate production in Crohn’s
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disease may play an important role, however the pathways utilised by Fusobacte-
ria releases ammonia as a by product which may also have an negative impact on
gut health.432 It has also been shown that Fusobacterium has an increased number
of putrefaction pathways which can lead to the production of a number of harm-
ful metabolites in the gut.276 Fusobacterium has also recently been identified as a
possible risk factor for colon cancer;433 while a study looking at oral periodontal in-
fections has suggested that Fusobacterium can aggravate periodontal infection via
protein fermentation.434 Therefore increases in Fusobacteria may play a role not only
in maintaining gut dysbiosis but also in gut epithelial cell damage. This makes Fu-
sobacteria of particular interest for further study.
Patterns of change The small intestine is rich in nutrients which can be used
by both the host and the microbiota to sustain growth. Proteobacteria, mainly
from the family the Enterobacteriaceae; and the Firmicutes, Lactobacillales and
Erysipelotrichales, are dominant groups within the normal small intestine. Increases
in these groups of bacteria appear to be a common feature of Crohn’s disease (Table
5.9). A feature highlighted from the ‘RISK’ study, is that bacteria associated with the
ileal mucosa (tissue samples) in healthy children tended to proliferate in the stool of
children with Crohn’s disease, whereas bacteria prevalent in stool samples of healthy
children are decreased in abundance in children with Crohn’s disease. Therefore in
the microbiota profile of Crohn’s patients, it appears that a loss of normal colonic
microbiota is being replaced with microbiota more typical of the small intestine. This
shift can also be viewed as an overall decrease in gram-positive bacteria being replaced
with gram-negative bacteria.
Although it is true that 16S rRNA and metagenomic sequencing provide a detailed
view of the gut microbiota, turning this data into meaningful clinical information has
been difficult.435 It has been challenging to separate larger scale functional effects due
to taxa differences at phylum and order level, with smaller scale differences at genus
or species level, which could also have direct effects on epithelial cells in the gut.
Given that the gut microbiota has a huge variation in abundance between different
species, where species have low abundance, especially in smaller scale studies these
bacteria may not generate enough statistical power for us to identify differences which
may be important in Crohn’s disease. Although, where larger cohorts are available,
studies such as Wang et al.401 have shown that the phylogenetic trees of bacteria
associated with Crohn’s disease and those associated with healthy individuals do not
overlap and therefore have distinct lineages. The current study backs up this finding
(Fig. 5.8), however the large inter-patient variability in IBD makes it impossible to
fit individuals to a clear model of IBD at this stage.
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Drivers of behavioural changes in bacteria Different taxa within the gut mi-
crobiota when found together can enhance inflammatory effects. A rat model for
intra-abdominal sepsis has shown that obligate anaerobes such as Bacteroides fragilis
or Fusobacterium varium when combined with facultative aerobes like E. coli or the
Bacilli Enterococcus faecalis result in peritonitis and abscess development436 where
neither alone lead to abscess formation. Mice infected with a combination of E. coli
and B. fragilis in the peritoneal cavity saw an increase in TNF-α production in the
peritoneal tissues which was not seen when infected by these bacterial species inde-
pendently.437 This is important because these are genera we see increased in Crohn’s
disease, thus further work identifying the behaviour of specific strains from Crohn’s
patients, in mixed communities could shed light on what is driving inflammation.
This group also showed when mice were co-infected with E. coli, expression of cytokine-
KC increased; however when co-infected with a Lactobacillus species, cytokine-KC
mRNA expression decreased. It is therefore possible that increased Proteobacteria
along with reduction of Lactobacillus species could potentially alter the behaviour
of Bacteroides species in such a way as to drive inflammation. Further studies have
also shown that a B. fragilis by-product can impair the ability of host neutrophils
to kill E.coli by phagocytosis438;439 and suppress the E. coli associated LPS-induced
cell adhesiveness for neutrophils in the gut.439 Therefore understanding the changing
behaviour of dominant commensal bacteria in the presence of other bacterial groups
could be key to understanding inflammation in the gut in Crohn’s disease.
5.4.6 Gut microbiota profile as a predictor of Crohn’s disease
Like the current study, the larger scale studies that have focused on treatment na¨ıve
children, which have less confounding factors than adults,194 have confirmed the
findings of other studies that dysbiosis is present not only in well established Crohn’s
disease, but also at disease onset. Given that these recent studies identify Crohn’s dis-
ease as having decreased abundance of the phyla Firmicutes and Bacteroidetes, along
with an increase in abundance of Proteobacteria, the obvious question is, whether
these differences in microbiota community structure can be used to diagnose IBD.
We also need to know if the microbiota profile from faecal samples can have the same
predictive power as tissue biopsy samples.
The idea that we can use the gut microbiota community structure to identify patients
with IBD is based on the concept that either a loss or gain in specific bacteria is
responsible for IBD, and this may not be the case. The results of the current study
show that the local contribution to β-diversity is significantly higher in children with
Crohn’s disease and UC showing that their gut bacteria profile tends to be highly
dissimilar from other children with the same condition. This might suggest that the
risk factors or causative agents that drive inflammation could be unique to individuals
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or sub-groups of IBD patients, making it very challenging to use community structure
as a marker for IBD. It is possible that large scale future research will be able to
focus in and identify a discriminatory group of bacteria, or specific bacterial genes
associated with inflammation in the gut. However if inflammation associated with
Crohn’s disease and IBD is due to changes in bacterial behaviour, rather than presence
or absence of bacterial groups, this will make clinical disease profiling from bacteria
impossible at present.
Although at baseline tissue samples appear to be more indicative of specific dysbiosis,
faecal samples are picking up the same pattern of reduced Firmicutes, Bacteroidales
and increased Proteobacteria (Table 5.9). In contrast to the Gevers et al.194 study,
Wang et al. found that both faecal and ileal tissue samples had equal predictive
power, while Papa et al.,440 a study using adults with established Crohn’s, found
that stool samples were more predictive than ileal tissue samples. However, we need
to be cautious when comparing biopsies with stool samples, as tissue samples can
contain mucus in relatively greater amounts than found in faecal samples, possibly
accounting for differences in some studies, since mucus is known to inhibit PCR
reactions. Not amplifying enough bacterial DNA from tissue samples could lead to a
sampling bias which may not be a true representation of mucosal bacteria. Another
issue is that studies often use different DNA extraction methods between faecal and
tissue samples to try and maximize DNA yield from biopsies, which could also account
for differences in results.304 Faecal samples are a non-invasive way to assess the gut
microbiota, thus hold the key to diagnosing IBD, if they can be shown to have
predictive power. Papa et al.440 showed a predictive power of AUC 0.83 from faecal
samples, however much of their cohort were not treatment na¨ıve thus, treatment and
perhaps prolonged inflammation, may affect the reliability of their results. Gevers et
al.194, a study which did use treatment na¨ıve children, concluded that faecal samples
were a poor predictor of IBD (AUC 0.66). Therefore more work needs to be done to
identify specific bacterial profiles which will have much greater predictive power.
5.4.7 Limitations in study designs and data
Non-IBD controls One potential issue with cross comparing IBD studies is that
the so-called ‘healthy’ controls used for many studies, especially those using tissue
biopsy samples, are actually non-IBD patients441;195;409 with a range of other condi-
tions including inflammatory conditions such as juvenile idiopathic arthritis.410 The
current study clearly shows that as a collective, children in the non-IBD patient group
also have dysbiosis and reduced diversity, and therefore do not represent the typical
healthy gut microbiota of truly healthy children. As such it is not correct, as many
studies do, to refer to this patient control group as ‘healthy children’.
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Sample bias and size The biggest issue with most studies investigating the role of
the gut microbiota in IBD, including this one, is that they are unable to obtain high
enough numbers of patients, and thus can become insufficiently powered to link dif-
ferences in gut microbiota with variables such as disease severity, disease location and
response to treatment. Like other studies, participation in this study was optional,
and it is possible that children who were the most unwell, were the same children who
declined to take part. For ethical reasons we could not look at the records of those
who declined to take part, and hence cannot be sure if children who participated,
fully represent, for disease activity or disease location, all children in the West of
Scotland with IBD. More robust data could be gathered if small studies using the
same methods were linked together over a large number of sites to remove sampling
bias.
Different methods lead to differing results A 2014 study by Kennedy et al.441
demonstrated the significant effect on DNA yield and bacterial DNA composition
when comparing DNA extracted from a faecal sample using different DNA extraction
kits. Thus researchers need to be cautious when cross-comparing studies that use
different DNA extraction methods. Another issue is sequencing method. The large
Japanese study by Andoh et al. 2012413 used Terminal restriction fragment length
polymorphism (T-RFLP) analysis. Although this method does not have the high
resolution of using a 16S rRNA clone library,442 it can be useful for assessing a large
number of samples as it allows faster comparison of gut bacteria profiles between
samples.443 However we can see that this method did not detected as many taxa
differences as seen in smaller 16S rRNA studies, including the current study (Table
5.9), making it less useful as a research tool. The Andoh et al.413 study did however
have an excellent approach to collecting control samples, as they selected individuals
from five different regional districts of Japan (matched with the five IBD centres), to
test for the presence of regional differences due to environmental or dietary differences,
and concluded that any differences in gut microbiota profile between districts was
negligible.
Having used region V4 primers (515F-806R) to amplify the 16S rRNA in the current
study, recent studies have shown that V4 can result in an under representation of the
phylum Actinobacteria, including Bifidobacterium;444 hence it is possible that along
with other studies, we may not have detected a true representation of Bifidobacterium
species due to our choice of PCR primer region. Choosing primers can be very
challenging as getting the balance right between maximising the detection of bacterial
groups and comparing results with other studies are important considerations, and
future studies may begin to combine a number of primers aimed at different 16S
regions to obtain a truer representation of taxa.
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Age affects gut bacteria The gut microbiota research community may need to be
cautious when comparing adult studies with paediatric studies because ageing has
been associated with continual changes in the gut microbiota, including a gradual
decrease in Bifidobacterium.195;445;446 It is possible that adult Crohn’s disease studies
do not detect the same differences in Bifidobacterium seen in paediatric studies, due
to children having a higher abundance of this bacterial group (Table 5.9). It would
be useful to carry out adult and paediatric studies together in the same analysis for
comparison, to avoid assumptions about differences which might be due to methods
or researcher based bias. However, this type of combined study can be difficult, due
to service provision for children and adults being located in different hospitals, and
research sometimes funded from different sources.
Dysbiosis is not unique to IBD By studying the gut microbiota at baseline in this
new-onset paediatric population, we have shown along with other studies,194 that
faecal dysbiosis is present prior to treatment. However, data from other studies into
non-IBD conditions, would suggest that dysbiotic states reported for Crohn’s disease
are not unique, and occur in a number of intestinal diseases and other inflammatory
conditions. It may be that some aspects of dysbiosis such as reduced Clostridia is a
risk factor for a wide range of conditions. Comparing the gut microbiota in children
with Crohn’s disease with those of healthy children does not identify features unique
to Crohn’s disease, or ascertain if dysbiosis is the consequence of inflammation as
opposed to causing the disease. To achieve these goals, groups studying various
inflammatory conditions such as rheumatoid arthritis, psoriasis, Type-1 diabetes,
and other gastrointestinal conditions such as IBS and coeliac disease need to come
together, and using the same metagenomic methods, link studies to see how dysbiosis
varies between these conditions. This would help us to understand which bacteria
might be driving inflammatory conditions and which bacterial changes are a result
of inflammation, as well as leading to the identification of unique bio-markers which
differentiate Crohn’s disease from other dysbiotic diseases, including UC.
Other microbial members The term ‘microbiota’ should include single celled eu-
karyotes, fungi and viruses all of which are important functional components of the
gut micro-environment. However, the majority of microbiota studies have focused
on the bacterial community, and future research will need to unravel the interaction
between all of these players, as other gut inhabitants such as bacteriophages, could
be driving a reduction in commensals or reducing diversity. Interestingly as a com-
mensal species, Clostridium bacteriophage diversity447 is also increased in Crohn’s
disease patients with increased bacteriophages being higher in non-ulcerated mucosal
samples.448 Understanding bacterial homoeostasis in the gut may be dependant on
uncovering the role that bacteriophages and other members of the gut microbiota
play in altering the normal healthy bacterial composition.
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This and other studies show that although there is no single species associated with
Crohn’s disease there are some clear potential culprits; mainly increased abundance
of Enterobacteriaceae, Pasteurellacaea, Veillonellaceae and Fusobacteriaceae, accom-
panied with a decreased abundance of commensal Firmicutes, especially from the
class Clostridia.
5.4.8 Microbiota changes during EEN
The majority of the studies looking at the impact of treatment with EEN on gut
microbiota have been on children, with many having small sample sizes which limit
our ability to draw real conclusions from datasets. It has also been difficult to draw
comparisons across studies due to the high level of inter-individual variation, as well
as having to compare results from different sample types (faecal and tissue biopsies).
However, overall, these studies see a decrease in bacterial diversity during treatment
with EEN.223;145;144;216 Although one small study of four children reported an increase
in diversity during treatment with EEN, this was only seen in one child who failed
to go into remission on EEN.449 It is worth pointing out that although most children
have a reduction of species richness on EEN, around 1/3 of children on the current
study had an increase in diversity during EEN, with these children having a gut bac-
terial profile distinct from children who decreased species richness. Children who had
increased richness during EEN tended to have higher levels of Firmicutes especially
Lachnospiraceae species such as Dorea and Ruminococcaceae species, than children
who had reduced species richness. This difference at baseline did not predict either
response to treatment with EEN or time to relapse once children went onto normal
diet. Hence it cannot be suggested that these bacterial differences which are asso-
ciated with an increase or decrease in species richness during EEN, are linked with
reduced inflammation and healing.
Changes in bacterial richness (α-diversity) during EEN
In the current study there was a no decrease in the number of species (richness) and in
evenness of diversity in children after 4-weeks and 8-weeks on EEN. It should be noted
however that species richness increased in some children while decreasing in other
children independent of clinical response to EEN. This is curious given that these
children are on identical diets. This would explain why small studies have different
findings when reporting diversity during EEN. A small study450 of only five patients
reported decreased diversity, as did a later larger study.145;144 Another study, again
with a small sample size of only eight adult patients, saw no difference in diversity
during EEN.219 Dunn et al.227 followed nine children with Crohn’s disease who went
into remission after 12-weeks of EEN, for a further 12-weeks on normal diet and found
that in five patients who maintained remission α-diversity (Chao-1) had increased
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between baseline and 12-weeks EEN, whereas in the four patients who relapsed at
24-weeks there had been a decrease in diversity during EEN. It is surprising that if
later relapse is really associated with reduced diversity during EEN, that Dunn et
al.227 did not find or report the same pattern in diversity between responders and
non-responders to EEN. The current study did not find any relationship between
decreased diversity during EEN and time to relapse; and was able to show that the
children who increased in species richness during EEN had distinct differences in
gut microbiota at baseline which discriminated from those children who decreased
in species richness during EEN (Fig. 5.19). Although two children who failed EEN
were among the group that increased species richness during EEN, and four patients
who failed EEN where in the group who decreased in species richness during EEN,
it is possible that with larger sample sizes, a correlation between change in species
richness and response to EEN may emerge.
Further research with larger sample sizes, perhaps including patient genomics, and
environmental data, will need to be done to establish what other factors affect whether
species will decrease or increase during treatment with EEN. Evidence shows a link
between a number of diseases and reduced bacterial diversity in the gut. Therefore
it is important for future studies to determine, where diversity is further reduced by
treatment with EEN, if long-term damage could be occurring in a similar way that
antibiotics have been implicated to harm normal gut homoeostasis. On a reassuring
note, studies that have reported decreased diversity during EEN, have also reported
a return to pretreatment diversity levels once children are back onto their normal
habitual diet.145 Although the current study also saw a returned increase in diversity
once children returned back onto normal diet, the species composition was often
altered, and in some children normal healthy commensals such as Bacteroides were
lost. Longer term monitoring of gut bacteria post-EEN, would elucidate whether this
type of commensal bacteria loss is permanent or indeed harmful to those individuals
affected.
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Changes in bacterial abundance (β-diversity) during EEN
In the current study, although the number of species reduced on EEN, there were
many species which significantly increased in abundance during EEN. This is in-
teresting since we hypothesised that Modulen, a liquid feed with no fibre, which is
mostly absorbed in the small intestine, might lead to a reduction in abundance for
most species. One reason we might see this increased abundance, is if these species
are resident in the small intestine where they are able to take advantage of the low
residue feed, while colonic bacteria reduce in number and abundance as the feed is
mostly absorbed by the time it reaches the colon.
As seen in previous studies,73;144;145 the current study saw a marked shift in com-
munity structure (β-diversity) after 4-weeks of EEN which continued to shift further
away from healthy controls by 8-weeks EEN. When children with Crohn’s disease
were split into those who responded or failed EEN, the current study saw a significant
change in diversity for children who responded to EEN not seen in non-responders
(Fig. 5.13). Although the small sample size for non-responders makes it impossible to
draw any firm conclusion from this, the data for both number of species (α-diversity)
and abundance (β-diversity) suggest that non-responders to treatment were less likely
to have reduced diversity or a change in abundance during EEN. It cannot be eas-
ily ruled out that children who fail EEN perhaps struggle to fully comply with the
liquid diet regime, thus explaining why we see less change in bacterial diversity and
abundance in these children.
5.4.9 Changes in bacteria during EEN
If bacterial richness and overall abundance is reducing during EEN, it is important to
know which groups of commensal bacteria are reducing in order to understand how
these changes might lead to reduced inflammation. It is also important, particularly
in children, to know if any potentially pathogenic bacteria which are normally of low
abundance in the gut are increasing to fill a niche left by commensals during EEN.
The current study found after 4-weeks of EEN, children saw a decreased abundance in
gram-negative bacteria from Proteobacteria and Fusobacteria. Veillonellaceae (class:
Negativicutes), notable for having a cell wall similar to gram-negative bacteria, were
also decreased after treatment with EEN. However two families of gram-negative
bacteria were also increased during EEN, the Enterobacteriaceae and Verrucomicro-
biaceae. All other bacteria which increased in abundance during EEN were from the
Firmicutes. It is difficult to pick out why some bacteria are increasing in abundance
while others are reducing since we might expect Firmicutes to be decreasing due to
the loss of fibre in the liquid feed diet, however this is not the case for all species.
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Changes in Firmicutes It had been hypothesised that Faecalibacterium prausnitzii
might play a role in mucosal healing during EEN. However the current study in-
line with others saw a significant reduction in the relative abundance of Faecalibac-
terium during EEN (p=0.02). Another study focusing on two strains of F. prausnitzii,
showed the low levels recorded at baseline were not restored after 2-weeks of treatment
with EEN.218 Gerasimidis et al.145 also showed that F. prausnitzii was reduced along
with Bifidobacterium during EEN (p<0.01) and was therefore unlikely to play a role in
reducing inflammation and mucosal healing seen during treatment on EEN. An Aus-
tralian study223 which focused on six families of Firmicutes (Erysipelotrichaceae, Ru-
minococcaceae, Lachnospiraceae, Streptococcaceae, Veillonellaceae and Peptostrep-
tococcaceae) found an overall reduction in relative abundance of these families cor-
related with clinical improvement; however there was a great deal of variation be-
tween study subjects. These studies suggest that reduced abundance of predominant
healthy commensals, including F. prausnitzii, during EEN could be linked with re-
duced inflammation, supporting the theory that Crohn’s disease is caused by an
inappropriate response to normal commensal bacteria.
Changes in Bifidobacteriaceae The current study, in line with four previous stud-
ies,145;144;216;219 found Bifidobacteriaceae were reduced during EEN in both children
who responded to EEN and those who failed EEN. Bifidobacterium are healthy com-
mensals with anti-inflammatory properties, which are normally depleted in active
Crohn’s disease.194 However like F. prausnitzii and other Firmicutes it is reducing
during EEN in patients who have reduced inflammation and go into remission, sug-
gesting it does not have a direct role in healing.
Changes in Bacteroidetes Specific Bacteroidetes do not seem to follow a clear pat-
tern of change during EEN as seen across different studies. Dunn et al.227 report an
increase in Parabacteroides during EEN, while Schwerd et al.224 report a decrease
in abundance of three Bacteroidetes families: Bacteroidaceae; Porphyromonadaceae
and Rikenellaceae. Shiga et al.219 reported that Bacteroides fragilis was reduced by
EEN (p=0.03). Leach et al.216 reported that the Bacteroides-Prevotella group were
reduced in six children during EEN, which they linked with clinical improvement,
while Gerasimidis et al.145 reported the same decrease in fifteen children who had
clinical improvement. In the current study family level decreases were seen dur-
ing EEN in Bacteroidales S24-7 and Prevotellaceae. Overall, studies appear to be
reporting a decrease in different Bacteroidetes families during EEN.
Bacteroides, early colonisers of the gut, play a positive role in regulation of the
immune system.451;452 However a recent study has suggested a role for a strain of
Bacteroides vulgatus in the development of IBD via activation of the NF-κB sig-
nalling pathway.453 Another study investigating Bacteroides species found some act
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as colitis-promoting species while others are colitis-protective in murine models.454 If
composition of Bacteroides species are able to shape the balance between immune reg-
ulatory Treg cells and pro-inflammatory T-cells, an imbalance in Bacteroides species
could result in a loss of immunological homeostasis. Therefore, given that the phy-
lum Bacteroidetes contains a huge number of species, it is likely some will be vital in
immune regulation while other species and strains could be drivers of inflammation.
Further detailed research into Bacteroidetes species and others known to be involved
in immune regulation, could help to reveal how management of these bacteria might
be used to control inflammation in a clinical setting.
Given that Bacteroidetes are the largest phylum of gram-negative bacteria, which
as part of the normal healthy microbiota are considered major players in maintain-
ing homoeostasis in the gut, it is perhaps also concerning that EEN appears to be
reducing the abundance of these important commensals in this and other studies.
Changes in Proteobacteria Given that studies looking at gut microbial diversity
have consistently shown an expansion and increase of Proteobacteria species in pa-
tients with IBD,226 it might be assumed that treatment with EEN works by reducing
this group of bacteria, particularly Enterobacteria. However studies seem to show
the converse is true. Dunn et al.227 reported in nine children who responded to EEN
that in the five children who then relapsed within 12-weeks, an increase in the Pro-
teobacteria family Enterobacteriaceae during EEN. The current study also found an
increase in Enterobacteriaceae and other gram-negative families in both patients who
responded to EEN and those who failed to respond during EEN. The larger study
by Quince et al.144 also reported a increase in the genera Escherichia/Shigella for
all children on EEN, while a small study of only four children on EEN reported a
decrease in Escherichia/Shigella and Sutterella.222 An Australian study223 clearly il-
lustrated how Proteobacteria were increasing in some patients during EEN while in
others abundance fell. It is likely that low sample size along with high inter-patient
variation leads to opposing results, but perhaps the key point is that changes in
Proteobacteria in individual children during EEN are not consistent.
Although gram-negative Enterobacteriaceae such as E.coli are a normal part of the
healthy gut, many are opportunistic pathogens which are held in relatively low abun-
dance in the healthy gut. If treatment with EEN is increasing Enterobacteriaceae
species in some individuals, this may not be an issue for most children, since levels
appear to reduce once children are back onto normal diet. However some children
may have more virulent strains of Enterobacteriaceae species, which during EEN are
able to gain a previously unavailable advantage. The increase of pathogenic species
could in turn lead to increased inflammation and explain why some children fail to
respond to treatment on EEN.
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There is a normal oxygen gradient throughout the colon which affects gut microbiota
composition. A greater abundance of Proteobacteria is found at the mucosal sur-
face due to greater environmental ratios of oxygen.455 Epithelial inflammation which
causes cell damage and bleeding in active Crohn’s disease is likely to provide higher
ratios of luminal oxygen, thus favouring members of the Proteobacteria, particu-
larly the Enterobacteriaceae. It is known that some Enterobacteriaceae species can
utilise inflammatory compounds as terminal electron acceptors, further promoting
their growth and giving them an edge under inflammatory conditions.456 Understand-
ing functional pathways such as nitrate reductase activity, the genomes of which are
more commonly found in Enterobacteriaceae, may in future lead to better dietary
treatments including EEN which are adapted to keep Enterobacteriaceae abundance
in check by interfering with the availability of nitrate.
Community structure Although we see changes in bacterial abundance during
EEN there is no overall pattern of change common to all children. Since all children
are taking the same diet during EEN, it would appear the niches created by this
liquid feed which contains no fibre, are being filled by different genera in each child,
perhaps dependent on which bacteria are present at baseline, environmental factors
and host genetics. Given that 1:5 children fail treatment with EEN, and dietary
treatment in itself appears not to determine which bacterial genera will increase or
decrease, makes it difficult to predict who will respond to treatment.
The large study into microbiota changes during EEN by Quince et al.,144 reported a
decrease in relative abundance of thirty-four genera coming from a range of different
phyla, which is in line with the current study which found a decreased abundance
in twenty-one bacterial genera. As yet, we have no understanding of the long term
outcomes for children with Crohn’s disease using diet (EEN) as a medical treatment
to drive major bacterial changes in their gut. It is important that future studies start
to track the long term progress of children who take EEN to better understand if
bacterial changes that happen during EEN, have an a positive or negative impact on
disease progression into adulthood.
5.4.10 Predicting response to EEN
Given that studies have associated active Crohn’s disease with decreased abundance
of Firmicutes and Bacteroidetes and increased Proteobacteria, what can the baseline
gut microbiota structure tell us about which patients will respond well to treatment
and which might need more aggressive therapies? Although studies have tried to link
the microbiota with treatment outcomes there is poor evidence from these studies
that microbiota profiling either before or during EEN could be used to accurately
identify which patients are more likely to fail EEN. Studies have also been unable to
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reliably link the reduction of specific groups or species of bacteria during EEN with
a reduction in inflammation and mucosal healing.
Dunn et al.,227 using ten children with Crohn’s disease on EEN and five healthy chil-
dren, compared the microbiota profile between five patients that maintained remission
for 6-months after EEN, and four patients who did not achieve or maintain remis-
sion. They reported that during EEN, Proteobacteria increased further in those who
did not maintain remission. They also found that the genus Bacteroides (including
B. fragilis and B. ovatus), was one of the most predominant species associated with
sustained remission, however Bacteroides (including B. plebeius) were also associated
with failure to sustain remission.227 The Dunn study is however seriously flawed, as
only 4/10 patients relapsed and two of these children had been on antibiotics prior to
the 12-week sample collection time-point. Treatment with antibiotics therefore will
have contributed to results and it was misleading of the authors to claim that what
they measured was due to treatment with EEN.
One issue with most studies investigating the gut microbiota is that they are insuffi-
ciently powered to link the microbiota with disease severity and treatment over time.
This makes it difficult to identify any relationships between bacteria and specific dis-
ease traits such as disease location or severity and treatment outcomes. The ‘RISK’
study,194 which included 447 Crohn’s disease patients and 221 non-IBD patients tried
to identify multiple factors (genetics, microbiota and immunology) in children that
could help predict response. This study focused on biopsies (terminal ileum and rec-
tum) with a subset of children who gave faecal samples. They did not however collect
dietary data which could have helped assess the relationship between diet and gut
microbiota and Crohn’s disease. Follow-up biopsies were also not available, making it
impossible to asses changes in gut bacteria during treatment. They concluded from
this study that the gut microbiota profile at baseline did not play a role in disease
progression. However another study by Shaw et al.457 did concluded that it might be
possible to predict response to treatment with 76.5% accuracy (AUC=0.75).
For ethical reasons repeat colonoscopy in order to understand serial changes of mu-
cosal bacteria and mucosal healing in children with Crohn’s disease is not possible,
and this lack of knowledge about pre/post treatment, impacts our understanding of
the mechanisms that underlie the success of EEN to induce remission. Therefore
studies are reliant on faecal samples to try and understand changes in gut microbiota
over time. Although faecal samples may not be fully representative of the mucosal
microbiota, they may be able to tell us enough about global gut microbiota changes
to act as a reliable marker of changing gut mucosa health.194
In summary, current understanding has shown that during treatment with EEN,
bacterial diversity is further decreased and the community structure moves further
from that of healthy children. Also the abundance of key Firmicutes species such
as F. prausnitzii are reduced. Therefore previous suggestions that EEN worked by
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improving the functionality of the gut by restoring a more healthy gut microbiota,
paradoxically seems not to be true. It might be that a reduction in availability of
bacterial substrate, either as a whole, or by targeting specific members of the bacterial
community in the gut lumen, which is driving a reduction in inflammation. Studies to
date including this current study have failed to provide a meaningful link between the
gut community structure at baseline and response to treatment on EEN, and given
the huge amount of variability in inter-patient community structure in patients with
Crohn’s disease, a feature of the disease, it may not be possible to predict response
from baseline gut microbiota alone. However as we develop more complex models of
analysis, a combination of data from microbiota structure, host genetic risk, and gut
bacteria metabolites may not only allow us to predict response to EEN, but also to
tailor treatment with prebiotics and probiotics to individual patient needs. Gaining
a better understanding of the mechanisms of how EEN works will lead to improved
outcomes for children with Crohn’s disease and it may become possible to extend the
benefits to include maintenance of remission.
5.4.11 Microbiota changes associated with MEN
Remission induced by EEN is not maintained, with 60-70% of children relapsing
within 1-year,4 and although drug therapy to maintain remission is effective, it is not
risk free and can have side effects. As such, finding a dietary solution is extremely
attractive as a safe alternative to maintain remission over the long term. Current
evidence suggests that maintenance enteral nutrition (MEN) might be as effective as
some medication in maintaining remission,356 which would make it an ideal therapy
option, particularity for growing children. Therefore after completion of EEN, when
the normal habitual diet is slowly re-introduced, enteral nutrition has been trialled
as a supplement to try and maintain remission for longer periods of time154 as well
as improving linear growth,146 with mixed results.
Given that treatment with EEN has been shown to alter the gut microbiota, the
follow-on question was to look at whether the gut microbiota profile would return
to pre-treatment levels once children revert back onto their normal diet post-EEN.
Studies such as that by Gerasimidis et al.145 show that the gut microbiota does
return to pretreatment levels within 2-weeks post EEN. The next logical step was
therefore to explore whether the benefit of EEN could be extended post EEN, and as
such studies have attempted to follow changes in the gut microbiota in patients with
Crohn’s disease, while using MEN, to try and establish if microbial changes during
EEN can be maintained. A study on nine children with active Crohn’s disease, at end
of treatment with EEN, had children return to normal diet with a supplement of 40%
of daily energy intake from a polymeric formula.215 Using 16S-rRNA PCR and TGGE,
changes in bacterial composition seen after treatment on EEN, was maintained for
several months once children went back onto normal diet. However a major drawback
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Table 5.11: Studies showing the effect of maintenance enteral nutrition (MEN) on gut microbiota.
Study subjects samples MEN Method Results
Lionetti
et al.
2005215
9 CD
(9-17yrs)
5 HC
(10-15yrs)
faecal;
during MEN
polymeric
MEN (40%)
TGGE analysis
of 16S rRNA
They only show evidence for 4 patients
and 1 healthy child. They also failed to
provide any data or analysis of bands
and hence their results were very sub-
jective.
Leach
et al.
2008216
6 CD
(2-13yrs)
7 HC
(2-12yrs)
faecal:
baseline
8, 18wks
post-EEN.
HC
2-samples
8-wks apart
formula
not given
PCR of
16S rRNA
followed by
DGGE
CD children had a greater degree
of change in the bacterial composi-
tion during EEN compared to con-
trols on a normal diet (p<0.05).
The greatest change was seen in Ru-
minococcaceae (p<0.001) and the least
in the Bacteroides-Prevotella group
(p<0.01). Study was underpowered.
Kaakoush
et al.
2015223
1 CD MEN
(13yrs)
4 CD non-
MEN
(7-10yrs)
4, 8, 12wks
post-EEN
polymeric
MEN
(Osmolite)
amount
unknown
454 sequencing All children were on different mainte-
nance therapy. Thus unable to make
proper comparisons.
CD - Crohn’s disease; HC - healthy controls; NGS - next-generation sequencing; T-RFLP - Terminal restriction fragment
length polymorphism; TGGE - temperature gradient gel electrophoresis; DGGE - denaturating gel electrophoresis
Modulen - Polymeric enriched with TGF-β2
was that this study did not include a non-MEN control group and thus it is impossible
to tell if MEN had any effect that would not have also been seen in children who were
returning to normal diet without MEN supplementation.
A small 16S-rRNA study using DGGE with six Crohn’s disease children who had
completed EEN, followed children for a subsequent 4-months of MEN.216 It was
interesting however that in the five children who continued on MEN, although there
was a partial return to the bacterial profile found at the start of treatment (40%
similarity), the gut bacteria composition was still to some degree altered at 4-months
post-treatment with EEN. The study suggested that C. leptum stability after EEN,
was associated with a reduction in gut inflammation and disease activity.216 Although
five children went onto MEN, two began medication on aminosalicylates while two
started azathioprine, hence we cannot be sure whether medication use contributed
to these results. This study was also limited in that it only looked at five species of
bacteria using PCR: Eubacteria; Bifidobacteria; Bacteroides-Prevotella; C. coccoides
and C. leptum.
The Kaakoush et al. study223 included one child taking MEN, and reported that this
child had a large drop in the abundance of Erysipelotrichaceae, Ruminococcaceae,
and Lachnospiraceae which correlated with both treatment on EEN and improvement
in disease activity. This was accompanied by a large increase in the abundance of
Veillonellaceae once back onto normal diet plus MEN, which corresponded with a mild
exacerbation of symptoms at 12-weeks therapy. However given that the five children
on this study were given a different type of maintenance therapy it is impossible to
draw any meaningful conclusion from their results (Table 5.11).
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The current study also saw an increase in Negativicutes from the family Veillonel-
laceae such as Veillonella; Dialister ; Anaeroglobus and Selenomonas particularly in
children who took MEN once back onto normal diet (Fig 5.25). Given that children
with Crohn’s disease tend to have higher abundance of Negativicutes at baseline com-
pared with healthy children, it is possible they play a role in inflammation. A study
looking at mucosal biopsies from patients with Ankylosing Spondylitis458 found that
degree of inflammation was positively correlated with abundance of the genus Dialis-
ter (Spearman’s rho=0.62; q<0.01) in each individual, and was further supported by
a significantly lower abundance of Dialister in non-inflamed ileal and colonic biopsies
from both patients and healthy controls. Therefore the pro-inflammatory potential
of bacteria from the Negativicutes needs to be investigated as possible drivers of
inflammation post-EEN.
The Firmicutes, Ruminococcus, genera from Lachnospiraceae and Roseburia, were
also among the bacteria which increased in abundance, suggesting that levels of this
genera which were reduced during EEN were being restored once children were back
onto normal diet. This is not surprising as these bacteria are associated with the
fermentation of plant based complex carbohydrates found in the normal diet, which
are lacking in enteral nutrition.
Many of the bacteria that significantly reduced in abundance once children went back
onto normal diet were gram-negative bacteria: Enterobacteriaceae such as Citrobac-
ter, Cronobacter, Enterobacter and Pantoea; as well as other Proteobacteria such
as Sutterella, Campylobacter and Eikenella. The Actinobacteria Varibaculum which
stains gram-negative, was also decreased on normal diet in children who took an im-
munosuppressant (Fig 5.25). Many of the Enterobacteriaceae species are associated
with the fermentation of sugars in the small intestine. It is not surprising therefore
that the EEN feed containing glucose syrup, casein and sucrose leads to an increase in
Enterobacteriaceae species during EEN, which then reduce once the diet is stopped.
Many studies have suggested that adhesive invasive E. coli (AIEC) may be directly
involved in the aetiology of Crohn’s disease,459 however if this were true it is difficult
to explain why an increase in Enterobacteriaceae during EEN leads to a reduction in
inflammation rather than increasing symptoms.
A study by Lewis et al.73 evaluating changes in gut microbiota from faecal samples
taken at 1-week, 4-weeks and 8-weeks EEN, also gave a group of children partial
enteral nutrition which made up 53% of the child’s daily intake. When they compared
the gut bacteria profile in children treated with EEN, with those children treated
with partial enteral nutrition the same pattern of change was not seen (p=0.83),
hence they concluded that either changes to bacterial profile seen during EEN are
dose dependant, or that only total removal of normal diet altered the microbiota
composition during treatment. Setting up research studies to answer these questions
would not be easy to achieve as large groups of patients would need to take various
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different doses of enteral nutrition to try and establish if EEN and MEN are dose
dependant. However if 50% partial enteral nutrition fails to have an impact on gut
microbiota composition, as Lewis et al. suggest,73 it might imply that MEN, which
is usually around 20% of daily calorific intake, is unlikely to alter the gut microbiota
enough to effectively sustain remission. However trails comparing the use of polymeric
formula (Modulen; 50g twice/day) with the aminosalicylate anti-inflammatory drug
5-ASA to maintain remission, suggest that MEN may be as good as 5-ASA. 42%
(18/43) of patients using MEN relapsed at 6-months compared with 55% (22/40) of
patient who took mesalamine as maintenance therapy (RR 0.76; 95% CI0.49-1.19).460
A study by Hani et al. also looked at an elemental feed used as MEN compared with
6-MP and found 38% (12/32) of MEN patients relapsed by 12-months compared with
23% (7/30) of patients who took 6-MP as maintenance therapy (RR 1.61; 95% CI0.73-
3.53).152 A recent Cochrane review356 has concluded that studies to date have not
been able to show any firm evidence about the efficacy and safety of enteral nutrition
in quiescent Crohn’s disease. Therefore more work needs to be done to establish the
efficacy of different maintenance therapies so that children with Crohn’s disease have
the best chance to maintain disease remission in the longer term.
Bacterial changes in individuals returning to normal diet In a sub-group of
eight children on this current study who went on to an immunosuppressant; MEN;
or both, we can see that once children go back onto their normal diet (Fig. 5.26)
the gut bacteria are distinct, not only from treatment with EEN, but also from their
baseline gut bacterial profile. Given that Bacteroides is considered a major part of
the normal healthy gut microbiota, it raises questions about the long term benefits
of using EEN therapy if important bacterial species are lost from the gut microbial
system as seen in patient S016 (Fig. 5.26). This was matched with an increase in
Escherichia/Shigella during EEN, and still present at 2-weeks and 8-weeks of normal
diet. Escherichia/Shigella was not detected at baseline in this patient, suggesting
that the shift in Escherichia/Shigella could be due to dietary treatment. However
in contrast to this, another patient (S018) who had Escherichia/Shigella at baseline,
had reduced abundance during EEN, with this genus not being detected once they
returned to normal diet.
In another child (S023) we see a notable change in gut microbiota profile both dur-
ing EEN and then again during the maintenance phase, with increased Cronobacter
(Enterobacteriaceae) and Fusobacteriaceae during EEN, which was reduced during
normal diet. Abundance of Akkermansia became high once the child went onto nor-
mal diet but had not been detected at baseline or during EEN. It is not clear if
these changes are part of normal variation within gut community structure, or if diet
therapy is driving changes in the bacteria profile which could have either beneficial
or deleterious consequences for the health of the gut. Careful questions need to be
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raised, as it appears that treatment with EEN, and possibly both dietary and phar-
maceutical maintenance therapies may have medium to long term changes in the
gut microbiota, which we cannot determine at this stage as beneficial to individual
patients. There is an assumption that because EEN is not a drug, that its use to
induce remission in children with Crohn’s disease is safe, but this has yet to be fully
established from long-term patient outcomes.
Based on previous years, the current study calculated that around 55% of children
once they had completed 8-weeks EEN, would refuse MEN as maintenance therapy.
However out of the twenty-three children who went into remission on EEN only six
(26%) children opted not to take MEN and two of these children failed to provide
faecal samples during maintenance therapy leaving the study with a control group
of only four patients. It is possible that by introducing the nature of the study
to patients, subsequent knowledge about gut microbiota influenced their decision to
take MEN as a supplement post-EEN. Human observational studies are limited as
they cannot determine treatment and hence can lack good quality controls. Using an
animal model would allow the use of clear non-treatment controls to see the effect
of both enteral nutrition and immunosuppressants on the resident gut bacteria. The
use of such controls in humans would be unethical, making it almost impossible to
design MEN studies which eliminate confounding factors such as habitual diet and
immunosuppressant drug therapy.
Another issue with the current study was that Crohn’s children with mild disease
at diagnosis were more likely to be given MEN only as maintenance therapy, where
as children with severe disease at diagnosis were more likely to be given combined
MEN and immunosuppressant therapy (Table 5.12). Therefore it could be argued
that observed differences between groups in both outcome and microbiota changes
could be due to disease severity rather than treatment group.
Table 5.12: Number of patients on each maintenance therapy showing
disease severity at diagnosis
disease activity
treatment group mild moderate severe
MEN only 5 3 1
IM only 4 1 1
MEN and IM 1 2 5
Disease severity was measured at baseline using the weighted paediatric
Crohn’s disease activity index (wPCDAI) (Methods section 2.4.3).
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5.4.12 Summary of key findings
The current study:
 Supports previous studies which show reduced microbiota diversity in children
with Crohn’s disease and UC, compared with healthy children.
 Supports previous findings that commensals are decreased in abundance while
gram-negative potential pathobionts are increased in children with Crohn’s dis-
ease.
 Supports a recent finding that, despite reducing inflammation, EEN pushes
dysbiosis further from that of healthy children.
New findings from this study:
 Although at baseline twenty-five species (SNVs) were distinct between respon-
ders and non-responders to EEN, no pattern in species type was seen; suggesting
it is not possible to predict response to EEN from the microbiota profile.
 Show that MEN does not sustain microbiota profiles achieved during EEN.
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6 Changes in short chain fatty acids in children with Crohn’s
disease during treatment with enteral nutrition
6.1 Introduction
Data produced by the Human Microbiome Consortium has shown that despite a huge
deal of variation and diversity in gut microbiota profiles between different individuals,
the metabolic profile which includes short chain fatty acids (SCFA) is much more
constant among groups of individuals.234 This is because biochemical pathways are
consistent across different bacterial species, even up to the level of phyla.235 SCFA
as a product of bacterial metabolism, are also an additional source of energy to host
cells. Thus dietary components which the host is unable to digest directly in the
small intestine are converted by bacteria in the colon to SCFA where around 90% of
these are absorbed by the host.236
SCFA are carboxylic acids with between one and six carbon atoms with attached
functional groups such as hydroxyl or dicarboxyl. In the human gut, they arise
from bacterial fermentation of carbohydrate, peptides, protein or glycoprotein pre-
cursors,232 and are important sources of fuel since they produce large quantities of
ATP when metabolised. The groups of bacteria which typically ferment fibres in
the colon to produce SCFA, have been shown to be reduced in abundance in both
the mucosa and faeces of patients with IBD in comparison to healthy controls. This
feature of IBD is important because the SCFA, particularly acetate, propionate and
butyrate, have been shown to be involved in maintaining intestinal homoeostasis.
It is important to note that individuals with IBD as well as having reduced abun-
dance of dominant butyrate producing bacteria like Faecalibacterium prausnitzii and
Roseburia intestinalis, have been shown to have reduced levels of SCFA, especially
butyrate, detected in faeces compared to healthy individuals.225;461;462;463
6.1.1 SCFA and gut barrier integrity
Bacteria-derived butyrate has been shown to improve gut epithelial barrier function
via epithelial oxygen consumption leading to stabilisation of hypoxia-inducible factor-
1 (HIF-1), a transcription factor which regulates gut barrier integrity.464 In both
antibiotic treated and germ-free mice, HIF-1α expression and butyrate levels were
reduced, but could be restored with butyrate supplementation.464
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Butyrate is know to improve gut barrier function via activation of transcription factors
such as STAT3 and SP1 which control tight-junctions. It has been shown butyrate
can increase trans-epithelial electrical resistance in human cell models253;254;255;256
and murine small intestine cells.240 Butyrate has also been shown to improve trans-
epithelial electrical resistance in piglet small intestine cells when exposed to inflamma-
tory conditions,477 showing it can mitigate the ability of bacterial lipopolysaccharide
(LPS) to damage epithelial integrity. This effect has also been shown in vitro using
a supplement of butyrate producing bacteria added to the microbiota of a Crohn’s
disease patient, to enhance gut epithelial barrier integrity.478 These studies support
the idea that butyrate has the potential to restore intestinal barrier function in IBD,
where gut epithelial healing is a key therapeutic target.
6.1.2 The role of SCFA in intestinal immunoregulation
Butyrate has been associated with beneficial anti-inflammatory effects on epithelial
cells,479 with a 2007 study linking the down-regulation of the butyrate transporter
with inflammation in the colonic mucosa of IBD patients.480 In addition, butyrate-
producing bacteria were shown to be decreased in colonic gut mucosa and in faecal
samples, of patients with IBD compared to control patients.189 This might suggest
that butyrate insufficiency, could play a role in the pathogenesis of IBD. Butyrate
enemas, either given alone, or with a mix of other SCFA, have decreased colonic in-
flammation in patients with IBD.262;481 However, the underlying mechanisms behind
this improvement are not understood. In addition studies have linked butyrate to gut
microbiota-mediated induction of functional Treg cells in the gut mucosa, providing a
potential mechanism of how metabolites produced by colonic bacterial fermentation
in the gut could bring about gut immune homoeostasis via host-microbiota crosstalk.
Bacterial cross-feeding is the foundation of most butyrate production in the colon,
thus variation in dietary substrate availability to gut bacteria may be driving changes
to microbiota and consequent metabolic composition, which could in turn play a role
in gut inflammation.
It is known that SCFA exert anti-inflammatory effects in the gut mucosa via histone
deacetylases inhibition.267;268 The discovery that SCFA act as natural ligands for
receptors across a wide range of cell types has led to the current interest in SCFA
as signalling molecules between the gut microbiota and host immunoregulation, but
these have yet to be demonstrated in vivo.
6.1.3 SCFA levels in IBD and Crohn’s disease
A 2008 Japanese study471 reported that the concentration of butyrate and propionate
were significantly decreased in twelve adult patients with Crohn’s disease compared
to ten healthy controls (Table 6.1). In 2010 a small Malaysian study of only eight
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patients with IBD (2 Crohn’s; 6 UC) also reported significantly less butyrate and
propionate than seen in fifty healthy controls (p<0.05).469 Another study by Vernia
et al. found that in forty-eight adults with IBD, concentrations of all SCFA, espe-
cially butyrate, were decreased but only in UC when compared with healthy controls
and those with Crohn’s disease. It should be noted that 8/20 Crohn’s patients were
on corticosteroids and the cohort were not treatment naive, which may account for
differences between Crohn’s disease and UC in this study.473 It has also been reported
that in those Crohn’s disease patients who have ileal disease, butyrate producing Ru-
minococcaceae, particularly the genus Faecalibacterium were reduced compared to
patients without ileal involvement.482 Decreases in propionate and butyrate are sup-
ported by metagenomic and metaproteomic studies which have confirmed a decrease
in butyrate and propionate metabolism genes in ileal Crohn’s disease195 along with
a measured reduction in butyrate and other SCFA.483
6.1.4 Changes in SCFA during exclusive enteral nutrition (EEN)
Two studies have recorded faecal SCFA in children with Crohn’s disease undergo-
ing treatment with EEN. Tjellstrom et al. 2012129 used the pattern of SCFA to
explore the functional status of the gut microbiota by collecting samples from eigh-
teen children with Crohn’s disease, before and after 6-weeks EEN. The pattern of
SCFA was used to create two indices: index A represented the fermentation of car-
bohydrates (acetate minus butyrate plus propionate as a proportion of total SCFA);
and index B represented fermentation of proteins (iso-butyrate plus iso-valerate).
Therefore they suggest index A reflects the pro-inflammatory properties and index
B anti-inflammatory properties of bacterial fermentation via SCFA.484 Tjellstrom
et al. reported a significant decrease in pro-inflammatory index A after treatment
with EEN, as well as a rise in anti-inflammatory index B, suggesting this might ex-
plain the anti-inflammatory effect of EEN.129 However, the use of these indices is an
oversimplification of fermentation in the gut, and may not be an accurate model of
pro-/anti-inflammatory conditions in the colon. A potential factor is that children
with serve disease who are feeling unwell may have an altered dietary intake at base-
line, thus differences in SCFA between Crohn’s disease children and healthy controls,
as well as before and after treatment with EEN, may be a product of dietary differ-
ences not directly linked with inflammation. It should also be noted that although
Tjellstrom et al. reported median data for a total of eighteen children, only eight
gave paired samples at the start and end of EEN. Given the high interquartile ranges
of their SCFA results, their findings are flawed.
In 2014 Gerasimidis et al.485 showed, in twelve children with Crohn’s disease that the
concentration and ratio of butyrate decreased after 4-weeks and 8-weeks of EEN; with
median concentration of butyrate falling to 50% pre-treatment levels (p<0.01). No
significant decrease was seen in either acetate or propionate during EEN. The decrease
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in butyrate returned to pre-treatment levels once children went back on their normal
habitual diet as measured at 8-weeks post EEN. This group also reported that an
increase in the inflammatory marker, faecal calprotectin, was positively linked with
the concentration of propionate and total SCFA (Spearman rho=0.58; p=0.039), once
children went back onto their normal habitual diet. Faecal pH as a marker of reduced
bacterial fermentation capacity increased from a median 7.1 to 7.8 (p<0.001) after
treatment with EEN.486
Whelan et al. has also shown that EEN negatively reduced concentrations of total
SCFA and butyrate; as well as concentration of F. prausnitzii in non-IBD patient
controls.487 A follow up study in 2016 on seventeen adult patients with Crohn’s
disease saw a significant reduction in the production of toxic microbial metabolites,
as well as SCFA, after 2-weeks of EEN.488 This leads on to the hypothesis that it
is the reduction of any potentially toxic metabolites after EEN, rather than SCFA
which makes the diet effective at reducing inflammation in Crohn’s disease patients.
6.1.5 Changes in SCFA post-EEN
The only study to look at changes in short chain fatty acids post-EEN is interesting
because, both the concentration and the proportion of faecal butyrate at 15-days post-
EEN was higher in seven children with Crohn’s disease who failed to achieve clinical
remission. This group of children also did not achieve the same reductions in short
chain fatty acids during EEN as those children who did achieve disease remission.489
The total SCFA for all children on EEN was significantly increased post-EEN (15-
days normal diet) back towards pre-treatment levels.489 As yet no studies have looked
at the effect of maintenance enteral nutrition (MEN) on the production of SCFA in
the gut.
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6.1.6 Hypotheses
Given that differences are seen in gut bacteria both at baseline and during treat-
ment with EEN in children with Crohn’s disease, the current chapter will go on to
hypothesise that:
 The pattern of SCFA as a product of fermentation in the gut will be distinct
in children with Crohn’s disease and UC compared with healthy children and
non-IBD controls.
 Along with reduced numbers of Firmicutes species, butyrate will be reduced in
children with IBD.
 Due to lack of fibre, and a reduction in bacterial commensal species, total SCFA
production in children with Crohn’s disease during treatment with exclusive
enteral nutrition (EEN) will be reduced.
 The loss of bacterial commensal species, which contain many butyrate producers
will result in a disproportionate loss of butyrate during EEN.
 Treatment with maintenance enteral nutrition (MEN) will maintain SCFA pro-
files achieved on EEN.
The chapter will go on to discuss the role that SCFA may play in driving or reducing
inflammation in the gut, and how this might help researchers to design more robust
experiments, which could in turn lead to better long term treatments for children
with Crohn’s disease.
6.2 Methods
There is no practical method to measure the precise amount of SCFA produced by
gut bacteria in the colon of humans. SCFA measured from faecal samples are the
result of both bacterial production and host absorption in the colon, and therefore
do not accurately measure true amounts produced. They can however act as a proxy
for SCFA production in the gut.
Figure 6.1: Methods used to process faecal samples for SCFA analysis. Results were expresses as
µmol/g of wet faecal sample or as a ratio of total fatty acid concentrations.
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A summary of methods is shown in figure 6.1, with detailed methods being described
in Methods section 2.7. In brief faecal samples were collected as described in Methods
section 2.4.4 with SCFA being stabilised for storage using sodium hydroxide (NaOH)
and immediately stored at -80 C. Samples were then freeze dried (Edwards apparatus
Micro Modulyo, Thermo Scientific ) for 36-hours. Water content was determined by
weighing samples before and after freeze drying.
To extract SCFA, 100mg of freeze dried faecal sample was weighed out into corning
tubes with 300!L of distilled water. 100!L of orthophosphoric acid and 100!L of
2-ethyl butyric acid (internal standard) was added. Di-ethyl ether was added to the
tube and shaken for one minute. The upper ether phase was removed to a separate
tube and the process repeated three times. Extracted supernatant was transferred
to glass vials and sealed with silicone seal crimp tops, before being analysed using
gas-chromatography. All samples were extracted and analysed in duplicate; where
duplicates did not agree the extraction and analysis was repeated. Results for Hep-
tanoate (C7) were not included in the analysis because concentrations were too low
to be reliably detected using this method. The concentration of SCFA was expressed
as µmol/g of wet faecal sample, calculated from the percentage of water in individual
samples, and as a percentage of Total SCFA (C2-C8).
6.3 Results
6.3.1 SCFA differences between patient groups and healthy children
At baseline children with Crohn’s disease and UC had a lower median concentration of
total SCFA than both non-IBD patients and healthy children (Table 6.2). However as
all groups of children had a very large IQR, differences were not close to significance.
No differences were seen between groups for the SCFA acetate (C2), propionate (C3)
and butyrate (C4). The reduced concentration and ratio of valerate (C5), seen in
children with Crohn’s disease and UC at baseline was significant when compared
with healthy children. The concentration and ratio of the medium chain fatty acids
(MCFA), hexanoate (C6) and octanoate (C8), were also significantly lower in children
with Crohn’s disease compared with healthy children. Children with UC also had less
hexanoate and octanoate than healthy children but this did not reach significance for
hexanoate. No difference was seen between any of the patient groups and healthy
children for the branch-chain fatty acids, iso-butyrate (iC4) and iso-valerate (iC5)
(Table 6.2).
The SCFA/MCFA profile of healthy children and those with Crohn’s disease was
visualised using a metric multidimensional scaling (MDS) plot (Fig. 6.2). It shows
that the SCFA/MCFA profile of children with Crohn’s disease, was dissimilar to that
seen in healthy children (R2=0.07; p=0.011).
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Table 6.2: Median (IQR) short chain fatty acids (SCFA) from the faecal samples of patient groups and
healthy children
carbons Crohn’s UC non-IBD Healthy KW
Fatty acid n=29 n=7 n=8 n=19
Amount (µmol/g)
Acetate C2 58.4 (43.7) 54.6 (52.3) 92.9 (52.2) 69.0 (35.8) p=0.33
Propionate C3 14.1 (13.6) 13.4 (12.8) 17.4 (14.0) 14.8 ( 8.9) p=0.82
Butyrate C4 8.6 (11.2) 7.3 ( 6.2) 14.3 (12.8) 8.6 ( 8.8) p=0.77
Valerate C5 *0.9 (2.1) *0.2 (1.0) 1.9 (1.4) 2.0 (1.7) p=0.02
Iso-butyrate C4 2.3 ( 2.1) 2.2 ( 1.5) 2.0 ( 1.7) 3.0 ( 1.9) p=0.37
Iso-valerate C5 2.9 (2.6) 2.7 (0.9) 2.8 (2.4) 3.8 (3.0) p=0.31
MCFA
Hexanoate C6 ***0.1 (0.1) †0.1 (0.3) 0.2 (0.3) 0.6 (0.9) p<0.001
Octanoate C8 ***0.2 (0.3) ***0.0 (0.2) 0.4 (0.3) 0.5 (0.4) p<0.001
Total 88.2 (72.9) 82.1 (78.3) 140.6 (87.6) 109.7 (63.3) p=0.41
Ratio
% Acetate C2 67.2 (12.6) 68.3 (4.6) 69.5 (7.3) 68.23 (6.9) p=0.89
% Propionate C3 15.3 (10.4) 14.4 (8.0) 14.15 (6.6) 13.7 (5.2) p=0.65
% Butyrate C4 9.7 (4.5) 9.8 (2.4) 9.8 (1.6) 8.6 (3.1) p=0.75
% Valerate C5 *1.1 (1.6) *0.6 (1.1) 1.8 (0.7) 1.8 (1.0) p=0.02
% Iso-butyrate iC4 2.2 (2.4) 2.4 (1.6) 2.0 (0.8) 2.3 (1.4) p=0.65
% Iso-valerate iC5 2.8 (2.7) 3.1 (2.6) 2.6 (1.2) 3.6 (2.4) p=0.52
% Hexanoate C6 ***0.1 (0.1) † 0.1 (0.1) 0.1 (0.3) 0.6 (0.6) p<0.001
% Octanoate C8 ***0.2 (0.2) **0.1 (0.2) 0.4 (0.5) 0.5 (0.6) p<0.001
Amount is expressed per g of wet faecal sample. KW- Kruskal-Wallis test (Dunn’s test of multiple compar-
isons was used following a significant Kruskal-Wallis test). Difference from healthy children is significant at
* p≤0.05; ** p≤0.01; *** p≤0.001; † p=0.07
6.3.2 Linking SCFA at baseline with gut bacteria
A Kendall rank correlation (Methods 2.10.3) showed a non-significant relationship
between the number of bacteria and the ratio of faecal SCFA, mostly from the Fir-
micutes phylum (Fig. 6.3). Only five genera were from the Proteobacteria and only
two of these (Aggregatibacter and Thalassospira) reaching statistical significance in
children with Crohn’s disease.
The correlation of acetate, propionate, and butyrate with a number of Firmicutes
genera, was different between healthy children and children with Crohn’s disease, but
was not significant. For some genera the association of valerate (C5) and octanoate
(C8) was different between healthy children and children with Crohn’s disease (NS)
but these differences were across a number of different groups of bacteria and did
not show any obvious pattern. There was however a significant difference between
healthy children and children with Crohn’s disease for hexanoate (C6) suggesting
that children with Crohn’s disease have a significant positive correlation across a
number of genera, mostly Firmicutes, which was not seen in healthy children (Fig.
6.3). However this positive correlation is associated with a significant reduction in
the ratio of Hexanoate (Table 6.2) as well as a reduced abundance of these genera in
children with Crohn’s disease when compared with healthy children.
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Figure 6.2: Difference in faecal SCFA profiles between children with Crohn’s disease (black) and
healthy children (red) as shown by metric multidimensional scaling (MDS) spider plot. PER-
MANOVA: R2=0.07; p=0.011. MDS polygon plot is shown in appendix 6
Clear non-significant differences could be seen in the ratio of iso-butyrate (iC4) and
iso-valerate (iC5) between healthy children and children with Crohn’s disease (Fig.
6.3). A lot of these differences were in gram negative Proteobacteria such as Ag-
gregatibacter, Thalassospira and Escherichia; the gram negative Fusobacterium; the
gram-negative Bacteroidetes genera Prevotella-7 and Paraprevotella; as well as Aci-
daminococcus from the class Negativicutes. These bacteria which showed a negative
non-significant correlation with the ratio of iC4 and iC5 in healthy children, show a
non-significant positive correlation in the group of children with Crohn’s disease.
217
Figure 6.3: Correlation between the ratio of faecal SFCA and gut microbiota genera in children with
Crohn’s disease (CD) and healthy children (HC) at baseline. Kendall rank correlation significant at
* p≤0.05; ** p≤0.01 (Multiple comparison - Benjamini-Hochberg method). The positive correlation
for Hexanoate is associated with a significant reduction in Hexanoate in children with Crohn’s disease
when compared to healthy children.
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Figure 6.4: Changes in SCFA profiles in children with Crohn’s disease after 8-weeks treatment with
EEN (week 08; green) compared with baseline (week 00; red), shown by metric multidimensional
scaling (MDS) plot. PERMANOVA: R2=0.108; p=0.002 Healthy children (black) are shown for
comparison. MDS polygon plot is shown in appendix 6
6.3.3 Changes in SCFA during treatment with EEN
To look at how SCFA levels changed during treatment with exclusive enteral nu-
trition (EEN), the difference between baseline concentration in paired samples, was
compared with SCFA concentration after 4-weeks EEN. (Table 6.3). Once children
with Crohn’s disease had been on treatment with EEN for 4-weeks, all fatty acids
combined (total) fell significantly (p=0.012). [Changes which include all children
with Crohn’s disease, i.e. unpaired samples, are shown in figure 6.5a p=0.007]. The
median concentration of acetate (C2), propionate (C3) and butyrate (C4) for paired
samples, were significantly reduced in children with Crohn’s disease after 4-weeks of
treatment (Table 6.3). The medium chain fatty acids hexanoate (C6) and octanoate
(C8) were also reduced after 4-weeks on EEN, but octanoate did not reach signif-
icance (Table 6.3). However the ratio of individual fatty acids to total fatty acid,
showed there was no difference in the ratio of acetate and propionate. The ratio
of butyrate (C4) however saw a marked reduction during EEN, also shown in figure
6.5b p<0.001. The ratio of valerate (C5) increased during EEN but did not reach sig-
nificance (p=0.074)(Table 6.3). The ratios of SCFA suggest, that SCFA production
with the exception of butyrate (C4) are falling as a product of an overall reduction
in colonic fermentation. The ratio of branched chain fatty acids iso-butyrate (iC4)
and iso-valerate (iC5) increased slightly on EEN, but the difference did not reach
significance (p=0.086 & p=0.070 respectively). The SCFA/MCFA profile was visu-
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Table 6.3: Difference in median (IQR) fatty acids measured from faecal samples of children with
Crohn’s disease at baseline (week-0) and after 4-weeks of treatment with EEN.
Fatty acid carbons week-0 week-4 Wilcoxon
Amount (µmol/g)
Acetate C2 73.5 (53.1) 50.4 (37.5) p=0.006
Propionate C3 15.1 (15.8) 10.2 ( 4.7) p=0.015
Butyrate C4 11.7 (12.0) 5.1 ( 3.7) p=0.001
Valerate C5 1.2 ( 2.3) 1.2 ( 1.6) p=0.538
BCFA (µmol/g)
Iso-butyrate C4 2.5 ( 2.2) 1.8 ( 1.7) p=0.920
Iso-valerate C5 3.3 ( 3.1) 2.7 ( 2.2) p=0.732
MCFA amount (µmol/g)
Hexanoate C6 0.1 (0.12) 0.0 (0.10) p=0.025
Octanoate C8 0.2 (0.40) 0.2 (0.10) p=0.092
Total fatty acids C2-C8 123.6 (77.9) 68.3 (43.4) p=0.012
Ratio
% Acetate C2 67.5 ( 9.0) 68.8 ( 8.1) p=0.313
% Propionate C3 14.8 ( 6.4) 14.0 ( 3.4) p=0.701
% Butyrate C4 10.1 ( 5.5) 6.4 ( 2.4) p=0.010
% Valerate C5 1.5 ( 1.6) 1.9 ( 1.5) p=0.074
% Iso-butyrate iC4 2.2 ( 1.8) 3.2 ( 1.7) p=0.086
% Iso-valerate iC5 2.9 ( 2.2) 4.2 ( 1.8) p=0.070
% Hexanoate C6 0.10 (0.12) 0.05 (0.10) p=0.189
% Octanoate C8 0.20 (0.30) 0.25 (0.12) p=0.977
Amount is expressed per g of wet faecal sample. All samples are paired n=20. Significant results are
shown in bold.
alised using a metric multidimensional scaling (MDS) plot (Fig. 6.4) and shows that
the SCFA/MCFA profile, after 8-weeks EEN, moved towards that seen in healthy
children (R2=0.108; p=0.002).
6.3.4 Return to normal diet
As children with Crohn’s disease returned to normal habitual diet at 8-weeks post-
EEN (study week-16), all fatty acids combined (total) had a median increase which
did not reach significance (p=0.074 for paired samples) (Table 6.4). The median con-
centration of propionate (C3) and butyrate (C4) significantly increased after 8-weeks
normal diet (p<0.001), however only the increase in the ratio of butyrate reached
significance (p<0.001). The ratio of acetate fell from 71.6% to 66.7% after 8-weeks
normal diet but did not reach significance (p=0.070) while the ratio of propionate
increased from 12.8% to 16% (p=0.140). The concentration and ratio of octanoate
(C8) had a significant increase after 8-weeks normal diet (p=0.006 and p=0.035)
(Table 6.4).
Treatment with MEN Children with Crohn’s disease who were taking maintenance
enteral nutrition (MEN) along with normal diet post-EEN (n=11), had a lower me-
dian ratio of acetate (C2) and a higher ratio of propionate (C3) than children who
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Table 6.4: Difference in median (IQR) fatty acids measured from faecal samples of children with
Crohn’s disease at end of EEN (week-8) and again after 8-weeks of normal diet (week-16).
Fatty acid Carbons week-8 week-16 Wilcoxon
Amount (µmol/g)
Acetate C2 51.8 (26.5) 55.8 (48.1) p=0.252
Propionate C3 9.8 ( 8.2) 12.9 ( 7.6) p<0.001
Butyrate C4 3.4 ( 3.3) 9.2 ( 9.9) p<0.001
Valerate C5 1.2 ( 1.1) 1.3 ( 1.2) p=0.821
BCFA amount (µg/g)
Iso-butyrate C4 2.3 (1.7) 2.2 (1.5) p=0.900
Iso-valerate C5 2.9 (2.0) 3.0 (1.9) p=0.528
MCFA amount (µg/g)
Hexanoate C6 0.04 (0.11) 0.03 (0.06) p=0.505
Octanoate C8 0.12 (0.14) 0.38 (0.39) p=0.006
Total fatty acids C2-C8 76.1 (40.2) 85.3 (61.4) p=0.074
Ratio
Acetate % C2 71.6 (9.1) 66.7 (14.4) p=0.070
Propionate % C3 12.8 (3.9) 16.0 (6.6) p=0.140
Butyrate % C4 5.05 (1.2) 10.2 (3.8) p<0.001
Valerate % C5 1.9 (0.8) 1.5 (1.2) p=0.258
Iso-butyrate % iC4 3.2 (0.8) 2.6 (1.5) p=0.339
Iso-valerate % iC5 4.2 (0.7) 3.6 (0.7) p=0.393
Hexanoate % C6 0.10 (0.12) 0.05 (0.10) p=0.212
Octanoate % C8 0.25 (0.12) 0.50 (0.30) p=0.035
Amount is expressed per g of wet faecal sample. All samples are paired n=16. Significance differences
are shown in bold.
went onto normal diet without MEN (non-MEN; n=4) (Fig. 6.6). The median ratio
of butyrate (C4) was also higher in the MEN groups but this difference disappeared
by 8-weeks normal diet. The median ratio of valerate (C5) was higher in the MEN
group at 8-weeks normal diet but no differences were seen for the medium chain fatty
acids (C6-8) or the branch chain fatty acids (iC4-iC5). Due to this being an obser-
vational study, the lack of non-MEN participants, resulted in the sample size being
too low to carry out reliable statistical analysis.
6.3.5 Changes in SCFA and markers of inflammation
To test the effect that EEN had on all children with Crohn’s disease samples are shown
at baseline (study week-00), 4-weeks and 8-weeks of EEN, and then after 2-weeks and
8-weeks of normal diet (study week-10 and week-16). Figure 6.5a shows that overall
faecal SCFA was significantly reduced during EEN but started to return towards
pre-treatment levels once back onto normal diet. This effect was most pronounced
for the ratio of butyrate (Fig. 6.5b). Faecal pH, as a marker of fermentation in the
gut, showed the same pattern with a highly significant increase in pH at 4-weeks and
8-weeks on EEN (Fig. 6.5c). The pH again decreased once back onto normal diet at
study week-10 and week-16, showing increased colonic fermentation. Calprotectin as
a marker of inflammation (Fig. 6.5d), decreased during EEN (week-4 and week-8) in
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most children and increased gradually as children returned to normal diet (week-10
and week-16).
p adj=0.007**
(a)
p adj<0.0001****
(b)
p adj<0.0001****
(c)
p adj=0.0004***
(d)
Figure 6.5: Differences in SCFA during EEN (week-4 & week-8) and on return to normal diet (week-
10 & week-16) for (a) the concentration of all (total) fatty acids and (b) for the ratio of butyrate.
As a marker of fermentation (c) feacal pH and (d) calprotectin as a marker of inflammation were
measured at all time-points. Some patients were unable to provide a faecal sample for every time-
point. ANOVA used to test for significance.
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6.4 Discussion
6.4.1 Summary of results
The current study results show at baseline, both the amount and ratio of valerate
(C5), hexanoate (C6) and octanoate (C8) were all significantly reduced in children
with Crohn’s disease compared to healthy children. Hexanoate was shown to posi-
tively correlate with a number of bacterial genera (mostly Firmicutes), but only in
children with Crohn’s disease.
During EEN SCFA/MCFA profiles moved towards that of healthy children, although
production of SCFA fell, particularly Butyrate (C4). Within 2-weeks post-EEN
SCFA had returned to pre-treatment levels. Although some possible differences in
SCFA/MCFA were seen between children who took MEN or declined MEN (non-
MEN) post-EEN, the non-MEN group of only four children in this observational
study was too low to show significance.
6.4.2 Differences in short chain fatty acids (SCFA) in IBD
Despite low samples sizes in some studies, and high levels of inter-group variation,
there appears to be a clear consensus that SCFA levels are reduced in Crohn’s dis-
ease and UC compared with healthy controls.474;465;466;469;471;475 However the current
study along with two other studies, did not find significantly lower levels of acetate,
propionate and butyrate.465;470 SCFA are very volatile, especially acetate and propi-
onate, thus some methods/studies may be better at extracting all SCFA, while some
detection methods are more sensitive; therefore increasing the chances of differences
becoming significant.465 Three studies have recorded an increase in butyrate in pa-
tients with Crohn’s disease475;468;467 with one of these, Walton et al. also recording an
increase in propionate.467 However, the latter study467 appears to have had problems
with either extraction or detection as many samples show zero amounts of propionate
and butyrate.
An early in vitro study showed an increased capacity via in vitro fermentation of
Crohn’s disease microbiota to have increased total SCFA (particularly acetate) when
compared with healthy controls.475;490 However this finding has not been supported
by studies directly analysing SCFA from faecal samples (Table 6.1).
The current study along with other studies465;470 have reported significantly reduced
amounts of valerate (C5) in Crohn’s disease. SCFA in the form mono-valerin and
tri-valerin which are esters of valeric acid, when given as feed additives to chickens
have been shown to reduce the colonisation of Salmonella enteritidis,273 as well as
reducing the incidence of necrotic enteritis caused by Clostridium perfringens ;274
which suggests valerate needs to be properly investigated in terms of the role it
might play in protecting the gut from both pathogens and inflammation.
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A recent study has suggested that valerate may play a role in gene expression, being
a potential contributor to the histone deacetylase inhibitory effect.271 Valerate has
a structure similar to the inhibitory neurotransmitter GABA, with a study showing
valerate can act as a GABA-agonist in rats.272 The mechanism of action of valeric acid
could be similar to its analogue, valproic acid, which is known to increase production
of GABA, resulting in decreased succinic acid synthesis.491 This is relevant because
succinic acid has been identified as a metabolite in innate immune signalling, which
enhances IL-1β production during inflammation.280
6.4.3 Differences in medium chain fatty acids (MCFA)
Interestingly, medium chain fatty acids (MCFA; C6–C12) have been shown to pos-
sess antibacterial properties at much lower concentrations than SCFA (Chapter 1,
section 1.10.1).492;277;278;279;279 Of three studies which measured MCFA (C6-8) in
Crohn’s disease patients (adults and children), all three reported reduced hexanoate
(C6),465;470;468 while two reported reduced concentrations of octanoate (C8).465;470
These findings were supported by the current study which also saw significantly re-
duced concentration and ratios of hexanoate and octanoate in children with Crohn’s
disease.
Although the current study does not support the hypothesis that the faecal SCFA,
acetate, propionate and butyrate in patients with Crohn’s disease are distinct from
healthy children; our findings do support the hypothesis that the SCFA valerate and
the MCFA hexanoate and octanoate are reduced in children with Crohn’s disease
when compared with healthy children.
6.4.4 The impact of reduced fermentation capacity in Crohn’s disease
The essential role of the gut bacteria in producing SCFA have been highlighted by
studies using germ-free mice, whereby the lack of bacteria result in low levels of
SCFA production when compared with normal mice;493 showing how little SCFA is
obtained directly from the diet. The current study saw the loss of species of SCFA
producing bacteria from the genera Anaerostipes, Blautia, Coprococcus, Faecalibac-
terium, Lachnospira, Ruminococcus and Roseburia from faecal samples of patients
with Crohn’s disease. These findings are in line with previous studies.494;495;466;217;463
Species from the genus Roseburia are among the most abundant butyrate-producing
bacteria in the gut (∼0.9 to 5.0% of total bacteria),496 and reduction of this genus
could explain why some studies record reduced faecal butyrate in Crohn’s disease.
A metagenomic and proteomics study looking at the microbiota in ileal Crohn’s dis-
ease, has shown that genes for SCFA production are reduced, along with a decrease
in proteins from the important butyrate producers Faecalibacterium prausnitzii and
Roseburia species.495
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Acetate, butyrate and propionate as products of bacterial fermentation are involved
in shaping the colonic environment by affecting gut transit; host nutrient uptake; pH
levels and bacterial homeostasis within the gut.241 Where a consistent reduction in
these bacterial groups is seen, suggests there may be a corresponding loss of SCFA
available to patients with Crohn’s disease to help with functions such regulation of
inflammatory processes or tissue repair.241
Mucosal damage A high concentration of butyrate has been used to create a reliable
colitis model in adult mice,497 and studies in rats using colon histological injury scores
have shown that SCFA have the ability to damage normal mucosa.498 The effect of
SCFA administration was however minimal in post-weaned rats of 23-24 days old,
suggesting that bacterial maturation of the gut protects against these effects.498 Thus
although the current study did not see increased amounts of SCFA in patients with
Crohn’s disease, it is possible that dysbiosis and low bacteria diversity create an
environment where SCFA can damage the mucosa. Given that in healthy individuals
about 90% of SCFA from the digestion of foods are absorbed in colon, with the rest
excreted in faeces,236 SCFA never reach high concentrations in the gut lumen. If
malabsorption and inflammation affect the ability of colonocytes to take up SCFA
such as butyrate, it might be possible for the concentration of SCFA to build up in
the gut, to high enough levels to cause further damage. However the results of the
current study suggest this is not the case since children with IBD did not have higher
concentrations of faecal SCFA than healthy children (Table 6.2).
Butyrate derived from commensal bacteria has been shown to increase mitochondrial-
dependent oxygen consumption in enterocytes, as well as stabilising the hypoxia
inducible factor involved in gut barrier protection.464 SCFA have also been shown
to directly drive lower mucosal oxygen concentrations, leading to a less favourable
environment for aerobic pathogens to grow.499 Thus low butyrate concentrations in
the gut could in theory lead to reduced mucosal protection. Although some studies
have reported a reduction in butyrate in patients with Crohn’s disease,469;471;475 these
findings were not supported by five studies including the current study.489;465;468;474
Pro/anti-inflammatory effects It is known that SCFA exert anti-inflammatory
effects in the gut mucosa via histone deacetylases inhibition.267;268 The discovery that
SCFA act as natural ligands for receptors across a wide range of cell types has led to
the current interest in SCFA as signalling molecules between the gut microbiota and
host immunoregulation. SCFA also have immunomodulatory and anti-inflammatory
effects, via mediating homeostasis of colonic Treg cells,
241;267;269;500 although the anti-
inflammatory effect of SCFA could be via other mechanisms. However it is also
known that metabolites produced by F. prausnitzii can block NF-κB activation and
IL-8 production.217 This might suggest that SCFA producing species have the ability
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to shift in the direction of an inflammation promoting microbiota, possibly driving
inflammation towards more severe Crohn’s disease. As such, there is a need for
well designed human studies which could reveal the significance that SCFA play in
regulating host immunology and inflammation in the gut.
6.4.5 How might SCFA be used to treat Crohn’s disease
Metabolic profiling including SCFA could become an effective exploratory tool for
understanding metabolic pathways and how these might be altered in conditions
such as Crohn’s disease and UC. It has been suggested that supplementing patients
with either butyrate producing bacteria or butyrate could be used as an intervention
strategy.268
Schulthess et al.501 have shown via intracellular staining of calprotectin proteins, a
marked up-regulation of calprotectin in macrophages after 5-days of differentiation
with butyrate in vitro. The same group then tested results in a murine model and
found that butyrate treated-mice exhibited a significantly higher antimicrobial ac-
tivity against Salmonella and Citrobacter compared to controls.501 This study has
important implications in Crohn’s disease and UC, given that some studies have found
reduced butyrate levels in patients with these conditions (Table 6.1); and Schulthess
et al. have suggested a valid model by which low levels of butyrate could lead to
increased pathogenic bacteria, which in turn drive inflammation.
It has been shown that the abundance of Roseburia inulinivorans along with other
butyrate producing species is reduced in patients with Crohn’s disease compared
to healthy individuals.463 An in vitro study has shown that the introduction of six
butyrate-producing species including F. prausnitzii, Roseburia hominis and R. in-
ulinivorans, to the microbiota of Crohn’s patients, increased the level of butyrate
in the dysbiotic bacterial community as well as improving the barrier function in a
Caco-2 epithelial cell model.478 This opens up the potential for butyrate-producing
bacteria to be used as a therapeutic probiotic in a clinical setting. However more
work needs to be done to understand how probiotics might affect individual Crohn’s
disease patients, since the pattern of dysbiosis varies greatly between individuals.
The administration of butyrate by giving human patients butyrate tablets or en-
emas, have only been carried out on UC patients. At a molecular level butyrate
enemas have been shown to decrease NFκB nuclear translocation in lamina propria
macrophages, in tissue taken from UC patients.258 It has also been shown to decrease
lipopolysaccharide induced cytokine expression and NFκB activation of lamina pro-
pria mononuclear cells; as well as peripheral blood mononuclear cells (PBMCs) in
tissue taken from Crohn’s disease patients.502 However administering butyrate in hu-
man trials have not been successful for a number of reasons, including delivery issues
and poor patient compliance.281 Butyrate has been shown to be less effective in pro-
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ducing an anti-inflammatory response in a colitis mouse model when compared to
inoculation with F. prausnitzii. However both F. prausnitzii and butyrate were each
shown to increase IL-10 production, and reduced IL-12 and TNF-α production.217 It
is likely there would need to be a constant production and delivery of SCFA to the
gut mucosa, in order to gain a sustained anti-inflammatory effect. Therefore using
butyrate producing bacteria to increase butyrate production in the gut could be a
better target for potential therapy.503
Future research Subsequent research will need to find good candidate probiotic
bacteria, which have good tolerance to stomach and small intestinal conditions to
ensure they reach the colon, as well as demonstrating potency in terms of butyrate
production in the colonic microbiota. It might also be possible that bacteria which
are not in themselves butyrate producers, but rather stimulate butyrate production
among the gut microbiota, could also be a good candidate to improve butyrate levels
in the gut of IBD patients.504;505
SCFA have the potential, not only to increase our understanding of Crohn’s disease
and UC, but also diagnose and treat these conditions. SCFA/MCFA profiles and
other metabolites could possibly be used as biomarkers, easily measured from non-
invasive urine, faeces or blood samples.
6.4.6 Changes in SCFA during EEN
The lack of understanding as to how exactly exclusive enteral nutrition (EEN) works
has discouraged its use in some centres.506 There have been many suggestions as
to how EEN might work, but it now appears that the idea of bowel rest507 or the
reduction of possible food allergens508;509 are not correct. It might seem unlikely that
EEN works via immunosuppression, because patients with UC would be expected to
benefit if this were the case. However EEN is ineffective in the treatment of UC.510
There is increasing evidence that inflammation in Crohn’s disease is linked with an
inappropriate immune response against the gut microbiota. Therefore it is possible
that changes in the metabolic activity of certain members of the microbiota might
play a role in regulating this immune response.467;511
Gerasimidis et al.145 saw a reduction in total SCFA during EEN along with a sig-
nificant reduction in both the amount and ratio of butyrate during treatment with
EEN in seven children who went into remission. Although this study suggested these
differences were not seen in nine children who either failed EEN, or did not achieve
complete clinical remission; there were clear, although less pronounced reductions in
all SCFA, especially butyrate during EEN in these nine patients. It should also be
noted that patients who responded to EEN had a higher median concentration and
ratio of butyrate at baseline (15.4, 16.9%), compared with patients who failed EEN
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(7.2, 8.3%). It is therefore not surprising that on a fixed diet of EEN for 2-weeks,
those with higher baseline amounts, had a larger reduction of butyrate on EEN (9.1,
9.3%) than children who failed EEN (4.0, 6.8%). After 8-weeks on EEN, children
who responded actually had a higher ratio of butyrate (9.3%), compared with those
who failed to achieved remission (7.8%).470
In 2012 Tjellstrom et al.129 proposed the use of a SCFA fermentation index; where
acetate which they argue has pro-inflammatory properties, less anti-inflammatory
propionate and butyrate, expressed as a percentage of total SCFA, could be used to
asses the pro/anti-inflammatory capability of the gut microbiota. The study showed
that in nine children who went into remission on EEN that there was a significant
decrease in the SCFA index. They also showed that five children with perianal disease
who failed EEN, that the index significantly increased during EEN. Their study failed
to show data for another four children who failed EEN hence it is not clear if the
difference in SCFA index was due to these patients having perianal disease or an
indicator of having failed treatment with EEN. However, it is interesting that in the
current study figure 6.4 clearly reflects the findings of Tjellstrom et al. in that acetate
(C2), propionate (C3) and butyrate (C4) are associated with a move towards active
Crohn’s disease, and a shift in the ratio of these SCFA during EEN brings profiles
towards that of healthy children. The findings of the current study do not support
the use of this SCFA index. The index based on the current study data (n=(19),
contrary to the findings of Tjellstrom et al. (n=9), showed a slight non-significant
increase in median index value (Fig. 6.7). It is possible that the low samples sizes in
the Tjellstrom study have created a Type I error (false positive).
Figure 6.7: Boxplot showing SCFA inflammatory index proposed by Tjellstrom et al.129 using the
current study data. Contrary to Tjellstrom the current study did not see a decrease in SCFA index
A after EEN. Index A=(C2-C3-C4)/total SCFA
The current study after 4-weeks EEN, using paired samples, also saw a reduction in
total fatty acid. The median concentration of acetate, propionate and butyrate, were
reduced along with the medium chain fatty acids hexanoate and octanoate. Only the
ratio of butyrate however was markedly reduction during EEN. The ratios of SCFA
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in the current study suggest that SCFA production with the exception of butyrate
fell as a product of a reduction in colonic fermentation.
6.4.7 Drivers of SCFA changes during EEN
Although this and other studies see a reduction in faecal butyrate during EEN, it is
possible that this is due to better absorption and utilization of butyrate by colonocytes
as a result of reduced inflammation and mucosal healing in the gut. It has been
proposed that the uptake of butyrate is impaired during active disease in IBD.512 If
this were the case then we would expect to see only a decrease in butyrate among
those children who responded to treatment. However this is impossible to accurately
measure, since EEN is a residue free diet with no fibre, which leads to a reduction in
butyrate producing bacteria. Reduced faecal concentrations of butyrate could be due
to both reduced production by bacteria and malabsorption in different proportions
in different individuals. Interestingly a recent study looking at the effect of 7-days
EEN on healthy adult volunteers saw a similar significant reduction in SCFA, as that
seen in children with Crohn’s disease on EEN.513 This study also showed that a low
residue ordinary solid food diet with a similar nutrient composition to EEN, was able
to achieve similar reduction of SCFA to EEN. However post-treatment amounts of
SCFA in the solid food diet, with the exception of propionate, were not as low as
those seen with EEN.513 If SCFA play in role in regulating the immune response to
gut microbiota, this type of solid food diet, could potentially have an important role
to play, not only in attaining remission in children with Crohn’s disease but also in
maintaining long term remission and preventing disease relapse.
Treatment with EEN leads to reduced fermentation, and thus potentially a reduc-
tion of toxic metabolites, such as 1-propanol, p-cresol, phenol, 1-butanol, dimethyl
disulphide and fatty acid ethyl esters. This could explain why EEN leads to mucosal
healing, and is supported by a study showing these faecal toxic metabolites were
present in Crohn’s disease patients but not in healthy controls.488 Similar metabolites
have also been identified in UC patients, but interestingly unlike Crohn’s patients,
these did not reduce after treatment with EEN.467 This finding supports the idea
that dysbiosis in patients with UC differs from Crohn’s disease, which the current
study findings support at a bacterial species level. It is therefore possible that toxic
metabolites produced from abnormal bacterial metabolism could be an important
factor in Crohn’s disease.
A 2011 study514 comparing peripheral blood mononuclear cells (PBMCs) from twenty-
two Crohn’s and nine UC patients with twenty healthy controls, showed that to
inhibit the release of IL-12/23p40 from PBMCs after activation via TLR2-agonist,
larger amounts of butyrate were needed in patients with Crohn’s and UC compared to
healthy controls. It is possible that toxic metabolite signalling could be impairing the
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sensitivity of PBMCs to butyrate; thus impaired sensitivity to the inhibitory effect
of butyrate in Crohn’s disease could play a role in disease aetiology. Further work
using cell models could go on to examine whether toxic metabolites such as ammonia
or phenol have the ability in vitro to alter the sensitivity of PBMCs to butyrate.
6.4.8 SCFA and maintenance enteral nutrition (MEN)
As yet no studies have looked at the effect of maintenance enteral nutrition (MEN)
on the production of SCFA in the gut. The current study is the first study which
attempted to look at SCFA levels in patients taking MEN post-EEN. After 2-weeks
on normal habitual diet the median ratio of acetate was lower (NS), while propionate
and butyrate were marginally higher (NS) in children taking MEN as a supplement.
For butyrate this difference was no longer seen at 8-weeks normal diet. Due to this
being an observational study, and possibly because clinical staff and patients had
information about MEN, only four patients on the study chose not to take MEN. In
the previous 2-years 54% of children had chosen not to take MEN. The numbers were
therefore too low to carry out any statistical analysis and ongoing studies would need
to factor in ways to ensure a larger non-MEN control. This could be challenging as
it may be deemed unethical not to offer MEN to some children.
When all children on normal diet in the current study were combined, a significant
increase in the concentration of propionate and butyrate was seen after children had
been on normal diet for 8-weeks post-EEN. There was also a significant increase in oc-
tanoate. Total SCFA was also increased but the difference did not reach significance.
Only the ratio of butyrate and octanoate were significantly increased 8-weeks post-
EEN. In a previous 2009 study the total SCFA for all children on EEN was shown to
be significantly increased at 2-week post-EEN.489 Both these studies show that once
children go back onto normal diet that SCFA increase back towards pre-treatment
levels and are not maintained, even when MEN is added as a supplement to the diet.
This is not surprising as the increase in dietary fibre leading to an increase in numbers
of SCFA-producing bacteria will result in increased SCFA production regardless of
whether the diet is supplemented with residue-free MEN.
A 2006 study123 using partial enteral nutrition (50% EDA) to induce remission in chil-
dren with Crohn’s disease (n=24), compared with those taking EEN (n=26), found
that EEN was associated with a significant rise in serum albumin and reduced ESR,
which was not seen in those taking partial enteral nutrition. This study suggests that
partial enteral nutrition of 50% or less does not have the same immunomodulatory
properties as EEN, and gives some indication as to why the dose of MEN may be
too low to have an effect in maintaining remission. It would be interesting for future
studies using murine models, to look at the effect enteral nutrition dose has on SCFA
production in the gut and how this in turn relates to inflammatory processes.
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6.4.9 SCFA and the microbiota
A decrease in Firmicutes and an increase in Proteobacteria have been a consistent
outcome from IBD gut microbiota studies.515 The reduced abundance of Firmicutes
mainly coming from the families Ruminococcaceae (clostridial cluster IV ) and Lach-
nospiraceae (clostridial cluster XIVa) is a key feature of dysbiosis in Crohn’s dis-
ease, particularly in active disease.515;516;517;518 These families are important func-
tional members of the gut microbiota, because the majority of butyrate producing
bacteria come from these families, thus reduced abundance in these groups can be
linked to reduced butyrate producing capacity of the gut microbiota in patients with
Crohn’s disease.519 Hence if butyrate has a protective effect on the gut, these benefits
are also lost along with butyrate-producing bacteria in Crohn’s disease.
The substantial production of butyrate by F. prausnitzii makes this bacterium of
particular interest. Butyrate being the major source of energy for colonocytes520 also
plays a role in modulating the immune system by inhibiting NF-κB transcription
factor activation, up-regulating PPARγ, and inhibiting IFNγ, potentially reducing
inflammation.521 It is important to understand the interdependency of many bacteria
and that these anti-inflammatory properties of bacteria such as F. prausnitzii rely on
cross feeding with other members of the microbiota.
In vitro studies show Bifidobacteria degrade oligofructose to produce acetate, utilised
via cross-feeding by commensal bacteria including F. prausnitzii, Anaerostipes and
Roseburia species, which produce butyrate.520;522;523;524 B. thetaiotaomicron (acetate
producer), has been shown to increase goblet cell differentiation, expression of mucus
genes and the ratio of sialylated/sulfated mucins in rats; suggesting that B. thetaio-
taomicron stimulates mucus production.525 However when B. thetaiotaomicron was
mixed with F. prausnitzii, (acetate consumer/butyrate producer), the effect on goblet
cells and mucus glycans were diminished. This murine model suggests an imbalance of
butyrate and acetate producers in the gut reduces the ability of the mucus layer to act
as a barrier against pathogens, allowing pathogenic bacteria to access gut epithelial
layers, triggering inflammation.525 Increases in specific bacteria, overall dysbiosis and
a loss of cross-feeding could lead to an imbalance in SCFA production. It is therefore
possible, that loss of functional homeostasis in the form of SCFA rather than bacteria
themselves, lead to mucosal damage and inflammation. Evidence from the current
study supports this idea since SCFA profiles of children with Crohn’s disease move
towards that of non-IBD controls after treatment with EEN (Fig. 6.4). This would
explain why EEN works despite further losses of what would be considered healthy
commensals such as Firmicutes and an increase in Proteobacteria. It is a change in
the ratios of SCFA which is driving a reduction in inflammation. This would also
explain why inflammatory markers increase once children return back onto habitual
diet post-EEN as SCFA levels start to increase.
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A recent elegant study by Schulthess et al.501 has shown that macrophages which
differentiated in the presence of butyrate had enhanced antimicrobial activity in
vivo and increased resistance to pathogenic species of bacteria including Salmonella;
adherent-invasive Escherichia coli (AIEC); Staphylococcus species and Citrobacter.
They concluded that increased gut butyrate could be used as a strategy to increase
host defence. However studies looking at children taking EEN as therapy see a marked
reduction in butyrate accompanied with increased Enterobacteria species, which is
associated with a reduction in inflammation. Mucosal healing and reduced inflamma-
tion may be more dependent on reduced bacterial abundance than levels of butyrate.
It is therefore possible that increases in pathogenic species of bacteria during EEN
could explain why some children fail EEN; and treatment with butyrate may increase
the success of EEN. However, boosting the diet of children with Crohn’s disease with
butyrate to try and reduce inflammation would need further research.
Looking at the effect of butyrate on normal healthy cells in the colon, butyrate
has been shown to illicit effects via the G protein receptors GPR109A; GPR41 and
GPR43. Transported into cells via the SMCT1 (SLC5A8) a co-transporter for H+
and butyrate and MCT1 (SLC16A1) a co-transporter for Na+ and butyrate. If a
lot of butyrate is present and Na+ is transported into cells water tends to follow;
and for this reason butyrate is regarded as an anti-diarrhoeal agent. However during
treatment with EEN, the converse appears to be true since a significant decrease in
the amount and ratio of butyrate is associated with a reduction in diarrhoeal samples.
The majority of research into butyrate suggests it has anti-inflammatory properties,
yet paradoxically, treatment with EEN where butyrate is significantly reduced, is
associated with decreased inflammation as shown by inflammatory markers such as
calprotectin and mucosal healing. It is therefore possible, as some studies suggest,
that normal pathways associated with butyrate are dysfunctional in some way.
6.4.10 Future research
In 2015 an interesting study526 looking at a much wider range of metabolites as
volatile organic compounds (VOC) in exhaled air, which includes esters of SCFA has
suggested that these can be used not only as a marker of Crohn’s disease, but also a
marker of disease activity. Taking this work further by assessing the sensitivity and
specificity of this method against other inflammatory conditions, and working out how
to make the test kit inexpensive, should be a focus of future research. This type of
testing has the potential to make clinical diagnostics much easier, and could possibly
be used by GP practices, as well as be developed for home testing, allowing patients
to monitor disease activity in a non-invasive manner. A breath test kit could in the
long term save money by helping patients maintain remission by accessing treatment
strategies before their disease condition is severe.
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Studies looking at the composition of the gut microbiota in IBD are much more
numerous, than studies into the functional capability of these communities. The role
of gut bacteria metabolites in IBD are still poorly understood and more needs to
be done to explore the role that metabolites such as butyrate have in controlling
or driving inflammation in the gut. It would be easy to overlook the role that these
ubiquitous bacterial molecules play but they are in fact important signalling molecules
between the gut bacteria and host as well as the role they play in regulating host
cellular metabolism in many different tissues around the body.
There are metabolic mechanisms which might explain the link between dysbiosis and
Crohn’s disease. It is possible that dysbiosis drives inflammation via the loss of SCFA
producing bacteria. Changes in SCFA could limit resources to gut epithelial cells,
increase production of inflammatory cytokines, as well as decrease the suppression of
pathogenic Proteobacteria. On the other hand it is possible that dysbiosis is caused
by the gut inflammation in Crohn’s disease. Proteobacteria are facultative anaerobes
which have a high resistance to the reactive oxygen species produced by inflamma-
tion, thus giving them a selective advantage over the obligate anaerobes from the
Firmicutes and Bacteroidetes phyla. However it should be noted that these mecha-
nisms are not mutually exclusive. It is likely that bacterial dysbiosis both contributes
to, and is further driven by, inflammation in the gut of patients with Crohn’s disease.
The future challenge is not only to identify bacteria but also the compounds they
produce which might either drive or protect the gut from inflammation. This also
leads to the possibility of using SCFA produced by bacteria to manipulate the gut
microbiota profile towards a healthy state.
It is possible that within the gut microbiota individual bacteria secrete particular
profiles of SCFA/MCFA which work to inhibit the growth of competing species. Fu-
ture studies should be designed to address the role of SCFA and MCFA on biofilm
formation and maintenance, as this might be key to understanding the lack of bac-
terial diversity in IBD. It is also important that future studies identify the impact
SCFA have, either directly or indirectly, on mucosal maintenance and integrity (Table
6.5).
It is important to remember that the metabolism of the gut microbiota is not driven
by a clear set of linear pathways but rather a complex web of interconnected re-
actions facilitated by enzymes that connect multiple molecules across many path-
ways.527 Hence the development of more complex analysis models which can look at
multiple factors will likely help to unravel the complex processes which are driving
inflammation in Crohn’s disease and UC.
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6.4.11 Summary
Evidence is now beginning to show that gut bacteria not only play a fundamental
role in energy homoeostasis but is also necessary for a healthy homeostasis of the
immune system which has been educated toward appropriate and non-appropriate
responses. Gut bacteria which ferment fibre to produce SCFA, especially butyrate,
can play a role in regulation of innate and adaptive immune cell generation; traf-
ficking and function. Butyrate inhibits recruitment and pro-inflammatory activity of
macrophages; neutrophils; dendritic cells and effector T-cells as well as increasing the
amount and activity of Treg cells.
Causative links between gut bacterial dysbiosis and Crohn’s disease has been difficult
to prove. Reduced numbers of SCFA-producing bacteria along with reduced butyrate
is linked with an increase in the amount of pro-inflammatory immune cells present
in the gut mucosa of patients. Therefore understanding the relationship between
bacterial dysbiosis along with reduced butyrate production in Crohn’s disease could
lead to new novel therapies.
Table 6.5: Summary of key factors from SCFA research which could directly or indirectly
explain inflammation in Crohn’s disease
Summary of key points from SCFA research
SCFA have been shown to affect mucosal thickness.498
SCFA can improve epithelial integrity and tissue repair.498;464;477;240
At high concentration SCFA can damage normal mucosa.497
SCFA can alter pH level and oxygen availability in the gut.464;499
SCFA/MCFA have direct and indirect antimicrobial properties.501;271;278;279
6.4.12 Key findings
The current study:
 Support recent findings that low levels of MCFA C5, C6 and C8 differentiate IBD from healthy
individuals.
 Support recent findings that SCFA, specifically ratios of butyrate are reduced during EEN
but return to pretreatment levels once back on normal diet.
New findings from this study:
 In children with Crohn’s disease, hexanoate (C6) is positively associated with a number of
bacterial genera, particularly from Firmicutes; both of which are significantly reduced in
patients with Crohn’s disease.
 During EEN the overall ratios of SCFA move towards that of healthy children.
 SCFA return to pre-treatment levels once children return to normal diet; and treatment with
MEN post-EEN does not maintain SCFA profiles achieved during EEN.
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7 The role of diet in inducing and maintaining remission in
children with Crohn’s disease
7.1 Introduction
Recent research is changing our understanding of the role diet might play in IBD.
Awareness of susceptibility not directly related to host genetics, has highlighted that
development of IBD has an environmental component. Microbiota studies have shown
that gut bacteria have an important role in IBD pathogenesis, with diet likely impact-
ing the composition and functionality of the gut bacteria. Clinical studies show that
diet, particularly exclusive enteral nutrition (EEN), can induce remission in Crohn’s
disease, and possibly aid maintenance of remission reducing the need for surgery.
The following chapter will look at composition of dietary intake at baseline in children
with Crohn’s disease, UC, non-IBD controls and healthy children and will examine
whether any differences can explain gender bias in the incidence of Crohn’s disease.
Whether dietary intake at baseline can predict response to treatment with EEN; as
well as how the composition of EEN differs from the child’s normal habitual diet will
also be explored. The effect of treatment with EEN on post-EEN dietary choices
will also be explored in children with Crohn’s disease. This chapter will then go onto
explore any links between diet and the gut microbiota since children with Crohn’s
disease are also known to have reduced bacterial diversity, particularly Firmicutes.
As a consequence, this chapter will examine whether low fibre intake in children with
Crohn’s disease could explain the reductions in bacterial species driving dysbiosis.
7.1.1 Diet as a risk factor for IBD
Although several studies have shown associations between the consumption of spe-
cific foods or dietary patterns and the risk of developing IBD, the dietary collection
methods, mostly food frequency questionnaires (FFQs), are varied making it difficult
to compare and assess results (Table 7.1). However there is consistency across all
four of these studies which suggest low fibre, low fruit and vegetables and high fat
(particularly animal fat) are risk factors for Crohn’s disease. A Japanese study also
reported that vegetable protein was protective against Crohn’s disease.528
In infants, the first dietary option is between breast milk or a milk formula typically
derived from cow’s milk. Breastfeeding has been linked with lower incidence of IBD
in a recent meta-analysis (odds ratio, 0.69),529 and is more likely due to a protec-
tive effect of breast milk,530 rather than a negative effect of formula milk, as IBD is
rare before weaning.531 Although studies have also shown that breast milk changes
composition of the gut microbiota in neonates,532 there are significant changes in
the gut microbiota profile after weaning irrespective of whether a child was breast
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or formula fed.533 This would suggest that solid food is important for early risk of
IBD.A study looking at the metagenomic analysis of faecal samples from ninety-eight
Swedish infants has shown, in comparison to vaginally delivered infants, the gut mi-
crobiota of those delivered by C-section had significantly less resemblance to their
mothers. Interestingly, maturation into an adult-like microbiota profile was associ-
ated with the end of breast-feeding, rather than the introduction of solid food.534
The cessation of breast milk had a profound effect on the bacterial profile taken from
faecal samples of 12-month old infants, shifting the gut bacteria profile towards a
more adult composition which was enriched with the genera Bacteroides, Roseburia,
Clostridium, and Anaerostipes.534 In contrast, the gut bacteria of infants which were
still being breast fed at 12-months were dominated by Bifidobacterium, Lactobacil-
lus, Collinsella, Megasphaera, and Veillonella; bacteria which have been shown to
be present in breast milk.535 This might have implications for IBD risk since two
meta-studies529;536 have suggested a possible protective effect of breast milk; with a
more recent study showing being breast-fed for more than 12-months decreased the
adjusted odds for Crohn’s disease in an Asian population (aOR 0.10; CI 0.04-0.30).537
This leads to the possible conclusion that very early dietary exposures are involved
in disease aetiology and that an altered gut microbiota due to diet could increase the
risk of Crohn’s disease later in life.
Fibre Observational studies have reported an inverse relationship between intake
of fibre and risk of Crohn’s disease; with one prospective study showing long term
intake of dietary fibre being linked with a reduced risk of Crohn’s disease (odds-ratio
0.59, 95% CI 0.39–0.90).540 Reduced risk was greater for fruit based fibre, whereas
no protective effect was seen from fibre from cereals, whole grains or legumes.540 The
protective effect of fibre has been proposed to come from SCFA, derived from the fer-
mentation processes of gut bacteria, inhibiting the transcription of pro-inflammatory
mediators.568 Fibre also helps to maintain gut barrier integrity as well as reduce
translocation of pathogen such as E. coli across Peyer’s patches in vitro.569 Studies
dating from the 1970s noted that IBD patients at baseline ate less fibre, in the form
of raw fruits and vegetables compared to healthy controls.570 Depriving gut bacteria
of fibre in murine models, has been shown to favour bacterial taxa able to use alter-
native carbon sources from within the gut mucosal layer; which in turn depletes the
thickness of mucus and hence barrier function; resulting in immunological activation
and tissue damage.571 Two more recent studies539;547 also show reduced fruit and
vegetable intake to be risk factors for Crohn’s disease (Table 7.1).
Protein Protein intake has also been linked with Crohn’s disease risk, particularly
animal protein.538;528;544 A study which positively linked animal protein intake with
risk of Crohn’s found that milk was especially high, but that fish did not contribute
to risk. The study also found a negative correlation with vegetable protein.528
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Table 7.1: IBD dietary risk factors based on epidemiology studies
study cohort methods results
Jantchou et
al. 2010538
France
30 CD; 43 UC;
67,504 controls
(adult women)
self-completed
dietary
questionnaire
(Cox proportional
hazards)
High animal protein intake is an increased risk for CD
(p=0.04) and IBD in general (p=0.007) but not dairy or
eggs.
D’Souza et al.
2008539
Canada
149 CD;
251 HC
(children)
FFQ -factor
analyses &
unconditional
logistic regression
(adjusted)
A diet of meat, fried food, fast food, snacks and desserts
were positively associated with CD (p=0.03); whereas a
diet of vegetables, fruit, yoghurt, dairy, eggs, olive oil,
fish, white rice, tofu, grains, and nuts is negatively
associated with CD (p=0.02).
Shoda et al.
1996528
Japan
242 CD; 68,000
control
(adults)
dietary interview
for 5-days
annually (19-yrs)
Positive correlation between increase in total fat and
incidence of CD (p<0.001); also with animal protein
(especially milk) but not fish protein (p<0.001); negative
correlation between vegetable protein and CD (p<0.001).
Ananthakr-
ishnan et al.
2013540
USA
269 CD;
338 UC
(adult women,
nurses)
FFQ every 4-yrs
(over 26-yrs)
Higher intake of fibre associated with lower incidence of
CD, but not UC. Strongest negative correlation was with
fruit fibre and CD (p<0.05). No significant correlation
between vegetable, whole grain, bran and legume fibre
and CD.
Costea et al.
2014541
Canada
182 CD;
250 controls
(children)
FFQ -logistic
regression using
energy-adjusted
nutrients
Higher consumption of dietary ratio of n-6/n-3 PUFA
was susceptible for Crohn’s if also carriers of specific
variants of CYP4F3 and FADS2 genes. NB// Western
diets tend to have high n-6 and low n-3 PUFA intake,542
which may influence PUFA metabolic pathway in favour
of n-6 pathway, leading to gut inflammation in
genetically susceptible people.
Chan et al.
2014543
(8 European
countries)
EPIC-IBD
cohort: 110
CD; 244 UC
(adults)
self-completed
FFQ to measure
carb, sugar,
starch
No significant risk association for carb, sugar or starch
for CD or UC. Study did not look at fibre.
Tragnone et
al. 1995544
Italy
51 CD; 53 UC;
208 control
recall
questionnaire by
interview
Increased intake of protein associated with increased risk
of CD (p=0.04) and UC; increased intake of mono- and
polysaccharides associated with increased risk of CD; no
difference in pre-intake levels of fat.
Reif et al.
1997545
Israel
33 CD;
54 UC;
144 control
quantified
questionnaire
similar to FFQ
(180 items) by
interview
Although not significant due to small sample size,
findings suggest low fibre and high animal fat were risk
factors while high fruit, Vit C, vegetable and fibre were
protective.
Sakamoto et
al. 2005546
Japan
128 CD;
111 UC;
219 control
self-completed
semi-quantitative
FFQ
Higher intakes of sugars and sweeteners, as well as fats
and oils, fish and shellfish (p<0.05) were associated with
an increased risk of CD; total fat intake increased risk
for CD in dose-response relationship(p=0.002).
Amre et al.
2007547
Canada
130 CD;
202 control
validated youth
adolescent FFQ;
151 items
Lower fibre intake increased risk of CD (p=0.01);
carbohydrates without fibre were not a risk factor with
CD (p=0.67); high vegetable (p=0.03) and fruit
(p=0.02) intake decreased risk of CD.
CD -Crohn’s disease; UC -ulcerative colitis; FFQ -food frequency questionnaire; carb -carbohydrate
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Table 7.2: Evidence from animal and in vitro studies that link diet with immunological function in
the gut
Diet Study Model/method Effect
High fat/high
sugar diet
Martinez-
Medina et al.
2014548
CEABAC-10 mice
Decreased MUC2 expression Depleted Goblet cells
Increased intestinal permeability
Increased TNF-α secretion
High fat/high
sugar diet
Agus et al.
2016549
CEABAC-10 mice
Decreased FoxP3 Tregs in mesenteric lymph nodes
Decreased butyrate production
Reduced expression of the butyrate GPR43 receptor
Dysbiosis
Significantly decreased SCFA concentrations
High fat diet
Ma. et al.
2008550
WT C57BL/6 mice
Higher numbers of non-CD1d-restricted natural killer T
cells in the colonic IEL
Increased TNF-α and IFN-γ expression
Decreased levels of colonic Tregs
High fat diet
Suzuki. et al.
2010551
LETO and OLETF
rats; human Caco-2
cells
Increased intestinal permeability
Decreased T-junction proteins expression (claudin-1,
claudin-3, occludin and junctional adhesion molecule-1)
High fat diet
Gruber et al.
2013552
TNFδARE/WT
mouse and WT
C57BL/6
Aggravation of ileal inflammation
Reduced expression of occludin
Increased translocation of endotoxin
Increased pro-inflammatory markers
Recruitment of dendritic cells and Th17-biased
lymphocyte into the lamina propria
Sodium caprate
(constituent of
milk fat)
So¨derholm et
al. 1998553
Rat ileum Increased tight junction permeability
Sodium caprate
So¨derholm et
al. 2002554
Specimens from
distal ileum of CD
patients
Rapid increased in paracellular permeability
Gluten
Ejsing-Duun et
al. 2008555
NOD and BALB/c
mice
Decreased the occurrence of Tregs by 10%–15% (p<0.05)
Gluten
Wagner et al.
2013556
TNFδ ARE/WT
mouse
Increased intestinal permeability
Reduced occludin expression
Induced chronic ileitis
Gluten (gliadin)
Lammers et al.
2008557
Human intestinal
epithelial cell, Caco2
cells, IEC6 cells
Zonulin released, causedtight junction disassembly
Gluten (gliadin)
Hollon et al.
2015558
Ex vivo human
duodenal biopsies
Increased intestinal permeability
Higher concentration of IL-10 in controls compared with
coeliac disease in remission or gluten sensitivity
Wheat (ATIs)
Junkers et al.
2012559
Human cells and
biopsies
ATIs are potent activators of human innate immune
responses in monocytes, macrophages and dendritic cells
Wheat (ATIs)
Zevallos et al.
2017560
TLR4-responsive
mouse and human
cell lines
Activation of dendritic cells in mesenteric lymph nodes
Released inflammatory mediators
Soluble fibres
and resistant
starch
Bassaganya-
Riera et al.
2011561
C57BL/6J WT mice
IL-10-/- mice
Decreased ileal and colonic inflammatory lesions
Decreased IFN-γ production by effector CD4+ T cells
from Peyer’s patches
Resistant starch increased the IL-10-expressing cells
Suppressed gut inflammation
Dietary pectin
Ye et al.
2010562
IL-10-/- mice
Reduced expression of TNF-R and GATA-3
Lower levels of IgE, IgG and IgM expression
Modulation of production of pro-inflammatory cytokines
and immunoglobulins
Fermentable
fibre (guar gum,
partially
hydrolysed GG)
Hung et al.
2016563
BALB/c mice aged
7 weeks
Increased expression of occludin and claudin-3, claudin-4
and claudin-7 (reduced permeability)
Greater total faecal SCFA concentrations
Reduced inflammation score
Multifibre mix
diet
Wang et al.
2016564
IL-10-/- mice
Reduced disease activity index score
Decreased CD4+CD45+ lymphocytes, IFN-γ/IL-17A,
TNF-α /TNF-R2 mRNA expression
Increased Tregs and SCFA production
Increased epithelial expression and correct localisation of
tight junction proteins
Alcohol
Forsyth et al.
2017565
Mice
Colonic (but not ileal) hypermobility
Decreased butyrate/total SCFA ratio in stool
Dietary salt
Tubbs et al.
2017566
IL-10-/- murine
model of colitis
Exacerbation of inflammatory pathology
Enhanced expression of numerous pro-inflammatory
cytokines
TLR4 activation
CD - Crohn’s disease; UC - ulcerative colitis FFQ - food frequency questionnaire
Table adapted from Levine 2018 567
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Fats Increased intake of fats have also been linked with risk of Crohn’s disease
in Japanese studies,528;546 but only an increased ratio of omega-6/omega-3 polyun-
saturated fatty acids (PUFAs) has been associated with risk in a North American
study; and only in those who carried particular genetic variants.541 Although an
IL-10 knockout mouse model has suggested that saturated fat is associated with pro-
inflammatory T-helper type 1 immune response,572 this association has not been seen
in prospective human studies.573
A 2014 European study543 which included 110 adult Crohn’s patients saw no increased
risk association for any dietary macronutrients. However, the study failed to look at
fibre intake. It is also possible that by spreading their questionnaire across eight
different countries with potential cultural differences in diet, might have masked
dietary differences seen in one country not found in another, and hence may not be
an accurate assessment of dietary risk.
7.1.2 Using diet to treat IBD
Studies have examined links between diet and IBD symptoms, with patients often
reporting that specific food groups aggravate their symptoms.574 However, despite
dietary connections being apparent to many clinicians in individual patients, it is
challenging in humans to prove dietary links via qualitative and quantitative means.
Evidence from animal studies however support the idea of dietary components having
immunomodulatory effects (Table 7.2). EEN is known to be effective at bringing
about remission and reducing gut inflammation in children with Crohn’s disease as
well as maintaining their linear growth; but a review based on forty-eight studies
which isolate specific food groups from habitual diets, suggests that individuals react
differently on exposure or exclusion, to particular foods.574 The main aim of dietary
research in Crohn’s disease is to identify ways to prolong remission particularly in
children, using dietary measures, thus reducing the need for medication and surgical
intervention.
Exclusive enteral nutrition (EEN) It has been long understood that EEN, since
it contains no fibre, it is easily digested and absorbed in the small intestine thus
suppressing the growth of bacteria in the colon (Chapter 1, section 1.9.6). It is thus
thought to provide ‘bowel rest’, and has been shown to be efficacious in achieving
disease remission especially in children with Crohn’s disease.120 Metagenomic stud-
ies have shown that EEN alters the gut microbiota (Chapter 5, Table 5.10) with
one study showing that changes in the gut bacteria happen as soon as 1-week after
treatment initiation.73 However, changes due to EEN push the gut bacteria profile
even further away from that of healthy children.145 The use of EEN is likely dose
dependant, since changes to the gut microbiota profile was not seen in children using
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partial enteral nutrition where the diet consisted of 50% formula and the rest normal
diet.138 This might suggest that exclusion of normal diet could be the key factor in
driving changes which lead to remission in Crohn’s disease. Since the effectiveness of
clinical and mucosal remission is greatest when 100% EEN is used,116;132 and because
many patients feel that EEN is overly restrictive and interferes with normal family
mealtimes, research is moving towards the goal of creating a whole food diet that will
have the same benefit as EEN.
Maintenance enteral nutrition Although using EEN to induce remission in chil-
dren with Crohn’s disease is of clear benefit, it is not feasible to use such an extreme
exclusion diet to attain the long-term maintenance of remission. Studies have gone
on to look at supplementing the normal diet with enteral nutrition (MEN) post-EEN
(Chapter 1; Table 1.6) and although results from these studies might suggest MEN
is comparable with immunosuppressants at maintaining remission, out of ten studies
only one was a randomised controlled trial.151 Sample sizes are small (∼20 MEN pa-
tients) and patients with less severe disease are often more likely to be treated with
MEN. Eight of these studies took place in Japan575;576;148;577;45;578;150 and hence the
same treatment may not be as successful in other countries where habitual diet is
different. Therefore the efficacy of enteral nutrition to maintain remission in children
with inactive Crohn’s disease has yet to be determined.
Specific exclusion diets The specific carbohydrate diet (SCD) is an exclusion diet
with reported success in maintaining remission in IBD. The SCD diet was created in
the 1920s for children with coeliac disease, excluding all grains, corn and rice; starchy
tubers; all dairy containing lactose and any processed sugars. In 2016 Suskind et al.579
developed an online anonymous survey for patients (both children and adults) with
Crohn’s disease (n=188) and UC (n=174) who had started using SCD as dietary
therapy at home. After 2-months on the diet 33% reported remission and after 6-
months and 12-months 42% reported they had reached remission. Although patients
symptoms improved, it is possible they had ongoing inflammation; however 47% of
patients who reported reaching remission on the diet also reported improved clinical
blood markers but the study did not give details.579 A recent North American study
reported clinical remission in 8/10 children with active Crohn’s disease after initia-
tion of the SCD diet without use of concomitant treatment, which were also linked
with significant changes in gut bacterial composition.580 The Crohn’s Disease Exclu-
sion Diet (CDED) was created by a research group in Israel in 2014,581 following the
hypothesis that efficacy of EEN is due to exclusion of dietary constituents, which
either increase gut permeability or a pro-inflammatory gut microbiota composition.
It excludes: gluten, dairy, animal fat, processed meats, emulsifiers and all processed
foods. In a study of patients with mild/moderate Crohn’s disease, treatment using
50% polymeric formula plus the CDED exclusion diet, the combined diet was suc-
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cessful in achieving clinical remission in 21/29 children and 6/11 adults; including a
reduction in inflammatory markers.581 Interestingly a group of seven patients on this
study, who refused the polymeric formula, achieved either clinical remission (6/7) or
response (1/7) using CDED alone.581
A study in adult Crohn’s patients has also shown that after induction of remission on
EEN, that in forty patients who excluded foods which they perceived as ‘triggering’
symptoms, had extended remission along with reduced inflammatory markers when
compared with thirty-eight patients who remained on their normal habitual diet.582
Although not as well studied, low-lactose and FODMAP (low fermentable oligosac-
charides, disaccharides, monosaccharides, and polyols) diets have been reported to
reduce symptoms of IBD.583;584 In one study fifty-two adult Crohn’s disease and
twenty UC patients were given FODMAP dietary advice with telephone follow-up
on compliance and symptoms.583 Around 70% of patients adhered, while around
50% responded to diet (p<0.02). For Crohn’s disease, efficacy was associated with
dietary adherence (p=0.033) and inefficacy with non-adherence (p=0.013).583 In an-
other study of thirty-nine adult Crohn’s disease patients using a FODMAP diet 72%
reported a reduction in gastrointestinal symptoms.584 Although neither of these stud-
ies looked at whether the diet had an impact on inflammatory markers, and data
showing reduced gut mucosal inflammation is lacking, low FODMAP diets, in a simi-
lar way to EEN, have been shown to reduce colonic healthy commensal bacteria such
as F. prausnitzii within the colon, as well as faecal butyrate.585 Achieving adequate
fibre intake on a low FODMAP diet is challenging as it excludes a number of high
fibre foods, thus any mechanism to reduce inflammation on a FODMAP diet may
simply be due to lack of fibre in the colon.
Excluding sugar has shown little evidence of amelioration in Crohn’s disease586 while
omega-3 fatty acids have shown some promise in reducing symptoms.587 Although
exclusion diets may have a role in maintenance of remission in Crohn’s disease, it will
be necessary to characterise their effect on mucosal healing, as well as gut microbiota
and metabolite composition. Careful nutrient assessment of potential exclusion diets
will also be necessary for children who are still growing.
Diet is important in gut homeostasis; interacting with the microbiota; host barrier
function and immune sensing.588 It therefore makes sense to explore the potential
role of dietary factors in the pathogenesis of Crohn’s disease. Modifying diet as a
target for prevention and treatment of IBD is attainable, however understanding its
role in Crohn’s disease in terms of ability to modify gut microbiota composition and
the production of metabolites, is much more complex. The following chapter, using
estimated diet from food frequency questionnaires (FFQs), will look at differences
in diet between healthy children and children with Crohn’s disease; before going on
to examine how EEN is nutritionally different from normal habitual diet, and what
impact this might have on controlling inflammation in the gut.
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7.1.3 Hypotheses
 The composition of dietary intake at baseline in children with Crohn’s disease is
different from that of healthy children. Given that children with Crohn’s have
reduced bacterial diversity, particularly among the Firmicutes, it is predicted
they will also have reduced intake of dietary fibre.
 The incidence of Crohn’s disease is higher in boys. It is therefore predicted that
dietary intake in boys with Crohn’s disease is different from that of girls.
 That dietary intake at baseline predicts response to treatment with EEN.
 That attaining remission using EEN for 8-weeks will affect dietary choices post-
EEN i.e. That habitual dietary intake post-EEN will differ from dietary intake
at baseline.
 Diet at baseline is associated with the gut microbiota profile and inflammatory
status of children with Crohn’s Disease.
7.2 Methods
The detailed composition of enteral nutrition (Modulen IBD) is given in appendix 7.2,
and details of treatment with exclusive and maintenance enteral nutrition are given in
Methods 2.3. To establish the child’s normal habitual diet, additional information on
dietary intake was gathered using child specific food frequency questionnaires (FFQ)
and 3-day food diaries which were collected at each time-point over the course of the
study.
Details about other dietary methods which were used at the start of the study, along
with detailed FFQ methods are described in Methods 2.5. In brief the FFQ, a con-
structed list of foods and drinks with a frequency response tick-box section, was used
to report the frequency of all foods eaten based on the previous 2-weeks diet. Calcu-
lations for nutrient intake were estimated by the diet survey team at the University
of Aberdeen (calculations multiply frequency of item eaten by amount of nutrient
in each serving).290 Paper copies of the Scottish Collaborative Group validated FFQ
(Appendix 7.1.2) were used and include ∼150 commonly eaten UK foods or drink.291
Two versions were used: one which is designed for children aged between 3-11 and
normally completed by parents/guardian; a second version designed for young people
aged between 12-17, which includes coffee and alcohol, and is completed by the young
person themselves.
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Figure 7.1: Number of FFQ questionnaires collected from each study group at baseline and children
with Crohn’s disease at: A -baseline; D -2wks and E -8wks normal habitual diet. * Composition of
diet at B and C -4wks and 8wks EEN was calculated from the known amounts of enteral nutrition
taken during dietary treatment.
An FFQ was given to each participant at baseline and subsequently at each time point
for children with Crohn’s disease when faecal samples were requested. Participants
were prompted to think about hidden ingredients in composite foods such as milk
and sugar in tea; or butter in sandwiches. They were asked to record the foods and
drinks they had consumed in the previous 2-weeks. Participants were also requested
to fill out a 3-day food diary shown in (Appendix 7.1.1). Although fourteen healthy
children completed these, only three children with Crohn’s disease completed the
requested 3-day food diary at 2-weeks and 8-weeks post EEN. No children with non-
IBD conditions or UC returned their 3-day diary. Compliance was so poor, that a
decision was reached not to include 3-day diaries in the study. Perhaps because the
study was about Crohn’s disease, those with UC and non-IBD conditions often failed
to complete and return FFQs after a reminder was sent, leaving the study with only
six FFQs for children with UC and five for non-IBD conditions. At each subsequent
time-point fewer children with Crohn’s disease returned their FFQ (Fig. 7.1).
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7.3 Results
7.3.1 Differences in dietary intake at baseline
Four children with Crohn’s disease and two children with UC, reported they were
struggling to eat their normal diet, reflected in their median estimated energy intake
(Fig. 7.2). Although median energy intake (kcal) for children with Crohn’s and UC
was less than healthy children, the difference was not significant (p=0.24)(Table 7.3).
There was no difference between children with Crohn’s disease and healthy controls or
other patient groups for carbohydrates (including sugars), protein or fat (Table 7.3).
Fibre intake was reduced compared with healthy children in all three patient groups,
and was significant for both children with Crohn’s and UC (p<0.05). Estimated
intake of vitamin A (retinol), vitamin E, vitamin B7 (biotin) and vitamin C were
significantly reduced in children with Crohn’s disease (Table 7.3; Fig. 7.4). There
was a strong significant correlation between fibre and vitamin C intake in healthy
children, however the same relationship was not seen in children with Crohn’s disease
(Fig. 7.3).
Figure 7.2: Estimated energy intake from FFQs for all groups of children at baseline. No significant
difference seen between groups: Kruskal-Wallis p=0.24
Figure 7.3: Relationship between fibre and vitamin C intake from FFQs in children with Crohn’s
disease and healthy children at baseline. Shaded area shows the 95% confidence interval Spearman
rank.
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Table 7.3: Estimated dietary intake (FFQ) at baseline
Crohn’s UC non-IBD healthy p-value
Dietary component (n=22) (n=6) (n=5) (n=21) KW ⋆
Macro-nutrients
Water 789 (305) 635.28 (272) 843 (155) 988 (430) p=0.27
Energy (kcal) 1488 (480) 1276 (651) 1273 (231) 1643 (633) p=0.24
Carbohydrate (g) 211 (80) 155 (53) 167 (16) 221 (67) p=0.41
Protein (g) 56.8 (16.6) 51.3 (30.1) 46.9 (13.7) 59.1 (15.2) p=0.32
Fat (g) 52.3 (16.3) 53.2 (21.4) 47.7 (13.5) 59.9 (20.1) p=0.11
SFA (g) 23.0 (9.0) 23.2 (8.9) 21.4 (5.2) 27.8 (13.4) p=0.16
MUFA (g) 17.8 (5.6) 18.3 (6.2) 16.1 (4.8) 20.5 (8.6) p=0.13
PUFA (g) 8.2 (2.3) 6.9 (4.0) 6.18 (1.7) 9.0 (3.0) p=0.06
Choline (mg) 155 (37.8) 161 (89.7) 153 (46.0) 161 (84.5) p=0.73
Sugars (g) 86.0 (42.3) 70.7(38.6) 95.4 (10.9) 105.9 (48.6) p=0.33
Starch (g) 108.5 (39.3) 103.5 (48.2) 104 (28.2) 101 (40.0) p=0.68
Fibre (g) *9.15 (4.08) *7.93 (3.55) 8.18 (2.15) 13.18 (4.72) p=0.02
Micro-nutrients
Na (mg) 2131 (881) 2187 (755) 2004 (212.01) 2206 (1142) p=0.44
Cl (mg) 3203 (1142) 3203 (1230) 3088 (426) 3499 (1401) p=0.42
K (mg) 2176 (912) 1668 (338) 1771 (80) 2476 (1036) p=0.06
Ca (mg) 932 (486) 577 (218) 822 (136) 926 (216) p=0.50
Mg (mg) 207 (92) 150 (51) 169 (28) 227 (79) p=0.12
P (mg) 1105 (504) 826 (432) 916 (227) 1140 (399) p=0.23
Fe (mg) 8 (3) 7 (3) 7 (2) 10 (5) p=0.31
Cu (mg) 0.9 (0.3) 0.6 (0.3) 0.8 (0.2) 0.8 (0.3) p=0.20
Zn (mg) 6.7 (2.6) 5.7 (3.1) 5.6 (1.7) 7.0 (2.0) p=0.30
Mn (mg) 2.0 (0.7) 1.5 (0.7) 1.7 (0.4) 2.4 (0.9) p=0.08
Se (ug) 28 (9.6) 28 (11.1) 22 (1.5) 31 (11.9) p=0.63
I (ug) 168 (75) 132 (79) 119 (13) 181 (39) p=0.21
Vit A retinol (ug) **212 (108) 256 (145) 193 (40) 309 (156) p=0.02
Carotene (ug) 1271 (1086) 1300 (604) 1391 (589) 1600 (1130) p=0.14
Vit D (ug) 1.4 (0.7) 1.2 (0.6) 1.2 (0.4) 1.6 (0.8) p=0.25
Vit E (mg) *5.5 (1.4) 4.8 (2.5) *4.3 (1.2) 6.5 (2.3) p=0.01
Vit B1 thiamine (mg) 1.3 (0.5) 1.2 (0.6) 1.1 (0.1) 1.3 (0.6) p=0.66
Vit B2 riboflavin (mg) 2.0 (1.3) 1.4 (0.6) 1.6 (0.4) 1.9 (0.9) p=0.76
Vit B3 niacin (mg) 17.6 (8.9) 14.2 (5.9) 11.9 (1.5) 14.0 (5.3) p=0.69
Vit B5 pan. acid (mg) 5.3 (2.2) 3.5 (1.6) 3.7 (0.3) 5.2 (1.8) p=0.42
Vit B6 (mg) 1.7 (0.7) 1.2 (0.3) 1.3 (0.1) 1.4 (0.5) p=0.79
Vit B7 biotin (ug) *24 (12) 14 (14) 21 (6) 30 (11) p=0.05
Vit B9 (ug) 238 (135) 237 (146) 200 (37) 244 (130) p=0.62
Vit B12 (ug) 5.0 (1.4) 3.1 (1.9) 3.8 (1.3) 5.3 (2.1) p=0.47
Vit C (ug) ***62.5 (34.8) 80.5 (36.3) 96.0 (35.6) 123.0 (81.5) p<0.001
Median (IQR) are shown. Dunn’s test of multiple comparisons following a significant ⋆ Kruskal-Wallis
(KW) test was used. Difference from healthy children is significant at * p≤0.05 ** p≤0.01, *** p≤0.001.
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(a)
Vitamin C
(b)
Vitamin A
(c)
Vitamin E
(d)
Figure 7.4: The key differences between children with Crohn’s disease and healthy children, in
estimated daily dietary intake based on FFQ questionnaires at baseline for (a) fibre; (b) vitamin
C (ascorbic acid); (c) vitamin A (retinol) and (d) vitamin E. Dunn’s test of multiple comparisons
following a significant Kruskal-Wallis test was used.
7.3.2 Dietary intake and gender
A metric distance scaling plot (MDS) was used create profiles of macronutrient intake
at baseline, based on estimated diet from FFQs, to look for any differences between
boys and girls with Crohn’s disease. No difference was seen between baseline dietary
profiles based on gender (Fig. 7.5).
7.3.3 Diet at baseline as a predictor of response to EEN
No relationship was seen between energy intake at baseline in children with Crohn’s
disease and disease severity measured using the weighted paediatric Crohn’s disease
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Figure 7.5: Estimated baseline macronutrients as estimated from FFQs, in children with Crohn’s
disease split by gender. No gender difference is seen between baseline dietary profiles. Metric
distance scaling plot (MDS), PERMANOVA: R2=0.092; p=0.142
activity index (wPCDAI) score (Fig. 7.6). Thus reduced energy intake at baseline
did not predict disease activity. The composition of diet at baseline did not predict
which children would respond to treatment with EEN (Table 7.4; Fig. 7.7).
rho;-0.012; p=0.957
(a)
rho;-0.010; p=0.964
(b)
Figure 7.6: Relationship between energy intake (kcal) at baseline, expressed as a percentage of esti-
mated average requirement (EAR) to correct for age and gender, and disease activity measured using
(a) the weighted paediatric Crohn’s disease activity index (wPCDAI) and (b) faecal calprotectin in
children with Crohn’s disease. Spearman: no correlation seen.
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Table 7.4: Estimated dietary intake from food frequency questionnaires (FFQ) at base-
line in non-responders and responders to EEN, based on dietary components which were
significantly reduced in children with Crohn’s disease.
Children with Crohn’s disease
non-responder responder
Dietary component * (n=8) (n=13) MWU test
Fibre (g) 9.2 (6.6) 9.4 (5.2) p=0.915
Vitamin A retinol (ug) 193 (96.2) 206 (122) p=0.456
Vitamin E (mg) 5.6 (2.5) 5.5 (1.9) p=0.645
Vitamin B7 biotin (ug) 22.7 (12.5) 24.5 (13.5) p=0.972
Vitamin C (mg) 61.5 (34) 74 (37) p=0.972
Results are shown as the median (IQR). Significance of difference at baseline between
non-responders and responders to treatment with EEN calculated using Mann-Whitney.
* Dietary components shown were all significantly reduced in children with Crohn’s com-
pared with healthy children.
(a)
Figure 7.7: Diet at baseline as a predictor of response to EEN in children with Crohn’s disease: for
estimated daily dietary intake based on FFQ questionnaires for macronutrients. No difference is
seen in dietary profiles between responders and non-responders; Metric distance scaling plot (MDS)
PERMANOVA.
7.3.4 Dietary intake during treatment with EEN
Twenty-three (72%) children with Crohn’s disease took EEN as 5-6 ∼300ml shakes
per day orally and nine (28%) children via nasogastric tube (NG-tube). Children
opted to use a NG-tube if they felt unable to tolerate the taste after being given
samples to try. Two of the nine children who took EEN via NG-tube began taking
EEN orally, but switched to NG-tube within the first week. Although children who
used an NG-tube were less likely to fail EEN, the difference was not significant (χ2
p=0.18) (Chapter 3; Table 3.13) Of the thirty-two children with Crohn’s disease who
were treated with EEN there was no difference in time to relapse between children
who took EEN via NG-tube and those who took it orally (Fig. 7.8)
Children who responded well to the treatment were kept on EEN for 8-weeks to induce
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Figure 7.8: Number of days from start of treatment with EEN to disease relapse in children with
Crohn’s disease who took the feed orally (oral) and those who took EEN via nasogastric tube
(NG-tube). (No difference between groups).
remission. Three children who did not respond to EEN managed to stay on EEN for
the full 8-weeks. Two children who failed to respond were on EEN for 6-weeks and
another two children stopped at around 4-weeks treatment. Two children, who were
clear non-responders to treatment, stopped EEN after only 1-week. Children who
failed treatment with EEN were treated with corticosteroids.
To get an understanding of how EEN is nutritionally different from the child’s base-
line diet, the estimated daily food intake (FFQ) for each child with Crohn’s disease,
was compared with their 8-week prescribed intake of EEN (composition of Modulen
given in appendix 7.2). The first major difference was that Modulen as a liquid
feed increased the water content of the child’s diet (Table 7.5). The proportions of
macronutrients as a ratio of total energy intake on EEN are similar to the estimated
baseline diet of children with Crohn’s disease, but with a reduced ratio of carbohy-
drate (57%) intake compared with baseline (66%), and a higher ratio of fat (24%)
compared with baseline diet (16%). The composition of fatty acids was different on
EEN, with a higher proportion of saturated fatty acid on EEN (67%) compared with
estimated baseline diet (46%).
Modulen is deliberately given as a low residue diet and thus has no fibre content.
The amount of sugar is also reduced on EEN suggesting the median reduced from
86g on baseline diet to 66g of sugar on EEN, although sugar at baseline was highly
variable (Table 7.5). In terms of micronutrients sodium was greatly reduced on EEN
from an estimate of 2,131mg (IQR 881) at baseline to 748mg (IQR 101) on EEN,
while all other micronutrients were increased on EEN. All vitamins recorded were
also increased on EEN when compared with the estimate of baseline diet from FFQs
(Table 7.5).
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Table 7.5: Differences between estimated dietary intake from food frequency
questionnaires (FFQ) and known intake at 4-weeks EEN (Modulen) given as
median (IQR)
wk-0 (baseline) wk-4 (EEN) Wilcoxon
Dietary component (n=12) (n=12) paired test
Macro-nutrients
Water 749 (395) 1870 (340) p<0.001
Energy (kcal) 1370 (698) 2200 (400) p=0.003
Carbohydrate (g) 188 (95) 238 (43) p=0.077
Protein (g) 55 (24) 79 (14) p=0.002
Fat (g) 52 (20) 101 (18) p<0.001
SFA (g) 20 (11) 57 (10) p<0.001
MUFA (g) 18 (6.2) 17 (3.1) p=0.970
PUFA (g) 8.0 (2.8) 11 (1.9) p=0.034
Choline (mg) 150 (50) 154 (28) p=0.388
Sugars (g) 70 (51) 66 (12) p=0.380
Fibre (g) 8.8 (5.0) 0 (0) p<0.001
Micro-nutrients
Na (mg) 2177 (959) 748 (136) p<0.001
Cl (mg) 3306 (1455) 1606 (292) p=0.002
K (mg) 1926 (848) 2640 (480) p<0.001
Ca (mg) 712 (568) 1958 (356) p<0.001
Mg (mg) 181 (89) 440 (80) p<0.001
P (mg) 933 (516) 1320 (240) p<0.001
Fe (mg) 7.5 (4.0) 24 (4.3) p<0.001
Cu (mg) 0.8 (0.3) 2.2 (0.4) p=0.003
Zn (mg) 6.6 (3.2) 21 (3.8) p<0.001
Mn (mg) 2.0 (1.0) 4.3 (0.8) p<0.001
Se (ug) 29 (12) 75 (14) p<0.001
I (ug) 149 (113) 216 (39) p=0.002
Vitamin A retinol (ug) 164 (92) 1804 (328) p<0.001
Vitamin D (ug) 1.5 (1.0) 22 (3.9) p<0.001
Vitamin E (mg) 5.3 (1.5) 29 (5.2) p<0.001
Vitamin B1 thiamine (mg) 1.2 (0.5) 2.6 (0.5) p<0.001
Vitamin B2 riboflavin (mg) 1.7 (1.2) 2.8 (0.5) p<0.001
Vitamin B3 niacin (mg) 15.7 (8.1) 25.5 (4.6) p<0.001
Vitamin B5 pantothenic acid (mg) 4.3 (3.2) 10.6 (1.9) p<0.001
Vitamin B6 (mg) 1.4 (0.8) 3.6 (0.7) p<0.001
Vitamin B7 biotin (ug) 23 (14) 70 (13) p<0.001
Vitamin B9 (ug) 198 (133) 528 (96) p<0.001
Vitamin B12 (ug) 3.9 (3.0) 7.0 (1.3) p<0.001
Vitamin C (mg) 61 (30) 207 (38) p<0.001
Significance of difference from baseline and 4-weeks EEN calculated using
Wilcoxon paired test. Unpaired data from all time-points are shown in appendix
7.3.
251
7.3.5 Dietary intake post-EEN
Paired data showing the estimated dietary intake at baseline and again at 2-weeks
post-EEN (study week-10) for patients with Crohn’s disease, shows a median energy
increase which was not statistically significant (Table 7.6).
Table 7.6: Differences between estimated dietary intake from food frequency
questionnaires (FFQ) at baseline (week-0) and 2-weeks post-EEN (week-10)
wk-0 wk-10 Wilcoxon
Dietary component (n=9) (n=9) paired test
Macro-nutrients
Water 739 (277) 800 (391) p=0.203
Energy (kcal) 1210 (475) 1456 (385) p=0.359
Carbohydrate (g) 172 (58) 191 (75) p=0.426
Protein (g) 49.7 (20.7) 51.7 (26.7) p=0.496
Fat (g) 46.6 (17.2) 54.6 (7.6) p=0.496
SFA (g) 17.1 (9.3) 22.4 (4.5) p=0.301
MUFA (g) 17.2 (4.8) 18.4 (2.0) p=0.652
PUFA (g) 7.1 (2.1) 7.8 (1.0) p=0.820
Choline (mg) 148 (58) 129 (113) p=0.203
Sugars (g) 67.9 (39.2) 93.9 (30.1) p=0.203
Fibre (g) 8.7 (2.0) 10.0 (4.4) p=0.652
Micro-nutrients
Na (mg) 1898 (1033) 1657 (607) p=0.820
Cl (mg) 2886 (1636) 2554 (1017) p=0.910
K (mg) 1607 (766) 2140 (856) p=0.098
Ca (mg) 616 (456) 707 (271) p=0.203
Mg (mg) 157 (73) 169 (80) p=0.213
P (mg) 751 (430) 958 (415) p=0.203
Fe (mg) 7.0 (2.4) 6.9 (1.8) p=0.426
Cu (mg) 0.7 (0.2) 0.7 (0.2) p=0.820
Zn (mg) 6.0 (2.7) 5.8 (2.6) p=0.734
Mn (mg) 1.8 (1.0) 1.9 (1.1) p=0.734
Se (ug) 26 (16) 28 (16) p=0.779
I (ug) 115 (116) 168 (53) p=0.098
Vitamin A retinol (ug) 163 (71) 214 (53) p=0.039
Vitamin D (ug) 1.4 (0.9) 1.3 (0.7) p=0.820
Vitamin E (mg) 5.1 (1.6) 6.2 (2.0) p=0.496
Vitamin B1 thiamine (mg) 1.1 (0.5) 1.1 (0.4) p=0.820
Vitamin B2 riboflavin (mg) 1.4 (1.3) 1.5 (0.2) p=0.359
Vitamin B3 niacin (mg) 13.7 (9.3) 12.9 (7.3) p=0.820
Vitamin B5 pantothenic acid (mg) 3.3 (2.9) 4.1 (2.0) p=0.426
Vitamin B6 (mg) 1.2 (0.8) 1.4 (0.6) p=0.734
Vitamin B7 biotin (ug) 21.6 (11.1) 20.2 (10.3) p=0.129
Vitamin B9 (ug) 195 (59) 209 (111) p=0.250
Vitamin B12 (ug) 3.0 (2.3) 3.6 (1.0) p=0.570
Vitamin C (mg) 74 (28) 68 (59) p=0.440
Results are given as median and (IQR). Difference from baseline is significant
at p≤0.05. Study week-10 represents 2-weeks of normal habitual diet post-
EEN. Unpaired data from all time-points is shown in appendix 7.3.
Seven children who went into remission on EEN and completed an FFQ at both
baseline and 2-weeks post EEN (study week-10) are shown in figure 7.9. At 2-months
post EEN patient 036 had relapsed; by 8-months post EEN patients 031, 038 and
041 had also relapsed and gone onto treatment with steroids. Three patients 015,
016 and 055 were still in remission at the end of the study (11-months post-EEN).
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Figure 7.9: Changes in estimated diet at baseline (wk-0) and post-EEN (wk-10) for estimated dietary
intake based on FFQ questionnaires for: (a) energy (kcal); (b) fibre intake; (c) vitamin C intake;
(d) dairy intake; (e) fruit intake, and (f) vegetable intake.
7.3.6 Linking dietary intake with gut microbiota
At genus level taxonomy, differences in the correlation between children with Crohn’s
disease and healthy children were seen for macronutrient intake at baseline (Fig.
7.10): including fat (particularly PUFA); protein and fibre. Five genera, including
three Firmicutes, a Proteobacteria and an Archaea genus were significant between
children with Crohn’s disease and healthy children (p<0.05).
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Figure 7.10: Correlation between macronutrient dietary intake (FFQ) and gut microbiota genera in
children with Crohn’s disease (CD) and healthy children (HC) at baseline. Kendall rank correlation
significant at * p≤0.05 (Multiple comparison - Benjamini-Hochberg).
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7.4 Discussion
7.4.1 Summary of results
Compared with healthy children, the composition of dietary intake at baseline in
children with Crohn’s disease had significantly less estimated intake of vitamin A, E,
B7 and C. Fibre intake was also significantly reduced in both children with Crohn’s
disease and UC. No differences in macronutrient intake were seen between boys and
girls with Crohn’s disease to explain the increased incidence in boys.
Neither energy intake or composition of diet at baseline predicted which children
would respond to treatment with EEN. As known, fibre intake is reduce to zero on
EEN. However due to EEN being fortified, all vitamins and micronutrients (except
NaCl), along with energy and water intake were significantly increased during EEN,
making many aspects of the diet compositionally different from their baseline diet.
Although as a group no significant differences were seen in dietary intake between chil-
dren with Crohn’s disease at baseline and 2-weeks post EEN; three of these children
decreased their fibre, fruit and vegetable intake at 2-weeks post EEN (one relaps-
ing at 6-weeks and two relapsing at 8-months post-EEN). Four children increased
their fibre, fruit and vegetable intake at 2-weeks post EEN (three of these were still
in remission at 11-months post-EEN). Hence all children made alterations to their
baseline diet at 2-weeks post-EEN.
In the current study, diet at baseline was significantly associated with five genera,
including three Firmicutes, a Proteobacteria and an Archaea genus. Ruminococcus
1 showed a positive correlation in healthy children but a negative correlation in
children with Crohn’s disease, which was significant for fat and protein. Of five
Ruminococcus 1 species (SNVs) which showed this correlation pattern, only two
abundant species showed a significant correlation (data not shown). Isolating strains
of Ruminococcus from Crohn’s disease patients, to look at how nutrition in vivo
affects behavioural changes in fermentation capacity in these strains, might help to
explain these differences.
7.4.2 Differences in dietary intake between Crohn’s and healthy children
A 2011 systematic review looking at dietary risk factors concluded that total fats,
PUFAs, omega-6 fatty acids, and meat were linked with an increased risk of IBD.68
The review concluded that increased fibre and fruit intake reduced the risk of Crohn’s
disease. Although the FFQ might be considered a blunt tool, the current study find-
ings support the review, in that, children with Crohn’s disease had significantly lower
intake of fibre and vitamin C (Table 7.3). Data from the current study suggests
children with IBD have a reduced intake of vitamins including vitamin A, E, B7
and C, when compared with healthy children. Given malabsorption is a key feature
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of Crohn’s disease and UC, low intake of key vitamins could have negative effect on
inflammation. Increased levels of vitamin E has been shown in mouse models, to mod-
ulate neutrophil migration in the mucosa of the lung, increasing polymorphonuclear
leukocyte elastase activity, boosting antimicrobial defence against pneumococci.589
Vitamin A (retinol) deficiency has been associated with an increase in infectious dis-
ease.590 Retinol imprints the homing of leukocytes to the gut enhancing induction of
Treg cells,
591 and is a dominant mediator of CD4+ T-cell immunity and homoeosta-
sis. It is also known Th1 and Th17 cell immunity are dependant on metabolites of
retinol.592 It has been shown that vitamin deficiency for serum retinol and vitamin E
is significantly more prevalent in Crohn’s disease patients who had active disease.593
Vitamin D It has been proposed that increased incidence of Crohn’s disease in
northern Europe is due to lack of sunlight, resulting in loss of vitamin D3.
594 Although
in the current study there was no significant difference in estimated dietary vitamin
D intake between groups, the estimated daily intake for all children including healthy
children at around 1.6 g was well below the recommended daily intake of 10 g.
Vitamin D is a hormone which has a diverse range of effects such as increased den-
dritic cell function, autophagy and expression of the Crohn’s disease associated gene
NOD2 which is involved in bacterial sensing. Vitamin D deficiency is starting to be
recognised as a potential driver of IBD.595 In vitro studies have looked at the role of
vitamin D in macrophages and mouse models of IBD.596;597;598 A 2010 study found
vitamin D deficiency left mice prone to colitis via dysregulation of colonic antimicro-
bial activity and impaired bacterial homoeostasis.599 Deficiency also has an effect by
reducing the expression of epithelial tight junction proteins,600 and elevating Th1-
driven inflammation in the gut601 A 2015 meta-analysis showed that of 938 patients
with IBD 64% were more likely to be vitamin D deficient compared to 953 healthy
controls (OR=1.64; 95% CI: 1.30, 2.08; I2=7%; p<0.0001). This study also found
no association between IBD and vitamin D deficiency and latitude (p=0.34).602 The
study does have some limitations as the odds ratios came from dichotomous (cate-
gorical) data in many of the studies, and confounding factors such as diet were not
recorded. It is therefore unclear whether vitamin D deficiency in patients with IBD
is a result of disease related malabsorption caused by damage to the mucosa,603 or
whether it might be a contributing factor to disease onset and progression.604;605
Although supplementation with vitamin D3 has a potential therapeutic impact on the
course of Crohn’s disease,594 lack of sunlight and vitamin D3 alone cannot explain the
marked increase in incidence over time.594 Therefore, large randomised control trials
administering variable doses of vitamin D supplementation with data on IBD type,
disease location and disease activity would help us understand the potential thera-
peutic significance of vitamin D, but further work using animal models are needed to
uncover the mechanisms in terms of both immunology and the gut microbiota.
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Vitamin C Although vitamin C does not play a direct role in immune function, it
plays a role in redox recycling of other important antioxidants such as regenerating
vitamin E from its oxidised form.606 Vitamin C also increases the bioavailability of
iron from ingested food by increasing the gut absorption of non-heme iron.607 A neg-
ative correlation between vitamin C intake and risk of Crohn’s545 and risk of UC has
been shown.546 Since vitamin C intake is linked with the intake of fruit and vegetable
fibre it is difficult to separate vitamin C from fibre as a risk factor. A recent Chinese
study using a colitis mouse model has shown that vitamin C reduced inflammation, by
blocking pro-inflammatory cytokines, and increasing tight-junction proteins occludin
and ZO-1.608 The study also reported that vitamin C promoted the production of
SCFA in the gut, as well as playing a role in regulating the microbiota.608 It is in-
teresting in the current study that six parents of children with IBD were well aware
of poor fruit and vegetable intake, with one family reporting their child refused to
eat any type of fruit. Therefore it might be useful for future studies to explore any
potential anti-inflammatory properties of vitamin C, in children with Crohn’s.
Zinc undernutrition has also been shown to impair mediators of innate immunity
including natural-killer cell activity.609 Overall undernutrition could have implications
in helping to maintain gut inflammation in children with Crohn’s disease especially
where malabsorption and diarrhoea are key symptoms.
Fibre With increasing evidence that IBD is linked to a dysbiosis of the gut micro-
biota, there is growing interest in whether diet can positively influence disease activ-
ity. Using dietary fibres as pre-biotics, such as inulin-type fructans and arabinoxylan-
oligosaccharides, have been shown to increase numbers of Bifidobacteria in the gut.610;523
Bifidobacteria have been shown to be important in the gut by degrading non-digestible
carbohydrates; providing protection against pathogens; synthesising B vitamins; con-
jugating linoleic acids and stimulate the immune system.611 Increasing dietary fibre
has also been shown to increase butyrate in the human colon which as the preferred
energy source for the colonocytes, maintains gut barrier functions as well as having
immunomodulatory and anti-inflammatory effects. It has been shown the butyrogenic
effects of dietary fibre such as fructans and oligosaccharides, are due to cross-feeding
interactions between Bifidobacteria and butyrate-producing colon bacteria, such as
Faecalibacterium prausnitzii (clostridial cluster IV); Anaerostipes, Eubacterium and
Roseburia species (clostridial cluster XIVa).523 These cross-feeding interactions could
favour the co-existence of other beneficial bacterial strains and butyrate-producing
bacteria in the colon, leading to increased diversity and a more stable microbiome.
It is therefore interesting to see a significantly reduced dietary fibre in children with
IBD compared with healthy children in the current study. These findings support the
evidence that dietary fibre is a risk factor for IBD.547;540 Murine studies using soluble
fibres and resistant starch;561 pectin;562 guar gum;563 and a multi-fibre mix,564 all
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show fibre to have anti-inflammatory effects. There is a great deal of controversy
around whether fibre is beneficial to patients with Crohn’s disease, given EEN which
is used to induce remission contains no fibre, and is proposed to work by depriving
the colonic bacteria of a food source.
7.4.3 Gender and food choices
Although there is worldwide evidence showing variation in male/female ratios in
Crohn’s disease in Asia,90;91;92;93 across Europe and North-America,94 which might
suggest that boys have a higher risk of developing Crohn’s disease in childhood/adolescence
than girls, it has not been demonstrated this is a true gender difference based on bio-
logical differences. In adult populations studies including North America and Western
Europe suggest females have a higher incidence of Crohn’s disease, where Asian stud-
ies mostly see higher rates in adult males.612 Hence it is unlikely that incidence of
Crohn’s disease is linked with gender differences in genetic risk profiles. However,
variations in gender risk could be linked with cultural differences in gender roles, re-
sulting in exposure to different environmental risk factors such as dietary intake. The
gender difference in Scotland, inline with other developed countries is rising.84 The
fact that gender ratio is changing over time suggests exposure to the risk factors is
unequal between boys and girls, thus it makes sense to ask whether differences in diet
could provide clues as to why boys seem to be at higher risk of IBD and particularly
Crohn’s disease.84
The current study is the first in Scotland to compare the dietary intake of boys and
girls with Crohn’s disease. No difference in macronutrient profile was seen between
boys and girls (Fig. 7.5), however the current study had a low sample size, especially
girls (n=7). The FFQ is also an estimate of diet and thus a more detailed dietary
assessment such as the 5-step multi-pass dietary record conducted on a larger samples
size may show differences not seen in the current study.
As discussed in Chapter 1; section 1.7, a gender bias in incidence could be due to
behavioural differences in reporting symptoms, as well as differences in clinical refer-
ral and diagnosis.95 However if this were the case, we would expect to see baseline
gender differences in disease severity, as well as differences in SDS anthropometric
measures at baseline. However the current study found no difference in disease ac-
tivity or SDS-weight, SDS-height or SDS-BMI at baseline between boys and girls
(Fig. 3.8). Identifying any gender-specific dietary differences between children with
Crohn’s disease and healthy children are important, because combined analysis has
the potential to mask dietary associations which might be more distinct in one gender
than the other.
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7.4.4 Diet as a predictor of response to EEN
The current study showed compositional gut bacteria differences at baseline between
responders and non-responders to treatment with EEN, and therefore it was pre-
dicted children who failed EEN would have a diet compositionally different from
children who responded to treatment with EEN. However estimated dietary intake
from FFQ data in the current study, showed no differences between responders and
non-responders for fibre, vitamin A, vitamin B7 vitamin E, vitamin C, or energy
intake (dietary components that were significantly different between Crohn’s disease
and healthy children). However only eight non-responders returned in an FFQ, and
four of these were girls, hence low sample size and possible gender bias means further
study is required before rejecting the hypothesis that dietary intake at diagnosis could
predict response to EEN. Further studies which include higher numbers of patients,
detailed dietary records such as the five-step multi-pass, as well as separate gender
analysis, would help to answer this question.
7.4.5 The composition of EEN and its anti-inflammatory effects
The current study shows dietary intake at baseline in children with Crohn’s disease
is compositionally different from EEN (Modulen) in a number of ways (Table 7.5).
EEN is the primary therapy used across Europe to induce disease remission as well as
promote optimum growth,613;125 and to date Crohn’s disease studies into EEN have
focused on the fact it contains no fibre, with an assumption that lack of fibre starves
gut bacteria in the colon leading to mucosal healing.567 There are a number of ways
that different components of EEN could decrease inflammation in the gut (Table 7.7)
Table 7.7: EEN - Potential modes of action
Reduced exposure to gut microbiota
- lack of fibre leads to starvation of colonic bacteria144
Increased exposure to protective compounds
- caseins (binding with potential antigens)614;615;616
- micronutrients (especially iron, zinc)617;609
- vitamins (especially Vit A, D, C, E)618
Reduced exposure to deleterious compounds
- food triggers (wheat, gluten, dairy, lactose, emulsifiers, sulphites and others)619
- salt, high intake:
• stimulates gut TH17 response and exacerbates colitis in mice*620;621;622;566
• damages colonic mucosa via reduction in goblet calls in mice*
• increased gut permeability*620
• changed gut bacteria profile in mice623
* Indirect effect could be due to changes in gut bacteria.
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Reduced exposure to gut microbiota Twenty-three dietary fibre intervention stud-
ies on IBD adult patients (6 single-arm & 17 placebo-controlled) have tested different
fibres including: fructans; psyllium; oat bran; wheat bran and germinated barley
fibres.624 Studies looking at the effect of fructans concluded that supplementation
could reduce symptoms; improve gut immune function leading to a reduction in gut
inflammation via modulation of the gut microbiota in IBD patients.624 However other
types of fibre had mixed results, which is perhaps not surprising, since dietary fibre
constitutes a varied group of chemicals which have different properties.624 On one
hand reduced fibre is linked with risk for IBD and fibre intervention studies support
this finding by suggesting increased fibre may help to reduce gastrointestinal symp-
toms;619 however contrary to this, EEN a zero fibre diet, is shown to induce remission
in children with Crohn’s disease. This is perhaps not surprising if the gut bacteria
are the intermediary which drive increased inflammation. Low fibre diets could be
altering both cross-feeding between bacteria as well as altering genetic expression of
some bacteria causing them to switch to feeding on mucosal glycans which in turn
damage the gut mucosa. A zero fibre diet reduces colonic bacteria to such low levels,
that any negative effects from cross-feeding or mucosal degradation are prevented,
until the normal low fibre diet is resumed. If the reduction in fermentation leads to a
reduction in toxic metabolites such as 1-propanol, 1-butanol and methyl/ethyl esters
of SCFA,488 this might also explain why EEN leads to mucosal healing. The cur-
rent study shows how quickly after return to normal habitual diet the inflammatory
marker calprotectin increases (Fig. 6.5d),625 suggesting benefits from EEN are short
lived.
In the current study the number of bacterial species reduced on EEN, and hence it is
important to know which groups of commensal bacteria are reduced during EEN in
order to understand how these changes might lead to reduced inflammation. Future
metagenomic studies could help identify which bacterial genes might be triggering
the host inflammatory response.
A North American study540 has shown a reduced risk of Crohn’s disease in diets which
included fruit-based fibre but no protective effect from grain, cereals and legume
fibre. The protective effect is thought to come from the SCFA derived from the
fermentation process by gut bacteria, inhibiting the transcription of pro-inflammatory
mediators.626 Fibre also helps to maintain gut barrier integrity as well as reduce the
translocation of pathogens.569 Depriving the gut bacteria of fibre in murine models has
been shown to deplete mucosal thickness causing inflammation and tissue damage.571
Increased exposure to protective compounds Although the assumption that lack
of fibre in EEN drives the reduction in inflammation, particularly as low-fibre diets
are a risk factor for Crohn’s disease,540 the current study shows there are a number of
other nutritional components in EEN, which are significantly different from habitual
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diet. These could also play a role in regulating the inflammatory response, thus fibre
which is associated with other nutrients could be a confounding factor. On EEN,
mineral and vitamin intake is increased by 2-fold for most micronutrients; vitamin C
is increased 3-fold; vitamin E 5-fold; while vitamins A and E are increased 10-fold.
As mentioned previously vitamin D is a hormone which controls expression of the
NOD2 gene, involved in bacterial sensing, hence an increase could have the potential
to improve bacterial sensing in the gut. Increased vitamin D has also been shown
to protect mice from colitis,599 as well improve the integrity of tight-junctions in
the gut.600 Hence in the current study, it is possible the increase in vitamin D from
∼1.6 g pre-EEN to 21.6 g during EEN could play some role in mucosal healing.
Vitamin C plays a role in redox recycling of other important antioxidants such as
regenerating vitamin E from its oxidised form606 and increasing bioavailability of iron
from ingested food.607 Micronutrient deficiencies have a negative impact on patient
health in Crohn’s disease,618 with iron deficiency being the most common.627 Lack
of iron can affect cell-mediated immune effector pathways and cytokine activity.617
Under inflammatory conditions iron is diverted away from the circulation to storage
within the reticuloendothelial system, to prevent pathogenic bacteria accessing it,628
leading to anaemia in Crohn’s patients. Zinc undernutrition has been shown to
impair mediators of innate immunity including natural-killer cell activity;609 therefore
increased intake of iron and minerals such as zinc, in the presence of a depleted gut
microbiota due to low fibre during EEN, could play an important role in reducing
inflammation in children with Crohn’s disease.
In the current study fat intake during EEN was increased 2-fold which does not
seem to fit with the theory that increased fat intake is a risk factor for Crohn’s
disease.68 However only the amount of saturated fatty acid (SFA) increased during
EEN while medium and polyunsaturated fatty acids remained similar to normal diet
at baseline. Evidence from a study of 182 children with Crohn’s disease and 250
healthy children show a gene–diet interaction, in which variants in genes for fatty acid
metabolism affect the relationship between Crohn’s disease risk and the ratio of PUFA
consumption.541 Dietary fat has been suggested to determine the therapeutic effect
of enteral diets in Crohn’s disease, with one study comparing whole protein based
EEN with different fat compositions in sixty-two children with Crohn’s disease.629
The linoleate rich formula (n6 polyunsaturated fatty acid) had higher remission rates
(63% vs 27%; p=0.008) than an oleate formula (monounsaturated fatty acid).629 Thus
the type of dietary fat used in formulas could be important in the efficacy of EEN.
Milk caseins are immunomodulatory proteins, able to regulate leucocyte behaviour;
control cell growth and reduce inflammation.614;615;616 Interest in the immunomodu-
latory properties of caseins has focused on neonates,630 and although Modulen, the
formula most used for EEN, is advertised as ‘100% casein based which contains a
naturally occurring anti-inflammatory factor ’, little research has looked at the role
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caseins play in reducing inflammation in Crohn’s disease. In an in vitro model, en-
terocytes exposed to inflammatory stimuli, decreased response when incubated with
Modulen, suggesting the feed could be acting directly on enterocytes, altering intra-
cellular signalling to lower production of pro-inflammatory IL-8.631 A study looking
at five milk based diets in a colitis mouse model found Modulen was the most ef-
fective at reducing inflammation and neutrophil infiltration. All of the milk based
diets reduced cytokine expression and reduced inflammation to varying degrees.632
However this study did not control for the role which lack of dietary fibre might play
in reducing inflammation.632
Another study suggests glutamine, arginine and vitamin D3 found in polymeric for-
mulas, have the ability to block phosphorylation via the NF-κB pathway in an HT-29
colonic epithelial cell model, which led to a decrease in IL-8 production.633 Thus fur-
ther research is needed to assess whether EEN has a direct anti-inflammatory effect,
independent of altering the gut microbiota.
Further research using murine and cell models, is needed to understand which com-
ponents of polymeric formulas have a direct effect on host cells, and which have a
secondary effect by driving changes in the gut microbiota. In vitro fermentation
studies using gut bacteria from patients with Crohn’s disease, with or without fibre,
as well as different fat and micronutrient compositions, could help to explore what
role different dietary components have on gut bacterial diversity during EEN.
Reduced exposure to deleterious compounds Taking EEN might help children
avoid possible detrimental compounds present in their normal habitual diet. Large
studies on children taking EEN show remission rates are in the region of 80%.634;283;635
In one study patients who failed to fully comply with the exclusive diet had a 35%
lower remission rate (NS).634 This suggest reduced exposure to dietary components
rather than exposure to EEN alone, is responsible reducing inflammation. Although
some evidence suggests partial enteral nutrition (PEN) can induce remission, PEN
still leads to a significant reduction in exposure to normal foods.
It is also noteworthy that salt (NaCl) intake is reduced by∼1/3 during EEN compared
with normal diet in children with Crohn’s disease (Table 7.5). Studies have shown a
high salt diet stimulates the immune response as well as increase gut permeability in
mice (Table 7.7).566 Further work needs to be done to assess the role high salt diets
might play on the human gut mucosa and whether reducing salt intake could help to
maintain remission in Crohn’s patients.
7.4.6 Dietary choices post-EEN
In the current study participants and their parents were aware this was a study about
diet, and that treatment with EEN is zero fibre diet. Therefore their awareness of
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diet as a treatment, may have influenced their food choices post-EEN. Results from
the current study show that with the exception of Vitamin A there were no significant
differences between dietary intake pre-and 2-weeks post-EEN (Table 7.6). However
the differences in seven individual children who went into remission on EEN suggest
that those children who increased their fibre (g); vitamin C; fruit and vegetable
intake were less likely to relapse than children who reduced intake in these food
groups, regardless of treatment with MEN or an immunosuppressant (see summary
Fig. 7.11). This might suggest that diet post EEN, particularly fibre and vitamin
C from fruit and vegetables is more important than MEN or immunosuppressant
treatment at preventing disease relapse.
Given that studies have found reduced risk for Crohn’s disease in people who have
increased fruit fibre in the diet,540;547 it is possible that increasing fibre post-EEN
could prolong time to relapse. The largest study which focused on using MEN post-
EEN as maintenance therapy, has shown it does not appear to increase time to
relapse.153 The current study also saw no increased time to relapse in children using
MEN (Fig. 3.6).625 Given that MEN has zero fibre, if increased fibre can increase the
length of time in disease remission then using MEN could potentially reduce daily
fibre intake and thus reduce length of remission post-EEN. Studies using a murine
model, followed by human clinical trials, are urgently needed to assess whether MEN,
or paradoxically, increased dietary fibre would keep children in disease remission for
longer.
Figure 7.11: A summary of changes in dietary intake at 2-weeks post-EEN compared with baseline
in seven children with Crohn’s disease who went into remission on EEN. Estimated dietary intake
(energy kcal, fibre, Vit C) and number of food items eaten (Fruit, Veg, Dairy) was calculated from
paired FFQs. Days to relapse are shown along with treatment post EEN. IM -immunosuppressant;
MEN -maintenance enteral nutrition. Summary of data shown in Fig. 7.9
7.4.7 Linking dietary intake with gut microbiota
Only a few studies have examined the role of diet on the gut microbiota of healthy
children.636;209 Research suggests the diet of people living in Western countries com-
pared with developing countries, contain a higher proportion of fats and protein while
being lower in foods such as fruit, vegetables and fibre. One of these studies which
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compared the gut microbiota of children between 1-6 years old from rural Africa
and Italy found in infants who were breastfed, the microbiota in both populations
was similar being dominated by Bifidobacterium.636 Yet, once African children were
weaned onto their local diet, which contained a higher proportion of fibre than Ital-
ian children the African children demonstrated an enrichment of their Bacteroidetes;
reflected by increased Prevotella and Xylanibacter genera, which contain genes for
both cellulose and xylan hydrolysis. Children on Italian diets had less Bacteroidetes
which were also from a different genus (Bacteroides); and had high abundance of
Firmicutes relating to higher levels of protein, fat and simple carbohydrates in their
diet. These results fitted with a previous proposal by Wu et al.212 suggesting di-
etary patterns are correlated with specific gut microbiota ‘enterotypes’ in adults.
A Prevotella enterotype being associated with an increased intake of carbohydrates
and simple sugars; and a Bacteroides enterotype being linked to an intake of higher
animal protein and saturated fats.212
Although useful, there are a number of limitations to the interpretation of data from
these studies on children. The impact of differences in genetics, climate, socioeco-
nomic status, sanitation, interaction with animals and other cultural practices which
might have had an impact on the gut microbiota between these populations cannot
be ruled out. Although it might be temping to consider the diet of rural African
populations as a standard for good gut health, this may not in fact be true. However
given that the UK is undergoing an obesity epidemic and that gut bacterial changes
driven by overnutrition can be found in a large number of ‘healthy’ children, it might
also be flawed to consider the healthy children in our study as an ideal.
In the current study five genera, three Firmicutes, a Proteobacteria and an Archaea
genus were significantly different between children with Crohn’s disease and healthy
children (Fig. 7.10). Of these Ruminococcus 1 was of particular interest as it has
been shown when fibre is restricted, some Ruminococcus strains can switch to di-
gesting mucosal proteins which in turn causes a loss of mucosal protection in turn
allowing access to potential pathogen such as Proteobacteria species.637 Mucin de-
grading Ruminococcus strains and commensals with similar genes, could play a key
role in dysbiosis by increasing the amount of bacteria associated with the mucosa in
Crohn’s disease.422
7.4.8 Study limitations - collecting dietary questionnaires
The current study had a poor return rate of 3-day food diaries, and with several re-
turned by young adults being incomplete. Therefore the study was unable to include
these and had to rely on FFQ data for estimated nutrient intakes (Fig. 7.1). A list of
issues which lead to changes in the way dietary data was collected as well as reasons
for poor return rates are given in Table 7.8. Future studies should consider the diffi-
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Table 7.8: Assessment of barriers to completing and returning food questionnaires
Person Issue *
Child
- Difficult for young children to remember what they ate at school
lunches, friends house, or clubs.
- Found task boring because it took too long to complete.
- Could not find time: five children with CD were competing in sport at
competition level and were out most evenings and weekends training.
Parent Finding time was impossible due to:
- having young children or a baby in the house.
- demands of a single parent family.
- having a child with learning difficulty/autism.
- feeling overwhelmed by the number of questionnaires.
- feeling they had done this already at baseline, and did not see the
need to complete the same questionnaire again.
Researcher
- Talking to child and parent on the phone at the same time was
impractical.
- Younger children lacked confidence to speak on the phone.
- Parent lacked knowledge about what children ate outside the home.
- Parents report what they offer children to eat, which might not be
fully consumed.
CD - Crohn’s disease. * Comments were recorded from verbal and written communications from
participants and parents.
culties of collecting dietary information from children and young adults, and consider
whether collecting this information in a clinical setting with the assistance of a dieti-
tian would be more effective. This would potentially increase costs as the dietitian
might need to spend extra time-with patients; however since patients usually see a
dietitian at review appointments, and patients often sit in the waiting area between
seeing clinicians/IBD nurse/dietitian/phlebotomists, there could be an opportunity
to use this wait time, to complete dietary questionnaires. Asking patients to attend
an appointment with a researcher to discuss diet, after visiting the clinician, the IBD
nurse, the dietitian and then a phlebotomist was challenging, since most families were
aiming to get back to work/school as quickly as possible. Understanding the practical
dynamics of both the clinical setting, as well as patient/family needs are important
in planning a successful dietary study.
7.4.9 Summary
As suggested in chapter 5, EEN may work either by altering specific bacterial groups
involved in inflammation, or via a total reduction in bacterial load ‘gut rest’. It
has been proposed that the pathogenesis of IBD could be linked with a Western
type diet which is high in fat, n-6 PUFA, processed meat and low in fibre rich green
vegetables and fruit. Therefore it is possible EEN is either providing direct nutritional
improvements or, some aspect of the diet such as casein proteins are having a direct
anti-inflammatory effect on gut epithelial cells. However animal models suggest the
presence of gut bacteria is necessary for inflammation to occur, and modulation of
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bacteria using probiotics and antibiotics have been linked to inflammation in the gut.
If diet is directly driving inflammation, antibiotics would have little or no effect in the
induction of remission in patients with Crohn’s disease. It is however possible dietary
antigens directly affect apical tight junctions or degrade the mucosal layer creating a
niche for some pathogenic bacteria which in turn drives the inflammatory response.
For example sodium caproate, a medium chain fatty acid found in milk fat, has been
shown to increase gut permeability in rat ileum by enlarging tight junctions.553 as
well as in ileal samples taken from patients with Crohn’s disease.554
On going and future research The role of diet in Crohn’s disease is of great interest
to the scientific community, because not only might diet be driving the rise in disease
in susceptible individuals, but diet also has the potential to become a successful
nutritional therapy at disease onset, and maintenance of remission in Crohn’s disease.
A number of research studies have started or are being planned to assess the role of
diet and the gut microbiota in relation to patients with IBD. The challenge for dietary
intervention is relating the gut microbiota impact directly to health outcomes, to
enable the exploration of food intake patterns in terms of carbohydrate, protein, or
fat profiles. Multifactorial experiments will be needed to tease out a dietary profile,
which leads to healthy gut bacterial and metabolite homoeostasis and is able to
maintain a stable anti-inflammatory state in the gut.
 The Food and Resulting Microbial Metabolites (FARMM) study is being con-
ducted by the Crohn’s and Colitis Foundation of America (CCFA)638
 Study on the Genetic, Environmental and Microbial interactions that cause IBD
(GEM Project) by the Crohn’s and Colitis Canada639
 The Prognostic effect of Environmental factors in Crohn’s and Colitis (PREdiCCt)
study640
The FARMM study638 is a controlled feeding study with healthy volunteers being
fed a ‘Western’ diet, EEN, or a vegan diet for 2-weeks to see the impact on the gut
microbiota and faecal metabolites. The GEM Project639 is looking at healthy first-
degree relatives of Crohn’s disease patients to assess genetic, environmental factors
and the gut microbiota, with the intention of identifying long term risk factors in the
development of disease. The PREdiCCT study640 aims to recruit IBD patients in re-
mission, to assess the relationship between diet, lifestyle, genetics and gut microbiota
to risk of disease relapse over 2-years. Although a huge amount of work has been
done to understand the use of enteral nutrition in recent years there still lies ahead
a great deal of research before EEN and MEN can be considered safe.
A focus of this research should aim to understand the interaction between dietary
components, the gut microbiota and inflammation in Crohn’s disease and UC. Work
should also focus on how dietary therapies including EEN and MEN could be used
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to manipulate the gut bacteria back to a non-dysbiotic state which protects the gut
from inflammation. More work also needs to be done to understand malnutrition at
the point of diagnosis and whether it is linked with disease outcomes. More work also
needs to be done looking into the long term safety of using dietary interventions such
as EEN and MEN as studies show these strategies seem to drive the gut microbiota
into a more extreme dysbiosis which could have long term effects on health if used
regularly. Therefore working out an optimal dietary regimen for maintenance of
remission which is both effective and safe is important.
7.4.10 Key findings
The current study:
 Children with Crohn’s disease have less intake of vitamins (A, E, B7 and C) and
fibre compared with healthy children.
 Energy intake and composition of diet at baseline did not predict response to
treatment with EEN.
 EEN is compositionally different in micro-nutrient and vitamin status, as well
as fibre from the normal habitual diet of patients with Crohn’s disease.
New findings from this study:
 The use of MEN as a dietary supplement was not associated with prolonged
remission time.
 Increased intake of fibre from fruit and vegetables post-EEN may increase re-
mission times in children with Crohn’s disease, and needs further investigation.
 Dietary intake at baseline highlights an altered relationship between children
with Crohn’s disease and healthy children for Ruminococcus 1 ; suggesting this
genera is functionally different between the two groups.
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8 General Discussion and Conclusions
Science of the microbiome is revolutionising not only how we think about gut disease
but also how we see ourselves as human beings. We consist of approximately 30
trillion human cells and around 39 trillion microbial cells,641 which translates to
approximately 20,000 human genes versus over 3.3 million microbial genes.642 It is
also worth noting that our human genome does not change much over time whereas
the microbiome changes not only from birth to old age but also on a daily basis,
depending on environment and diet.
The commensal microbiota have co-evolved with the host to assist in digestion,
providing energy for cellular metabolism; making compounds such as vitamins and
SCFA; to prime and maintain the intestinal immunology; as well as provide a first
line of defence against pathogens.
Research into the role of the microbiota in the development of IBD has reached a
milestone. In recent years genome-wide association studies have been able to link
IBD with genetic loci which point to an inappropriate immune response to the gut
microbiota.61 Also research into the microbiota community structure of IBD patients
has linked pathogenesis with characteristic changes in composition, which reinforce
the idea that IBD results from an altered interaction between gut bacteria and host
mucosal immunity. We have employed ‘omic’ technologies in the current study with
the aim of increasing our understanding of these interactions between host and the
resident gut microbiota.
8.1 Practical issues around recruitment and study design
Prior to the start of the research phase of the project, there were a number of prac-
tical and legal hurdles to complete before recruitment could begin. Eight-months of
administration was involved in setting up and gaining approval for this study. This
could have been reduced substantially by: a) avoiding recruitment from community
hospitals and clinics where the large amount of administration did not justify the
small number of patients recruited from these centres; b) having earlier support from
the University department of Research and Development who have a detailed working
knowledge of the processes involved; c) applying for NHS R&D approval at the same
time as ethics approval.
During the study it was apparent the researcher was asking patients questions and
taking anthropometric measurements which were already being taken by the dietitian.
Dietitians in one local hospital (Wishaw) shared a room with the researcher to avoid
this duplication, thus reducing time the child had to spend in clinic. The researcher
also did not have access to databases containing clinical appointments, and was thus
dependent on clinical staff to keep them up to date. This did not always work well in
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practice and a number of opportunities to meet patients for recruitment or to collect
samples were missed, as clinical staff were very busy and sometimes failed to pass on
details. A number of children with Crohn’s disease had follow-up appointments in
their local hospital and these clinic times often overlapped making it impossible for
one person to attend all clinics to follow-up patients recruited at baseline. Therefore
recruitment success could be more efficient and effective if it were carried out by a re-
search nurse/dietitian based within the clinical setting. Reducing the time burden on
patients would likely result in more patients completing the study. This study might
also have benefited from a shared research database between the clinical team; the
clinical research facility (CRF) team and the researcher; to improve communication
about appointments, needs or concerns about the participant; and could duplicate
as a log of recruitment and samples collected. This would have allowed members of
the clinical team to be more involved with the study, and saved time on research
paperwork.
Dietary questionnaires The current study had a poor return rate of detailed food
diaries, and had to rely on FFQ data for estimated nutrient intakes. The key is-
sues were that parents did not always know what their children had eaten at school
and that young adults 12+ who self completed forms did not take time to do these
thoroughly. Attempts to conduct the 5-step multi-pass questionnaire failed because
it was not possible to speak with both parent and child simultaneously, and many
families could not commit to 3-calls per week since they were involved in activities
outside of the home. Several parents also reported that they felt the burden of filling
out dietary questionnaires was too much.
Participants were asked to attend an appointment with a researcher to discuss diet,
after visiting the clinician, the IBD nurse, the dietitian and then a phlebotomist,
when most families had to return to work/school as quickly as possible, and therefore
struggled to spend a 3rd hour in clinic answering dietary questions. It would perhaps
have been better to collect dietary data in the clinical setting with the assistance
of a dietitian, where both child and parent are present. This would potentially
increase costs as the dietitian would need to spend extra time-with patients; however
since patients usually see a dietitian at review appointments, and patients often
sit in the waiting area between seeing clinicians/IBD nurse/dietitian/phlebotomists,
there could be an opportunity to use this time, to complete dietary questionnaires.
Therefore understanding the practical dynamics of both the clinical setting, as well
as patient/family needs are important in planning a successful dietary study.
One drawback of the current study and others is that baseline faecal samples may
not fully represent the child’s normal diet. Many children are unwell at the point
of attending hospital pre-diagnosis, and not managing to consume their normal diet.
Hence it is difficult to know if differences seen in the gut bacteria profiles at baseline
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are temporary changes due to a limited diet, or are linked with long-term habitual
diet. Future studies could use animal models to control for diet at baseline and assess
the impact of enteral nutrition independent of dietary variations. Although human
studies may seem the obvious choice to understand human disease, the inability to
control variables such as diet or medication can make them poor models to under-
stand which factors affect outcomes. However animal models of colitis may not fully
represent inflammation in humans so also have limitations.
Treatment with MEN Since the current study was observational, it could not
influence the numbers of children choosing to take maintenance enteral nutrition
(MEN) post-EEN. ∼55% of children had refused MEN in previous years, however
only 6/23 (26%) of children who went into remission on EEN opted not to take MEN,
one then going onto MEN around 17-weeks post-EEN. It is unclear why uptake was
so high, but it is possible after explaining the study, participants became more aware
of possible benefits of MEN as a therapy. It is also conceivable that in discussions
with clinical staff, IBD-nurses and dietitians the researcher influenced the likelihood
they would recommend MEN as maintenance treatment. A combination of both of
these may have influenced the uptake of MEN.
Although all children who opted not to take MEN were on an immunosuppressant,
only 8/17 children taking MEN were taking an immunosuppressant, creating a third
subgroup. Children taking an immunosuppressant as well as MEN creates a confound-
ing factor, as it could have an effect on the gut microbiota profile and metabolites,
making understanding differences between these three groups more challenging, due
to the lower numbers in each group.
Variation in populations Bacterial activity has a huge influence on the availability
and bio-activity of many compounds including SCFA derived from the diet, and it
is becoming clear, although all healthy individuals have a common core microbiota,
there are pathways which are found only in some populations or individuals. For
example, a species of Bacteroides which can degrade the sulphated algal polysaccha-
ride porphyran has only been detected in Japanese individuals;643 and the ability to
convert the soy isoflavone to equol is not present in all people.644 Thus the potential
for complex inter-individual variation in the effects of these derived molecules due to
variations in microbiota diversity is substantial. It is therefore important to replicate
studies across different populations, including gender and age, since functional dys-
biosis in the form of SCFA may be the result of unique disrupted microbial pathways
in different populations.
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8.2 Crohn’s disease at diagnosis
Malnutrition is common in children with IBD, particularly in active Crohn’s disease
where weight loss at diagnosis can be as high as 90%.48;49 The fact that children
with Crohn’s disease have reduced age related growth, as supported by the current
study, is important especially since it is associated with a delay in puberty.10;11 The
current study showed that albumin, CRP and ESR correlated with BMI z-scores at
baseline, suggesting increased disease severity, led to an increased risk of poor growth
outcomes in children with Crohn’s disease. For this reason finding a dietary approach
to reduce inflammation in children with Crohn’s may help to achieve age appropriate
growth targets.
Inflammatory markers including faecal calprotectin are increased in IBD patients.
Not all children with Crohn’s disease have raised CRP or ESR, however the current
study shows that children with Crohn’s disease have an overall blood inflammatory
marker profile which is distinct from that of children with UC, non-IBD conditions
and healthy children. Although individual clinical blood tests are examined in light
of other test results, they have not been used to differentiate Crohn’s, UC and non-
IBD conditions. Using an overall profile which includes CRP, ESR, albumin, WBC
and AST/ALT could be included as part of a larger study in future, to test whether
Crohn’s disease could be differentiated from UC; and at no additional cost since these
blood tests are undertaken routinely.
By analysing the global microbiota community, the current study has shown, along
with similar recent studies, that patients with Crohn’s disease have reduced micro-
biota diversity compared with healthy children and non-IBD control patients. Many
healthy commensals including butyrate producing species of Firmicutes are decreased
in abundance, while a number of gram-negative potential pathobionts are increased
in children with Crohn’s disease (Fig. 8.1).
Figure 8.1: Inflammation in children with Crohn’s disease is possibly due to reduced bacterial
diversity of key commensal species along with increased potential pathogenic and mucin degrading
species in the gut.
It has been suggested an increase in mucin-degrading bacteria, could be driving in-
flammation in Crohn’s disease by damaging the protective layer and opening a niche
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for pathogens.645 Since some bacteria switch to mucin feeding when fibre is unavail-
able this theory holds weight. The current study has shown that children with Crohn’s
disease have a reduced intake of fibre particularly from fruit, which perhaps puts them
at greater risk from mucin-degrading species.
The contribution of mucin-degrading bacteria towards microbial dysbiosis has still to
be explored. To date only a few species have been identified as mucin-degrading645
but they include commensal species of Bacteroides, which the current study and
others have shown to be increased in Crohn’s disease patients. Bacteroides and
similar commensals could be present in high enough numbers to cause damage to
the mucosa under low fibre conditions. However, known mucin-degraders such as
Akkermansia,204 are reduced in Crohn’s disease patients227 and have been associated
with a healthy mucosa;646 thus the relationship between mucin feeding bacteria and
a healthy mucosa is complex and needs to be better understood.
It is important to see the gut microbiota as an ecosystem, and that a number of prin-
ciples of microbial ecology, such as ‘stability’ and ‘resistance’, apply to these complex
systems. A number of studies including the Human Microbiome project have shown,
although there is a huge amount of bacterial diversity between healthy individuals,
when we look functionally at the metabolic pathways a lot of this variability tends
to disappear, and the functional genome is much more stable between individuals.234
The current study supports recent studies465;470 which show reduced levels of the
fatty acids valerate (C5), hexanoate (C6) and octanoate (C8) differentiate IBD from
healthy individuals. It was shown in Chapter 6 that in children with Crohn’s disease,
hexanoate (C6) is positively associated with a number of bacterial genera, partic-
ularly commensal Firmicutes. This is of interest because studies have shown these
medium chain fatty acids have antimicrobial properties which are commonly used in
animal husbandry to control pathogens such as Salmonella.273;274It is therefore pos-
sible that reduced levels of these fatty acids in children with Crohn’s results in loss
of protection from pathogens, and may explain why Proteobacteria, especially the
Enterobacteriaceae are increased in Crohn’s disease patients.
Bacteria have the potential to induce both acute and persistent infection. The ca-
pacity of bacteria to cause chronic disease is dependant on their ability to influence
or control their environment within a host. Some bacteria can establish a niche for
themselves within intestinal epithelial cells or circulating immune cells. Regardless
of host defences intracellular microbes can survive by hiding themselves from normal
immunological pathways.431;647 As a final defence the host cells can induce apoptosis,
thus removing these intracellular microbes. However some bacterial pathogens can
keep these infected cells alive for long periods, facilitating intracellular replication of
bacteria, resulting in persistent inflammation, particularly where macrophages and
dendritic cells are involved.647;648
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A recent systematic review68 looking at dietary intake and the risk of developing IBD
concluded that increased fibre and fruit intake reduced the risk of Crohn’s disease,
and patients in the current study have significantly reduced fibre intake at baseline
along with a lower intake of vitamins (A, E, B7 and C) compared with healthy
children. Given malabsorption is a feature of Crohn’s disease, this reduced vitamin
intake could have negative effects since vitamins A, E and C have direct and indirect
immunoregulatory roles.589;589;590;591;592 It has also been shown that vitamin A and E
deficiency is more prevalent in Crohn’s disease patients who have active disease.593
Vitamin C intake is linked with the intake of fruit and vegetable fibre, hence it is
difficult to separate these as risk factors. Thus future studies could further explore
whether vitamin C intake in patients, is truly a risk factor in Crohn’s disease.
It was shown in Chapter 5 that dietary intake at baseline had a positive association
with Ruminococcus 1 in children with Crohn’s disease but a negative association in
healthy children. This suggests that the strains of this genus have a functionally
different relationship with nutritional status in children with Crohn’s disease. It is
not clear from the current study if it is the same strain which has altered behaviour
due to a different environment or if children with Crohn’s disease in fact have a
different strain of Ruminococcus 1. Sequencing Ruminococcus strains to identify
mucin-degrading genes might help to answer this question.
8.2.1 What is driving dysbiosis?
Malnutrition Reduced fibre intake (Chapter 7) in children with Crohn’s disease
may lead to a reduction in diversity of Firmicutes, particularly the Clostridiales.
This could open a niche for Proteobacteria particularly Enterobacteriaceae to thrive.
This change in microbiota also leads to changes in SCFA/MCFA which could lead
to a loss of antimicrobial protection against gram-negative bacteria again opening
a niche for Proteobacteria species. The loss of fibre may have an additional effect
by activating some bacterial species to switch from fermenting fibre, to feeding on
mucin glycans and damaging the protective layer of the gut mucosa (Fig. 8.2). This
theory that low fibre intake under certain conditions, could be driving inflammation,
is supported by recent findings which show increasing fibre intake post-EEN keeps
children in remission and maintains low levels of calprotectin.619
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Figure 8.2: Proposed model of the potential factors which drive inflammation in Crohn’s disease.
Dashed arrows show the factors which could lead directly to inflammation in the gut.
The cuckoo effect In Chapter 5 it was shown that Crohn’s disease patients often
have individual species which dominate the luminal flora or are higher in abundance
than would be expected. Dysbiosis in Crohn’s disease could be driven and maintained
by bacteriocin producing strains of bacteria which act like ‘cuckoos’ to push other
bacteria into decline, opening a niche for themselves to dominate the ecosystem.
Due to lack of crosstalk with host cells, this would lead to a loss of microbial and
immunological homeostasis. Identifying and isolating bacteria which dominate the
microbiota in individual patients, and characterising the effect bacteriocins have on
other commensals, could help to eliminate this as a possible driver of dysbiosis in
Crohn’s disease.
8.3 Treatment with exclusive enteral nutrition (EEN)
EEN has been used to induce remission in children with Crohn’s disease for many
years, however only recently has research tried to uncover the mechanisms by which
EEN leads to reduced inflammation. Although some studies have suggested that
EEN might affect the gut barrier by increasing tight junction function or have di-
rect anti-inflammatory effects,631;649;650 there is now clear evidence that EEN leads
to significant and meaningful changes in the gut microbiota. Furthermore, SCFA
concentrations have been shown to decrease during treatment with EEN. Studies
show that these changes are rapid, usually with 1-week, and are maintained through-
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out the course of treatment with EEN. These alterations in microbial structure and
metabolic function in the current study (Chapters 5 & 6) parallel both clinical im-
provements, and a decrease in faecal calprotectin; all of which return to pre-treatment
levels shortly after cessation of treatment. In fact, the current study found that 1-
year after the start of treatment with EEN, only 35% of respondents remained in
disease remission.
Studies looking at changes in gut microbiota during EEN, including the current study,
have highlighted the large amount of inter-patient variation in the way the gut micro-
biota change during EEN. This is surprising given that all patients are on an identical
diet, and suggests that the baseline microbiota profile combined with host genetics
determine changes during EEN; and may explain why EEN fails to induce remission
in 1:5 children with Crohn’s disease.
Three studies, including the current study,217;144 reported a decrease in F. prausnitzii
during EEN, a prominent bacterium known to provide positive metabolic functions
in the healthy gut. Although this decrease along with other commensal Firmicutes is
explained by the complete loss of fibre, there remains a paradox as to why this loss
in healthy commensals, occurs alongside mucosal healing and reduced inflammation.
The current study is the first study to look at the multi-dimensional profile of
SCFA/MCFA as they change during treatment with EEN. Unlike the gut microbiota
which move further away from that of healthy children during EEN, the SCFA/MCFA
profile actually moves towards that of healthy children (Fig. 8.3). This would suggest
that, although fermentation is reduced during EEN, particularly butyrate, changes
in fatty acid ratios might restore an anti-inflammatory state to the gut thus driving
mucosal healing. Thus it is possibly the relationship between different SCFA/MCFA,
rather that the amounts, which are key to the overall control of functional pathways
involved with immune-regulation.
Figure 8.3: Results summary showing that treatment with exclusive enteral nutrition (EEN) unlike
short and medium chain fatty acids (SCFA/MCFA) does not push microbiota profiles towards that
of healthy controls.
The fact that EEN has been consistently shown to drive microbial dysbiosis away from
that associated with healthy children however may be of concern. Around 10% of
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patients on the ‘RISK’ study72 were on antibiotics, thus the group were able to report
that antibiotic use amplified microbial dysbiosis associated with Crohn’s disease in a
similar way to that seen during EEN, with a reduction in healthy commensals and
an increase in pathobionts. Serious consideration needs to be given to the potential
damage that EENmight have in further reducing species diversity in some individuals,
and longer term monitoring of the gut microbiota is needed to ensure that healthy
commensals return to pre-treatment levels in the longer term especially given that in
the current study, 75% of children relapsed within 1-year.
An interesting add-on to the current study was that multidimensional scaling of
routine clinical blood profiles suggests it might be possible, using selected features
of routine bloods, to design a test which could not only identify IBD patients but
distinguish Crohn’s disease from UC patients. It was not within the scope of the
current study to analyse the numbers needed to test the sensitivity or specificity
of such a test, but it would be relativity easy to conduct such an analysis, perhaps
including other inflammatory conditions such as idiopathic juvenile arthritis or coeliac
disease, as these are routine clinical tests.
Weight gain on EEN In chapter 3 EEN was shown to be particularly effective in
addressing growth velocity. Children with Crohn’s disease who were underweight
pre-EEN put on more weight during EEN than those who were normal weight at
baseline. Although no child with Crohn’s disease was overweight at the start of the
study, two were overweight 8-weeks post-EEN and three children were overweight by
the end of the study.
A recent study reported that at 3-months post-EEN 17% of children on MEN were
overweight compared with 8% of the non-MEN group.153 At 12-months this had re-
duced to 10% and 8% respectively. Therefore enteral nutrition on occasions might be
given in quantities which move children towards an unhealthy weight. It would be
useful for treatment centres to monitor not only weight-gain, but also SDS z-scores
and re-evaluate the amounts of enteral nutrition given to individual children depen-
dant on their BMI, so that children of a healthy weight do not become overweight on
EEN or MEN.
8.4 Predicting response to EEN
Although it might be possible in future to characterise key aspects of the gut micro-
biota to predict the response to EEN, and also the risk of subsequent disease relapse,
this will be challenging. The current study and others, have demonstrated a large
inter-patient variability which would make the design of such markers difficult. Al-
though the current study showed that twenty-five species (SNVs) could discriminate
between responders from non-responders, a larger cohort including both children and
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adults, as well as accounting for variability due to different cultures and diets, would
be needed to see which bacteria discriminate responders from non-responders across
these populations, before this could be developed and tested as a marker to predict
response to EEN.
Blood-markers CRP, ESR, albumin and the faecal marker calprotectin have been sug-
gested as possible markers of response to EEN, given the assumption that those with
more severe disease might be less likely to respond. However the current study has
shown that disease severity along with blood and faecal markers was not associated
with response to EEN. This was supported by anthropometric measures which showed
no differences in BMI or growth between responders and non-responders to EEN, ei-
ther at baseline or at 28-weeks post-EEN. The current study also found that energy
intake and composition of diet at baseline did not predict response to treatment.
Although a recent meta-analysis was unable to link disease location with efficacy
of treatment with EEN due to lack of data,26 the current study agrees with those
studies which found patients with ileal involvement were more likely to respond to
treatment with EEN.27;28;146 However study sizes to date have not been large enough
to say with certainty if children with isolated colonic disease are more likely to fail
EEN than children with ileal involvement.
Collecting dietary data from FFQs allowed the current study to look at all the com-
position differences between EEN (Modulen) in terms of micro-nutrient and vitamin
status, as well as fibre intake, and the baseline diet of patients with Crohn’s disease.
The lack of fibre in EEN and its effect in lowering the bacterial load has been well
documented, however there are other key differences which could have an effect on gut
inflammatory status. EEN may provide increased exposure to protective compounds
such as caseins which bind with antigens.614;615;616 Increased exposure to micronutri-
ents, especially iron and zinc both of which are involved in immune pathways, may
help to reduce inflammation.617;609 Vitamin intake is also increased on EEN, includ-
ing vitamin-D which is known to control expression of the NOD2 gene involved in
gut bacterial sensing, as well as improving tight-junction integrity.599;600 Vitamin D
increased 10-fold during EEN and could play a role in mucosal healing.
8.5 Treatment with maintenance enteral nutrition (MEN)
Following successful treatment with EEN, studies have proposed that supplementing
the normal post-EEN diet with enteral nutrition (MEN), could maintain long-term
remission.101 Several methods have been tested, including overnight nasogastric feeds
combined with daytime diet and the addition of a daily supplement of around 20%
energy intake.
The current study found that, although children with Crohn’s disease had age appro-
priate growth during EEN, growth velocity was not maintained once children went
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back onto normal diet, despite the diet being supplemented with 20% MEN. To date
no study has reported on the combined use of immunosuppressants, meaning drug
use as a confounding factor is ignored, hence the current study spilt patients up into
those treated with MEN only; an immunosuppressant only; or both. No differences in
growth were seen between the three types of maintenance therapy, however samples
sizes were too small to reject the hypothesis.
The current study also showed that faecal calprotectin returns to pre-treatment levels
more rapidly than previously recognised once children return to normal diet; and
that MEN had no effect in maintaining the anti-inflammatory effect of treatment
with EEN. The current study also demonstrated that MEN does not sustain the
microbiota profiles achieved during EEN. The same was true of SCFA profiles which
returned to pre-treatment levels once back onto normal diet; and treatment with
MEN post-EEN did not help to maintain SCFA profiles achieved during EEN. The
use of MEN as a dietary supplement was also not associated with prolonged remission
time. Thus the current study does not support the hypothesis that 20% MEN can
extend remission times in children with Crohn’s disease.
Although not significant, results from the current study suggest intake of fibre from
fruit and vegetables post-EEN may increase the length of remission times and there-
fore needs further investigation. It is probable that EEN, as a zero fibre diet, reduces
colonic bacteria to low enough levels, that any negative effects from cross-feeding
or mucosal degradation are prevented, until the normal low fibre diet is resumed.
However as bacterial levels recover, the fibre intake in children with Crohn’s disease,
may not be high enough to provide nutrition to those genera, which under low fibre
conditions are mucin-degraders. Although sample sizes were not high enough, there
is some evidence from the current study that those children who increased their fibre
intake post-EEN, particularly fruit, were more likely to maintain remission than chil-
dren who decreased their fibre intake. Further work is needed to assess if increasing
fruit intake post-EEN could help to extend remission times in children with Crohn’s
disease.
A recent Israeli study of seventy-eight children,619 where half were trialled with an
exclusion diet also containing increased fruit and vegetables (CDED) plus 50% (Mod-
ulen) for 6-weeks, followed by CDED with 25% Modulen for 6-weeks; and half which
received EEN for 6-weeks followed by a free diet with 25% Modulen for 6-weeks. 75%
reach remission on the CDED plus Modulen compared with 59% on EEN. During the
first 6-week the CDED was based on either excluding or reducing the following: ani-
mal/dairy fat; high fat from other sources; wheat; red or processed meat and protein
sources rich in taurine; emulsifiers; artificial sweeteners; carrageenan and sulphites.619
Once children were in remission the next phase increased exposure to fruits, vegeta-
bles and legumes, thus increasing fibre intake with the aim of supporting commensal
Firmicutes and healthy SCFA production. The most interesting finding from this
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study is that calprotectin levels were not only maintained once children went back
onto normal diet but continued to fall. In the CDED group Firmicutes also continued
to increase while the decrease in Proteobacteria achieved during the induction period
was sustained. The EEN group which were taking 50% MEN post-EEN were unable
to maintain reduced Proteobacteria and Firmicutes started to decrease.619 Another
attractive feature of the CDED diet is that it did not reduce bacterial α-diversity in
the way EEN does, thus patients do not face the risk of losing commensal species
required for healthy metabolic function. Although the group put the focus on the
exclusion part of the diet, it is just as likely that the increase in fibre is responsible
for maintaining remission in these children.
8.6 Summary
The idea that alterations in the gut microbiota as a collective might be driving
inflammation rather than a single causative agent is the largest development in IBD
research. Research has entered a new era of ‘omics’ research, allowing us to generate
high-throughput microbiota data which could help to change the way clinicians carry
out diagnostic testing and treat IBD. Microbiota data combined with host genetics
could also lead towards more personalised therapies, whereby we can identify which
children will respond well to induction diets, possibly including personalised probiotic
treatment, as well as which children may benefit from a more drugs based approach.
No specific diet has been clearly demonstrated to cause or prevent Crohn’s disease,
and it is vitally important to improve our understanding of the relationship between
individual dietary intake and the gut microbiota before dietary manipulation can be
used safely in the longer-term to induce remission or reduce flare-ups. The current
study was conducted to try and fill a gap in our understanding of the role diet plays in
Crohn’s disease in children. Despite difficulties in obtaining dietary data the current
study has shown that the diet of children with Crohn’s disease is lacking in fibre
particularly from fruit intake. This was reflected in the faecal microbiota data with
reduced numbers of butyrate producing bacteria which rely on dietary fibre.
Crohn’s disease has been shown to be a complex disease and will require a multifaceted
research approach to properly understand the relationship between diet, microbiome
and host genetics. Recent advances in sequencing and computational biology are
continuing to create new methods which allow the study of more complex systems
and how different factors within microbial communities relate to one another and the
host.72
In the final analysis, this PhD provided several novel insights into the relationship
between the gut microbiota, diet and Crohn’s disease (Fig. 8.4). This was explored
by studying three aspects: a) gut microbial diversity b) bacterial metabolites in the
form of SCFA, and c) dietary intake.
279
Conclusion The gut microbiota and the metabolites they produce relate to disease
activity as shown by inflammatory markers and therefore play a role in Crohn’s dis-
ease aetiology. Treatment with EEN is linked with distinct changes in microbiota and
SCFA profiles which move in opposite directions during EEN. The study concludes
that since SCFA profiles move towards controls it is more likely that changes in SCFA
drive the reduction in inflammation.
Treatment with MEN does not maintain the gut microbiota or SCFA profiles achieved
during EEN, and is accompanied by a rapid increase in calprotectin post-EEN. Evi-
dence also suggests that increasing fibre and possibly vitamin C, in the diet of children
during EEN and post-EEN may help to improve both induction and maintenance of
disease remission in children with Crohn’s disease.
Future research There is a need to co-ordinate microbiota and metabolite research,
particularly small studies, so they use comparable methods which will allow these
studies to pool data. Future studies also need to include other inflammatory condi-
tions such as JIA and coeliac disease, so that specificity against these conditions can
be tested.
More detailed work using animal colitis models is urgently needed, which can control
for diet and test a number factors including fibre and vitamin C, which may have an
indirect role in gut immunoregulation. In vivo fermentation models could be used
to explore the role that increased calprotectin plays in altering the gut microbiota
by limiting Zn and Fe. It is also possible that mucin-degrading bacterial strains
are involved in mucosal damage; hence identifying mucin-degrading genes, as well as
growing these strains in a mucosal cell model to test the impact of these strains under
different conditions (e.g. low/high fibre), would highlight any impact these strains
play in Crohn’s disease.
Although some bacteria discriminate responders from non-responders to EEN, wider
population studies are needed before this could be used as a tool to identify which
children might respond treatment with EEN or other treatment diets.
Further studies are needed in larger cohorts to examine whether increased fibre,
exclusion diets, or EEN are more effective and safer to induce and maintain remission
in children with Crohn’s disease. Understanding which microbiota or SCFA/MCFA
profiles reduce inflammation in Crohn’s disease would lead to improved treatments.
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Figure 8.4: Flowchart of PhD showing chapters and main findings.
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 d
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p
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c
u
m
e
n
ta
ti
o
n
, 
s
u
b
je
c
t 
to
 t
h
e
 c
o
n
d
it
io
n
s
 s
p
e
c
if
ie
d
 b
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a
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v
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r
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 d
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c
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 d
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 f
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b
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d
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 b
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c
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 p
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c
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 l
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c
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c
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c
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c
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c
k
 f
o
rm
 a
v
a
ila
b
le
 o
n
 t
h
e
 H
R
A
 w
e
b
s
it
e
: 
h
tt
p
:/
/w
w
w
.h
ra
.n
h
s
.u
k
/a
b
o
u
t-
th
e
-h
ra
/g
o
v
e
rn
a
n
c
e
/q
u
a
lit
y
-a
s
s
u
ra
n
c
e
/
1
4
/W
S
/1
0
0
4
P
le
a
s
e
 q
u
o
te
 t
h
is
 n
u
m
b
e
r 
o
n
 a
ll
 c
o
rr
e
s
p
o
n
d
e
n
c
e
W
e
 a
re
 p
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e
n
te
ra
l 
n
u
tr
it
io
n
 t
o
 i
m
p
ro
v
e
 t
h
e
ir
 s
y
m
p
to
m
s 
w
e
 w
o
u
ld
 a
im
 t
o
 f
o
llo
w
 
c
h
a
n
g
e
s 
in
 
y
o
u
r 
 
g
u
t 
b
a
c
te
ri
a
 
w
h
ile
 
th
e
y
 
a
re
 
o
n
 
e
n
te
ra
l 
n
u
tr
it
io
n
 a
n
d
 c
o
m
p
a
re
 t
h
is
 w
it
h
 y
o
u
r 
 n
o
rm
a
l 
d
ie
t 
o
n
c
e
 t
h
e
y
 
h
a
v
e
 f
in
is
h
e
d
 t
h
e
ir
 t
re
a
tm
e
n
t.
  
D
o
 w
e
 h
a
v
e
 t
o
 t
a
k
e
 p
a
rt
?
 
N
o
. 
It
 i
s 
u
p
 t
o
 y
o
u
 a
n
d
 y
o
u
r 
c
h
ild
 t
o
 d
e
c
id
e
 w
h
e
th
e
r 
o
r 
n
o
t 
to
 t
a
k
e
 
p
a
rt
. 
If
 y
o
u
r 
c
h
ild
 i
s 
h
a
p
p
y
 t
o
 t
a
k
e
 p
a
rt
 y
o
u
 w
ill
 b
o
th
 b
e
 g
iv
e
n
 a
n
 
in
fo
rm
a
ti
o
n
 s
h
e
e
t 
to
 k
e
e
p
 a
n
d
 b
e
 a
sk
e
d
 t
o
 s
ig
n
 a
 c
o
n
se
n
t 
fo
rm
. 
If
 
y
o
u
r 
c
h
ild
 d
e
c
id
e
s 
to
 t
a
k
e
 p
a
rt
 t
h
e
y
 w
ill
 b
e
 f
re
e
 t
o
 w
it
h
d
ra
w
 f
ro
m
th
e
 
st
u
d
y
 a
t 
a
n
y
 p
o
in
t 
th
e
y
 w
is
h
, 
a
n
d
 w
it
h
o
u
t 
g
iv
in
g
 a
 r
e
a
so
n
. 
Th
is
 s
tu
d
y
 
w
ill
 r
u
n
 a
lo
n
g
si
d
e
 y
o
u
r 
c
h
ild
's
 c
lin
ic
a
l 
c
a
re
 a
n
d
 i
s 
su
p
e
rv
is
e
d
 b
y
 t
h
e
ir
 
g
a
st
ro
in
te
st
in
a
l 
c
a
re
 t
e
a
m
 b
u
t 
w
ill
 n
o
t 
im
p
a
c
t 
o
n
 y
o
u
r 
 c
a
re
 i
n
 
a
n
y
 w
a
y
. 
 
2 Appendix: BIG Study information leaflets
2.1 Appendix: Parent/guardian information leaflets
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A
 r
e
se
a
rc
h
e
r 
w
ill
 p
ro
v
id
e
 y
o
u
 w
it
h
 d
e
ta
ile
d
 i
n
fo
rm
a
ti
o
n
 a
n
d
 i
f 
y
o
u
r 
c
h
ild
 
w
o
u
ld
 l
ik
e
 t
o
 t
a
k
e
 p
a
rt
 i
n
 t
h
e
 s
tu
d
y
 w
e
 w
ill
 a
sk
: 
 
q
u
e
st
io
n
s 
a
b
o
u
t 
y
o
u
r 
 h
e
a
lt
h
 a
n
d
 w
h
a
t 
m
e
d
ic
a
ti
o
n
s 
th
e
y
 u
se
. 
to
 c
o
m
p
le
te
 a
 q
u
e
st
io
n
n
a
ir
e
 a
b
o
u
t 
y
o
u
r 
 d
ie
t.
 
to
 m
e
a
su
re
 y
o
u
r 
 h
e
ig
h
t,
 w
e
ig
h
t,
 a
n
d
 h
a
n
d
 g
ri
p
 s
tr
e
n
g
th
. 
 
to
 p
e
rm
it
 u
s,
 w
it
h
 a
p
p
ro
v
a
l 
o
f 
y
o
u
r
c
lin
ic
ia
n
, 
to
 a
c
c
e
ss
 y
o
u
r 
 m
e
d
ic
a
l 
n
o
te
s 
fo
r 
d
a
ta
 o
n
 m
e
d
ic
a
ti
o
n
, 
d
is
e
a
se
 a
c
ti
v
it
y
, 
h
e
ig
h
t,
 w
e
ig
h
t 
e
tc
. 
 
y
o
u
r 
c
h
ild
 t
o
 p
ro
v
id
e
 a
 s
to
o
l 
a
n
d
 u
ri
n
e
 s
a
m
p
le
. 
Th
is
 c
a
n
 b
e
 c
o
lle
c
te
d
 a
t 
a
 
la
te
r 
d
a
te
 f
ro
m
 y
o
u
r 
h
o
m
e
 b
y
 a
 r
e
se
a
rc
h
e
r,
 o
r 
 w
h
e
n
 y
o
u
 n
e
x
t 
v
is
it
 t
h
e
 c
lin
ic
. 
W
e
 w
ill
 a
sk
 y
o
u
 f
o
r 
fu
rt
h
e
r 
sa
m
p
le
s 
if
 y
o
u
r 
c
h
ild
 h
a
s 
g
u
t 
in
fl
a
m
m
a
ti
o
n
, 
b
u
t 
th
is
 
is
 u
p
 t
o
 y
o
u
. 
y
o
u
r 
 
h
o
sp
it
a
l 
d
o
c
to
r 
to
 
p
ro
v
id
e
 
u
s 
w
it
h
 
a
n
 
e
x
tr
a
 
sm
a
ll 
tu
b
e
 
(t
e
a
sp
o
o
n
) 
o
f 
b
lo
o
d
 w
h
e
n
 y
o
u
r 
c
h
ild
 i
s 
h
a
v
in
g
 a
 b
lo
o
d
 s
a
m
p
le
 t
a
k
e
n
 f
o
r 
ro
u
ti
n
e
 m
e
d
ic
a
l r
e
a
so
n
s,
 s
o
 n
o
 e
x
tr
a
 n
e
e
d
le
 in
se
rt
io
n
. 
fo
r 
p
e
rm
is
si
o
n
 t
o
 t
a
k
e
 s
o
m
e
 a
d
d
it
io
n
a
l 
m
u
c
o
sa
l 
b
io
p
si
e
s 
(t
in
y
 s
k
in
 s
a
m
p
le
s)
 
d
u
ri
n
g
 y
o
u
r 
 c
o
lo
n
o
sc
o
p
y
. 
P
le
a
se
 n
o
te
 t
h
a
t 
y
o
u
r 
c
h
ild
 c
a
n
 s
ti
ll 
ta
k
e
 p
a
rt
 e
v
e
n
 i
f 
th
e
y
 
 w
a
n
t 
to
 g
iv
e
 a
d
d
it
io
n
a
l 
sk
in
 s
a
m
p
le
s.
 Y
o
u
r 
d
o
c
to
r 
w
ill
 b
e
 h
a
p
p
y
 t
o
 d
is
c
u
ss
 t
h
is
 w
it
h
 y
o
u
 b
e
fo
re
 y
o
u
r 
c
h
ild
 h
a
s 
th
e
ir
 c
o
lo
n
o
sc
o
p
y
 
  If
 a
ft
e
r 
c
o
lo
n
o
sc
o
p
y
, 
y
o
u
r 
c
h
il
d
 i
s 
fo
u
n
d
 n
o
t 
to
 h
a
v
e
 a
n
y
 g
u
t 
in
fl
a
m
m
a
ti
o
n
, 
w
e
 
w
il
l 
sa
y
 t
h
a
n
k
 y
o
u
 f
o
r 
ta
k
in
g
 p
a
rt
 a
n
d
 w
il
l 
n
o
t 
a
sk
 y
o
u
 f
o
r 
a
n
y
 f
u
rt
h
e
r 
sa
m
p
le
s.
  
If
 h
o
w
e
v
e
r 
y
o
u
r 
d
o
c
to
r 
te
lls
 u
s 
th
a
t 
y
o
u
r 
c
h
ild
 h
a
s 
g
u
t 
in
fl
a
m
m
a
ti
o
n
 w
h
ic
h
 i
s 
c
o
n
si
st
e
n
t 
w
it
h
 
 d
is
e
a
se
 a
n
d
 y
o
u
r 
d
o
c
to
r 
d
e
c
id
e
s 
to
 p
u
t 
y
o
u
r 
c
h
ild
 o
n
 a
 
sp
e
c
ia
l 
d
ie
t,
 t
o
 t
ry
 a
n
d
 i
m
p
ro
v
e
 t
h
e
ir
 h
e
a
lt
h
, 
w
e
 w
ill
 a
sk
 y
o
u
 a
n
d
 y
o
u
r 
c
h
ild
 t
o
 
c
o
n
ti
n
u
e
 o
n
 t
h
e
 s
tu
d
y
. 
W
e
 w
o
u
ld
 t
h
e
n
 a
sk
 y
o
u
r 
c
h
ild
 f
o
r 
5
 m
o
re
 s
to
o
l 
&
 u
ri
n
e
 
sa
m
p
le
s 
a
n
d
 
2
 
b
lo
o
d
 
sa
m
p
le
s 
o
v
e
r 
th
e
 
n
e
x
t 
y
e
a
r 
a
n
d
 a
ls
o
 
o
c
c
a
si
o
n
a
lly
 a
sk
 
a
b
o
u
t 
y
o
u
r 
 d
ie
t.
 W
e
 w
ill
 p
ro
v
id
e
 y
o
u
 w
it
h
 a
 d
e
ta
ile
d
 s
h
e
e
t 
o
f 
h
o
w
 a
n
d
 
w
h
e
n
 
sa
m
p
le
 
c
o
lle
c
ti
o
n
s 
w
ill
 
h
a
p
p
e
n
, 
b
u
t 
th
is
 
w
ill
 
a
lw
a
y
s 
b
e
 
a
t 
y
o
u
r 
c
o
n
v
e
n
ie
n
c
e
, 
a
n
d
 y
o
u
 c
a
n
 w
it
h
d
ra
w
 f
ro
m
 t
h
e
 s
tu
d
y
 a
t 
a
n
y
 t
im
e
 y
o
u
 l
ik
e
. 
W
e
 
w
ill
 
k
e
e
p
 
th
e
se
 
sa
m
p
le
s 
fo
r 
fu
tu
re
 
m
e
a
su
re
m
e
n
ts
 
a
s 
n
e
w
 
te
st
s 
b
e
c
o
m
e
 
a
v
a
ila
b
le
. 
 
A
re
 t
h
e
re
 a
n
y
 b
e
n
e
fi
ts
 o
r 
ri
sk
s 
 i
f 
w
e
 t
a
k
e
 p
a
rt
?
 
A
lt
h
o
u
g
h
 t
h
e
re
 a
re
 n
o
 b
e
n
e
fi
ts
 f
ro
m
 t
a
k
in
g
 p
a
rt
 i
n
 t
h
e
 s
tu
d
y
, 
w
e
 h
o
p
e
 
th
a
t 
y
o
u
 m
ig
h
t 
fi
n
d
 i
t 
a
 p
o
si
ti
v
e
 a
n
d
 r
e
w
a
rd
in
g
 e
x
p
e
ri
e
n
c
e
, 
in
 h
e
lp
in
g
 u
s 
to
 
b
e
tt
e
r 
u
n
d
e
rs
ta
n
d
 
th
e
 
ro
le
 
th
a
t 
g
u
t 
b
a
c
te
ri
a
 
p
la
y
 
in
 
c
a
u
si
n
g
 
o
r 
p
ro
te
c
ti
n
g
 
fr
o
m
 
d
is
e
a
se
s 
th
a
t 
in
v
o
lv
e
 
in
fl
a
m
m
a
ti
o
n
 
in
 
th
e
 
g
u
t.
 
D
u
ri
n
g
 
c
o
lo
n
o
sc
o
p
y
, 
a
d
d
it
io
n
a
l 
b
io
p
si
e
s 
w
ill
 o
n
ly
 b
e
 t
a
k
e
n
 b
y
 y
o
u
r 
su
rg
e
o
n
 i
f 
th
e
y
 f
e
e
l 
it
 i
s 
sa
fe
 t
o
 d
o
 s
o
, 
b
u
t 
y
o
u
 w
ill
 s
ti
ll 
b
e
 a
b
le
 t
o
 t
a
k
e
 p
a
rt
 i
n
 t
h
e
 
st
u
d
y
 i
f 
n
o
 b
io
p
si
e
s 
a
re
 t
a
k
e
n
. 
W
e
 d
o
 n
o
t 
a
n
ti
c
ip
a
te
 a
n
y
 r
is
k
s 
fr
o
m
 t
h
is
 
re
se
a
rc
h
 s
tu
d
y
. 
W
h
a
t 
d
o
 w
e
 n
e
e
d
 t
o
 d
o
 t
o
 t
a
k
e
 p
a
rt
?
 
 
Th
e
 s
tu
d
y
 r
e
se
a
rc
h
e
r 
 
C
la
re
 C
la
rk
 w
ill
 a
lw
a
y
s 
b
e
 h
a
p
p
y
 t
o
 a
n
sw
e
r 
a
n
y
 q
u
e
st
io
n
s 
y
o
u
 
m
ig
h
t 
h
a
v
e
 a
b
o
u
t 
th
e
 s
tu
d
y
. 
 
P
le
a
se
 c
o
n
ta
c
t 
C
la
re
 b
y
 e
m
a
il:
 
c
.c
la
rk
.1
@
re
se
a
rc
h
.g
la
.a
c
.u
k
 
o
r 
b
y
 p
h
o
n
e
/t
e
x
t 
0
7
7
3
0
 4
6
5
2
3
0
 /
 0
1
4
1
 2
0
1
 8
6
8
8
 
 
Y
e
s.
P
a
rt
ic
ip
a
n
ts
 w
h
o
 h
a
v
e
 g
iv
e
n
 c
o
n
se
n
t 
to
 t
a
k
e
 p
a
rt
 i
n
 t
h
e
 s
tu
d
y
 w
ill
 
b
e
 
a
llo
c
a
te
d
 
a
n
 
a
n
o
n
y
m
o
u
s 
c
o
d
e
 
w
h
ic
h
 
w
ill
 
b
e
 
u
se
d
 
to
 
la
b
e
l 
a
ll 
sa
m
p
le
s 
a
n
d
 d
a
ta
, 
in
 o
rd
e
r 
to
 p
ro
te
c
t 
y
o
u
r 
 i
d
e
n
ti
ty
 d
u
ri
n
g
 a
ll 
la
b
 w
o
rk
 a
n
d
 a
n
a
ly
si
s 
o
f 
sa
m
p
le
 d
a
ta
. 
R
e
le
v
a
n
t 
m
e
d
ic
a
l 
h
is
to
ry
 w
ill
 b
e
 
c
o
lle
c
te
d
 f
ro
m
 m
e
d
ic
a
l 
n
o
te
s 
in
 l
in
e
 w
it
h
 t
h
e
 N
H
S
 C
o
d
e
 o
f 
P
ra
c
ti
c
e
 
(S
c
o
tl
a
n
d
) 
V
e
rs
io
n
 1
.0
 a
n
d
 c
u
rr
e
n
t 
d
a
ta
 p
ro
te
c
ti
o
n
 l
a
w
s.
 O
th
e
r 
th
a
n
 t
h
e
 
d
ir
e
c
t
re
se
a
rc
h
 
te
a
m
, 
d
a
ta
 m
a
y
 
a
ls
o
 b
e
 m
o
n
it
o
re
d
 
b
y
 
re
p
re
se
n
ta
ti
v
e
s 
o
f 
N
H
S
 G
G
&
C
 t
o
 e
n
su
re
 c
o
m
p
lia
n
c
e
 w
it
h
 r
e
g
u
la
ti
o
n
s.
 
 H
o
w
 w
ill
 t
h
e
 i
n
fo
rm
a
ti
o
n
 I
 p
ro
v
id
e
 b
e
 u
se
d
?
 
Th
e
 a
n
o
n
y
m
o
u
s 
d
a
ta
 g
e
n
e
ra
te
d
 f
ro
m
 y
o
u
r 
 s
a
m
p
le
s 
w
ill
 b
e
 u
se
d
 
to
p
ro
d
u
c
e
 a
 r
e
p
o
rt
 a
n
d
 t
h
e
si
s 
o
n
 h
o
w
 d
ie
t,
 g
u
t 
b
a
c
te
ri
a
 a
n
d
 o
th
e
r 
fa
c
to
rs
 a
ff
e
c
t 
in
fl
a
m
m
a
ti
o
n
 i
n
 c
h
ild
re
n
 w
it
h
 g
u
t 
in
fl
a
m
m
a
ti
o
n
. 
W
e
 w
ill
 
p
re
se
n
t 
th
e
 r
e
su
lt
s 
a
t 
sc
ie
n
ti
fi
c
 c
o
n
fe
re
n
c
e
s,
 p
u
b
lis
h
 i
n
 s
c
ie
n
ti
fi
c
 j
o
u
rn
a
ls
 a
n
d
 
p
ro
v
id
e
 a
 r
e
p
o
rt
 o
f 
o
u
r 
fi
n
d
in
g
s 
fo
r 
c
h
ild
re
n
 a
n
d
 p
a
re
n
ts
 w
h
o
 w
o
u
ld
 l
ik
e
 t
h
is
 
in
fo
rm
a
ti
o
n
. 
Th
e
re
 
w
ill
 
b
e
 
n
o
 
p
e
rs
o
n
a
l 
in
fo
rm
a
ti
o
n
 
in
 
a
n
y
 
o
f 
th
e
se
 
re
p
o
rt
s.
 
W
h
o
 i
s 
o
rg
a
n
is
in
g
 &
 f
u
n
d
in
g
 t
h
e
 s
tu
d
y
?
 
Th
is
 r
e
se
a
rc
h
 i
s 
c
o
-o
rg
a
n
is
e
d
 b
y
 t
h
e
 U
n
iv
e
rs
it
y
 o
f 
G
la
sg
o
w
 a
n
d
 c
lin
ic
a
l 
st
a
ff
 a
t 
th
e
 R
o
y
a
l 
H
o
sp
it
a
l 
fo
r 
S
ic
k
 C
h
ild
re
n
 i
n
 G
la
sg
o
w
. 
It
 i
s 
fu
n
d
e
d
 b
y
 
Th
e
 Y
o
rk
h
ill
 C
h
ild
re
n
's
 C
h
a
ri
ty
 a
n
d
 h
a
s 
b
e
e
n
 r
e
v
ie
w
e
d
 b
y
 t
h
e
 W
e
st
 o
f 
S
c
o
tl
a
n
d
 R
e
se
a
rc
h
 E
th
ic
s 
C
o
m
m
it
te
e
. 
W
h
a
t 
if
 I
 h
a
v
e
 q
u
e
st
io
n
s 
o
r 
c
o
n
c
e
rn
s?
 
If
 
y
o
u
 
h
a
v
e
a
n
y
 
c
o
n
c
e
rn
s 
o
r 
q
u
e
st
io
n
s 
a
b
o
u
t 
th
e
 
st
u
d
y
 
y
o
u
 
c
a
n
 
c
o
n
ta
c
t 
th
e
 
re
se
a
rc
h
e
r,
 
C
la
re
 
C
la
rk
. 
If
 
y
o
u
 
w
o
u
ld
 
lik
e
 
to
 
sp
e
a
k
 
to
 
so
m
e
o
n
e
 o
th
e
r 
th
a
n
 t
h
e
 r
e
se
a
rc
h
e
r 
p
le
a
se
 c
o
n
ta
c
t 
D
r 
D
a
lia
 M
a
lk
o
v
a
, 
U
n
iv
e
rs
it
y
 o
f 
G
la
sg
o
w
 H
u
m
a
n
 N
u
tr
it
io
n
 S
e
c
ti
o
n
, 
G
la
sg
o
w
 R
o
y
a
l 
In
fi
rm
a
ry
 o
n
 
0
1
4
1
 2
0
1
 8
6
9
0
. 
  
 
D
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n
fo
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a
fl
e
t 
c
o
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n
o
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o
p
y
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8
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B
a
c
te
ri
a
 &
 
In
fl
a
m
m
a
ti
o
n
 i
n
 
th
e
 G
u
t 
Gut microbial taxonomy and metabolism in paediatric Crohn’s disease during 
exclusive and supplementary enteral nutrition using OMICS technologies  
A
n
 i
n
fo
rm
a
ti
o
n
 
le
a
fl
e
t 
fo
r 
c
a
re
rs
 o
f 
y
o
u
n
g
 p
e
o
p
le
 
in
te
re
st
e
d
 i
n
 j
o
in
in
g
 
a
 r
e
se
a
rc
h
 p
ro
je
c
t 
a
b
o
u
t 
g
u
t 
in
fl
a
m
m
a
ti
o
n
. 
In
v
it
a
ti
o
n
 
W
h
y
 a
re
 w
e
 d
o
in
g
 t
h
is
 s
tu
d
y
?
 
W
h
y
 h
a
s 
m
y
 c
h
ild
 b
e
e
n
 c
h
o
se
n
?
 
W
e
 a
re
 a
sk
in
g
 y
o
u
 b
e
c
a
u
se
 y
o
u
r 
c
h
ild
 h
a
s 
C
ro
h
n
's
 d
is
e
a
se
, 
a
n
d
 y
o
u
r 
d
o
c
to
r 
h
a
s 
a
sk
e
d
 h
im
/h
e
r 
to
 u
n
d
e
rg
o
 t
re
a
tm
e
n
t 
w
it
h
 a
 s
p
e
c
ia
l 
liq
u
id
 
d
ie
t 
c
a
lle
d
 e
n
te
ra
l 
n
u
tr
it
io
n
 t
o
 t
ry
 a
n
d
 i
m
p
ro
v
e
 t
h
e
ir
 s
y
m
p
to
m
s.
 W
e
 
w
a
n
t 
to
 f
in
d
 o
u
t 
h
o
w
 e
n
te
ra
l 
n
u
tr
it
io
n
 w
o
rk
s,
 b
y
 m
e
a
su
ri
n
g
 c
h
a
n
g
e
s 
in
 y
o
u
r 
c
h
ild
’s
 g
u
t 
b
a
c
te
ri
a
 w
h
ile
 t
h
e
y
 a
re
 o
n
 e
n
te
ra
l 
n
u
tr
it
io
n
 a
n
d
 
c
o
m
p
a
re
 t
h
is
 w
it
h
 y
o
u
r 
c
h
ild
’s
 n
o
rm
a
l 
d
ie
t 
o
n
c
e
 t
h
e
y
 h
a
v
e
 f
in
is
h
e
d
 
th
e
ir
 t
re
a
tm
e
n
t.
 
D
o
 w
e
 h
a
v
e
 t
o
 t
a
k
e
 p
a
rt
?
 
N
o
. 
It
 i
s 
u
p
 t
o
 y
o
u
 a
n
d
 y
o
u
r 
c
h
ild
 t
o
 d
e
c
id
e
 w
h
e
th
e
r 
o
r 
n
o
t 
to
 t
a
k
e
 
p
a
rt
. 
If
 y
o
u
r 
c
h
ild
 i
s 
h
a
p
p
y
 t
o
 t
a
k
e
 p
a
rt
 y
o
u
 w
ill
 b
o
th
 b
e
 g
iv
e
n
 a
n
 
in
fo
rm
a
ti
o
n
 s
h
e
e
t 
to
 k
e
e
p
 a
n
d
 b
e
 a
sk
e
d
 t
o
 s
ig
n
 a
 c
o
n
se
n
t 
fo
rm
. 
If
 
y
o
u
r 
c
h
ild
 d
e
c
id
e
s 
to
 t
a
k
e
 p
a
rt
 t
h
e
y
 w
ill
 b
e
 f
re
e
 t
o
 w
it
h
d
ra
w
 f
ro
m
 t
h
e
 
st
u
d
y
 a
t 
a
n
y
 p
o
in
t 
th
e
y
 w
is
h
, 
a
n
d
 w
it
h
o
u
t 
g
iv
in
g
 a
 r
e
a
so
n
. 
Th
is
 s
tu
d
y
 
w
ill
 r
u
n
 a
lo
n
g
si
d
e
 y
o
u
r 
c
h
ild
's
 c
lin
ic
a
l 
c
a
re
 a
n
d
 i
s 
su
p
e
rv
is
e
d
 b
y
 t
h
e
ir
 
g
a
st
ro
in
te
st
in
a
l 
c
a
re
 t
e
a
m
 b
u
t 
w
ill
 n
o
t 
im
p
a
c
t 
o
n
 y
o
u
r 
c
h
ild
’s
 c
a
re
 i
n
 
a
n
y
 w
a
y
. 
 
W
e
 w
o
u
ld
 l
ik
e
 t
o
 i
n
v
it
e
 y
o
u
 a
n
d
 y
o
u
r 
c
h
ild
 t
o
 t
a
k
e
 p
a
rt
 i
n
 a
 r
e
se
a
rc
h
 
st
u
d
y
. 
B
e
fo
re
 
y
o
u
 
d
e
c
id
e
 
p
le
a
se
 
re
a
d
 
th
e
 
fo
llo
w
in
g
 
in
fo
rm
a
ti
o
n
 
le
a
fl
e
t 
a
n
d
 p
le
a
se
 c
o
n
ta
c
t 
u
s 
if
 y
o
u
 w
o
u
ld
 l
ik
e
 m
o
re
 i
n
fo
rm
a
ti
o
n
. 
Th
is
 
st
u
d
y
 
is
 
u
n
d
e
rt
a
k
e
n
 
b
y
 
C
la
re
 
C
la
rk
 
(B
S
c
. 
M
R
e
s)
 
a
s 
p
a
rt
 
o
f 
h
e
r 
U
n
iv
e
rs
it
y
 
o
f 
G
la
sg
o
w
, 
3
 
y
e
a
r 
p
o
st
g
ra
d
u
a
te
 
re
se
a
rc
h
 
p
ro
je
c
t.
 
Th
e
 
st
u
d
y
 
is
 
su
p
e
rv
is
e
d
 
jo
in
tl
y
 
b
y
 
th
e
 
U
n
iv
e
rs
it
y
 
o
f 
G
la
sg
o
w
 
H
u
m
a
n
 
N
u
tr
it
io
n
 
se
c
ti
o
n
 
a
n
d
 
th
e
 
g
a
st
ro
e
n
te
ro
lo
g
y
 
te
a
m
 
a
t 
th
e
 
R
o
y
a
l 
H
o
sp
it
a
l f
o
r 
S
ic
k
 C
h
ild
re
n
, 
Y
o
rk
h
ill
. 
 
W
e
 a
re
 i
n
te
re
st
e
d
 i
n
 t
h
e
 r
o
le
 t
h
a
t 
g
u
t 
b
a
c
te
ri
a
 p
la
y
 i
n
 i
n
fl
a
m
m
a
to
ry
 
c
o
n
d
it
io
n
s 
lik
e
 C
ro
h
n
’s
 d
is
e
a
se
. 
9
0
%
 o
f 
th
e
 c
e
lls
 i
n
 a
 h
u
m
a
n
 b
o
d
y
 a
re
 
b
a
c
te
ri
a
, 
b
u
t 
v
e
ry
 l
it
tl
e
 i
s 
k
n
o
w
n
 a
b
o
u
t 
th
e
 r
o
le
 t
h
e
se
 b
a
c
te
ri
a
 p
la
y
 i
n
 
b
o
th
 p
ro
te
c
ti
n
g
 a
n
d
 h
a
rm
in
g
 t
h
e
 h
u
m
a
n
 g
u
t.
 N
e
w
 t
e
c
h
n
iq
u
e
s 
h
a
v
e
 
sh
o
w
n
 
th
a
t 
th
e
 
b
a
c
te
ri
a
 
in
 
g
u
ts
 
o
f 
C
ro
h
n
’s
 
d
is
e
a
se
 
p
a
ti
e
n
ts
 
a
re
 
d
if
fe
re
n
t.
 
It
 
is
 
im
p
o
rt
a
n
t 
fo
r 
u
s 
to
 
tr
y
 
a
n
d
 
e
st
a
b
lis
h
 
w
h
e
th
e
r 
th
e
se
 
d
if
fe
re
n
c
e
s 
in
 
g
u
t 
b
a
c
te
ri
a
 
a
re
 
th
e
 
c
o
n
se
q
u
e
n
c
e
 
o
r 
th
e
 
c
a
u
se
 
o
f 
C
ro
h
n
’s
 d
is
e
a
se
. 
Th
is
 s
tu
d
y
 w
ill
 a
im
 t
o
 c
o
n
fi
rm
 w
h
ic
h
 b
a
c
te
ri
a
 m
ig
h
t 
b
e
 i
n
v
o
lv
e
d
 a
n
d
 i
d
e
n
ti
fy
 b
a
c
te
ri
a
l 
m
a
rk
e
rs
 w
h
ic
h
 w
o
u
ld
 h
e
lp
 d
o
c
to
rs
 
to
 
ta
rg
e
t 
th
e
 
b
e
st
 
in
d
iv
id
u
a
l 
tr
e
a
tm
e
n
t 
fo
r 
c
h
ild
re
n
 
w
it
h
 
g
u
t 
in
fl
a
m
m
a
ti
o
n
. 
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W
h
a
t 
d
o
 w
e
 n
e
e
d
 t
o
 d
o
 t
o
 t
a
k
e
 p
a
rt
?
 
A
 r
e
se
a
rc
h
e
r 
w
ill
 p
ro
v
id
e
 y
o
u
 w
it
h
 d
e
ta
ile
d
 i
n
fo
rm
a
ti
o
n
 a
n
d
 i
f 
y
o
u
r 
c
h
ild
 w
o
u
ld
 l
ik
e
 t
o
 t
a
k
e
 p
a
rt
 i
n
 t
h
e
 s
tu
d
y
 w
e
 w
ill
 a
sk
: 
 
•
q
u
e
st
io
n
s 
a
b
o
u
t 
y
o
u
r 
c
h
ild
’s
 
h
e
a
lt
h
 
a
n
d
 
w
h
a
t 
m
e
d
ic
a
ti
o
n
s 
th
e
y
 u
se
. 
•
y
o
u
 t
o
 c
o
m
p
le
te
 a
 q
u
e
st
io
n
n
a
ir
e
 a
b
o
u
t 
y
o
u
r 
c
h
ild
’s
 d
ie
t.
 
•
to
 
m
e
a
su
re
 
y
o
u
r 
c
h
ild
’s
 
h
e
ig
h
t,
 
w
e
ig
h
t,
 
a
n
d
 
h
a
n
d
 
g
ri
p
 
st
re
n
g
th
. 
 
•
to
 
p
e
rm
it
 
u
s,
 
w
it
h
 
a
p
p
ro
v
a
l 
o
f 
y
o
u
r 
c
lin
ic
ia
n
, 
to
 
a
c
c
e
ss
 
y
o
u
r 
c
h
ild
’s
 m
e
d
ic
a
l 
n
o
te
s 
fo
r 
d
a
ta
 o
n
 m
e
d
ic
a
ti
o
n
, 
d
is
e
a
se
 a
c
ti
v
it
y
, 
h
e
ig
h
t,
 w
e
ig
h
t 
e
tc
. 
 
•
y
o
u
r 
c
h
ild
 t
o
 p
ro
v
id
e
 6
 s
to
o
l 
a
n
d
 u
ri
n
e
 s
a
m
p
le
s 
o
v
e
r 
th
e
 c
o
u
rs
e
 
o
f 
o
n
e
 y
e
a
r.
 T
h
e
se
 w
ill
 b
e
 c
o
lle
c
te
d
 f
ro
m
 y
o
u
r 
h
o
m
e
 a
t 
a
 t
im
e
 
th
a
t 
is
 c
o
n
v
e
n
ie
n
t 
fo
r 
y
o
u
, 
o
r 
w
h
e
n
 y
o
u
 v
is
it
 t
h
e
 c
lin
ic
. 
•
y
o
u
r 
c
h
ild
’s
 h
o
sp
it
a
l 
d
o
c
to
r 
to
 p
ro
v
id
e
 u
s 
w
it
h
 a
n
 e
x
tr
a
 s
m
a
ll 
tu
b
e
 (
te
a
sp
o
o
n
) 
o
f 
b
lo
o
d
 w
h
e
n
 y
o
u
 c
o
m
e
 i
n
to
 c
lin
ic
, 
b
u
t 
o
n
ly
 
w
h
e
n
 
y
o
u
r 
c
h
ild
 i
s 
h
a
v
in
g
 
a
 
b
lo
o
d
 
sa
m
p
le
 
ta
k
e
n
 
fo
r 
ro
u
ti
n
e
 
m
e
d
ic
a
l 
re
a
so
n
s,
 s
o
 n
o
 e
x
tr
a
 n
e
e
d
le
 i
n
se
rt
io
n
 i
s 
re
q
u
ir
e
d
. 
 
W
e
 
w
ill
 
p
ro
v
id
e
 
y
o
u
 
w
it
h
 
a
 
d
e
ta
ile
d
 
sh
e
e
t 
o
f 
h
o
w
 
a
n
d
 
w
h
e
n
 
sa
m
p
le
 
c
o
lle
c
ti
o
n
s 
w
ill
 
h
a
p
p
e
n
, 
b
u
t 
th
is
 
w
ill
 
a
lw
a
y
s 
b
e
 
a
t 
y
o
u
r 
c
o
n
v
e
n
ie
n
c
e
, 
a
n
d
 y
o
u
 c
a
n
 w
it
h
d
ra
w
 f
ro
m
 t
h
e
 s
tu
d
y
 a
y
 a
n
y
 t
im
e
 
y
o
u
 l
ik
e
. 
W
e
 w
ill
 k
e
e
p
 t
h
e
se
 s
a
m
p
le
s 
fo
r 
fu
tu
re
 m
e
a
su
re
m
e
n
ts
 
a
s 
n
e
w
 t
e
st
s 
b
e
c
o
m
e
 a
v
a
ila
b
le
. 
 
 A
re
 t
h
e
re
 a
n
y
 b
e
n
e
fi
ts
 o
r 
ri
sk
s 
 i
f 
I 
ta
k
e
 p
a
rt
?
 
Th
e
re
 a
re
 n
o
 d
ir
e
c
t 
ri
sk
s 
o
r 
b
e
n
e
fi
ts
 f
ro
m
 t
a
k
in
g
 p
a
rt
 i
n
 t
h
e
 s
tu
d
y
. 
H
o
w
e
v
e
r 
w
e
 h
o
p
e
 t
h
a
t 
y
o
u
 a
n
d
 y
o
u
r 
c
h
ild
 m
ig
h
t 
fi
n
d
 i
t 
a
 p
o
si
ti
v
e
 
a
n
d
 r
e
w
a
rd
in
g
 e
x
p
e
ri
e
n
c
e
, 
in
 h
e
lp
in
g
 u
s 
to
 b
e
tt
e
r 
u
n
d
e
rs
ta
n
d
 t
h
e
 
ro
le
 
th
a
t 
g
u
t 
b
a
c
te
ri
a
 
p
la
y
 
in
 
c
a
u
si
n
g
 
o
r 
p
ro
te
c
ti
n
g
 
th
e
 
g
u
t 
in
 
c
h
ild
re
n
 w
it
h
 C
ro
h
n
’s
 d
is
e
a
se
 .
  
H
o
w
 w
ill
 t
h
e
 i
n
fo
rm
a
ti
o
n
 I
 p
ro
v
id
e
 b
e
 u
se
d
?
 
W
h
o
 i
s 
o
rg
a
n
is
in
g
 &
 f
u
n
d
in
g
 t
h
e
 s
tu
d
y
?
 
Y
e
s.
 P
a
rt
ic
ip
a
n
ts
 w
h
o
 h
a
v
e
 g
iv
e
n
 c
o
n
se
n
t 
to
 t
a
k
e
 p
a
rt
 i
n
 t
h
e
 s
tu
d
y
 w
ill
 
b
e
 
a
llo
c
a
te
d
 
a
n
 
a
n
o
n
y
m
o
u
s 
c
o
d
e
 
w
h
ic
h
 
w
ill
 
b
e
 
u
se
d
 
to
 
la
b
e
l 
a
ll 
sa
m
p
le
s 
a
n
d
 d
a
ta
, 
in
 o
rd
e
r 
to
 p
ro
te
c
t 
y
o
u
r 
c
h
ild
’s
 i
d
e
n
ti
ty
 d
u
ri
n
g
 a
ll 
la
b
 w
o
rk
 a
n
d
 a
n
a
ly
si
s 
o
f 
sa
m
p
le
 d
a
ta
. 
R
e
le
v
a
n
t 
m
e
d
ic
a
l 
h
is
to
ry
 w
ill
 b
e
 
c
o
lle
c
te
d
 f
ro
m
 m
e
d
ic
a
l 
n
o
te
s 
in
 l
in
e
 w
it
h
 t
h
e
 N
H
S
 C
o
d
e
 o
f 
P
ra
c
ti
c
e
 
(S
c
o
tl
a
n
d
) 
V
e
rs
io
n
 1
.0
 a
n
d
 c
u
rr
e
n
t 
d
a
ta
 p
ro
te
c
ti
o
n
 l
a
w
s.
 O
th
e
r 
th
a
n
 t
h
e
 
d
ir
e
c
t 
re
se
a
rc
h
 
te
a
m
, 
d
a
ta
 m
a
y
 
a
ls
o
 b
e
 m
o
n
it
o
re
d
 b
y
 
re
p
re
se
n
ta
ti
v
e
s 
o
f 
N
H
S
 G
G
&
C
 t
o
 e
n
su
re
 c
o
m
p
lia
n
c
e
 w
it
h
 r
e
g
u
la
ti
o
n
s.
 
 Th
e
 a
n
o
n
y
m
o
u
s 
d
a
ta
 g
e
n
e
ra
te
d
 f
ro
m
 y
o
u
r 
c
h
ild
’s
 s
a
m
p
le
s 
w
ill
 b
e
 u
se
d
 
to
 p
ro
d
u
c
e
 a
 r
e
p
o
rt
 a
n
d
 t
h
e
si
s 
o
n
 h
o
w
 d
ie
t,
 g
u
t 
b
a
c
te
ri
a
 a
n
d
 o
th
e
r 
fa
c
to
rs
 a
ff
e
c
t 
in
fl
a
m
m
a
ti
o
n
 i
n
 c
h
ild
re
n
 w
it
h
 g
u
t 
in
fl
a
m
m
a
ti
o
n
. 
W
e
 w
ill
 
p
re
se
n
t 
th
e
 r
e
su
lt
s 
a
t 
sc
ie
n
ti
fi
c
 c
o
n
fe
re
n
c
e
s,
 p
u
b
lis
h
 i
n
 s
c
ie
n
ti
fi
c
 j
o
u
rn
a
ls
 a
n
d
 
p
ro
v
id
e
 a
 r
e
p
o
rt
 o
f 
o
u
r 
fi
n
d
in
g
s 
fo
r 
c
h
ild
re
n
 a
n
d
 p
a
re
n
ts
 w
h
o
 w
o
u
ld
 l
ik
e
 t
h
is
 
in
fo
rm
a
ti
o
n
. 
Th
e
re
 
w
ill
 
b
e
 
n
o
 
p
e
rs
o
n
a
l 
in
fo
rm
a
ti
o
n
 
in
 
a
n
y
 
o
f 
th
e
se
 
re
p
o
rt
s.
 
Th
is
 r
e
se
a
rc
h
 i
s 
c
o
-o
rg
a
n
is
e
d
 b
y
 t
h
e
 U
n
iv
e
rs
it
y
 o
f 
G
la
sg
o
w
 a
n
d
 c
lin
ic
a
l 
st
a
ff
 a
t 
th
e
 R
o
y
a
l 
H
o
sp
it
a
l 
fo
r 
S
ic
k
 C
h
ild
re
n
 i
n
 G
la
sg
o
w
. 
It
 i
s 
fu
n
d
e
d
 b
y
 
Th
e
 Y
o
rk
h
ill
 C
h
ild
re
n
's
 C
h
a
ri
ty
 a
n
d
 h
a
s 
b
e
e
n
 r
e
v
ie
w
e
d
 b
y
 t
h
e
 W
e
st
 o
f 
S
c
o
tl
a
n
d
 R
e
se
a
rc
h
 E
th
ic
s 
C
o
m
m
it
te
e
. 
W
h
a
t 
if
 I
 h
a
v
e
 q
u
e
st
io
n
s 
o
r 
c
o
n
c
e
rn
s?
 
 
Th
e
 s
tu
d
y
 r
e
se
a
rc
h
e
r 
 
C
la
re
 C
la
rk
 w
ill
 a
lw
a
y
s 
b
e
 h
a
p
p
y
 t
o
 a
n
sw
e
r 
a
n
y
 q
u
e
st
io
n
s 
y
o
u
 
m
ig
h
t 
h
a
v
e
 a
b
o
u
t 
th
e
 s
tu
d
y
. 
 
P
le
a
se
 c
o
n
ta
c
t 
C
la
re
 b
y
 e
m
a
il:
 
c
.c
la
rk
.1
@
re
se
a
rc
h
.g
la
.a
c
.u
k
 
o
r 
b
y
 p
h
o
n
e
/t
e
x
t 
0
7
7
3
0
 4
6
5
2
3
0
 /
 0
1
4
1
 2
0
1
 8
6
8
8
 
 
 
If
 
y
o
u
 
h
a
v
e
 
a
n
y
 
c
o
n
c
e
rn
s 
o
r 
q
u
e
st
io
n
s 
a
b
o
u
t 
th
e
 
st
u
d
y
 
y
o
u
 
c
a
n
 
c
o
n
ta
c
t 
th
e
 
re
se
a
rc
h
e
r,
 
C
la
re
 
C
la
rk
. 
If
 
y
o
u
 
w
o
u
ld
 
lik
e
 
to
 
sp
e
a
k
 
to
 
so
m
e
o
n
e
 o
th
e
r 
th
a
n
 t
h
e
 r
e
se
a
rc
h
e
r 
p
le
a
se
 c
o
n
ta
c
t 
D
r 
D
a
lia
 M
a
lk
o
v
a
, 
U
n
iv
e
rs
it
y
 o
f 
G
la
sg
o
w
 H
u
m
a
n
 N
u
tr
it
io
n
 S
e
c
ti
o
n
, 
G
la
sg
o
w
 R
o
y
a
l 
In
fi
rm
a
ry
 o
n
 
0
1
4
1
 2
0
1
 8
6
9
0
. 
  
W
ill
 m
y
 c
h
ild
’s
 p
a
rt
ic
ip
a
ti
o
n
 b
e
 k
e
p
t 
c
o
n
fi
d
e
n
ti
a
l?
 
E
 I
n
fo
 le
a
fl
e
t 
C
ro
h
n
’s
 d
is
e
a
se
 1
8
/4
/1
4
 V
1
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B
a
c
te
ri
a
 &
 
In
fl
a
m
m
a
ti
o
n
 i
n
 
th
e
 G
u
t 
A
n
 i
n
fo
rm
a
ti
o
n
 
le
a
fl
e
t 
fo
r 
p
a
re
n
ts
/c
a
re
rs
 o
f 
h
e
a
lt
h
y
 c
h
il
d
re
n
 
in
te
re
st
e
d
 i
n
 h
e
lp
in
g
 
a
 r
e
se
a
rc
h
 p
ro
je
c
t 
a
b
o
u
t 
g
u
t 
b
a
c
te
ri
a
. 
Gut microbial taxonomy and metabolism in paediatric Crohn’s disease during 
exclusive and supplementary enteral nutrition using OMICS technologies  
In
v
it
a
ti
o
n
 
W
h
y
 a
re
 w
e
 d
o
in
g
 t
h
is
 s
tu
d
y
?
 
W
h
y
 h
a
s 
m
y
 c
h
ild
 b
e
e
n
 c
h
o
se
n
?
 
Y
o
u
r 
c
h
ild
 h
a
s 
b
e
e
n
 c
h
o
se
n
 b
e
c
a
u
se
 t
h
e
y
 a
re
 h
e
a
lt
h
y
 a
n
d
 w
ill
 
b
e
 c
o
m
p
a
re
d
 w
it
h
 c
h
ild
re
n
 w
h
o
 h
a
v
e
 c
o
n
d
it
io
n
s 
th
a
t 
in
v
o
lv
e
 
g
u
t 
in
fl
a
m
m
a
ti
o
n
 s
u
c
h
 a
s 
C
ro
h
n
’s
 D
is
e
a
se
. 
W
e
 w
ill
 b
e
 i
n
v
it
in
g
 
a
b
o
u
t 
4
0
 o
th
e
r 
h
e
a
lt
h
y
 c
h
ild
re
n
 o
f 
d
if
fe
re
n
t 
a
g
e
s 
to
 t
a
k
e
 p
a
rt
 i
n
 
th
is
 s
tu
d
y
. 
 
D
o
 w
e
 h
a
v
e
 t
o
 t
a
k
e
 p
a
rt
?
 
N
o
. 
It
 i
s 
u
p
 t
o
 y
o
u
 a
n
d
 y
o
u
r 
c
h
ild
 t
o
 d
e
c
id
e
 w
h
e
th
e
r 
o
r 
n
o
t 
to
 
ta
k
e
 
p
a
rt
. 
If
 
y
o
u
 
d
e
c
id
e
 
to
 
ta
k
e
 
p
a
rt
 
y
o
u
 
w
ill
 
b
e
 
g
iv
e
n
 
a
n
 
in
fo
rm
a
ti
o
n
 s
h
e
e
t 
to
 k
e
e
p
 a
n
d
 b
e
 a
sk
e
d
 t
o
 s
ig
n
 a
 c
o
n
se
n
t 
fo
rm
. 
If
 y
o
u
 a
re
 w
ill
in
g
 t
o
 t
a
k
e
 p
a
rt
 y
o
u
 w
ill
 b
e
 f
re
e
 t
o
 w
it
h
d
ra
w
 f
ro
m
 
th
e
 s
tu
d
y
 a
t 
a
n
y
 p
o
in
t 
y
o
u
 w
is
h
 a
n
d
 w
it
h
o
u
t 
g
iv
in
g
 a
 r
e
a
so
n
. 
 
W
e
 
w
o
u
ld
 l
ik
e
 
to
 
in
v
it
e
 
y
o
u
 
a
n
d
 
y
o
u
r 
c
h
ild
 
to
 
ta
k
e
 
p
a
rt
 
in
 
a
 
re
se
a
rc
h
 
st
u
d
y
. 
B
e
fo
re
 
y
o
u
 
d
e
c
id
e
 
p
le
a
se
 
re
a
d
 
th
e
 
fo
llo
w
in
g
 
in
fo
rm
a
ti
o
n
 l
e
a
fl
e
t 
a
n
d
 p
le
a
se
 c
o
n
ta
c
t 
u
s 
if
 y
o
u
 w
o
u
ld
 l
ik
e
 m
o
re
 
in
fo
rm
a
ti
o
n
. 
Th
is
 s
tu
d
y
 i
s 
u
n
d
e
rt
a
k
e
n
 b
y
 C
la
re
 C
la
rk
 (
B
S
c
. 
M
R
e
s)
 
a
s 
p
a
rt
 
o
f 
h
e
r 
U
n
iv
e
rs
it
y
 
o
f 
G
la
sg
o
w
, 
3
 
y
e
a
r 
p
o
st
g
ra
d
u
a
te
 
re
se
a
rc
h
 p
ro
je
c
t.
 T
h
e
 s
tu
d
y
 i
s 
su
p
e
rv
is
e
d
 j
o
in
tl
y
 b
y
 t
h
e
 U
n
iv
e
rs
it
y
 
o
f 
G
la
sg
o
w
 H
u
m
a
n
 N
u
tr
it
io
n
 s
e
c
ti
o
n
 a
n
d
 t
h
e
 g
a
st
ro
e
n
te
ro
lo
g
y
 
te
a
m
 a
t 
th
e
 R
o
y
a
l H
o
sp
it
a
l f
o
r 
S
ic
k
 C
h
ild
re
n
, 
Y
o
rk
h
ill
. 
 
W
e
 
a
re
 
in
te
re
st
e
d
 
in
 
th
e
 
ro
le
 
th
a
t 
g
u
t 
b
a
c
te
ri
a
 
p
la
y
 
in
 
a
u
to
im
m
u
n
e
 d
is
e
a
se
s 
lik
e
 C
ro
h
n
’s
 d
is
e
a
se
. 
9
0
%
 o
f 
th
e
 c
e
lls
 i
n
 a
 
h
u
m
a
n
 b
o
d
y
 a
re
 b
a
c
te
ri
a
, 
b
u
t 
w
e
 d
o
n
’t
 k
n
o
w
 e
n
o
u
g
h
 a
b
o
u
t 
th
e
 r
o
le
 t
h
a
t 
b
a
c
te
ri
a
 p
la
y
 i
n
 b
o
th
 p
ro
te
c
ti
n
g
 a
n
d
 h
a
rm
in
g
 t
h
e
 
h
u
m
a
n
 g
u
t.
 N
e
w
 t
e
c
h
n
iq
u
e
s 
w
h
ic
h
 i
d
e
n
ti
fy
 b
a
c
te
ri
a
 i
n
 t
h
e
 g
u
t,
 
h
a
v
e
 
sh
o
w
n
 
th
a
t 
th
e
 
b
a
c
te
ri
a
 
in
 
g
u
ts
 
o
f 
C
ro
h
n
’s
 
d
is
e
a
se
 
p
a
ti
e
n
ts
 a
re
 d
if
fe
re
n
t.
 W
e
 a
re
 t
ry
in
g
 t
o
 f
in
d
 o
u
t 
w
h
e
th
e
r 
th
e
se
 
b
a
c
te
ri
a
l 
d
if
fe
re
n
c
e
s 
a
re
 
th
e
 
c
o
n
se
q
u
e
n
c
e
 
o
r 
th
e
 
c
a
u
se
 
o
f 
C
ro
h
n
’s
 d
is
e
a
se
, 
a
n
d
 t
o
 i
d
e
n
ti
fy
 b
a
c
te
ri
a
l 
m
a
rk
e
rs
 w
h
ic
h
 w
o
u
ld
 
h
e
lp
 
d
o
c
to
rs
 
im
p
ro
v
e
 
tr
e
a
tm
e
n
t 
fo
r 
c
h
ild
re
n
 
w
it
h
 
C
ro
h
n
’s
 
d
is
e
a
se
 .
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W
h
a
t 
d
o
 w
e
 n
e
e
d
 t
o
 d
o
 t
o
 t
a
k
e
 p
a
rt
?
 
A
 
re
se
a
rc
h
e
r 
w
ill
 
p
ro
v
id
e
 
y
o
u
 
a
n
d
 
y
o
u
r 
c
h
ild
 
w
it
h
 
d
e
ta
ile
d
 
in
fo
rm
a
ti
o
n
 a
n
d
 a
sk
 w
h
e
th
e
r 
y
o
u
 w
o
u
ld
 l
ik
e
 t
o
 t
a
k
e
 p
a
rt
 i
n
 t
h
e
 
re
se
a
rc
h
 s
tu
d
y
. 
If
 y
o
u
 a
n
d
 y
o
u
r 
c
h
ild
 a
g
re
e
 w
e
 w
ill
: 
 
•
a
sk
 q
u
e
st
io
n
s 
a
b
o
u
t 
y
o
u
r 
c
h
ild
’s
 h
e
a
lt
h
 a
n
d
 a
n
y
 m
e
d
ic
a
ti
o
n
 
th
e
y
 a
re
 t
a
k
in
g
. 
•
a
sk
 y
o
u
 t
o
 c
o
m
p
le
te
 a
 q
u
e
st
io
n
n
a
ir
e
 a
b
o
u
t 
y
o
u
r 
c
h
ild
’s
 d
ie
t.
 
•
m
e
a
su
re
 y
o
u
r 
c
h
ild
’s
 h
e
ig
h
t,
 w
e
ig
h
t,
 a
n
d
 h
a
n
d
 g
ri
p
 s
tr
e
n
g
th
 
to
 s
e
e
 h
o
w
 s
tr
o
n
g
 t
h
e
y
 a
re
. 
 
•
a
sk
 y
o
u
r 
c
h
ild
 t
o
 p
ro
v
id
e
 a
 s
to
o
l 
a
n
d
 u
ri
n
e
 s
a
m
p
le
. 
Th
is
 c
a
n
 
b
e
 
c
o
lle
c
te
d
 
fr
o
m
 
y
o
u
r 
h
o
m
e
 
a
t 
a
 
d
a
te
/t
im
e
 
th
a
t 
is
 
c
o
n
v
e
n
ie
n
t 
fo
r 
y
o
u
. 
 
W
e
 w
ill
 k
e
e
p
 t
h
e
se
 s
a
m
p
le
s 
fo
r 
fu
tu
re
 m
e
a
su
re
m
e
n
ts
 a
s 
n
e
w
 t
e
st
s 
b
e
c
o
m
e
 a
v
a
ila
b
le
. 
 
 
 A
re
 t
h
e
re
 a
n
y
 b
e
n
e
fi
ts
 o
r 
ri
sk
s 
 i
f 
I 
ta
k
e
 p
a
rt
?
 
Th
e
re
 a
re
 n
o
 d
ir
e
c
t 
b
e
n
e
fi
ts
 o
r 
ri
sk
s 
fr
o
m
 t
a
k
in
g
 p
a
rt
 i
n
 t
h
e
 s
tu
d
y
. 
H
o
w
e
v
e
r 
w
e
 w
o
u
ld
 h
o
p
e
 t
h
a
t 
y
o
u
 m
ig
h
t 
fi
n
d
 i
t 
a
 p
o
si
ti
v
e
 a
n
d
 
re
w
a
rd
in
g
 
e
x
p
e
ri
e
n
c
e
 
in
 
h
e
lp
in
g
 
u
s 
to
 
b
e
tt
e
r 
u
n
d
e
rs
ta
n
d
 
th
e
 
ro
le
 
th
a
t 
g
u
t 
b
a
c
te
ri
a
 
p
la
y
 
in
 
c
a
u
si
n
g
 
o
r 
p
ro
te
c
ti
n
g
 
u
s 
fr
o
m
 
d
is
e
a
se
. 
 
 W
e
 w
ill
 a
ls
o
 b
e
 h
a
p
p
y
 t
o
 p
ro
v
id
e
 y
o
u
 w
it
h
 a
 r
e
p
o
rt
 w
h
ic
h
 s
u
m
s 
u
p
 t
h
e
 r
e
su
lt
s 
o
f 
th
is
 s
tu
d
y
 f
o
r 
y
o
u
 if
 y
o
u
 a
re
 i
n
te
re
st
e
d
. 
W
ill
 m
y
 c
h
ild
’s
 p
a
rt
ic
ip
a
ti
o
n
 b
e
 k
e
p
t 
c
o
n
fi
d
e
n
ti
a
l?
 
Y
e
s.
 P
a
rt
ic
ip
a
n
ts
 w
h
o
 g
iv
e
 c
o
n
se
n
t 
to
 t
a
k
e
 p
a
rt
 i
n
 t
h
e
 s
tu
d
y
 w
ill
 
b
e
 a
llo
c
a
te
d
 a
n
 a
lp
h
a
n
u
m
e
ri
c
 c
o
d
e
 w
h
ic
h
 w
ill
 b
e
 u
se
d
 t
o
 la
b
e
l 
a
ll 
sa
m
p
le
s 
a
n
d
 d
a
ta
, 
in
 o
rd
e
r 
to
 p
ro
te
c
t 
y
o
u
r 
c
h
ild
’s
 i
d
e
n
ti
ty
 
d
u
ri
n
g
 a
ll 
la
b
 w
o
rk
 a
n
d
 a
n
a
ly
si
s 
o
f 
sa
m
p
le
 d
a
ta
, 
in
 l
in
e
 w
it
h
 t
h
e
 
N
H
S
 C
o
d
e
 o
f 
P
ra
c
ti
c
e
 (
S
c
o
tl
a
n
d
) 
V
e
rs
io
n
 1
.0
 a
n
d
 c
u
rr
e
n
t 
d
a
ta
 
p
ro
te
c
ti
o
n
 
la
w
s.
 
O
th
e
r 
th
a
n
 
th
e
 
d
ir
e
c
t 
re
se
a
rc
h
 
te
a
m
, 
d
a
ta
 
m
a
y
 
a
ls
o
 
b
e
 
m
o
n
it
o
re
d
 
b
y
 
re
p
re
se
n
ta
ti
v
e
s 
o
f 
N
H
S
 
G
G
&
C
 
to
 
e
n
su
re
 c
o
m
p
lia
n
c
e
 w
it
h
 r
e
g
u
la
ti
o
n
s.
 
H
o
w
 w
ill
 t
h
e
 i
n
fo
rm
a
ti
o
n
 I
 p
ro
v
id
e
 b
e
 u
se
d
?
 
W
h
o
 i
s 
o
rg
a
n
is
in
g
 &
 f
u
n
d
in
g
 t
h
e
 s
tu
d
y
?
 
Th
is
 r
e
se
a
rc
h
 i
s 
c
o
-o
rg
a
n
is
e
d
 b
y
 t
h
e
 U
n
iv
e
rs
it
y
 o
f 
G
la
sg
o
w
 a
n
d
 
c
lin
ic
a
l 
st
a
ff
 a
t 
th
e
 R
o
y
a
l 
H
o
sp
it
a
l 
fo
r 
S
ic
k
 C
h
ild
re
n
 i
n
 G
la
sg
o
w
. 
It
 
is
 
fu
n
d
e
d
 
b
y
 
Th
e
 
Y
o
rk
h
ill
 
C
h
ild
re
n
's
 
C
h
a
ri
ty
 
a
n
d
 
h
a
s 
b
e
e
n
 
re
v
ie
w
e
d
 b
y
 t
h
e
 W
e
st
 o
f 
S
c
o
tl
a
n
d
 R
e
se
a
rc
h
 E
th
ic
s 
C
o
m
m
it
te
e
. 
Th
e
 a
n
o
n
y
m
o
u
s 
d
a
ta
 f
ro
m
 y
o
u
r 
c
h
ild
’s
 s
to
o
l, 
u
ri
n
e
 a
n
d
 d
ie
ta
ry
 
in
fo
rm
a
ti
o
n
, 
w
ill
 b
e
 u
se
d
 t
o
 p
ro
d
u
c
e
 a
 r
e
p
o
rt
 a
n
d
 t
h
e
si
s 
o
n
 
h
o
w
 
th
e
 
d
ie
t,
 
g
u
t 
b
a
c
te
ri
a
 
a
n
d
 
o
th
e
r 
fa
c
to
rs
 
in
 
h
e
a
lt
h
y
 
c
h
ild
re
n
 i
s 
d
if
fe
re
n
t 
fr
o
m
 c
h
ild
re
n
 w
h
o
 h
a
v
e
 C
ro
h
n
’s
 d
is
e
a
se
. 
W
e
 w
ill
 p
re
se
n
t 
th
e
 r
e
su
lt
s 
a
t 
sc
ie
n
ti
fi
c
 c
o
n
fe
re
n
c
e
s,
 p
u
b
lis
h
 i
n
 
sc
ie
n
ti
fi
c
 
jo
u
rn
a
ls
 
a
n
d
 
p
ro
v
id
e
 
a
 
re
p
o
rt
 
o
f 
o
u
r 
fi
n
d
in
g
s 
fo
r 
c
h
ild
re
n
 a
n
d
 p
a
re
n
ts
 w
h
o
 w
o
u
ld
 li
k
e
 t
h
is
 in
fo
rm
a
ti
o
n
. 
W
h
a
t 
if
 I
 h
a
v
e
 f
u
rt
h
e
r 
q
u
e
st
io
n
s 
o
r 
c
o
n
c
e
rn
s?
 
If
 y
o
u
 h
a
v
e
 a
n
y
 c
o
n
c
e
rn
s 
o
r 
q
u
e
st
io
n
s 
a
b
o
u
t 
th
e
 s
tu
d
y
 y
o
u
 c
a
n
 
c
o
n
ta
c
t 
th
e
 r
e
se
a
rc
h
e
r,
 C
la
re
 C
la
rk
. 
If
 y
o
u
 w
o
u
ld
 l
ik
e
 t
o
 s
p
e
a
k
 
to
 s
o
m
e
o
n
e
 o
th
e
r 
th
a
n
 t
h
e
 r
e
se
a
rc
h
e
r 
p
le
a
se
 c
o
n
ta
c
t 
D
r 
D
a
lia
 
M
a
lk
o
v
a
, 
U
n
iv
e
rs
it
y
 
o
f 
G
la
sg
o
w
 
H
u
m
a
n
 
N
u
tr
it
io
n
 
S
e
c
ti
o
n
, 
G
la
sg
o
w
 R
o
y
a
l I
n
fi
rm
a
ry
 o
n
 0
1
4
1
 2
0
1
 8
6
9
0
. 
 
Th
e
 s
tu
d
y
 r
e
se
a
rc
h
e
r 
 
C
la
re
 C
la
rk
 w
ill
 a
lw
a
y
s 
b
e
 h
a
p
p
y
 t
o
 a
n
sw
e
r 
a
n
y
 q
u
e
st
io
n
s 
y
o
u
 
m
ig
h
t 
h
a
v
e
 a
b
o
u
t 
th
e
 s
tu
d
y
. 
 
P
le
a
se
 c
o
n
ta
c
t 
C
la
re
 b
y
 e
m
a
il:
 
c
.c
la
rk
.1
@
re
se
a
rc
h
.g
la
.a
c
.u
k
 
o
r 
b
y
 p
h
o
n
e
/t
e
x
t 
0
7
7
3
0
 4
6
5
2
3
0
 /
 0
1
4
1
2
0
1
8
6
8
8
 
 
F
 I
n
fo
 le
a
fl
e
t 
h
e
a
lt
h
y
 c
h
ild
re
n
 1
8
/4
/1
4
 V
1
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In
fo
rm
a
ti
o
n
 S
h
e
e
t 
 
 
 
G
 I
n
fo
 3
-7
 C
o
l 
  
  
  
 V
1
_
2
0
/0
5
/1
4
 
           H
i! 
W
e 
w
an
t 
to
 f
in
d
 o
ut
 h
ow
 b
ug
s 
(b
ac
te
ri
a)
 t
h
at
 n
or
m
al
ly
 l
iv
e 
in
 o
ur
 t
um
m
ie
s 
ke
ep
 u
s 
h
ea
lt
h
y 
an
d
 p
ro
te
ct
 u
s 
fr
om
 b
ei
ng
 i
ll
. 
 
 W
h
a
t 
a
re
 b
a
ct
e
ri
a
?
 
B
ac
te
ri
a 
(b
ug
s)
 a
re
 s
o 
sm
al
l 
th
at
 w
e
 c
an
’t
 s
e
e
 t
h
e
m
 w
it
h
 o
ur
 e
ye
. 
B
ac
te
ri
a 
li
ve
 e
ve
ry
w
h
e
re
. 
T
h
ey
 a
re
 o
n 
yo
ur
 s
ki
n,
 i
n 
yo
ur
 n
os
e
, 
on
 y
ou
r 
te
e
th
 a
nd
 a
ls
o 
li
vi
ng
 i
n 
yo
ur
 t
um
m
y.
 W
e
 c
an
’t
 l
iv
e
 
w
it
h
ou
t 
th
em
. 
  W
h
y
 m
e
?
 
W
e 
ar
e 
as
ki
ng
 y
ou
 b
ec
au
se
 y
ou
 a
re
 c
om
in
g 
in
to
 h
os
pi
ta
l 
so
 y
ou
r 
d
oc
to
r 
ca
n 
h
av
e 
a 
lo
ok
 i
ns
id
e 
yo
ur
 t
um
m
y 
w
it
h
 a
 s
pe
ci
al
 c
am
er
a 
(c
ol
on
os
co
py
).
  
 D
o 
I
 h
a
ve
 t
o 
ta
k
e
 p
a
rt
?
 
N
o.
 I
t 
is
 u
p 
to
 y
ou
. I
f 
yo
u 
ag
re
e 
to
 t
ak
e
 p
ar
t 
w
e 
w
il
l 
as
k
 y
ou
 t
o 
si
gn
 a
 f
or
m
 w
h
ic
h
 s
ay
s 
yo
u 
ar
e 
h
ap
py
 t
o 
ta
ke
 p
ar
t.
 I
f 
yo
u 
ch
an
ge
 y
ou
r 
m
in
d
, 
th
at
’s
 f
in
e
. 
Y
ou
 c
an
 s
to
p 
at
 a
ny
 t
im
e 
b
y 
ju
st
 
te
lli
ng
 y
ou
r 
pa
re
nt
 o
r 
us
 t
h
at
 y
ou
 h
av
e
 c
h
an
ge
d
 y
ou
r 
m
in
d
.  
W
e
 w
il
l 
st
il
l 
lo
ok
 a
ft
er
 y
ou
 j
us
t 
as
 
w
el
l. 
W
h
a
t 
if
 I
 s
a
y
 y
e
s?
 
I
f 
yo
u 
ta
ke
 p
ar
t,
 a
 r
es
ea
rc
h
er
 w
il
l 
m
ea
su
re
 y
ou
r 
h
ei
gh
t 
an
d
 w
ei
gh
t 
an
d
 a
sk
 
so
m
e 
qu
es
ti
on
s 
ab
ou
t 
yo
ur
 h
ea
lt
h
. 
W
e 
w
il
l 
as
k 
yo
u 
an
d
 y
ou
r 
pa
re
nt
 q
ue
st
io
ns
 
ab
ou
t 
w
h
at
 y
ou
 e
at
 a
nd
 a
sk
 y
ou
 t
o 
gi
ve
 u
s 
a 
po
o 
(s
to
ol
) 
an
d
 p
ee
 (
ur
in
e
) 
sa
m
pl
e
. 
W
e 
w
il
l 
as
k 
yo
ur
 h
os
pi
ta
l 
d
oc
to
r 
to
 g
iv
es
 u
s 
an
 e
x
tr
a 
te
as
po
on
fu
l 
of
 b
lo
od
 a
nd
 
so
m
e 
ex
tr
a 
ti
ny
 s
ki
n 
sa
m
pl
es
 f
ro
m
 t
h
e 
sa
m
pl
es
 y
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n
 m
a
y
 p
la
y
 a
 r
o
le
 i
n
 a
 n
u
m
b
er
 o
f 
g
u
t 
d
is
ea
se
s,
 i
n
cl
u
d
in
g
 o
n
e 
ca
ll
ed
 C
ro
h
n
’s
 d
is
ea
se
. 
H
o
w
ev
er
, 
as
 y
et
, 
w
e 
d
o
 n
o
t 
k
n
o
w
 i
f 
th
es
e 
d
if
fe
re
n
ce
s 
in
 g
u
t 
b
ac
te
ri
a 
ar
e 
th
e 
re
su
lt
 o
r 
th
e 
ca
u
se
 o
f 
th
is
 t
y
p
e 
o
f 
il
ln
es
s.
  
 W
h
y
 h
a
v
e 
I 
b
ee
n
 c
h
o
se
n
?
 
B
ec
au
se
 y
o
u
 a
re
 c
o
m
in
g
 i
n
to
 h
o
sp
it
al
 t
o
 h
av
e 
a 
co
lo
n
o
sc
o
p
y
 t
es
t 
w
h
er
e 
a 
d
o
ct
o
r 
w
il
l 
lo
o
k
 i
n
si
d
e 
y
o
u
r 
in
te
st
in
es
 (
g
u
ts
) 
w
it
h
 a
 t
in
y
 v
id
eo
 c
am
er
a.
  
 D
o
 I
 h
a
v
e 
to
 t
a
k
e 
p
a
rt
?
 
N
o
. 
It
 i
s 
u
p
 t
o
 y
o
u
 a
n
d
 y
o
u
r 
ca
re
r/
p
ar
en
t 
to
 d
ec
id
e 
w
h
et
h
er
 y
o
u
 w
o
u
ld
 l
ik
e 
to
 t
ak
e 
p
ar
t.
 I
f 
y
o
u
 
d
ec
id
e 
to
 h
el
p
 u
s 
b
y
 t
ak
in
g
 p
ar
t 
y
o
u
 w
il
l 
b
e 
g
iv
en
 a
n
 i
n
fo
rm
at
io
n
 s
h
ee
t 
to
 k
ee
p
 a
n
d
 b
e 
as
k
ed
 t
o
 
si
g
n
 a
 c
o
n
se
n
t 
fo
rm
. 
A
t 
al
l 
ti
m
es
 t
h
ro
u
g
h
o
u
t 
th
e 
st
u
d
y
 y
o
u
 a
re
 f
re
e 
to
 w
it
h
d
ra
w
 a
n
d
 w
it
h
o
u
t 
g
iv
in
g
 a
 r
ea
so
n
. 
T
h
is
 s
tu
d
y
 w
il
l 
ru
n
 a
lo
n
g
si
d
e 
y
o
u
r 
cl
in
ic
al
 c
ar
e 
an
d
 i
s 
su
p
er
v
is
ed
 b
y
 y
o
u
r 
g
as
tr
o
in
te
st
in
al
 c
ar
e 
te
am
 b
u
t 
it
 w
il
l 
n
o
t 
im
p
ac
t 
o
n
 y
o
u
r 
ca
re
 i
n
 a
n
y
 w
a
y
. 
 
 W
h
a
t 
w
il
l 
h
a
p
p
en
 i
f 
I 
a
g
re
e 
to
 t
a
k
e 
p
a
rt
?
 
1
. 
W
e 
w
il
l 
as
k
 q
u
es
ti
o
n
s 
ab
o
u
t 
y
o
u
r 
h
ea
lt
h
 a
n
d
 a
n
y
 m
ed
ic
at
io
n
 y
o
u
 a
re
 t
ak
in
g
. 
2
. 
W
e 
w
il
l 
as
k
 q
u
es
ti
o
n
s 
ab
o
u
t 
y
o
u
r 
d
ie
t.
 
3
. 
W
e 
w
il
l 
as
k
 t
o
 m
ea
su
re
 y
o
u
r 
h
ei
g
h
t,
 w
ei
g
h
t,
 a
n
d
 h
an
d
 g
ri
p
 s
tr
en
g
th
 t
o
 s
ee
 h
o
w
 s
tr
o
n
g
 y
o
u
 a
re
. 
 
4
. 
W
e 
w
il
l 
as
k
 f
o
r 
y
o
u
 t
o
 p
ro
v
id
e 
a 
st
o
o
l 
(p
o
o
) 
an
d
 u
ri
n
e 
(p
ee
) 
sa
m
p
le
. 
T
h
is
 c
an
 b
e 
co
ll
ec
te
d
 w
h
en
 
y
o
u
 v
is
it
 t
h
e 
cl
in
ic
 o
r 
fr
o
m
 y
o
u
r 
h
o
m
e 
u
si
n
g
 a
 p
re
p
ai
d
 t
ax
i.
  
5
. 
W
e 
w
il
l 
as
k
 y
o
u
r 
h
o
sp
it
al
 d
o
ct
o
r 
to
 g
iv
e 
u
s 
an
 e
x
tr
a 
sm
al
l 
tu
b
e 
(t
ea
sp
o
o
n
) 
o
f 
b
lo
o
d
 w
h
en
 y
o
u
 
ar
e 
h
av
in
g
 t
h
is
 d
o
n
e 
an
y
w
a
y
 b
y
 t
h
e 
n
u
rs
e 
fo
r 
ro
u
ti
n
e 
m
ed
ic
al
 r
ea
so
n
s,
 s
o
 n
o
 e
x
tr
a 
n
ee
d
le
 
in
se
rt
io
n
 i
s 
n
ee
d
ed
. 
6
. 
W
e 
w
il
l 
as
k
 f
o
r 
so
m
e 
ex
tr
a 
ti
n
y
 b
io
p
sy
 s
am
p
le
s 
fr
o
m
 t
h
e 
g
u
t 
li
n
in
g
. 
Y
o
u
 w
il
l 
b
e 
as
le
ep
 (
u
n
d
er
 
g
en
er
al
 a
n
ae
st
h
et
ic
) 
d
u
ri
n
g
 t
h
is
 t
es
t 
an
d
 w
il
l 
n
o
t 
fe
el
 i
t 
o
r 
re
m
em
b
er
 h
av
in
g
 i
t 
d
o
n
e.
  Y
o
u
r 
d
o
ct
o
r 
ta
k
es
 t
in
y
 p
ie
ce
s 
o
f 
th
e 
li
n
in
g
 o
f 
th
e 
g
u
t,
 e
ac
h
 s
m
al
le
r 
th
an
 a
 g
ra
in
 o
f 
ri
ce
 (
b
io
p
si
es
) 
an
d
 v
ie
w
s 
th
em
 u
n
d
er
 a
 m
ic
ro
sc
o
p
e 
to
 f
in
d
 o
u
t 
w
h
at
’s
 b
ee
n
 c
au
si
n
g
 y
o
u
r 
m
ed
ic
al
 p
ro
b
le
m
s.
 
T
h
es
e 
a
re
 t
h
in
g
s 
yo
u
r 
h
o
sp
it
a
l 
d
o
ct
o
r 
w
il
l 
b
e 
d
o
in
g
 a
n
yw
a
y
, 
b
u
t 
yo
u
 c
a
n
 s
ti
ll
 t
a
ke
 p
a
rt
 e
ve
n
 i
f 
yo
u
 d
o
n
’t
 
w
a
n
t 
to
 g
iv
e 
u
s 
ti
ss
u
e 
sa
m
p
le
s.
  
7
. 
O
n
ly
 i
f 
y
o
u
r 
d
o
ct
o
r 
th
en
 d
ec
id
es
 y
o
u
 s
h
o
u
ld
 g
o
 o
n
 a
 s
p
ec
ia
l 
d
ie
t,
 t
o
 t
ry
 a
n
d
 i
m
p
ro
v
e 
y
o
u
r 
h
ea
lt
h
, 
w
e 
w
il
l 
co
ll
ec
t 
5
 m
o
re
 s
to
o
l 
&
 u
ri
n
e 
sa
m
p
le
s 
an
d
 2
 m
o
re
 b
lo
o
d
 s
am
p
le
s 
o
v
er
 t
h
e 
n
ex
t 
y
ea
r.
 W
e 
w
il
l 
al
so
 o
cc
as
io
n
al
ly
 a
sk
 a
b
o
u
t 
y
o
u
r 
d
ie
t.
 
 
W
e 
w
o
u
ld
 l
ik
e 
to
 k
ee
p
 a
ll
 t
h
es
e 
sa
m
p
le
s 
fo
r 
fu
tu
re
 m
ea
su
re
m
en
ts
 a
s 
n
ew
 t
es
ts
 b
ec
o
m
e 
a
va
il
a
b
le
. 
 
A
g
e
 1
2
+
  
fo
r 
y
o
u
n
g
 a
d
u
lt
s 
u
n
d
e
r 
in
v
e
st
ig
a
ti
o
n
 f
o
r 
g
u
t 
in
fl
a
m
m
a
ti
o
n
 
In
fo
rm
a
ti
o
n
 S
h
e
e
t 
 
I 
In
fo
 1
2
+
 C
o
l 
  
  
  
  
V
1
_
2
0
/0
5
/1
4
 
 W
h
a
t 
a
re
 t
h
e 
p
o
ss
ib
le
 b
en
ef
it
s 
a
n
d
 r
is
k
s 
o
f 
ta
k
in
g
 p
a
rt
?
 
T
h
er
e 
ar
e 
n
o
 
d
ir
ec
t 
b
en
ef
it
s 
fr
o
m
 
ta
k
in
g
 
p
ar
t 
in
 
th
e 
st
u
d
y
. 
D
u
ri
n
g
 
g
u
t 
ex
am
in
at
io
n
 
(c
o
lo
n
o
sc
o
p
y
),
 a
d
d
it
io
n
al
 g
u
t 
li
n
in
g
 s
am
p
le
s 
(b
io
p
si
es
) 
w
il
l 
o
n
ly
 b
e 
ta
k
en
 b
y
 y
o
u
r 
d
o
ct
o
r 
w
h
en
 
th
ey
 f
ee
l 
it
 i
s 
sa
fe
 t
o
 d
o
 s
o
. 
T
h
e 
b
o
w
el
 w
al
l 
h
as
 n
o
 p
ai
n
 n
er
v
es
, 
so
 t
h
e 
b
io
p
si
es
 w
il
l 
n
o
t 
h
u
rt
 a
t 
al
l,
 a
n
d
 a
n
y
 s
li
g
h
t 
b
le
ed
in
g
 u
su
al
ly
 s
to
p
s 
v
er
y
 q
u
ic
k
ly
. 
T
h
is
 i
s 
a 
sa
fe
 p
ro
ce
d
u
re
 d
o
n
e 
o
n
 
h
u
n
d
re
d
s 
o
f 
y
o
u
n
g
 p
eo
p
le
 i
n
 S
co
tl
an
d
 e
v
er
y
 y
ea
r 
an
d
 h
en
ce
 t
h
er
e 
ar
e 
n
o
 r
is
k
s 
fr
o
m
 t
ak
in
g
 p
ar
t.
 
W
e 
h
o
p
e 
y
o
u
 m
ig
h
t 
fi
n
d
 i
t 
a 
p
o
si
ti
v
e 
an
d
 r
ew
ar
d
in
g
 e
x
p
er
ie
n
ce
. 
Y
o
u
 c
an
 s
ti
ll
 t
ak
e 
p
ar
t 
in
 t
h
e 
st
u
d
y
 i
f 
n
o
 b
io
p
si
es
 a
re
 t
ak
en
. 
W
e 
w
il
l 
g
iv
e 
y
o
u
 a
 £
1
0
 s
h
o
p
p
in
g
 v
o
u
ch
er
 f
o
r 
ea
ch
 p
o
o
 (
st
o
o
l)
 
sa
m
p
le
 y
o
u
 g
iv
e 
to
 u
s 
an
d
 a
ls
o
 a
d
d
 y
o
u
r 
n
am
e 
in
to
 a
 p
ri
ze
 d
ra
w
, 
ju
st
 t
o
 s
ay
 t
h
an
k
 y
o
u
. 
 
 W
il
l 
m
y
 p
a
rt
ic
ip
a
ti
o
n
 b
e 
k
ep
t 
co
n
fi
d
en
ti
a
l?
 
Y
es
. 
W
h
en
 y
o
u
 g
iv
e 
co
n
se
n
t 
to
 t
ak
e 
p
ar
t 
in
 t
h
e 
st
u
d
y
 w
e 
w
il
l 
al
lo
ca
te
 y
o
u
 a
 c
o
d
e 
n
u
m
b
er
 w
h
ic
h
 
w
il
l 
b
e 
u
se
d
 t
o
 l
ab
el
 a
ll
 s
am
p
le
s 
an
d
 d
at
a.
 T
h
is
 h
id
es
 y
o
u
r 
id
en
ti
ty
 d
u
ri
n
g
 a
ll
 f
o
ll
o
w
in
g
 r
es
ea
rc
h
. 
O
n
ly
 t
h
e 
d
ir
ec
t 
re
se
ar
ch
 t
ea
m
 w
il
l 
h
av
e 
ac
ce
ss
 t
o
 y
o
u
r 
n
am
e 
an
d
 c
o
n
ta
ct
 d
et
ai
ls
, 
as
 w
el
l 
as
 t
h
e 
p
eo
p
le
 f
ro
m
 t
h
e 
h
ea
lt
h
 b
o
ar
d
 w
h
o
 c
h
ec
k
 t
h
at
 t
h
e 
st
u
d
y
 i
s 
g
o
in
g
 w
el
l.
 I
f 
y
o
u
 a
re
 h
ap
p
y
 w
e 
w
il
l 
in
fo
rm
 y
o
u
r 
G
P
 t
h
at
 y
o
u
 a
re
 p
ar
ti
ci
p
at
in
g
 i
n
 t
h
e 
st
u
d
y
. 
 
 H
o
w
 w
il
l 
th
e 
in
fo
rm
a
ti
o
n
 I
 p
ro
v
id
e 
b
e 
u
se
d
?
 
T
h
e 
d
at
a 
w
il
l 
b
e 
u
se
d
 t
o
 p
ro
d
u
ce
 a
 r
ep
o
rt
 o
n
 h
o
w
 d
ie
t,
 g
u
t 
b
ac
te
ri
a 
an
d
 o
th
er
 f
ac
to
rs
 a
ff
ec
t 
g
u
t 
h
ea
lt
h
 i
n
 s
o
m
e 
g
as
tr
o
in
te
st
in
al
 d
is
ea
se
s.
 
 W
h
o
 i
s 
d
o
in
g
 t
h
e 
st
u
d
y
?
 
C
la
re
 
C
la
rk
, 
a 
p
o
st
g
ra
d
u
at
e 
st
u
d
en
t 
re
se
ar
ch
er
, 
is
 
ca
rr
y
in
g
 
o
u
t 
th
is
 
st
u
d
y
 
to
 
in
cr
ea
se
 
o
u
r 
u
n
d
er
st
an
d
in
g
 o
f 
b
ac
te
ri
a 
in
 g
u
t 
p
ro
b
le
m
s.
 T
h
e 
st
u
d
y
 i
s 
fu
n
d
ed
 b
y
 Y
o
rk
h
il
l 
C
h
il
d
re
n
's
 C
h
ar
it
y
 
an
d
 w
il
l 
b
e 
su
p
er
v
is
ed
 b
y
 a
 t
ea
m
 o
f 
d
o
ct
o
rs
, 
d
ie
ti
ci
an
s 
an
d
 s
ci
en
ti
st
s 
b
as
ed
 a
t 
Y
o
rk
h
il
l 
an
d
 t
h
e 
U
n
iv
er
si
ty
 o
f 
G
la
sg
o
w
. 
 
 W
h
a
t 
if
 I
 h
a
v
e 
m
o
re
 q
u
es
ti
o
n
s?
 
If
 y
o
u
 h
av
e 
an
y
 q
u
es
ti
o
n
s 
y
o
u
 o
r 
y
o
u
r 
p
ar
en
t/
ca
re
r 
ca
n
 c
o
n
ta
ct
 u
s.
 C
la
re
 w
il
l 
al
w
ay
s 
b
e 
h
ap
p
y
 
to
 a
n
sw
er
 a
n
y
 q
u
es
ti
o
n
s 
y
o
u
 m
ig
h
t 
h
av
e 
ab
o
u
t 
th
e 
st
u
d
y
..
 
 
  
P
le
as
e 
co
n
ta
ct
 C
la
re
 b
y
 e
m
ai
l:
  
c.
cl
ar
k
.1
@
re
se
ar
ch
.g
la
.a
c.
u
k
 
 o
r 
b
y
 p
h
o
n
e/
te
x
t 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
m
o
b
il
e 
0
7
7
3
0
 4
6
5
2
3
0
 
(o
ff
ic
e 
- 
0
1
4
1
 2
0
1
 8
6
8
8
) 
 
 
If
 y
o
u
 w
o
u
ld
 l
ik
e 
to
 s
p
ea
k 
to
 s
o
m
eo
n
e 
o
th
er
 t
h
a
n
 t
h
e 
re
se
a
rc
h
er
, 
p
le
a
se
 c
o
n
ta
ct
 D
r 
D
a
li
a
 M
a
lk
o
va
, 
U
n
iv
er
si
ty
 
o
f 
G
la
sg
o
w
 H
u
m
a
n
 N
u
tr
it
io
n
 S
ec
ti
o
n
, 
G
la
sg
o
w
 R
o
ya
l 
In
fi
rm
a
ry
 o
n
 0
1
4
1
 2
0
1
 8
6
9
0
. 
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 I
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0
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            H
i! 
W
e 
w
an
t 
to
 f
in
d
 o
ut
 h
ow
 b
ug
s 
(b
ac
te
ri
a)
 t
h
at
 n
or
m
al
ly
 l
iv
e 
in
 o
ur
 t
um
m
ie
s 
ke
ep
 u
s 
h
ea
lt
h
y 
an
d
 p
ro
te
ct
 u
s 
fr
om
 b
ei
ng
 i
ll.
 
 W
h
a
t 
a
re
 b
a
ct
e
ri
a
?
 
B
ac
te
ri
a 
(b
ug
s)
 a
re
 s
o 
sm
al
l t
h
at
 w
e
 c
an
’t
 s
e
e
 t
h
e
m
 w
it
h
 o
ur
 e
ye
. B
ac
te
ri
a 
li
ve
 e
ve
ry
w
h
er
e
. 
T
h
e
y 
ar
e
 o
n 
yo
ur
 s
k
in
, 
in
 y
ou
r 
no
se
, 
on
 y
ou
r 
te
et
h
 a
nd
 a
ls
o 
li
vi
ng
 i
n 
yo
ur
 t
um
m
y.
 W
e
 c
an
’t
 
li
ve
 w
it
h
ou
t 
th
em
. 
 W
h
y
 m
e
?
 
W
e 
ar
e 
as
ki
ng
 y
ou
 b
ec
au
se
 y
ou
 h
av
e 
C
ro
h
n'
s 
d
is
ea
se
 a
nd
 y
ou
r 
d
oc
to
r 
h
as
 a
sk
ed
 y
ou
 t
o 
co
m
e 
in
to
 h
os
pi
ta
l 
fo
r 
tr
ea
tm
en
t 
on
 a
 s
pe
ci
al
 d
ie
t 
(w
h
ic
h
 y
ou
 m
ay
 h
av
e 
b
ee
n 
on
 b
ef
or
e)
 
to
 t
ry
 a
nd
 m
ak
e 
yo
u 
fe
e
l 
b
et
te
r.
 W
e 
w
an
t 
to
 f
in
d
 o
ut
 h
ow
 t
h
is
 d
ie
t 
h
el
ps
 y
ou
. 
 D
o 
I
 h
a
ve
 t
o 
ta
k
e
 p
a
rt
?
 
N
o.
 I
t 
is
 u
p 
to
 y
ou
. I
f 
yo
u 
ag
re
e 
to
 t
ak
e 
pa
rt
 w
e 
w
il
l a
sk
 y
ou
 t
o 
si
gn
 a
 f
or
m
 w
h
ic
h
 s
ay
s 
yo
u 
ar
e 
h
ap
py
 t
o 
ta
ke
 p
ar
t.
 I
f 
yo
u 
ch
an
ge
 y
ou
r 
m
in
d
, 
th
at
’s
 f
in
e
. 
Y
ou
 c
an
 s
to
p 
at
 a
ny
 t
im
e 
b
y 
ju
st
 t
el
lin
g 
yo
ur
 p
ar
en
t 
or
 u
s 
th
at
 y
ou
 h
av
e 
ch
an
ge
d
 y
ou
r 
m
in
d
. 
 W
e 
w
il
l 
st
il
l 
lo
ok
 a
ft
er
 
yo
u 
ju
st
 a
s 
w
el
l. 
  
W
h
a
t 
if
 I
 s
a
y
 y
e
s?
 
A
t 
d
if
fe
re
nt
 
ti
m
es
 
ov
er
 
th
e 
ne
x
t 
ye
ar
 
(1
 
to
 
3
 
m
on
th
s 
ap
ar
t)
 
a 
re
se
ar
ch
er
 
w
il
l 
m
ea
su
re
 
yo
ur
 
h
ei
gh
t 
an
d
 
w
ei
gh
t 
an
d
 
as
k 
so
m
e 
qu
es
ti
on
s 
ab
ou
t 
yo
ur
 h
ea
lt
h
. 
W
e 
w
il
l 
al
so
 a
sk
 y
ou
 a
nd
 y
ou
r 
pa
re
nt
 
qu
es
ti
on
s 
ab
ou
t 
w
h
at
 y
ou
 e
at
 a
nd
 w
il
l 
as
k 
yo
u 
to
 g
iv
e 
us
 6
 s
to
ol
 (
po
o)
 
an
d
 u
ri
ne
 (
pe
e)
 s
am
pl
es
. 
W
e
 w
il
l 
as
k 
yo
ur
 h
os
pi
ta
l 
d
oc
to
r 
to
 g
iv
es
 u
s 
an
 e
x
tr
a 
te
as
po
on
fu
l 
of
 b
lo
od
 b
ut
 o
nl
y 
at
 t
im
es
 w
h
en
 y
ou
r 
d
oc
to
r 
is
 
d
oi
ng
 t
h
is
 a
ny
w
ay
. W
e 
w
il
l 
al
so
 s
om
et
im
es
 r
ec
or
d
 y
ou
r 
d
ie
t.
 
  H
ow
 w
il
l 
it
 a
ff
e
ct
 m
e
?
 
It
 w
il
l 
no
t 
af
fe
ct
 y
ou
 i
n 
an
y 
b
ad
 w
ay
. Y
ou
 m
ig
h
t 
en
jo
y 
ta
ki
ng
 p
ar
t.
 W
e 
w
il
l 
gi
ve
 y
ou
 a
 £
10
 s
h
op
pi
ng
 v
ou
ch
er
 f
or
 e
ac
h
 p
oo
 (
st
oo
l)
 s
am
pl
e 
yo
u 
gi
ve
 t
o 
us
 a
nd
 p
ut
 y
ou
r 
na
m
e 
in
to
 a
 p
ri
ze
 d
ra
w
, 
ju
st
 t
o 
sa
y 
th
an
k 
yo
u.
 
W
h
a
t 
if
 I
 h
a
ve
 o
th
e
r 
co
nc
e
rn
s 
or
 q
ue
st
io
ns
?
 
If
 y
ou
 h
av
e 
an
y 
qu
es
ti
on
s 
te
ll 
yo
ur
 p
ar
en
t 
or
 c
ar
er
 a
nd
 t
h
ey
 w
il
l 
co
nt
ac
t 
us
 s
o 
w
e 
ca
n 
h
e
lp
 a
ns
w
er
 t
h
em
. 
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g
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 a
n
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n
d
e
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F
o
r 
ch
il
d
re
n
 w
it
h
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ro
h
n
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 d
is
e
a
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H
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’m
 a
 f
ri
e
n
d
ly
 
 b
a
c
t
e
ri
a
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N
ic
e
 t
o
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e
t
 y
o
u
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     T
h
is
 i
s 
w
h
e
n 
w
e
 w
il
l 
ta
ke
 s
a
m
pl
e
s 
if
 y
ou
 a
re
 h
a
pp
y
 t
o 
gi
ve
 t
h
e
m
. 
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4
 
           H
i!
 W
e 
ar
e 
as
k
in
g
 y
o
u
 t
o
 t
ak
e 
p
ar
t 
in
 o
u
r 
re
se
ar
ch
 p
ro
je
ct
, 
w
h
ic
h
 i
s 
ab
o
u
t 
th
e 
ro
le
 t
h
at
 
g
u
t 
b
ac
te
ri
a 
(b
u
g
s)
 p
la
y
 i
n
 c
h
il
d
re
n
 w
it
h
 s
to
m
ac
h
 p
ro
b
le
m
s.
 
 W
h
a
t 
a
re
 b
a
ct
er
ia
?
 
B
ac
te
ri
a 
ar
e 
ti
n
y
 b
u
g
s 
th
at
 l
iv
e 
ev
er
y
w
h
er
e.
 A
lt
h
o
u
g
h
 t
o
o
 s
m
al
l 
fo
r 
u
s 
to
 s
ee
, 
th
ey
 a
re
 
o
n
 y
o
u
r 
sk
in
 r
ig
h
t 
n
o
w
, 
in
 y
o
u
r 
n
o
se
, 
al
l 
o
v
er
 y
o
u
r 
te
et
h
 a
n
d
 a
ls
o
 l
iv
in
g
 i
n
 y
o
u
r 
g
u
ts
. 
In
 
fa
ct
 9
0
%
 o
f 
th
e 
ce
ll
s 
in
 a
 h
u
m
an
 b
o
d
y
 a
re
 a
ct
u
al
ly
 b
ac
te
ri
a 
an
d
 w
e 
co
u
ld
 n
o
t 
li
v
e 
w
it
h
o
u
t 
th
em
. 
 W
h
y
 a
re
 w
e 
d
o
in
g
 t
h
is
 r
es
ea
rc
h
?
 
V
er
y
 l
it
tl
e 
is
 k
n
o
w
n
 a
b
o
u
t 
h
o
w
 s
o
m
e 
b
ac
te
ri
a 
p
ro
te
ct
 a
n
d
 o
th
er
s 
h
ar
m
 t
h
e 
h
u
m
an
 g
u
t.
 N
ew
 
sc
ie
n
ti
fi
c 
m
et
h
o
d
s 
h
av
e 
sh
o
w
n
 t
h
at
 t
h
e 
b
ac
te
ri
a 
ar
e 
d
if
fe
re
n
t 
in
 t
h
e 
g
u
ts
 o
f 
so
m
e 
ch
il
d
re
n
 w
it
h
 
lo
n
g
 t
er
m
 g
u
t 
p
ro
b
le
m
s 
an
d
 w
e 
w
an
t 
to
 f
in
d
 o
u
t 
w
h
y
. 
T
h
is
 s
tu
d
y
 w
il
l 
ai
m
 t
o
 a
n
sw
er
 s
o
m
e 
o
f 
th
es
e 
q
u
es
ti
o
n
s.
 
 W
h
y
 h
a
v
e 
I 
b
ee
n
 c
h
o
se
n
?
 
W
e 
ar
e 
as
k
in
g
 y
o
u
 b
ec
au
se
 y
o
u
 h
av
e 
C
ro
h
n
's
 d
is
ea
se
, 
an
d
 y
o
u
r 
d
o
ct
o
r 
h
as
 a
sk
ed
 y
o
u
 t
o
 
co
m
e 
in
to
 h
o
sp
it
al
 f
o
r 
tr
ea
tm
en
t 
o
n
 a
 s
p
ec
ia
l 
li
q
u
id
 d
ie
t 
ca
ll
ed
 e
n
te
ra
l 
n
u
tr
it
io
n
 t
o
 t
ry
 a
n
d
 
m
ak
e 
y
o
u
 f
ee
l 
b
et
te
r.
 W
e 
w
an
t 
to
 f
in
d
 o
u
t 
h
o
w
 t
h
is
 d
ie
t 
h
el
p
s 
y
o
u
 b
y
 m
ea
su
ri
n
g
 c
h
an
g
es
 
in
 y
o
u
r 
g
u
t 
b
ac
te
ri
a 
w
h
il
e 
y
o
u
 a
re
 o
n
 t
h
e 
d
ie
t.
  
 D
o
 I
 h
a
v
e 
to
 t
a
k
e 
p
a
rt
?
 
N
o
, 
it
 i
s 
u
p
 t
o
 y
o
u
. 
If
 y
o
u
 a
g
re
e 
to
 t
ak
e 
p
ar
t 
y
o
u
 w
il
l 
b
e 
as
k
ed
 t
o
 s
ig
n
 a
 f
o
rm
 w
h
ic
h
 s
ay
s 
y
o
u
 a
re
 h
ap
p
y
 t
o
 t
ak
e 
p
ar
t.
 I
f 
y
o
u
 c
h
an
g
e 
y
o
u
r 
m
in
d
 y
o
u
 c
an
 s
to
p
 a
t 
an
y
 t
im
e 
w
it
h
o
u
t 
g
iv
in
g
 a
 r
ea
so
n
, 
b
y
 j
u
st
 t
el
li
n
g
 y
o
u
r 
p
ar
en
t 
y
o
u
 h
av
e 
ch
an
g
ed
 y
o
u
r 
m
in
d
. 
 W
e 
w
il
l 
st
il
l 
lo
o
k
 a
ft
er
 y
o
u
 j
u
st
 a
s 
w
el
l.
 
  
 
A
g
e
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1
  
fo
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il
d
re
n
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it
h
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ro
h
n
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 D
is
e
a
se
  
 
In
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a
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o
n
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h
e
e
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N
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n
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 8
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 V
1
_
2
0
/0
5
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4
 
 W
h
a
t 
w
il
l 
h
a
p
p
en
 i
f 
I 
ta
k
e 
p
a
rt
?
 
If
 y
o
u
 t
ak
e 
p
ar
t 
a 
re
se
ar
ch
er
 w
il
l 
m
ea
su
re
 y
o
u
r 
h
ei
g
h
t 
an
d
 w
ei
g
h
t 
an
d
 a
sk
 s
o
m
e 
q
u
es
ti
o
n
s 
ab
o
u
t 
y
o
u
r 
h
ea
lt
h
. 
O
v
er
 a
 y
ea
r 
w
e 
w
il
l 
as
k
 s
o
m
e 
q
u
es
ti
o
n
s 
ab
o
u
t 
w
h
at
 y
o
u
 e
at
 a
n
d
 a
sk
 
y
o
u
 t
o
 d
o
n
at
e 
6
 s
to
o
l 
(p
o
o
) 
an
d
 u
ri
n
e 
(p
ee
) 
sa
m
p
le
s.
 W
e 
w
il
l 
al
so
 a
sk
 y
o
u
r 
d
o
ct
o
r 
if
 w
e 
ca
n
 h
av
e 
an
 e
x
tr
a 
te
as
p
o
o
n
 o
f 
b
lo
o
d
, 
b
u
t 
o
n
ly
 i
f 
y
o
u
 a
re
 a
lr
ea
d
y
 h
av
in
g
 b
lo
o
d
 t
ak
en
 a
s 
p
ar
t 
o
f 
y
o
u
r 
ca
re
. 
W
e 
w
il
l 
o
cc
as
io
n
al
ly
 a
sk
 y
o
u
 a
b
o
u
t 
y
o
u
r 
d
ie
t.
 S
ee
 a
tt
a
ch
ed
 t
h
e 
sh
ee
t 
to
 s
ee
 w
h
en
 w
e 
w
il
l 
d
o
 t
h
es
e.
 
 A
re
 t
h
er
e 
a
n
y
 b
en
ef
it
s 
o
r 
ri
sk
s?
 
N
o
, 
th
er
e 
ar
e 
n
o
 r
is
k
s 
o
r 
b
en
ef
it
s 
fr
o
m
 t
h
e 
ta
k
in
g
 p
ar
t 
b
u
t 
w
e 
h
o
p
e 
to
 m
ak
e 
it
 e
n
jo
y
ab
le
 
fo
r 
y
o
u
. 
W
e 
w
il
l 
g
iv
e 
y
o
u
 a
 £
1
0
 s
h
o
p
p
in
g
 v
o
u
ch
er
 f
o
r 
ea
ch
 p
o
o
 (
st
o
o
l)
 s
am
p
le
 y
o
u
 g
iv
e 
to
 u
s 
an
d
 p
u
t 
y
o
u
r 
n
am
e 
in
to
 a
 p
ri
ze
 d
ra
w
, 
ju
st
 t
o
 s
ay
 t
h
an
k
 y
o
u
. 
W
e 
w
il
l 
al
so
 n
o
t 
te
ll
 
an
y
o
n
e 
ex
ce
p
t 
y
o
u
r 
G
P
 (
d
o
ct
o
r)
 t
h
at
 y
o
u
 a
re
 t
ak
in
g
 p
ar
t 
in
 t
h
e 
st
u
d
y
. 
 W
h
a
t 
w
il
l 
y
o
u
 d
o
 w
it
h
 m
y
 s
a
m
p
le
s?
 
W
e 
w
il
l 
d
o
 s
o
m
e 
sc
ie
n
ti
fi
c 
te
st
s 
o
n
 y
o
u
r 
sa
m
p
le
s 
to
 i
d
en
ti
fy
 w
h
ic
h
 b
ac
te
ri
a 
ar
e 
m
o
st
 
co
m
m
o
n
 i
n
 y
o
u
r 
g
u
t 
an
d
 a
ls
o
 m
ea
su
re
 s
o
m
e 
o
f 
th
e 
ch
em
ic
al
s 
th
at
 t
h
es
e
 
b
ac
te
ri
a 
p
ro
d
u
ce
 (
m
et
ab
o
li
te
s)
. 
T
h
is
 w
il
l 
h
el
p
 u
s 
to
 s
ee
 w
h
ic
h
 b
ac
te
ri
a 
m
ig
h
t 
h
el
p
 t
o
 k
ee
p
 u
s 
h
ea
lt
h
y
. 
W
e 
w
o
u
ld
 a
ls
o
 l
ik
e 
to
 k
ee
p
 t
h
es
e 
sa
m
p
le
s 
fo
r 
fu
tu
re
 m
ea
su
re
m
en
ts
 a
s 
n
ew
 t
es
ts
 b
ec
o
m
e 
av
ai
la
b
le
. 
 W
h
o
 i
s 
d
o
in
g
 t
h
e 
st
u
d
y
?
 
C
la
re
 C
la
rk
, 
a 
p
o
st
g
ra
d
u
at
e 
st
u
d
en
t 
re
se
ar
ch
er
, 
is
 c
ar
ry
in
g
 o
u
t 
th
is
 s
tu
d
y
 
to
 i
n
cr
ea
se
 o
u
r 
u
n
d
er
st
an
d
in
g
 o
f 
b
ac
te
ri
a 
in
 s
to
m
ac
h
 p
ro
b
le
m
s.
 T
h
e 
st
u
d
y
 
is
 f
u
n
d
ed
 b
y
 Y
o
rk
h
il
l 
C
h
il
d
re
n
's
 C
h
ar
it
y
 a
n
d
 i
s 
b
ei
n
g
 d
o
n
e 
w
it
h
 t
h
e 
ap
p
ro
v
al
 a
n
d
 s
u
p
er
v
is
io
n
 o
f 
y
o
u
r 
ca
re
 t
ea
m
 a
t 
N
H
S
 G
re
at
er
 G
la
sg
o
w
 &
 
C
ly
d
e 
an
d
 a
 t
ea
m
 o
f 
re
se
ar
ch
 s
ci
en
ti
st
s 
at
 U
n
iv
er
si
ty
 o
f 
G
la
sg
o
w
. 
 W
h
a
t 
if
 I
 h
a
v
e 
o
th
er
 c
o
n
ce
rn
s 
o
r 
q
u
es
ti
o
n
s?
 
If
 y
o
u
 h
av
e 
an
y
 q
u
es
ti
o
n
s 
te
ll
 y
o
u
r 
p
ar
en
t 
o
r 
ca
re
r 
an
d
 t
h
ey
 w
il
l 
co
n
ta
ct
 
u
s 
so
 w
e 
ca
n
 h
el
p
 a
n
sw
er
 t
h
em
. 
 
C
la
re
 w
il
l 
al
w
ay
s 
b
e 
h
ap
p
y
 t
o
 a
n
sw
er
 a
n
y
 q
u
es
ti
o
n
s 
y
o
u
 m
ig
h
t 
h
av
e 
ab
o
u
t 
th
e 
st
u
d
y
. 
  
P
le
as
e 
co
n
ta
ct
 C
la
re
 b
y
 e
m
ai
l:
  
c.
cl
a
rk
.1
@
re
se
a
rc
h
.g
la
.a
c.
u
k
 
o
r 
b
y
 p
h
o
n
e/
te
x
t 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
m
o
b
il
e 
0
7
7
3
0
 4
6
5
2
3
0
 
(o
ff
ic
e 
- 
0
1
4
1
 2
0
1
 8
6
8
8
) 
 
 
If
 y
o
u
 w
o
u
ld
 l
ik
e 
to
 s
p
ea
k 
to
 s
o
m
eo
n
e 
o
th
er
 t
h
a
n
 t
h
e 
re
se
a
rc
h
er
, 
p
le
a
se
 c
o
n
ta
ct
 D
r 
D
a
li
a
 M
a
lk
o
va
, 
 
U
n
iv
er
si
ty
 o
f 
G
la
sg
o
w
 H
u
m
a
n
 N
u
tr
it
io
n
 S
ec
ti
o
n
, 
G
la
sg
o
w
 R
o
ya
l 
In
fi
rm
a
ry
 o
n
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1
4
1
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0
1
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6
9
0
. 
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            W
e 
ar
e 
in
v
it
in
g
 
y
o
u
 t
o
 t
ak
e 
p
ar
t 
in
 a
 r
es
ea
rc
h
 s
tu
d
y
. 
B
ef
o
re
 
y
o
u
 d
ec
id
e 
p
le
as
e 
re
ad
 t
h
e 
fo
ll
o
w
in
g
 
in
fo
rm
at
io
n
 a
n
d
 a
sk
 u
s 
fo
r 
m
o
re
 i
n
fo
rm
at
io
n
 i
f 
y
o
u
 h
av
e 
q
u
es
ti
o
n
s.
  
 
 W
h
y
 a
re
 w
e 
d
o
in
g
 t
h
is
 r
es
ea
r
ch
?
 
9
0
%
 o
f 
th
e 
ce
ll
s 
in
 a
 h
u
m
an
 b
o
d
y
 a
re
 b
ac
te
ri
a,
 b
u
t 
v
er
y
 l
it
tl
e 
is
 k
n
o
w
n
 a
b
o
u
t 
th
e 
ro
le
 t
h
es
e 
b
ac
te
ri
a 
p
la
y
 
in
 b
o
th
 p
ro
te
ct
in
g
 a
n
d
 h
ar
m
in
g
 t
h
e 
h
u
m
an
 g
u
t.
 N
ew
 m
et
h
o
d
s 
h
av
e 
sh
o
w
n
 t
h
at
 t
h
e 
b
ac
te
ri
a 
in
 t
h
e 
g
u
ts
 o
f 
ch
il
d
re
n
 w
it
h
 C
ro
h
n
’s
 d
is
ea
se
 t
en
d
 t
o
 b
e
 d
if
fe
re
n
t.
 H
o
w
ev
er
, 
as
 y
et
, 
w
e 
d
o
n
’t
 k
n
o
w
 i
f 
th
es
e 
d
if
fe
re
n
ce
s 
in
 g
u
t 
b
ac
te
ri
a 
ar
e 
th
e 
re
su
lt
 o
r 
th
e 
ca
u
se
 o
f 
C
ro
h
n
’s
 d
is
ea
se
. 
T
h
e 
st
u
d
y
 w
il
l 
tr
y
 t
o
 h
el
p
 a
n
sw
er
 t
h
is
 
q
u
es
ti
o
n
. 
 W
h
y
 h
a
v
e 
I 
b
ee
n
 c
h
o
se
n
?
 
 
W
e 
ar
e 
as
k
in
g
 y
o
u
 b
ec
au
se
 y
o
u
 h
av
e 
C
ro
h
n
's
 d
is
ea
se
, 
an
d
 y
o
u
r 
d
o
ct
o
r 
h
as
 a
sk
ed
 y
o
u
 t
o
 c
o
m
e 
in
to
 
h
o
sp
it
al
 f
o
r 
tr
ea
tm
en
t 
o
n
 a
 s
p
ec
ia
l 
li
q
u
id
 d
ie
t 
ca
ll
ed
 e
n
te
ra
l 
n
u
tr
it
io
n
 (
w
h
ic
h
 y
o
u
 m
a
y
 h
av
e 
h
ad
 b
ef
o
re
) 
 
to
 t
ry
 a
n
d
 i
m
p
ro
v
e 
y
o
u
r 
sy
m
p
to
m
s.
 W
e 
w
an
t 
to
 f
in
d
 o
u
t 
h
o
w
 t
h
is
 d
ie
t 
h
el
p
s 
y
o
u
, 
b
y
 m
ea
su
ri
n
g
 c
h
an
g
es
 
in
 y
o
u
r 
g
u
t 
b
ac
te
ri
a 
w
h
il
e 
y
o
u
 a
re
 o
n
 t
h
e 
d
ie
t.
 
 D
o
 I
 h
a
v
e 
to
 t
a
k
e 
p
a
rt
?
 
N
o
. 
It
 i
s 
u
p
 t
o
 y
o
u
 a
n
d
 y
o
u
r 
ca
re
r/
p
ar
en
t 
to
 d
ec
id
e 
w
h
et
h
er
 y
o
u
 w
o
u
ld
 l
ik
e 
to
 t
ak
e 
p
ar
t.
 I
f 
y
o
u
 d
ec
id
e 
to
 
h
el
p
 u
s 
b
y
 t
ak
in
g
 p
ar
t 
y
o
u
 w
il
l 
b
e 
g
iv
en
 a
n
 i
n
fo
rm
at
io
n
 s
h
ee
t 
to
 k
ee
p
 a
n
d
 b
e 
as
k
ed
 t
o
 s
ig
n
 a
 c
o
n
se
n
t 
fo
rm
. 
A
t 
al
l 
ti
m
es
 t
h
ro
u
g
h
o
u
t 
th
e 
st
u
d
y
 y
o
u
 a
re
 f
re
e 
to
 w
it
h
d
ra
w
 a
n
d
 w
it
h
o
u
t 
g
iv
in
g
 a
 r
ea
so
n
. 
A
lt
h
o
u
g
h
 
th
is
 s
tu
d
y
 w
il
l 
ru
n
 a
lo
n
g
si
d
e 
y
o
u
r 
cl
in
ic
al
 c
ar
e 
an
d
 i
s 
su
p
er
v
is
ed
 b
y
 y
o
u
r 
g
as
tr
o
in
te
st
in
al
 c
ar
e 
te
am
 i
t 
w
il
l 
n
o
t 
im
p
ac
t 
o
n
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o
u
ch
er
 f
o
r 
ea
ch
 p
o
o
 (
st
o
o
l)
 s
am
p
le
 y
o
u
 
g
iv
e 
to
 u
s,
 a
n
d
 p
u
t 
y
o
u
r 
n
am
e 
in
to
 a
 p
ri
ze
 d
ra
w
, 
ju
st
 t
o
 s
ay
 t
h
an
k
 y
o
u
. 
W
e 
w
il
l 
al
so
 n
o
t 
te
ll
 a
n
y
o
n
e 
ex
ce
p
t 
y
o
u
r 
G
P
 (
d
o
ct
o
r)
 t
h
at
 y
o
u
 a
re
 t
ak
in
g
 p
ar
t 
in
 t
h
e 
st
u
d
y
. 
:K
DW
ZLO
O\R
XG
RZ
LWK
P
\V
DP
SOH
V"
W
e 
w
il
l 
d
o
 s
o
m
e 
sc
ie
n
ti
fi
c 
te
st
s 
o
n
 y
o
u
r 
sa
m
p
le
s 
to
 i
d
en
ti
fy
 w
h
ic
h
 
b
ac
te
ri
a 
ar
e 
m
o
st
 c
o
m
m
o
n
 i
n
 y
o
u
r 
g
u
t 
an
d
 a
ls
o
 m
ea
su
re
 s
o
m
e 
o
f 
th
e 
ch
em
ic
al
s 
th
at
 t
h
es
e 
b
ac
te
ri
a 
p
ro
d
u
ce
 (
m
et
ab
o
li
te
s)
. 
T
h
is
 w
il
l 
h
el
p
 
u
s 
to
 s
ee
 w
h
ic
h
 b
ac
te
ri
a 
m
ig
h
t 
h
el
p
 t
o
 k
ee
p
 u
s 
h
ea
lt
h
y
. 
W
e 
w
o
u
ld
 
al
so
 l
ik
e 
to
 k
ee
p
 t
h
es
e 
sa
m
p
le
s 
fo
r 
fu
tu
re
 m
ea
su
re
m
en
ts
 a
s 
n
ew
 t
es
ts
 
b
ec
o
m
e 
av
ai
la
b
le
. 
:K
RLV
GR
LQJ
WK
HV
WXG
\"
C
la
re
 C
la
rk
, 
a 
p
o
st
g
ra
d
u
at
e 
st
u
d
en
t 
re
se
ar
ch
er
, 
is
 c
ar
ry
in
g
 o
u
t 
th
is
 
st
u
d
y
 
to
 
in
cr
ea
se
 
o
u
r 
u
n
d
er
st
an
d
in
g
 
o
f 
b
ac
te
ri
a 
in
 
st
o
m
ac
h
 
p
ro
b
le
m
s.
 T
h
e 
st
u
d
y
 i
s 
fu
n
d
ed
 b
y
 Y
o
rk
h
il
l 
C
h
il
d
re
n
's
 C
h
ar
it
y
 a
n
d
 i
s 
d
o
n
e 
w
it
h
 
th
e 
su
p
er
v
is
io
n
 
o
f 
le
ad
in
g
 
d
o
ct
o
rs
 
at
 
Y
o
rk
h
il
l,
 
N
H
S
 
G
re
at
er
 
G
la
sg
o
w
 
&
 
C
ly
d
e 
an
d
 
a 
te
am
 
o
f 
re
se
ar
ch
 
sc
ie
n
ti
st
s 
at
 
U
n
iv
er
si
ty
 o
f 
G
la
sg
o
w
. 

:K
DW
LI,
KD
YH
RWK
HU
FRQ
FHU
QV
RU
TX
HVW
LRQ
V"
If
 y
o
u
 h
av
e 
an
y
 q
u
es
ti
o
n
s 
te
ll
 y
o
u
r 
p
ar
en
t 
o
r 
ca
re
r 
an
d
 t
h
ey
 w
il
l 
co
n
ta
ct
 u
s 
so
 w
e 
ca
n
 
h
el
p
 a
n
sw
er
 t
h
em
. 
C
la
re
 w
il
l 
al
w
ay
s 
b
e 
h
ap
p
y
 t
o
 a
n
sw
er
 a
n
y
 q
u
es
ti
o
n
s 
y
o
u
 m
ig
h
t 
h
av
e 
ab
o
u
t 
th
e 
st
u
d
y
. 
P
le
as
e 
co
n
ta
ct
 C
la
re
 b
y
 e
m
ai
l:
  
FF
ODU
N
#U
HVH
DUF
KJ
ODD
FX
N
o
r 
b
y
 p
h
o
n
e/
te
x
t 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
m
o
b
il
e
(o
ff
ic
e 
- 
0
1
4
1
 2
0
1
 8
6
8
8
)

If
 y
o
u
 w
o
u
ld
 l
ik
e 
to
 s
p
ea
k 
to
 s
o
m
eo
n
e 
o
th
er
 t
h
a
n
 t
h
e 
re
se
a
rc
h
er
, 
p
le
a
se
 c
o
n
ta
ct
 D
r 
D
a
li
a
 M
a
lk
o
va
, 
U
n
iv
er
si
ty
 o
f 
G
la
sg
o
w
 H
u
m
a
n
 N
u
tr
it
io
n
 S
ec
ti
o
n
, 
G
la
sg
o
w
 R
o
ya
l 
In
fi
rm
a
ry
 o
n
 0
1
4
1
 2
0
1
 8
6
9
0
.
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 p
ag
e 
2
 
 
 
 
           A
s 
a 
h
ea
lt
h
y
 y
o
u
n
g
 p
er
so
n
, 
w
e 
ar
e 
in
v
it
in
g
 y
o
u
 t
o
 t
ak
e 
p
ar
t 
in
 a
 r
es
ea
rc
h
 s
tu
d
y
 w
h
ic
h
 
w
il
l 
lo
o
k
 
at
 
h
o
w
 
g
u
t 
b
ac
te
ri
a 
m
ig
h
t 
co
n
tr
ib
u
te
 
to
 
in
fl
am
m
at
io
n
 
in
 
ch
il
d
re
n
 
w
it
h
 
g
as
tr
o
in
te
st
in
al
 d
is
ea
se
s 
su
ch
 a
s 
C
ro
h
n
's
 d
is
ea
se
. 
 W
h
y
 a
re
 w
e 
d
o
in
g
 t
h
is
 r
es
ea
rc
h
?
 
9
0
%
 o
f 
th
e 
ce
ll
s 
in
 a
 h
u
m
an
 b
o
d
y
 a
re
 b
ac
te
ri
a,
 b
u
t 
v
er
y
 l
it
tl
e 
is
 k
n
o
w
n
 a
b
o
u
t 
th
e 
ro
le
 
th
es
e 
b
ac
te
ri
a 
p
la
y
 i
n
 b
o
th
 p
ro
te
ct
in
g
 a
n
d
 h
ar
m
in
g
 t
h
e 
h
u
m
an
 g
u
t.
 N
ew
 m
et
h
o
d
s 
h
av
e 
sh
o
w
n
 t
h
at
 t
h
e 
b
ac
te
ri
a 
in
 t
h
e 
g
u
ts
 o
f 
ch
il
d
re
n
 w
it
h
 C
ro
h
n
’s
 d
is
ea
se
 a
re
 d
if
fe
re
n
t.
 
H
o
w
ev
er
, 
as
 y
et
, 
w
e 
d
o
n
’t
 k
n
o
w
 i
f 
th
es
e 
d
if
fe
re
n
ce
s 
in
 g
u
t 
b
ac
te
ri
a 
ar
e 
th
e 
re
su
lt
 o
r 
th
e 
ca
u
se
 o
f 
C
ro
h
n
’s
 d
is
ea
se
. 
T
h
e 
st
u
d
y
 w
il
l 
tr
y
 t
o
 h
el
p
 a
n
sw
er
 t
h
is
 q
u
es
ti
o
n
. 
 W
h
y
 h
a
v
e 
I 
b
ee
n
 c
h
o
se
n
?
 
W
e 
ar
e 
in
te
re
st
ed
 i
n
 i
ll
n
es
se
s 
w
h
ic
h
 a
ff
ec
t 
th
e 
h
ea
lt
h
 o
f 
th
e 
g
u
t.
 Y
o
u
 h
av
e 
b
ee
n
 c
h
o
se
n
 
b
ec
au
se
 y
o
u
 a
re
 h
ea
lt
h
y
 a
n
d
 s
o
 w
e 
ca
n
 c
o
m
p
ar
e 
y
o
u
 w
it
h
 c
h
il
d
re
n
 w
h
o
 a
re
 u
n
w
el
l 
w
it
h
 
co
n
d
it
io
n
s 
th
at
 i
n
v
o
lv
e 
th
e 
g
u
t.
 W
e 
w
il
l 
b
e 
in
v
it
in
g
 o
th
er
 h
ea
lt
h
y
 c
h
il
d
re
n
 o
f 
d
if
fe
re
n
t 
ag
es
 t
o
 t
ak
e 
p
ar
t 
in
 t
h
is
 s
tu
d
y
. 
 
 D
o
 I
 h
a
v
e 
to
 t
a
k
e 
p
a
rt
?
 
N
o
. 
It
 i
s 
u
p
 t
o
 y
o
u
 a
n
d
 y
o
u
r 
ca
re
r/
p
ar
en
t 
to
 d
ec
id
e 
w
h
et
h
er
 o
r 
n
o
t 
to
 t
ak
e 
p
ar
t.
 I
f 
y
o
u
 
d
ec
id
e 
to
 h
el
p
 u
s 
b
y
 t
ak
in
g
 p
ar
t 
y
o
u
 w
il
l 
b
e 
g
iv
en
 a
n
 i
n
fo
rm
at
io
n
 s
h
ee
t 
to
 k
ee
p
 a
n
d
 b
e 
as
k
ed
 t
o
 s
ig
n
 a
 c
o
n
se
n
t 
fo
rm
. 
If
 y
o
u
 d
o
 t
ak
e 
p
ar
t 
y
o
u
 w
il
l 
b
e 
fr
ee
 t
o
 w
it
h
d
ra
w
 f
ro
m
 t
h
e 
st
u
d
y
 a
t 
an
y
 p
o
in
t 
y
o
u
 w
is
h
 a
n
d
 w
it
h
o
u
t 
g
iv
in
g
 a
 r
ea
so
n
. 
 
 W
h
a
t 
w
il
l 
h
a
p
p
en
 i
f 
I 
a
g
re
e 
to
 t
a
k
e 
p
a
rt
?
 
1
. 
W
e 
w
il
l 
as
k
 q
u
es
ti
o
n
s 
ab
o
u
t 
y
o
u
r 
h
ea
lt
h
 a
n
d
 a
n
y
 m
ed
ic
at
io
n
 y
o
u
 a
re
 t
ak
in
g
. 
2
. 
W
e 
w
il
l 
as
k
 q
u
es
ti
o
n
s 
ab
o
u
t 
y
o
u
r 
d
ie
t.
 
3
. 
W
e 
w
il
l 
as
k
 t
o
 m
ea
su
re
 y
o
u
r 
h
ei
g
h
t,
 w
ei
g
h
t,
 a
n
d
 h
an
d
 g
ri
p
 s
tr
en
g
th
 t
o
 s
ee
 h
o
w
 s
tr
o
n
g
 
y
o
u
 a
re
. 
 
4
. 
W
e 
w
il
l 
as
k
 y
o
u
 t
o
 p
ro
v
id
e 
a 
st
o
o
l 
(p
o
o
) 
an
d
 u
ri
n
e 
(p
ee
) 
sa
m
p
le
. 
T
h
is
 w
il
l 
b
e 
at
 a
 d
at
e 
th
at
 i
s 
co
n
v
en
ie
n
t 
fo
r 
y
o
u
 a
n
d
 c
an
 b
e 
co
ll
ec
te
d
 f
ro
m
 y
o
u
r 
h
o
m
e 
u
si
n
g
 a
 p
re
p
ai
d
 t
ax
i.
  
 
W
e 
w
o
u
ld
 l
ik
e 
to
 k
ee
p
 t
h
es
e 
sa
m
p
le
s 
fo
r 
fu
tu
re
 m
ea
su
re
m
en
ts
 a
s 
n
ew
 t
es
ts
 b
ec
o
m
e 
a
va
il
a
b
le
. 
A
g
e
 1
2
+
 
H
e
a
lt
h
y
 y
o
u
n
g
 a
d
u
lt
s 
In
fo
rm
a
ti
o
n
 S
h
e
e
t 
L
 I
n
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 1
2
+
 H
C
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_
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0
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ag
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 A
re
 t
h
er
e 
a
n
y
 b
en
ef
it
s 
o
r 
ri
sk
s 
if
 I
 t
a
k
e 
p
a
rt
?
 
T
h
er
e 
ar
e 
n
o
 b
en
ef
it
s 
o
r 
ri
sk
s 
fr
o
m
 t
ak
in
g
 p
ar
t 
in
 t
h
e 
st
u
d
y
. 
H
o
w
ev
er
 w
e 
h
o
p
e 
th
at
 y
o
u
 
m
ig
h
t 
fi
n
d
 i
t 
a 
p
o
si
ti
v
e 
an
d
 r
ew
ar
d
in
g
 e
x
p
er
ie
n
ce
. 
W
e 
w
il
l 
g
iv
e 
y
o
u
 a
 £
1
0
 s
h
o
p
p
in
g
 
v
o
u
ch
er
 f
o
r 
ea
ch
 p
o
o
 (
st
o
o
l)
 s
am
p
le
 y
o
u
 g
iv
e 
to
 u
s 
an
d
 a
d
d
 y
o
u
r 
n
am
e 
in
to
 a
 p
ri
ze
 
d
ra
w
, 
ju
st
 t
o
 s
ay
 t
h
an
k
 y
o
u
. 
 W
il
l 
m
y
 p
a
rt
ic
ip
a
ti
o
n
 b
e 
k
ep
t 
co
n
fi
d
en
ti
a
l?
 
Y
es
. 
W
h
en
 y
o
u
 g
iv
e 
co
n
se
n
t 
to
 t
ak
e 
p
ar
t 
in
 t
h
e 
st
u
d
y
 w
e 
w
il
l 
al
lo
ca
te
 y
o
u
 a
 
co
d
e 
n
u
m
b
er
 w
h
ic
h
 w
il
l 
b
e 
u
se
d
 t
o
 l
ab
el
 a
ll
 s
am
p
le
s 
an
d
 d
at
a,
 i
n
 o
rd
er
 t
o
 
p
ro
te
ct
 y
o
u
r 
id
en
ti
ty
 d
u
ri
n
g
 a
ll
 f
o
ll
o
w
in
g
 l
ab
 w
o
rk
 a
n
d
 a
n
al
y
si
s 
o
f 
sa
m
p
le
 
d
at
a.
 
O
n
ly
 
th
e 
d
ir
ec
t 
re
se
ar
ch
 
te
am
 
w
il
l 
h
av
e 
ac
ce
ss
 
to
 
y
o
u
r 
n
am
e 
an
d
 
co
n
ta
ct
 d
et
ai
ls
. 
 H
o
w
 w
il
l 
th
e 
in
fo
rm
a
ti
o
n
 I
 p
ro
v
id
e 
b
e 
u
se
d
?
 
T
h
e 
in
fo
rm
at
io
n
 w
e 
o
b
ta
in
 f
ro
m
 y
o
u
r 
sa
m
p
le
s 
w
il
l 
b
e 
u
se
d
 t
o
 p
ro
d
u
ce
 a
 r
ep
o
rt
 o
n
 h
o
w
 
d
ie
t,
 g
u
t 
b
ac
te
ri
a 
an
d
 o
th
er
 f
ac
to
rs
 i
n
 t
h
e 
g
u
ts
 o
f 
ch
il
d
re
n
 w
h
o
 h
av
e 
C
ro
h
n
's
 d
is
ea
se
 
co
m
p
ar
e 
w
it
h
 h
ea
lt
h
y
 c
h
il
d
re
n
. 
 
 W
h
o
 i
s 
d
o
in
g
 t
h
e 
st
u
d
y
?
 
C
la
re
 C
la
rk
, 
a 
p
o
st
g
ra
d
u
at
e 
st
u
d
en
t 
re
se
ar
ch
er
, 
is
 c
ar
ry
in
g
 o
u
t 
th
is
 s
tu
d
y
 t
o
 i
n
cr
ea
se
 
o
u
r 
u
n
d
er
st
an
d
in
g
 o
f 
b
ac
te
ri
a 
in
 s
to
m
ac
h
 p
ro
b
le
m
s.
 T
h
e 
st
u
d
y
 i
s 
fu
n
d
ed
 b
y
 Y
o
rk
h
il
l 
C
h
il
d
re
n
's
 
C
h
ar
it
y
 
an
d
 
is
 
b
ei
n
g
 
d
o
n
e 
is
 
su
p
er
v
is
ed
 
b
y
 
d
o
ct
o
rs
 
at
 
Y
o
rk
h
il
l,
 
N
H
S
 
G
re
at
er
 G
la
sg
o
w
 &
 C
ly
d
e 
an
d
 a
 t
ea
m
 o
f 
re
se
ar
ch
 s
ci
en
ti
st
s 
at
 U
n
iv
er
si
ty
 o
f 
G
la
sg
o
w
. 
 W
h
a
t 
if
 I
 h
a
v
e 
m
o
re
 q
u
es
ti
o
n
s?
 
If
 y
o
u
 h
av
e 
an
y
 q
u
es
ti
o
n
s 
y
o
u
 o
r 
y
o
u
r 
p
ar
en
t/
ca
re
r 
ca
n
 c
o
n
ta
ct
 u
s.
 C
la
re
 w
il
l 
al
w
ay
s 
b
e 
h
ap
p
y
 t
o
 a
n
sw
er
 a
n
y
 q
u
es
ti
o
n
s 
y
o
u
 m
ig
h
t 
h
av
e 
ab
o
u
t 
th
e 
st
u
d
y
. 
   
P
le
as
e 
co
n
ta
ct
 C
la
re
 b
y
 e
m
ai
l:
  
c.
cl
a
r
k
.1
@
re
se
a
r
ch
.g
la
.a
c.
u
k
 
 o
r 
b
y
 p
h
o
n
e/
te
x
t 
0
7
7
3
0
 4
6
5
2
3
0
 
 
 
 
If
 y
o
u
 w
o
u
ld
 l
ik
e 
to
 s
p
ea
k 
to
 s
o
m
eo
n
e 
o
th
er
 t
h
a
n
 t
h
e 
re
se
a
rc
h
er
, 
p
le
a
se
 c
o
n
ta
ct
 D
r 
D
a
li
a
 M
a
lk
o
va
, 
 
U
n
iv
er
si
ty
 o
f 
G
la
sg
o
w
 H
u
m
a
n
 N
u
tr
it
io
n
 S
ec
ti
o
n
, 
G
la
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o
w
 R
o
ya
l 
In
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a
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n
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1
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0
1
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IN
S
T
R
U
C
T
IO
N
S
 F
O
R
 T
H
E
 C
O
LL
E
C
T
IO
N
 O
F
 A
 F
A
E
C
A
L 
S
A
M
P
LE
 
 
1
. 
Li
ft
 t
h
e
 t
o
il
e
t 
se
a
t.
  
2
. 
P
la
ce
 t
h
e
 b
ra
ck
e
t 
a
n
d
 t
h
e
 s
a
m
p
le
 p
o
t 
a
cr
o
ss
 t
h
e
 b
o
w
l.
 L
o
w
e
r 
th
e
 t
o
il
e
t 
se
a
t.
 
3
. 
S
it
 o
n
 t
h
e
 t
o
il
e
t 
se
a
t.
 C
h
e
ck
 t
o
 m
a
k
e
 s
u
re
 t
h
e
 s
a
m
p
le
 p
o
t 
is
 r
ig
h
t 
b
e
lo
w
 y
o
u
. 
 
4
. 
If
 n
e
e
d
e
d
 m
o
v
e
 t
h
e
 b
ra
ck
e
t 
a
n
d
 b
u
ck
e
t 
a
ro
u
n
d
. 
  
Y
o
u
 d
o
 n
o
t 
h
a
v
e
 t
o
 u
se
 t
h
e
 b
ra
ck
e
t 
if
 y
o
u
 d
o
 n
o
t 
fi
n
d
 i
t 
n
e
ce
ss
a
ry
. 
  
               5
. 
Le
t 
y
o
u
r 
e
n
ti
re
 b
o
w
e
l 
m
o
v
e
m
e
n
t 
fa
ll
 i
n
to
 t
h
e
 p
o
t 
(p
le
a
se
 p
ro
v
id
e
 w
h
o
le
 b
o
w
e
l 
m
o
v
e
m
e
n
t 
if
 y
o
u
 c
a
n
) 
  
D
o
 N
O
T
 u
ri
n
a
te
 o
r 
p
la
ce
 t
o
il
e
t 
p
a
p
e
r 
in
to
 t
h
e
 p
o
t.
 
6
. 
S
ta
n
d
 u
p
. 
Li
ft
 t
h
e
 p
o
t 
o
u
t 
o
f 
th
e
 b
ra
ck
e
t 
a
n
d
 c
o
v
e
r 
it
 w
it
h
 t
h
e
 l
id
. 
 
7
. 
R
e
m
o
v
e
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2.3 Appendix: Stool sample instruction leaflet
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3 Appendix: Paediatric Crohn’s disease activity index
Paediatric Crohn’s disease activity index (wPCDAI) form. Simple endoscopic score form for Crohn’s
disease shown below.
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4 Appendix: Blood markers of inflammation in IBD
Difference in blood result profiles between children with Crohn’s disease, UC and non-IBD conditions
shown by multi-dimensional scaling (MDS) spider plot. PERMANOVA: R2=0.197; p=0.0001
(vegan; euclidean).
Changes in blood result profiles between baseline (week 00) and after 8-week treatment with EEN
(week 08) in children with Crohn’s disease; shown by multi-dimensional scaling (MDS) plot. PER-
MANOVA: R2=0.225; p=0.0001; Children with non-IBD conditions (black) are shown for refer-
ence.
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5 Appendix: Classification of bacteria associated with IBD
Classification of bacteria/archaea associated with IBD
Phylum Class Order Family Genus
Archaea Methanobacteria Methanobacteriales Methanobacteriaceae Methanobrevibacter
(Euryarchaeota)
Actinobacteria Actinobacteria Actinomycetales Actinomycetaceae Varibaculum
Bifidobacteriales Bifidobacteriaceae Bifidobacterium
Corynebacteriales Corynebacteriaceae
Coriobacteriia Coriobacteriales Coriobacteriaceae Collinsella
Eggerthella
Slackia
Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides
Porphyromonadaceae Coprobacter
Parabacteroides
Prevotellaceae Paraprevotella
Prevotella
Rikenellaceae Alistipes
S24-7
Firmicutes Bacilli Bacillales Staphylococcaceae Staphylococcus
Lactobacillales Enterococcaceae Enterococcus
Lactobacillaceae Lactobacillus
Streptococcaceae Streptococcus
Erysipelotrichales Erysipelotrichaceae
Turicibacter
Clostridia Clostridiales Christensenellaceae
Clostridiaceae Clostridium
Hungatella
Defluviitaleaceae
Eubacteriaceae Eubacterium
Family XI
Family XIII
Lachnospiraceae Lachnoclostridium
Anaerostipes
Blautia
Butyrivibrio
Roseburia
Tyzzerella
Pseudobutyrivibrio
Peptococcaceae
Ruminococcaceae Anaerotruncus
Faecalibacterium
Ruminococcus
Subdoligranulum
Negativicutes Acidaminococcales Acidaminococcaceae Acidaminococcus
Selenomonadales Veillonellaceae Allisonella
Anaeroglobus
Dialister
Megasphaera
Selenomonas
Veillonella
Tenericutes Mollicutes
Fusobacteria Fusobacteriales Fusobacteriaceae
Proteobacteria α-proteobacteria Rhizobiales Brucellaceae Mycoplana
Rhodospirillales Rhodospirillaceae
β-proteobacteria Neisseriales Neisseriaceae Eikenella
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Classification of bacteria/archaea associated with IBD) (continued)
Phylum Class Order Family Genus
Burkholderiales Sutterellaceae Sutterella
δ-proteobacteria Desulfovibrionales Desulfovibrionaceae Bilophila
Desulfovibrio
ε-proteobacteria Campylobacterales Campylobacteraceae Campylobacter
Helicobacteraceae Helicobacter
γ-proteobacteria Enterobacteriales Enterobacteriaceae Enterobacter
Escherichia
Cronobacter
Citrobacter
Pantoea
Shigella
Morganellaceae Proteus
Pasteurellales Pasteurellaceae Haemophilus
Aggregatibacter
Pseudomonadales Pseudomonadaceae Pseudomonas
Verrucomicrobia Verrucomicrobiae Verrucomicrobiales Akkermansiaceae Akkermansia
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5.1 Appendix: Bacterial community structure at Family level taxa
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5.2 Appendix: Bacterial community structure at Order level taxa
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5.3 Appendix: Taxa increased/decreased at baseline in children with
Crohn’s disease compared with healthy children
Bacterial taxa where abundance was significantly increased/decreased in children with Crohn’s dis-
ease compared with healthy children (differential analysis using negative binomial)
Taxon
base
mean
log2 fold
change
log fold
SE
p-value p-adj
ր Phyla increased
Fusobacteria 52.05 5.90 0.67 9.71E-19 6.31E-18
Proteobacteria 1506.51 2.50 0.37 1.30E-11 5.62E-11
ր Families increased
Bacillales Family XI 20.31 2.81 0.57 8.52E-07 4.10E-06
Fusobacteriaceae 46.35 5.98 0.68 2.55E-18 6.77E-17
Enterobacteriaceae 354.06 3.60 0.61 4.50E-09 3.41E-08
Neisseriaceae 3.31 2.31 0.46 6.10E-07 3.23E-06
Pasteurellaceae 620.44 4.43 0.67 3.19E-11 3.38E-10
ր Species (SEQ variants) increased
SEQ 14 Bacteroides 639.34 2.71 0.74 2.40E-04 1.19E-03
SEQ 31 Bacteroides 410.18 2.05 0.84 1.41E-02 3.55E-02
SEQ 38 Bacteroides 309.78 2.19 0.75 3.51E-03 1.08E-02
SEQ 50 Bacteroides 127.14 2.36 0.87 6.32E-03 1.80E-02
SEQ 213 Bacteroides 9.23 3.92 0.63 4.11E-10 8.18E-09
SEQ 287 Clostridium sensu stricto 1 12.25 2.13 0.70 2.21E-03 7.49E-03
SEQ 284 Clostridium sensu stricto 1 9.73 2.23 0.67 9.12E-04 3.70E-03
SEQ 218 Collinsella 7.02 2.32 0.62 1.89E-04 9.74E-04
SEQ 385 Dialister pneumosintes 4.13 2.65 0.58 4.95E-06 4.03E-05
SEQ 195 Eggerthella 8.75 2.96 0.60 8.73E-07 8.70E-06
SEQ 15 Escherichia-Shigella 201.67 2.82 0.61 4.11E-06 3.49E-05
SEQ 162 Eubacterium hallii group 4.59 2.82 0.61 3.39E-06 2.98E-05
SEQ 71 Eubacterium oxidoreducens group 170.28 2.58 0.80 1.26E-03 4.75E-03
SEQ 94 Eubacterium oxidoreducens group 143.50 3.00 0.83 2.78E-04 1.34E-03
SEQ 79 Flavonifractor 48.73 3.49 0.65 8.79E-08 1.02E-06
SEQ 310 Fusobacterium 8.15 3.73 0.64 6.01E-09 8.93E-08
SEQ 321 Fusobacterium 8.07 3.53 0.63 2.48E-08 3.41E-07
SEQ 39 Haemophilus 536.81 4.25 0.68 3.20E-10 6.55E-09
SEQ 319 Haemophilus 5.86 2.12 0.62 6.40E-04 2.74E-03
SEQ 8 Lachnoclostridium 210.99 3.16 0.74 1.90E-05 1.25E-04
SEQ 113 Lachnoclostridium 20.73 2.25 0.65 5.22E-04 2.31E-03
SEQ 136 Lachnoclostridium 16.25 2.24 0.66 6.82E-04 2.89E-03
SEQ 149 Lachnoclostridium 6.78 3.44 0.62 2.98E-08 3.95E-07
SEQ 496 Lachnoclostridium 3.24 2.25 0.57 8.46E-05 4.85E-04
SEQ 392 Lachnoclostridium 2.83 2.02 0.57 3.67E-04 1.71E-03
SEQ 124 Lachnospiraceae 77.24 2.16 0.69 1.84E-03 6.43E-03
SEQ 184 Lachnospiraceae 21.23 5.16 0.72 5.40E-13 1.78E-11
SEQ 212 Lachnospiraceae UCG-008 25.72 3.03 0.71 1.89E-05 1.25E-04
SEQ 299 Megasphaera 12.56 4.38 0.66 3.34E-11 8.15E-10
SEQ 183 Paraprevotella 4.65 2.85 0.63 6.43E-06 5.12E-05
SEQ 227 Peptostreptococcus 31.73 5.53 0.71 7.25E-15 3.66E-13
SEQ 5 Prevotella 7 38.93 5.78 0.78 1.41E-13 5.08E-12
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Bacterial taxa where abundance was significantly increased/decreased in children with Crohn’s dis-
ease compared with healthy children (differential analysis using NB) (continued)
Taxon
base
mean
log2 fold
change
log fold
SE
p-value p-adj
SEQ 46 Veillonella 513.33 3.65 0.77 1.87E-06 1.75E-05
SEQ 58 Veillonella 103.03 3.50 0.70 5.69E-07 5.82E-06
SEQ 101 Veillonella 98.14 2.93 0.70 2.91E-05 1.81E-04
SEQ 144 Veillonella 18.46 3.52 0.66 1.07E-07 1.23E-06
SEQ 211 Veillonella 13.11 2.61 0.68 1.28E-04 6.98E-04
SEQ 325 Veillonella 5.82 3.20 0.64 6.16E-07 6.22E-06
SEQ 355 Veillonella 3.64 2.45 0.59 3.18E-05 1.96E-04
ց Phyla decreased
Euryarchaeota 32.05 -5.58 0.62 4.25E-19 5.53E-18
Tenericutes 31.98 -3.68 0.61 1.89E-09 6.16E-09
Verrucomicrobia 274.36 -3.01 0.73 3.58E-05 9.30E-05
ց Families decreased
Methanobacteriaceae 33.55 -5.90 0.62 1.79E-21 9.47E-20
Christensenellaceae 494.81 -4.07 0.57 7.15E-13 9.47E-12
Clostridiales vadinBB60 group 27.65 -4.25 0.53 1.98E-15 3.51E-14
Defluviitaleaceae 8.06 -2.59 0.48 5.12E-08 3.24E-07
Peptococcaceae 6.76 -2.68 0.44 1.00E-09 8.88E-09
Rhodospirillaceae 11.30 -3.21 0.59 5.50E-08 3.24E-07
Verrucomicrobiaceae 339.52 -3.29 0.75 1.29E-05 5.70E-05
ց Species (SEQ variants) decreased
SEQ 262 Acidaminococcus 3.10 -2.38 0.55 1.55E-05 1.07E-04
SEQ 11 Akkermansia 297.46 -3.24 0.83 9.05E-05 5.14E-04
SEQ 123 Akkermansia 5.52 -3.09 0.60 2.90E-07 3.10E-06
SEQ 166 Alistipes 96.81 -2.07 0.87 1.75E-02 4.28E-02
SEQ 188 Alistipes 6.48 -3.61 0.57 2.84E-10 5.97E-09
SEQ 366 Alistipes 6.28 -3.61 0.58 4.69E-10 9.11E-09
SEQ 887 Alistipes 2.89 -2.25 0.50 6.63E-06 5.22E-05
SEQ 254 Allisonella 8.45 -3.92 0.59 3.29E-11 8.15E-10
SEQ 527 Anaerostipes 6.67 -2.83 0.56 4.71E-07 4.88E-06
SEQ 289 Anaerotruncus 30.13 -3.74 0.70 7.49E-08 8.99E-07
SEQ 793 Anaerotruncus 4.96 -2.14 0.57 1.54E-04 8.20E-04
SEQ 725 Anaerotruncus 3.60 -2.02 0.52 9.86E-05 5.49E-04
SEQ 1034 Anaerotruncus 2.85 -2.23 0.50 6.87E-06 5.36E-05
SEQ 197 Bacteroidales S24-7 group 6.60 -3.63 0.61 3.22E-09 5.42E-08
SEQ 207 Bacteroidales S24-7 group 5.19 -3.25 0.59 3.85E-08 4.70E-07
SEQ 104 Bacteroides 10.92 -3.47 0.67 2.37E-07 2.56E-06
SEQ 141 Bacteroidetes VC2.1 Bac22 93.86 -3.26 0.69 2.17E-06 1.98E-05
SEQ 229 Barnesiella 22.30 -5.12 0.70 3.38E-13 1.16E-11
SEQ 210 Barnesiella 5.78 -3.42 0.58 3.89E-09 6.24E-08
SEQ 16 Bifidobacterium 948.13 -2.95 0.77 1.42E-04 7.60E-04
SEQ 142 Blautia 63.66 -2.48 0.76 1.19E-03 4.62E-03
SEQ 283 Blautia 29.07 -5.88 0.63 1.49E-20 1.88E-18
SEQ 839 Blautia 3.51 -2.60 0.54 1.31E-06 1.24E-05
SEQ 281 Butyrivibrio 4.46 -3.00 0.58 2.00E-07 2.20E-06
SEQ 683 Christensenellaceae 3.84 -2.23 0.52 1.64E-05 1.12E-04
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Bacterial taxa where abundance was significantly increased/decreased in children with Crohn’s dis-
ease compared with healthy children (differential analysis using NB) (continued)
Taxon
base
mean
log2 fold
change
log fold
SE
p-value p-adj
SEQ 57 Christensenellaceae R-7 group 316.48 -6.67 0.63 7.04E-26 2.66E-23
SEQ 121 Christensenellaceae R-7 group 46.57 -2.06 0.74 5.20E-03 1.50E-02
SEQ 202 Christensenellaceae R-7 group 44.39 -5.82 0.60 2.49E-22 4.72E-20
SEQ 252 Christensenellaceae R-7 group 43.22 -4.95 0.62 1.22E-15 7.12E-14
SEQ 308 Christensenellaceae R-7 group 12.37 -3.71 0.55 1.63E-11 4.57E-10
SEQ 435 Christensenellaceae R-7 group 5.39 -2.47 0.51 1.31E-06 1.24E-05
SEQ 501 Christensenellaceae R-7 group 4.17 -2.89 0.52 2.73E-08 3.69E-07
SEQ 576 Clostridiales vadinBB60 group 9.30 -4.17 0.61 9.75E-12 2.95E-10
SEQ 1041 Clostridiales vadinBB60 group 2.74 -2.15 0.47 3.86E-06 3.32E-05
SEQ 115 Clostridium sensu stricto 1 101.95 -2.36 0.65 2.99E-04 1.42E-03
SEQ 354 Collinsella 13.36 -4.31 0.57 4.25E-14 1.79E-12
SEQ 91 Coprococcus 2 207.88 -3.64 0.78 3.18E-06 2.83E-05
SEQ 110 Coprococcus 2 138.56 -2.63 0.76 5.06E-04 2.25E-03
SEQ 216 Coprococcus 2 55.11 -2.57 0.80 1.35E-03 5.01E-03
SEQ 454 Coriobacteriaceae 5.63 -2.09 0.47 8.29E-06 6.22E-05
SEQ 602 Coriobacteriaceae 3.34 -2.28 0.51 9.08E-06 6.74E-05
SEQ 647 Coriobacteriaceae 2.75 -2.16 0.49 1.13E-05 8.13E-05
SEQ 670 Defluviitaleaceae UCG-011 4.93 -2.46 0.54 4.52E-06 3.80E-05
SEQ 957 Defluviitaleaceae UCG-011 3.11 -2.39 0.50 1.90E-06 1.75E-05
SEQ 464 Enterorhabdus 7.64 -3.87 0.58 3.23E-11 8.15E-10
SEQ 688 Erysipelotrichaceae 5.21 -3.26 0.56 4.58E-09 7.07E-08
SEQ 40 Eubacterium coprostanoligenes group 265.24 -2.48 0.83 2.98E-03 9.32E-03
SEQ 164 Eubacterium coprostanoligenes group 22.81 -3.96 0.68 5.34E-09 8.08E-08
SEQ 443 Eubacterium coprostanoligenes group 7.58 -3.85 0.59 8.06E-11 1.85E-09
SEQ 667 Eubacterium coprostanoligenes group 5.71 -3.40 0.57 2.39E-09 4.21E-08
SEQ 156 Eubacterium coprostanoligenes group 2.98 -2.37 0.55 1.74E-05 1.18E-04
SEQ 696 Eubacterium oxidoreducens group 2.84 -2.22 0.50 8.05E-06 6.09E-05
SEQ 331 Eubacterium ruminantium group 21.26 -3.33 0.68 1.03E-06 1.01E-05
SEQ 208 Eubacterium ventriosum group 59.27 -3.17 0.61 1.72E-07 1.94E-06
SEQ 553 Family XIII UCG-001 6.22 -2.12 0.48 1.12E-05 8.13E-05
SEQ 429 Holdemanella 3.49 -2.59 0.57 4.84E-06 4.03E-05
SEQ 651 Holdemanella 2.94 -2.28 0.53 1.52E-05 1.06E-04
SEQ 382 Incertae Sedis 3.49 -2.58 0.57 4.92E-06 4.03E-05
SEQ 259 Lachnospira 24.52 -3.14 0.66 2.21E-06 1.99E-05
SEQ 440 Lachnospiraceae FCS020 group 9.23 -2.35 0.60 9.09E-05 5.14E-04
SEQ 750 Lachnospiraceae NC2004 group 3.48 -2.25 0.52 1.50E-05 1.05E-04
SEQ 452 Lachnospiraceae UCG-001 5.34 -2.38 0.55 1.34E-05 9.57E-05
SEQ 419 Lachnospiraceae UCG-003 8.81 -4.09 0.60 6.62E-12 2.09E-10
SEQ 311 Lachnospiraceae UCG-008 6.62 -2.82 0.54 1.80E-07 2.01E-06
SEQ 479 Lactococcus 7.06 -2.33 0.57 3.88E-05 2.37E-04
SEQ 421 Marvinbryantia 7.88 -2.57 0.57 7.30E-06 5.64E-05
SEQ 179 Methanobrevibacter 48.07 -6.62 0.66 1.06E-23 2.67E-21
SEQ 403 Mollicutes RF9 5.82 -3.43 0.59 6.68E-09 9.72E-08
SEQ 652 Olsenella 7.45 -3.83 0.60 1.37E-10 2.96E-09
SEQ 370 Paraprevotella 3.02 -2.33 0.54 1.41E-05 1.00E-04
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Bacterial taxa where abundance was significantly increased/decreased in children with Crohn’s dis-
ease compared with healthy children (differential analysis using NB) (continued)
Taxon
base
mean
log2 fold
change
log fold
SE
p-value p-adj
SEQ 55 Phascolarctobacterium 240.85 -5.17 0.87 2.94E-09 5.05E-08
SEQ 367 Pseudobutyrivibrio 24.40 -5.62 0.69 3.35E-16 2.11E-14
SEQ 98 Roseburia 120.88 -4.29 0.73 3.96E-09 6.24E-08
SEQ 131 Ruminiclostridium 5 39.31 -2.03 0.51 6.33E-05 3.69E-04
SEQ 397 Ruminiclostridium 5 10.66 -3.01 0.55 3.41E-08 4.38E-07
SEQ 444 Ruminiclostridium 5 7.88 -2.14 0.50 2.09E-05 1.34E-04
SEQ 618 Ruminiclostridium 5 4.35 -2.96 0.55 8.12E-08 9.60E-07
SEQ 1008 Ruminiclostridium 5 2.60 -2.06 0.49 2.30E-05 1.46E-04
SEQ 217 Ruminiclostridium 6 12.90 -4.34 0.57 3.25E-14 1.45E-12
SEQ 439 Ruminiclostridium 9 12.49 -4.62 0.56 1.28E-16 8.81E-15
SEQ 361 Ruminococcaceae 9.49 -2.89 0.47 5.25E-10 9.94E-09
SEQ 373 Ruminococcaceae 7.90 -3.92 0.60 9.30E-11 2.07E-09
SEQ 827 Ruminococcaceae 4.62 -3.06 0.55 3.03E-08 3.95E-07
SEQ 413 Ruminococcaceae 3.57 -2.63 0.52 4.50E-07 4.73E-06
SEQ 135 Ruminococcaceae NK4A214 group 68.04 -2.20 0.67 1.08E-03 4.24E-03
SEQ 379 Ruminococcaceae NK4A214 group 17.82 -3.35 0.69 1.16E-06 1.13E-05
SEQ 351 Ruminococcaceae NK4A214 group 17.55 -2.16 0.68 1.57E-03 5.72E-03
SEQ 48 Ruminococcaceae UCG-002 252.98 -3.35 0.76 9.98E-06 7.33E-05
SEQ 56 Ruminococcaceae UCG-002 150.08 -3.01 0.80 1.57E-04 8.32E-04
SEQ 187 Ruminococcaceae UCG-002 30.00 -5.98 0.70 1.44E-17 1.37E-15
SEQ 388 Ruminococcaceae UCG-002 18.66 -5.22 0.67 6.53E-15 3.53E-13
SEQ 327 Ruminococcaceae UCG-002 14.76 -4.87 0.65 9.33E-14 3.71E-12
SEQ 119 Ruminococcaceae UCG-005 119.94 -3.69 0.64 7.33E-09 1.05E-07
SEQ 161 Ruminococcaceae UCG-005 78.19 -5.29 0.60 1.54E-18 1.67E-16
SEQ 181 Ruminococcaceae UCG-005 36.10 -2.04 0.72 4.52E-03 1.35E-02
SEQ 295 Ruminococcaceae UCG-005 27.66 -4.52 0.59 1.21E-14 5.72E-13
SEQ 494 Ruminococcaceae UCG-010 9.82 -4.25 0.50 1.93E-17 1.63E-15
SEQ 662 Ruminococcaceae UCG-010 7.09 -3.75 0.57 3.99E-11 9.44E-10
SEQ 751 Ruminococcaceae UCG-010 4.37 -2.97 0.52 8.79E-09 1.23E-07
SEQ 622 Ruminococcaceae UCG-010 2.93 -2.27 0.53 1.81E-05 1.21E-04
SEQ 288 Ruminococcaceae UCG-013 11.80 -3.57 0.59 1.21E-09 2.23E-08
SEQ 190 Ruminococcaceae UCG-014 95.07 -7.61 0.66 1.68E-30 1.27E-27
SEQ 200 Ruminococcaceae UCG-014 20.00 -2.06 0.66 1.76E-03 6.23E-03
SEQ 209 Ruminococcaceae UCG-014 13.93 -4.78 0.64 9.80E-14 3.71E-12
SEQ 233 Ruminococcaceae UCG-014 10.96 -3.64 0.66 3.64E-08 4.55E-07
SEQ 418 Ruminococcaceae UCG-014 6.62 -3.64 0.60 1.39E-09 2.50E-08
SEQ 279 Ruminococcaceae UCG-014 3.75 -2.14 0.54 7.26E-05 4.20E-04
SEQ 574 Ruminococcaceae UCG-014 2.84 -2.22 0.52 2.07E-05 1.34E-04
SEQ 86 Ruminococcus 1 213.90 -2.36 0.74 1.37E-03 5.05E-03
SEQ 219 Ruminococcus 1 44.47 -6.07 0.64 2.20E-21 3.34E-19
SEQ 235 Ruminococcus 1 9.85 -4.26 0.63 1.14E-11 3.33E-10
SEQ 653 Ruminococcus 1 3.10 -2.38 0.51 3.72E-06 3.23E-05
SEQ 28 Ruminococcus 2 603.88 -3.50 0.78 7.69E-06 5.88E-05
SEQ 171 Ruminococcus 2 9.27 -2.99 0.65 5.02E-06 4.05E-05
SEQ 116 Ruminococcus gauvreauii group 28.30 -2.05 0.68 2.72E-03 8.78E-03
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Bacterial taxa where abundance was significantly increased/decreased in children with Crohn’s dis-
ease compared with healthy children (differential analysis using NB) (continued)
Taxon
base
mean
log2 fold
change
log fold
SE
p-value p-adj
SEQ 393 Ruminococcus gauvreauii group 4.33 -2.95 0.54 3.67E-08 4.55E-07
SEQ 342 Senegalimassilia 20.82 -3.81 0.65 3.80E-09 6.24E-08
SEQ 433 Slackia 13.80 -4.14 0.62 2.93E-11 7.91E-10
SEQ 372 Thalassospira 2.87 -2.24 0.52 2.03E-05 1.32E-04
SEQ 278 Turicibacter 9.45 -2.25 0.60 1.80E-04 9.33E-04
SEQ 81 Tyzzerella 4 38.54 -2.65 0.73 2.68E-04 1.32E-03
SEQ 365 unidentified 24.37 -5.62 0.67 7.35E-17 5.57E-15
5.4 Appendix: Changes in Taxa in children with Crohn’s disease after
4-weeks treatment on EEN
Bacterial taxa where abundance was significantly increased/decreased in children with Crohn’s dis-
ease after 4-weeks treatment on EEN (differential analysis using negative binomial)
Taxon
base
mean
log2
fold
change
log fold
SE
p-value p-adj
ր Phyla increased
Verrucomicrobia 310.00 4.53 0.96 2.57E-06 1.54E-05
Cyanobacteria 8.31 2.86 0.66 1.45E-05 5.78E-05
ր Families increased
Enterobacteriaceae 1225.08 2.58 0.64 5.69E-05 3.16E-04
Porphyromonadaceae 912.31 2.01 0.63 1.35E-03 5.50E-03
Verrucomicrobiaceae 284.16 4.31 0.91 2.28E-06 2.31E-05
Christensenellaceae 211.68 2.43 0.70 5.54E-04 2.60E-03
Family XIII 94.42 2.71 0.58 2.81E-06 2.45E-05
Rhodospirillaceae 21.61 4.02 0.71 1.43E-08 2.91E-07
Staphylococcaceae 8.68 2.66 0.61 1.46E-05 9.88E-05
Peptococcaceae 5.80 2.20 0.58 1.53E-04 7.79E-04
Corynebacteriaceae 3.76 2.19 0.46 2.06E-06 2.31E-05
ր Species (SEQ variants) increased
SEQ 7 Ruminococcus torques ATCC27756 2169.36 5.23 0.76 4.80E-12 1.51E-10
SEQ 8 Lachnoclostridium 918.91 2.46 0.72 6.35E-04 2.81E-03
SEQ 54 Cronobacter 481.73 7.13 0.81 8.90E-19 1.01E-16
SEQ 69 Ruminococcaceae 325.66 3.93 0.68 6.84E-09 1.62E-07
SEQ 79 Flavonifractor 235.28 2.56 0.68 1.67E-04 9.84E-04
SEQ 68 Ruminococcaceae UCG-002 231.74 2.17 0.84 9.93E-03 2.93E-02
SEQ 92 Clostridiales bacterium canine/085 201.66 3.61 0.69 1.60E-07 2.46E-06
SEQ 113 Lachnoclostridium 170.13 3.15 0.72 1.21E-05 1.11E-04
SEQ 145 Lachnoclostridium 120.04 6.21 0.73 1.75E-17 1.42E-15
SEQ 81 Tyzzerella 4 113.04 3.89 0.86 5.50E-06 5.38E-05
SEQ 136 Lachnoclostridium 100.68 2.92 0.74 7.19E-05 5.16E-04
SEQ 51 Bacteroidetes VC2.1 Bac22 96.91 3.21 0.92 5.27E-04 2.43E-03
SEQ 121 Christensenellaceae R-7 group 81.44 2.54 0.86 3.19E-03 1.12E-02
SEQ 84 Enterobacter 78.42 6.34 0.71 3.27E-19 4.64E-17
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Bacterial taxa where abundance was significantly increased/decreased in children with Crohn’s dis-
ease after 4-weeks treatment on EEN (differential analysis using NB) (continued)
Taxon
base
mean
log2
fold
change
log fold
SE
p-value p-adj
SEQ 150 Faecalitalea 78.02 5.78 0.77 6.51E-14 2.84E-12
SEQ 159 Hungatella 63.35 3.99 0.77 2.41E-07 3.42E-06
SEQ 77 Blautia 52.59 6.67 0.88 4.24E-14 2.18E-12
SEQ 178 Lachnospiraceae 52.25 2.99 0.77 9.56E-05 6.57E-04
SEQ 116 [Ruminococcus] gauvreauii group 49.66 2.66 0.79 7.71E-04 3.34E-03
SEQ 250 Family XIII AD3011 group 46.50 5.12 0.74 3.40E-12 1.13E-10
SEQ 195 Eggerthella 44.90 3.04 0.72 2.65E-05 2.21E-04
SEQ 40 [Eubacterium] coprostanoligenes group 42.16 2.68 0.86 1.89E-03 7.28E-03
SEQ 242 Hungatella 36.76 3.55 0.64 3.80E-08 7.70E-07
SEQ 192 Ruminiclostridium 9 35.89 4.23 0.72 5.05E-09 1.25E-07
SEQ 177 Christensenellaceae R-7 group 34.48 2.22 0.75 3.14E-03 1.11E-02
SEQ 275 Lachnoclostridium 32.34 3.70 0.72 3.05E-07 4.22E-06
SEQ 230 Ruminiclostridium 5 29.78 2.58 0.63 4.82E-05 3.60E-04
SEQ 272 Eisenbergiella 28.11 5.68 0.69 2.32E-16 1.46E-14
SEQ 169 Lachnoclostridium 26.56 3.48 0.64 5.64E-08 1.07E-06
SEQ 146 Veillonellaceae bacterium canine/211 20.07 4.25 0.78 5.01E-08 9.80E-07
SEQ 341 Ruminococcaceae UCG-004 19.63 2.05 0.70 3.46E-03 1.20E-02
SEQ 104 Bacteroides 17.84 3.93 0.80 1.01E-06 1.22E-05
SEQ 244 Incertae Sedis 16.77 3.43 0.65 1.13E-07 1.83E-06
SEQ 149 Lachnoclostridium 16.73 3.06 0.69 8.98E-06 8.48E-05
SEQ 181 Ruminococcaceae UCG-005 13.87 3.19 0.70 5.63E-06 5.41E-05
SEQ 292 Blautia 13.33 3.33 0.70 2.04E-06 2.26E-05
SEQ 286 Erysipelatoclostridium 12.19 3.05 0.64 1.80E-06 2.08E-05
SEQ 126 [Ruminococcus] gauvreauii group 10.32 3.25 0.76 1.97E-05 1.67E-04
SEQ 361 Ruminococcaceae 9.90 2.61 0.60 1.24E-05 1.11E-04
SEQ 499 Ruminiclostridium 5 9.75 3.06 0.64 1.70E-06 2.01E-05
SEQ 491 Flavonifractor 9.36 2.65 0.65 4.09E-05 3.22E-04
SEQ 142 Blautia 8.21 3.84 0.70 3.56E-08 7.48E-07
SEQ 280 Gastranaerophilales 8.07 3.62 0.68 9.26E-08 1.64E-06
SEQ 413 Ruminococcaceae 7.95 3.79 0.60 3.00E-10 8.51E-09
SEQ 99 Staphylococcus 7.55 3.24 0.65 6.85E-07 8.83E-06
SEQ 488 Lachnoclostridium 7.03 2.31 0.58 7.80E-05 5.53E-04
SEQ 118 Anaerostipes caccae DSM14662 6.85 2.35 0.63 2.05E-04 1.16E-03
SEQ 226 Clostridium sp. NHT38 6.65 3.51 0.66 9.54E-08 1.64E-06
SEQ 263 Butyricimonas 6.64 2.24 0.68 1.01E-03 4.11E-03
SEQ 599 Christensenella minuta 6.32 2.26 0.59 1.28E-04 8.04E-04
SEQ 202 Christensenellaceae R-7 group 6.17 2.50 0.65 1.34E-04 8.34E-04
SEQ 297 Marvinbryantia 5.76 2.60 0.62 3.09E-05 2.54E-04
SEQ 402 Anaerotruncus sp. NML070203 5.75 2.30 0.65 4.40E-04 2.10E-03
SEQ 472 Intestinimonas butyriciproducens 5.42 2.23 0.61 2.39E-04 1.32E-03
SEQ 432 Actinomyces 5.05 2.23 0.61 2.32E-04 1.29E-03
SEQ 123 Akkermansia 4.99 2.74 0.66 3.42E-05 2.77E-04
SEQ 554 Dorea 4.90 2.14 0.60 3.78E-04 1.86E-03
SEQ 435 Christensenellaceae R-7 group 4.88 2.00 0.51 8.92E-05 6.24E-04
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ease after 4-weeks treatment on EEN (differential analysis using NB) (continued)
Taxon
base
mean
log2
fold
change
log fold
SE
p-value p-adj
SEQ 316 Lachnospiraceae UCG-008 4.47 2.88 0.63 5.34E-06 5.31E-05
SEQ 373 Ruminococcaceae 4.35 2.83 0.61 3.86E-06 3.90E-05
SEQ 593 Oscillibacter 3.99 2.13 0.56 1.50E-04 9.08E-04
SEQ 251 Lachnoclostridium 3.98 2.68 0.61 9.99E-06 9.29E-05
SEQ 344 Ruminococcaceae UCG-004 3.93 2.33 0.57 4.92E-05 3.62E-04
SEQ 243 Sutterella 3.42 2.43 0.61 6.95E-05 5.05E-04
SEQ 147 Peptoclostridium difficile QCD23m63 3.18 2.30 0.59 9.79E-05 6.57E-04
SEQ 278 Turicibacter 3.12 2.27 0.60 1.42E-04 8.77E-04
SEQ 387 Butyricimonas 3.08 2.24 0.58 9.85E-05 6.57E-04
SEQ 366 Alistipes 2.98 2.27 0.59 1.14E-04 7.41E-04
SEQ 343 Lachnoclostridium 2.92 2.15 0.59 2.86E-04 1.54E-03
SEQ 339 Pantoea 2.91 2.15 0.59 2.91E-04 1.56E-03
SEQ 209 Ruminococcaceae UCG-014 2.87 2.13 0.58 2.62E-04 1.43E-03
SEQ 1111 Actinomyces 2.84 2.10 0.55 1.24E-04 7.91E-04
SEQ 679 Lachnoclostridium 2.83 2.10 0.56 1.84E-04 1.07E-03
SEQ 148 Bacteroides salyersiae DSM18765 2.77 2.06 0.58 3.50E-04 1.78E-03
ց Phyla decreased
Fusobacteria 21.98 -4.51 0.67 1.98E-11 2.37E-10
ց Families decreased
Veillonellaceae 880.05 -3.28 0.71 3.32E-06 2.53E-05
Prevotellaceae 864.20 -3.84 0.89 1.69E-05 1.03E-04
Pasteurellaceae 257.17 -5.19 0.70 8.09E-14 4.94E-12
Bacteroidales S24-7 group 22.83 -3.94 0.75 1.72E-07 2.62E-06
Fusobacteriaceae 18.70 -4.35 0.68 1.95E-10 5.93E-09
ց Species (SEQ variants) decreased
SEQ 18 Pseudobutyrivibrio 426.66 -3.84 0.89 1.62E-05 1.41E-04
SEQ 20 Bifidobacterium pseudocatenulatum 389.26 -2.34 0.95 1.42E-02 3.82E-02
SEQ 24 Dialister 321.86 -5.13 0.77 2.33E-11 6.95E-10
SEQ 10 Bifidobacterium longum infantis 252.91 -3.51 0.68 2.16E-07 3.14E-06
SEQ 6 Prevotella 9 238.90 -8.80 0.90 2.18E-22 1.24E-19
SEQ 39 Haemophilus 236.29 -5.14 0.71 3.41E-13 1.29E-11
SEQ 46 Veillonella 177.23 -6.34 0.70 1.62E-19 4.59E-17
SEQ 16 Bifidobacterium 165.42 -2.23 0.88 1.14E-02 3.28E-02
SEQ 25 Subdoligranulum 148.02 -6.30 0.75 2.83E-17 2.01E-15
SEQ 3 Prevotella 9 122.27 -6.28 0.86 3.90E-13 1.38E-11
SEQ 58 Veillonella 88.08 -5.55 0.69 6.31E-16 3.58E-14
SEQ 139 Blautia 54.18 -5.43 0.73 8.59E-14 3.48E-12
SEQ 101 Veillonella 54.15 -5.96 0.66 2.77E-19 4.64E-17
SEQ 103 Lachnospira 51.07 -4.51 0.73 5.14E-10 1.39E-08
SEQ 5 Prevotella 7 50.22 -2.77 0.90 2.07E-03 7.84E-03
SEQ 111 Lachnospiraceae UCG-008 49.84 -3.88 0.79 7.87E-07 9.91E-06
SEQ 50 Bacteroides 46.05 -2.85 0.81 4.75E-04 2.21E-03
SEQ 128 Incertae Sedis 43.54 -6.33 0.73 3.05E-18 2.88E-16
SEQ 64 Clostridium sensu stricto1 37.33 -2.90 0.77 1.55E-04 9.24E-04
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Taxon
base
mean
log2
fold
change
log fold
SE
p-value p-adj
SEQ 70 Parasutterella 36.33 -3.63 0.77 2.36E-06 2.57E-05
SEQ 32 Roseburia 27.92 -5.68 0.75 4.85E-14 2.29E-12
SEQ 71 [Eubacterium] oxidoreducens group 25.50 -2.87 0.74 1.06E-04 7.00E-04
SEQ 36 Bacteroides 21.64 -2.20 0.83 8.21E-03 2.52E-02
SEQ 290 Lachnospiraceae 17.85 -2.31 0.67 5.57E-04 2.55E-03
SEQ 144 Veillonella 12.90 -3.61 0.68 9.05E-08 1.64E-06
SEQ 282 Ruminiclostridium 9 11.54 -2.31 0.64 3.16E-04 1.64E-03
SEQ 28 Ruminococcus 2 11.52 -3.52 0.67 1.72E-07 2.57E-06
SEQ 86 Ruminococcus 1 10.64 -4.24 0.69 9.30E-10 2.40E-08
SEQ 78 Roseburia 9.89 -2.45 0.69 3.52E-04 1.78E-03
SEQ 245 RuminococcaceaeUCG-003 9.56 -2.89 0.62 3.21E-06 3.30E-05
SEQ 115 Clostridium sensu stricto1 7.87 -3.12 0.61 3.19E-07 4.31E-06
SEQ 73 Bifidobacterium bifidum NCIMB41171 7.67 -3.74 0.67 2.22E-08 5.04E-07
SEQ 208 [Eubacterium] ventriosum group 7.47 -2.63 0.60 1.33E-05 1.18E-04
SEQ 167 Roseburia 7.33 -2.17 0.65 8.17E-04 3.44E-03
SEQ 98 Roseburia 7.22 -3.65 0.65 2.54E-08 5.54E-07
SEQ 310 Fusobacterium 7.12 -3.43 0.65 1.16E-07 1.83E-06
SEQ 151 Ruminococcus 1 6.60 -3.50 0.66 1.16E-07 1.83E-06
SEQ 319 Haemophilus 6.11 -2.61 0.67 9.84E-05 6.57E-04
SEQ 206 Lachnospiraceae NK4A136 5.64 -3.26 0.64 4.34E-07 5.72E-06
SEQ 184 Lachnospiraceae 5.49 -3.36 0.68 8.44E-07 1.04E-05
SEQ 227 Peptostreptococcus 5.31 -2.03 0.60 7.43E-04 3.27E-03
SEQ 183 Paraprevotella 5.22 -3.13 0.67 2.49E-06 2.62E-05
SEQ 185 Subdoligranulum 5.04 -3.08 0.64 1.85E-06 2.10E-05
SEQ 299 Megasphaera 4.74 -2.59 0.63 4.48E-05 3.48E-04
SEQ 186 [Eubacterium] hallii group 4.31 -2.82 0.60 2.42E-06 2.59E-05
SEQ 211 Veillonella 3.95 -2.67 0.62 1.72E-05 1.48E-04
SEQ 300 Ruminococcus 1 3.45 -2.45 0.59 3.80E-05 3.03E-04
SEQ 198 Ruminococcus 1 3.29 -2.37 0.58 4.76E-05 3.60E-04
SEQ 189 Incertae Sedis 2.94 -2.17 0.57 1.47E-04 8.94E-04
SEQ 507 Lachnospiraceae FCS020 group 2.83 -2.10 0.55 1.21E-04 7.78E-04
SEQ 332 Ruminiclostridium 2.72 -2.03 0.55 2.00E-04 1.14E-03
SEQ 218 Collinsella 2.64 -2.06 0.58 4.24E-04 2.04E-03
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6 Appendix: Short chain fatty acids (MDS polygon plots)
Difference in faecal SCFA profiles between children with Crohn’s disease (black) and healthy children
(red) as shown by metric multi-dimensional scaling (MDS) polygon plot (vegan ). PERMANOVA:
R2=0.07; p=0.011
Changes in SCFA profiles in children with Crohn’s disease after 8-weeks treatment with EEN (week
08; green) compared with baseline (week 00; red), shown by metric multi-dimensional scaling (MDS)
polygon plot. PERMANOVA: R2=0.108; p=0.002; healthy children (black) are shown for compar-
ison.
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7 Appendix: Dietary intake
7.1 Appendix: Dietary questionnaires
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7.2 Appendix: Composition of Modulen IBD (enteral nutrition)
Appendix: Nutrient table for Modulen
NUTRIENT per 250ml per 1000ml
Energy (kJ) 1050 4200
Protein (g) 9 36
Carbohydrate (g) 27.5 110
Fat (g) 11.75 47
Fibre (g) 0 0
Vitamin A Retinol (IU) 700 2800
Vitamin D (IU) 100 400
Vitamin E (mg) 3.3 13.2
Vitamin K (mcg) 13.75 55
Vitamin C (mg) 24.25 97
Thiamine B1 (mg) 0.3 1.2
Riboflavin B2 (mg) 0.325 1.3
Niacin B3(mg) 3 12
Pantothenic Acid B5 (mg) 1.25 5
Vitamin B6 (mg) 0.425 1.7
Biotin B7 (mcg) 8 32
Folic Acid B9 (mcg) 60 240
Cobalamin B12 (mcg) 0.8 3.2
Choline (mg) 18 72
Sodium (mg) 87.5 350
Potassium (mg) 300 1200
Chloride (mg) 187.5 750
Calcium (mg) 227.5 910
Phosphorous (mg) 152.5 610
Magnesium (mg) 50 200
Copper (mg) 0.25 1
Zinc (mg) 2.4 9.6
Iron (mg) 2.75 11
Selenium (mcg) 8.75 35
Chromium (mcg) 12.75 51
Molybdenum (mcg) 18.75 75
Manganese (mcg) 500 2000
Iodine (mcg) 25 100
359
7
.3
A
p
p
e
n
d
ix
:
E
st
im
a
te
d
d
ie
ta
ry
in
ta
k
e
fr
o
m
F
F
Q
s
a
n
d
k
n
o
w
n
in
ta
k
e
d
u
ri
n
g
E
E
N
A
p
p
en
d
ix
:
E
st
im
at
ed
d
ie
ta
ry
in
ta
ke
fr
om
fo
o
d
fr
eq
u
en
cy
q
u
es
ti
on
n
ai
re
s
(F
F
Q
)
an
d
k
n
ow
n
in
ta
ke
d
u
ri
n
g
E
E
N
gi
ve
n
a
s
m
ed
ia
n
(I
Q
R
).
U
n
p
ai
re
d
d
at
a
is
sh
ow
n
.
E
E
N
︷
︸
︸
︷
w
k
-0
w
k
-4
w
k
-8
w
k
-1
0
w
k
-1
6
w
k
-3
6
h
ea
lt
h
y
D
ie
ta
ry
co
m
p
o
n
en
t
(n
=
2
2
)
(n
=
2
0
)
(n
=
1
8
)
(n
=
1
2
)
(n
=
9
)
(n
=
7
)
(n
=
2
1
)
M
a
c
ro
-n
u
tr
ie
n
ts
W
a
te
r
7
8
9
(3
0
5
)
1
8
7
0
(2
5
2
)
1
9
3
4
(2
6
8
)
8
1
0
(2
3
3
)
7
5
1
(1
9
1
)
8
5
7
(3
0
5
)
9
8
8
(4
3
0
)
k
C
a
l
1
4
8
8
(4
8
0
)
2
2
0
0
(2
6
7
)
2
2
7
5
(3
1
5
)
1
4
7
2
(4
3
1
)
1
4
3
0
(4
3
3
)
1
6
4
4
(5
6
0
)
1
6
4
3
(6
3
3
)
C
H
O
(g
)
2
1
1
(8
0
)
2
3
8
(3
2
)
2
4
6
(3
4
)
1
9
4
(5
9
)
1
9
3
(9
1
)
1
8
0
(2
4
)
2
2
1
(6
7
)
P
ro
te
in
(g
)
5
6
.8
(1
6
.6
)
7
9
.2
(1
0
.7
)
8
1
.9
(1
1
.3
)
5
1
.8
(2
1
.5
)
5
1
.2
(2
1
.3
)
5
3
.8
(2
8
.6
)
5
9
.1
(1
5
.2
)
F
a
t
(g
)
5
2
.3
(1
6
.3
)
1
0
1
.2
(1
3
.6
)
1
0
4
.6
(1
4
.5
)
5
5
.2
(5
.0
)
5
0
.9
(9
.9
)
6
8
.8
(3
3
.5
)
5
9
.9
(2
0
.1
)
S
F
A
(g
)
2
3
.0
(9
.0
)
5
7
.2
(7
.7
)
5
9
.1
(8
.2
)
2
4
.1
(5
.5
)
2
1
.4
(3
.4
)
2
9
.4
(1
3
.5
)
2
7
.8
(1
3
.4
)
M
U
F
A
(g
)
1
7
.8
(5
.6
)
1
7
.2
(2
.3
)
1
7
.7
(2
.5
)
1
8
.4
(2
.4
)
1
7
.7
(3
.2
)
2
2
.4
(9
.6
)
2
0
.5
(8
.6
)
P
U
F
A
(g
)
8
.2
(2
.3
)
1
0
.6
(1
.4
)
1
0
.9
(1
.5
)
8
.0
(1
.2
)
8
.1
(4
.5
)
9
.7
(3
.3
)
9
.0
(3
.0
)
C
h
o
li
n
e
(m
g
)
1
5
5
(3
7
.8
)
1
5
4
(2
0
.8
)
1
5
9
(2
2
.0
)
1
3
4
(5
0
.4
)
1
4
2
(4
7
.4
)
1
3
6
(5
4
.9
)
1
6
1
(8
4
.5
)
S
u
g
a
rs
(g
)
8
6
.0
(4
2
.3
)
6
6
.0
(8
.9
)
6
8
.2
(9
.4
)
9
5
.2
(3
5
.6
)
6
9
.8
(7
.8
)
8
6
.4
(1
6
.5
)
1
0
5
.9
(4
8
.6
)
F
ib
re
(g
)
*
9
.1
5
(4
.0
8
)
0
(0
)
0
(0
)
9
.4
(2
.6
)
9
.0
(4
.1
)
9
.8
(3
.3
)
1
3
.2
(4
.7
)
D
u
n
n
’s
te
st
o
f
m
u
lt
ip
le
co
m
p
a
ri
so
n
s
w
a
s
u
se
d
fo
ll
ow
in
g
a
si
g
n
ifi
ca
n
t
K
ru
sk
a
l-
W
a
ll
is
te
st
.
D
iff
er
en
ce
fr
o
m
h
ea
lt
h
y
ch
il
d
re
n
is
si
g
n
ifi
ca
n
t
a
t
*
p
≤
0
.0
5
*
*
p
≤
0
.0
1
,
*
*
*
p
≤
0
.0
0
1
.
360
A
p
p
en
d
ix
:
E
st
im
at
ed
d
ie
ta
ry
in
ta
ke
fr
om
fo
o
d
fr
eq
u
en
cy
q
u
es
ti
on
n
ai
re
s
(F
F
Q
)
an
d
k
n
ow
n
in
ta
k
e
d
u
ri
n
g
E
E
N
gi
v
en
as
m
ed
ia
n
(I
Q
R
).
U
n
p
ai
re
d
d
at
a
is
sh
ow
n
.
E
E
N
︷
︸
︸
︷
w
k
-0
w
k
-4
w
k
-8
w
k
-1
0
w
k
-1
6
w
k
-3
6
h
ea
lt
h
y
D
ie
ta
ry
co
m
p
o
n
en
t
(n
=
2
2
)
(n
=
2
0
)
(n
=
1
8
)
(n
=
1
2
)
(n
=
9
)
(n
=
7
)
(n
=
2
1
)
M
ic
ro
-n
u
tr
ie
n
ts
N
a
(m
g
)
2
1
3
1
(8
8
1
)
7
4
8
(1
0
1
)
7
7
3
(1
0
7
)
1
8
5
9
(5
0
6
)
2
3
3
4
(7
1
3
)
2
5
6
4
(9
7
7
)
2
2
0
6
(1
1
4
2
)
C
l
(m
g
)
3
2
0
3
(1
2
3
0
)
2
4
0
(2
1
6
)
1
6
6
1
(2
3
0
)
2
8
2
9
(8
0
1
)
3
5
7
9
(1
3
0
2
)
3
9
6
1
(1
4
0
4
)
3
4
9
9
(1
4
0
1
)
K
(m
g
)
2
1
7
6
(9
1
2
)
2
6
4
0
(3
5
6
)
2
7
3
0
(3
7
8
)
2
2
5
5
(7
0
3
)
1
9
3
8
(5
5
6
)
2
3
1
5
(1
0
4
5
)
2
4
7
6
(1
0
3
6
)
C
a
(m
g
)
9
3
2
(4
8
6
)
1
9
5
8
(2
6
4
)
2
0
2
5
(2
8
0
)
8
1
8
(2
8
9
)
7
8
7
(2
3
0
)
8
1
1
(2
7
8
)
9
2
6
(2
1
6
)
M
g
(m
g
)
2
0
7
(9
2
)
4
4
0
(5
9
)
4
5
5
(6
3
)
1
7
9
(5
4
)
1
9
1
(7
7
)
2
0
2
(7
6
)
2
2
7
(7
9
)
P
(m
g
)
1
1
0
5
(5
0
4
)
1
3
2
0
(1
7
8
)
1
3
6
5
(1
8
9
)
1
0
0
5
(3
6
3
)
1
0
7
0
(3
1
4
)
1
1
3
2
(4
2
0
)
1
1
4
0
(3
9
9
)
F
e
(m
g
)
8
.3
(3
.1
)
2
3
.8
(3
.2
)
2
4
.6
(3
.4
)
7
.3
(1
.7
)
8
.4
(4
.1
)
7
.4
(3
.2
)
9
.7
(4
.8
)
C
u
(m
g
)
0
.8
(0
.3
)
2
.2
(0
.3
)
2
.2
(0
.3
)
0
.7
(0
.2
)
0
.9
(0
.3
)
0
.9
(0
.4
)
0
.8
(0
.3
)
Z
n
(m
g
)
6
.7
(2
.6
)
2
0
.7
(2
.8
)
3
.6
(3
.0
)
5
.8
(2
.1
)
6
.3
(2
.0
)
6
.2
(2
.8
)
7
.0
(2
.0
)
M
n
(m
g
)
2
.0
(0
.7
)
4
.3
(0
.6
)
4
.5
(0
.6
)
2
.0
(0
.6
)
2
.1
(1
.3
)
1
.7
(0
.4
)
2
.4
(0
.9
)
S
e
(u
g
)
2
8
(9
.6
)
7
5
(1
0
.1
)
7
7
(1
0
.7
)
2
8
(8
.9
)
2
9
(1
0
.4
)
3
1
(1
0
.4
)
3
1
(1
1
.9
)
I
(u
g
)
1
6
8
(7
5
)
2
1
5
(2
9
)
2
2
3
(3
1
)
1
6
8
(5
9
)
1
5
3
(2
7
)
1
9
9
(8
9
)
1
8
1
(3
9
)
V
it
a
m
in
s
R
et
in
o
l
(u
g
)
*
*
2
1
2
(1
0
8
)
1
8
0
4
(2
4
3
)
1
8
6
5
(2
5
8
)
2
3
4
(8
2
)
2
1
0
(2
5
)
2
2
9
(1
4
5
)
3
0
9
(1
5
6
)
V
it
a
m
in
D
(u
g
)
1
.4
(0
.7
)
2
1
.6
(2
.9
)
2
2
.3
(3
.1
)
1
.2
(0
.6
)
1
.4
(1
.0
)
1
.4
(0
.8
)
1
.6
(0
.8
)
V
it
a
m
in
E
(m
g
)
*
5
.5
(1
.4
)
2
8
.6
(3
.9
)
2
9
.6
(4
.1
)
6
.3
(1
.5
)
5
.7
(3
.5
)
5
.6
(1
.8
)
6
.5
(2
.3
)
V
it
a
m
in
B
1
(m
g
)
1
.3
(0
.5
)
2
.6
(0
.3
)
2
.7
(0
.4
)
1
.2
(0
.4
)
1
.2
(0
.6
)
1
.4
(0
.7
)
1
.3
(0
.6
)
V
it
a
m
in
B
2
(m
g
)
2
.0
(1
.3
)
2
.8
(0
.4
)
2
.9
(0
.4
)
1
.6
(0
.8
)
1
.6
(0
.9
)
1
.8
(0
.9
)
1
.9
(0
.9
)
V
it
a
m
in
B
3
(m
g
)
1
7
.6
(8
.9
)
2
5
.5
(3
.4
)
2
6
.4
(3
.6
)
1
3
.7
(4
.4
)
1
5
.4
(7
.3
)
1
4
.9
(6
.6
)
1
4
.0
(5
.3
)
V
it
a
m
in
B
5
(m
g
)
5
.3
(2
.2
)
1
0
.6
(1
.4
)
1
0
.9
(1
.5
)
4
.3
(1
.9
)
4
.7
(0
.6
)
4
.8
(2
.9
)
5
.2
(1
.8
)
V
it
a
m
in
B
6
(m
g
)
1
.7
(0
.7
)
3
.6
(0
.5
)
3
.8
(0
.5
)
1
.5
(0
.4
)
1
.4
(0
.5
)
1
.6
(1
.0
)
1
.4
(0
.5
)
V
it
a
m
in
B
7
(u
g
)
2
4
(1
2
)
7
0
(9
)
7
3
(1
0
)
2
5
(7
)
2
1
(1
1
)
2
5
(1
0
)
3
0
(1
1
)
V
it
a
m
in
B
9
(u
g
)
2
3
8
(1
3
5
)
5
2
8
(7
1
)
5
4
6
(7
6
)
2
2
6
(1
1
3
)
2
4
5
(1
5
4
)
1
8
3
(7
1
)
2
4
4
(1
3
0
)
V
it
a
m
in
B
1
2
(u
g
)
5
.0
(1
.4
)
7
.0
(0
.9
)
7
.3
(1
.0
)
4
.1
(1
.7
)
4
.1
(0
.8
)
4
.3
(2
.3
)
5
.3
(2
.1
)
V
it
a
m
in
C
(m
g
)
*
*
*
6
2
.5
(3
4
.8
)
2
0
6
.5
(2
7
.9
)
2
1
3
.8
(2
9
.6
)
6
8
.0
(2
9
.6
)
6
4
.0
(1
7
.8
)
7
6
.0
(6
5
.2
)
1
2
3
.0
(8
1
.5
)
D
u
n
n
’s
te
st
o
f
m
u
lt
ip
le
co
m
p
a
ri
so
n
s
w
a
s
u
se
d
fo
ll
ow
in
g
a
si
g
n
ifi
ca
n
t
K
ru
sk
a
l-
W
a
ll
is
te
st
.
D
iff
er
en
ce
fr
o
m
h
ea
lt
h
y
ch
il
d
re
n
is
si
g
n
ifi
ca
n
t
a
t
*
p
≤
0
.0
5
*
*
p
≤
0
.0
1
,
*
*
*
p
≤
0
.0
0
1
.
361
